var images_info;if (!images_info) images_info =[]; images_info["55"]={"55001":{"type":"graphic_picture","displayName":"Severe Vibrio vulnificus infection","title":"Hemorrhagic lesions in severe Vibrio vulnificus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic lesions in severe Vibrio vulnificus infection</div><div class=\"cntnt\"><img style=\"width:353px; height:234px;\" src=\"images/ID/55001_Severe_V_vulnificus_infecti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive bullous hemorrhagic lesions in a patient with Vibrio vulnificus septicemia and shock. Mortality in this condition exceeds 50 percent.</div><div class=\"graphic_reference\">Courtesy of Daniel J Sexton, MD.</div><div id=\"graphicVersion\">Graphic 55001 Version 2.0</div></div></div>"},"55002":{"type":"graphic_picture","displayName":"Acute ISN Light III","title":"High power light micrograph of kidney biopsy of a patient with acute interstitial nephritis showing diffuse infiltration of mononuclear cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High power light micrograph of kidney biopsy of a patient with acute interstitial nephritis showing diffuse infiltration of mononuclear cells</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/55002_Acute_ISN_Light_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power light micrograph of interstitial nephritis showing diffuse interstitial infiltrate of mononuclear cells, many of which are actively invading the tubules leading to disruption of the tubular basement membranes (arrows). A white cell cast is present in the tubule in the upper right corner.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 55002 Version 3.0</div></div></div>"},"55003":{"type":"graphic_figure","displayName":"Dobutamine echo outcome","title":"Dobutamine echocardiography predicts outcome in an ischemic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Dobutamine echocardiography predicts outcome in an ischemic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:471px; height:294px;\" src=\"images/CARD/55003_Dobutamine_echo_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the event-free survival in 87 patients with an ischemic cardiomyopathy who underwent dobutamine echocardiography. Among patients with evidence of hibernating myocardium (≥5 of 12 segments showing viability) mortality was significantly lower among those undergoing revascularization (3 versus 31 percent for medical therapy, p = 0.01). In patients without evidence of hibernation (&lt;5 of 12 segments showing viability), there was no difference in mortality with revascularization or medical therapy (50 versus 44 percent).</div><div class=\"graphic_reference\">Data from: Senior R, Kaul S, Lahiri A. J Am Coll Cardiol 1999; 33:1848.</div><div id=\"graphicVersion\">Graphic 55003 Version 2.0</div></div></div>"},"55004":{"type":"graphic_picture","displayName":"Circummarginate placenta","title":"Circummarginate placenta","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Circummarginate placenta</div><div class=\"cntnt\"><img style=\"width:749px; height:672px;\" src=\"images/OBGYN/55004_Circummarginate_placenta_E1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the point of membrane insertion is inside the edge of the fetal side of the disc and the amnion and chorion 'double back' around this edge. Vessels radiate from the cord insertion site to the ring and then disappear from view.</div><div id=\"graphicVersion\">Graphic 55004 Version 2.0</div></div></div>"},"55006":{"type":"graphic_figure","displayName":"Lip laceration through the vermillion border","title":"Lip laceration through the vermillion border","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Lip laceration through the vermillion border</div><div class=\"cntnt\"><img style=\"width:460px; height:484px;\" src=\"images/EM/55006_Technique_for_lip_laceratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The edges of the vermillion border must be precisely aligned to achieve an optimal cosmetic outcome for lacerations that cross the vermillion border. To accomplish this, the first suture placed should bring the edges of the vermillion border together.</div><div id=\"graphicVersion\">Graphic 55006 Version 3.0</div></div></div>"},"55010":{"type":"graphic_table","displayName":"Causes of folate deficiency","title":"Causes of folate (folic acid) deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of folate (folic acid) deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nutritional deficiency</td> </tr> <tr> <td>Substance abuse</td> </tr> <tr> <td>Alcoholism</td> </tr> <tr> <td>Poor dietary intake</td> </tr> <tr> <td>Overcooked foods</td> </tr> <tr> <td>Depressed patients</td> </tr> <tr> <td>Nursing homes</td> </tr> <tr> <td class=\"subtitle1_single\">Malabsorption</td> </tr> <tr> <td>Celiac disease (sprue)</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Infiltrative bowel disease</td> </tr> <tr> <td>Short bowel syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs (various mechanisms)</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Trimethoprim</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td class=\"subtitle1_single\">Increased requirements</td> </tr> <tr> <td>Pregnancy, lactation</td> </tr> <tr> <td>Chronic hemolysis</td> </tr> <tr> <td>Exfoliative dermatitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55010 Version 4.0</div></div></div>"},"55011":{"type":"graphic_picture","displayName":"Mogan clamp applied to foreskin","title":"Mogan clamp applied to foreskin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mogan clamp applied to foreskin</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/55011_Mogan_clamp_applied_to_fore.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 55011 Version 1.0</div></div></div>"},"55012":{"type":"graphic_table","displayName":"Injury prevention resources US","title":"Injury prevention resources (US)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Injury prevention resources (US)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Advocates for Highway and Auto Safety</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">202-408-1711<a href=\"#\" title=\"Call: 202-408-1711\"><img alt=\"\" title=\"Call: 202-408-1711\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.saferoads.org/\" target=\"_blank\">www.saferoads.org</a></td> </tr> <tr> <td class=\"subtitle1_left\">American Academy of Pediatrics</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"https://www.healthychildren.org/English/Pages/default.aspx\" target=\"_blank\">www.healthychildren.org</a></td> </tr> <tr> <td class=\"subtitle1_left\">Centers for Disease Control and Prevention Protect the Ones You Love</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.cdc.gov/safechild\" target=\"_blank\">www.cdc.gov/safechild</a></td> </tr> <tr> <td class=\"subtitle1_single\">Child Welfare League of America</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">202-688-4200<a href=\"#\" title=\"Call: 202-688-4200\"><img alt=\"\" title=\"Call: 202-688-4200\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.cwla.org/\" target=\"_blank\">www.cwla.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">Children's Safety Network</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.childrenssafetynetwork.org/\" target=\"_blank\">www.childrenssafetynetwork.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">Harborview Injury Prevention and Research Center</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.depts.washington.edu/hiprc\" target=\"_blank\">www.depts.washington.edu/hiprc</a></td> </tr> <tr> <td class=\"subtitle1_single\">Injury Control and Emergency Health Services Section of the American Public Health Association</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.apha.org/apha-communities/member-sections/injury-control-and-emergency-health-services\" target=\"_blank\">www.apha.org/apha-communities/member-sections/injury-control-and-emergency-health-services</a></td> </tr> <tr> <td class=\"subtitle1_single\">Injury Prevention Research Center</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.public-health.uiowa.edu/IPRC\" target=\"_blank\">www.public-health.uiowa.edu/IPRC</a></td> </tr> <tr> <td class=\"subtitle1_single\">Mothers Against Drunk Driving-MADD</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">877-275-6233<a href=\"#\" title=\"Call: 877-275-6233\"><img alt=\"\" title=\"Call: 877-275-6233\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">877-ASK-MADD<a href=\"#\" title=\"Call: 877-ASK-MADD\"><img alt=\"\" title=\"Call: 877-ASK-MADD\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.madd.org/\" target=\"_blank\">www.madd.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Safe Kids Campaign</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">202-662-0600<a href=\"#\" title=\"Call: 202-662-0600\"><img alt=\"\" title=\"Call: 202-662-0600\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.safekids.org/\" target=\"_blank\">www.safekids.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Safety Council</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-621-7615<a href=\"#\" title=\"Call: 800-621-7615\"><img alt=\"\" title=\"Call: 800-621-7615\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.nsc.org/\" target=\"_blank\">www.nsc.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Center for Injury Prevention and Control (NCIPC)</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-232-4636<a href=\"#\" title=\"Call: 800-232-4636\"><img alt=\"\" title=\"Call: 800-232-4636\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.cdc.gov/injury/index.html\" target=\"_blank\">www.cdc.gov/injury/index.html</a></td> </tr> <tr> <td class=\"subtitle1_single\">US Consumer Product Safety Commission</td> </tr> <tr> <td class=\"indent1\"><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-638-2772<a href=\"#\" title=\"Call: 800-638-2772\"><img alt=\"\" title=\"Call: 800-638-2772\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (hotline), <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-638-CPSC<a href=\"#\" title=\"Call: 800-638-CPSC\"><img alt=\"\" title=\"Call: 800-638-CPSC\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.cpsc.gov/\" target=\"_blank\">www.cpsc.gov</a></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Mace SE, Gerardi MJ, Dietrich AM, et al. Ann Emerg Med 2001; 38:405.</div><div id=\"graphicVersion\">Graphic 55012 Version 6.0</div></div></div>"},"55014":{"type":"graphic_figure","displayName":"Dyspnea during pregnancy","title":"Dyspnea during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Dyspnea during pregnancy</div><div class=\"cntnt\"><img style=\"width:616px; height:374px;\" src=\"images/PULM/55014_Dyspnea_durng_pregnancy_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence, time course, and severity of dyspnea during normal pregnancy. Moderate dyspnea increases in frequency from the beginning of the second trimester, while severe dyspnea is seen only in the last few weeks of pregnancy (last bar).</div><div class=\"graphic_footnotes\">NP: not pregnant.</div><div class=\"graphic_reference\">Modified from: Milne JA. The respiratory response to pregnancy. Postgrad Med J 1979; 55:318.</div><div id=\"graphicVersion\">Graphic 55014 Version 3.0</div></div></div>"},"55015":{"type":"graphic_diagnosticimage","displayName":"Sequestration CXR I","title":"Intralobar sequestration left lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration left lower lobe</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/PULM/55015_Sequestration_CXR_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph demonstrates a left lower lobe mass.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55015 Version 2.0</div></div></div>"},"55016":{"type":"graphic_picture","displayName":"Umbilical vein varix","title":"Umbilical vein varix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical vein varix</div><div class=\"cntnt\"><img style=\"width:410px; height:543px;\" src=\"images/OBGYN/55016_US_umb_vein_varix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transverse view of the umbilical cord shows an umbilical vein varix associated with thrombosis.<br />(B) Pathologic specimen shows the abnormal vascular dilatation. Histopathological examination confirmed umbilical vein varix and thrombosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Roque A Carpio, MD.</div><div id=\"graphicVersion\">Graphic 55016 Version 4.0</div></div></div>"},"55017":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber contrast-enhanced left ventricle","title":"Apical 4-chamber view of an echocardiogram without and with contrast-enhanced imaging of the left ventricle","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Apical 4-chamber view of an echocardiogram without and with contrast-enhanced imaging of the left ventricle</div><div class=\"cntnt\"><img style=\"width:517px; height:534px;\" src=\"images/CARD/55017_Enhanced_imaging_left_ventr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four-chamber view is initially obtained by imaging at the fundamental (interrogating) frequency (panel A). The same image after administration of an echocardiographic contrast agent (panel B). Note that the endocardium is continuously seen. Harmonic imaging at 7 MHz following echocardiographic contrast administration demonstrates considerable improvement in the contrast effect; both the cavity outline and that of the myocardium are identified with greater confidence.</div><div id=\"graphicVersion\">Graphic 55017 Version 6.0</div></div></div>"},"55018":{"type":"graphic_table","displayName":"CF micro-organisms","title":"Micro-organisms isolated from respiratory secretions of patients with cystic fibrosis, all ages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Micro-organisms isolated from respiratory secretions of patients with cystic fibrosis, all ages</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">%&nbsp;with positive respiratory cultures</td> </tr> <tr> <td class=\"sublist1_start\"><em>Staphylococcus aureus</em></td> <td class=\"sublist_other_start\">70.6</td> </tr> <tr> <td class=\"sublist1\">Methicillin-resistant <em>S. aureus </em>(MRSA)</td> <td class=\"sublist_other\">26.0</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><em>Pseudomonas aeruginosa</em></td> <td class=\"sublist_other_start\">47.5</td> </tr> <tr> <td class=\"sublist1\">Multidrug-resistant <em>P. aeruginosa </em>(MDR-PA)</td> <td class=\"sublist_other\">9.2</td> </tr> <tr class=\"divider_top\"> <td><em>Haemophilus influenzae</em></td> <td>15.5</td> </tr> <tr class=\"divider_top\"> <td><em>Stenotrophomonas maltophilia</em></td> <td>13.6</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\"><em>Burkholderia cepacia</em> complex</td> <td rowspan=\"4\">2.6</td> </tr> <tr> <td class=\"sublist1\"><em>B. cenocepacia</em></td> </tr> <tr> <td class=\"sublist1\"><em>B. multivorans</em></td> </tr> <tr> <td class=\"sublist1\">Others</td> </tr> <tr class=\"divider_top\"> <td><em>Achromobacter (Alcaligenes) xylosoxidans</em></td> <td>6.1</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Nontuberculous mycobacteria (NTM)</td> <td>19.0*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For NTM, this is the percentage of patients with data in the Cystic Fibrosis Foundation Registry for years 2011-2015 who had one or more mycobacterial species isolated.</div><div class=\"graphic_reference\">Data from: the Cystic Fibrosis Foundation Registry, 2015.</div><div id=\"graphicVersion\">Graphic 55018 Version 9.0</div></div></div>"},"55019":{"type":"graphic_figure","displayName":"Superficial veins of lower extremity anterior view","title":"Superficial veins of lower extremity anterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial veins of lower extremity anterior view</div><div class=\"cntnt\"><img style=\"width:386px; height:682px;\" src=\"images/SURG/55019_Great_saphenous_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows the superficial veins of the anterior lower extremity. Many of these veins are tributaries to the great saphenous vein, which drains into the main deep vein of the lower extremity, the common femoral vein.</div><div id=\"graphicVersion\">Graphic 55019 Version 3.0</div></div></div>"},"55020":{"type":"graphic_figure","displayName":"Effects of variation in CYP2D6 metabolism","title":"Effects of variation in CYP2D6 metabolism with clinical response to two therapeutic agents","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Effects of variation in CYP2D6 metabolism with clinical response to two therapeutic agents</div><div class=\"cntnt\"><img style=\"width:468px; height:432px;\" src=\"images/PC/55020_Variation_CYP2D6_metab.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Based upon genetic make-up and the resultant ability to metabolize therapeutic agents, individuals can be classified as extensive (normal) metabolizers (EM), poor metabolizers (PM), or ultrarapid metabolizers (UM). Since codeine is metabolized into an active agent (morphine), poor metabolizers may require increased dosing for a given therapeutic effect, while ultrarapid metabolizers may build up excessive levels of morphine, leading to adverse sequelae. Conversely, nortriptyline is the active therapeutic agent and is metabolized to an inactive form. In this case, poor metabolism leads to adequate therapy but an increased incidence of side effects, while extensive metabolizers may require increased dosing for therapeutic effect.</div><div class=\"graphic_footnotes\">C: codeine; M: morphine; N: nortriptyline; I: inactive nortriptyline; EM: extensive metabolizers; PM: poor metabolizers; UM: ultrarapid metabolizers.</div><div class=\"graphic_reference\">Reproduced with permission from PharmGKB. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 55020 Version 2.0</div></div></div>"},"55021":{"type":"graphic_diagnosticimage","displayName":"Pneumocystis pneumonia CT II","title":"Pneumocystis jirovecii pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumocystis jirovecii pneumonia</div><div class=\"cntnt\"><img style=\"width:353px; height:236px;\" src=\"images/PULM/55021_Pneumocystis_pneumonia_CT1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pneumocystis jirovecii pneumonia&nbsp;in a patient on high doses of corticosteroids. Confluent consolidation is interspersed with ground glass opacities and thickening of the interlobular septa.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55021 Version 3.0</div></div></div>"},"55022":{"type":"graphic_picture","displayName":"Cartilage inflammation in RPC","title":"Cartilage inflammation in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartilage inflammation in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/RHEUM/55022_Cartilage_inflammation_in_R.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advancing disease with granulation tissue invading and replacing regions of cartilage (arrows), leading to the creation of sequestered islands in a patient with relapsing polychondritis.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 55022 Version 1.0</div></div></div>"},"55023":{"type":"graphic_table","displayName":"Young and Burgess classification of pelvic fractures","title":"Young and Burgess classification of pelvic fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Young and Burgess classification of pelvic fractures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle2_left\">LC: anterior injury = rami fractures</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">LC I: sacral fracture on side of impact</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">LC II: crescent fracture on side of impact</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">LC III: type I or II injury on side of impact with contralateral open book injury</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">AP compression (APC): anterior injury = symphysis diastasis/rami fractures</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">APC I: minor opening of symphysis and SI joint anteriorly</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">APC II: opening of anterior SI, intact posterior SI ligaments</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">APC III: complete disruption of SI joint</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Vertical shear (VS) type:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Vertical displacement of hemipelvis with symphysis diastasis or rami fractures anteriorly, iliac wing, sacral facture, or SI dislocation posteriorly</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Combined mechanism (CM) type: any combination of above injuries</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">6/1/2010--Requested permission (JD). 6/11/2010--Permission granted; figures to Terrence, agreement mailed back to Arnetta (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13692&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Young_Burgess_fx_scheme.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55023 Version 11.0</div></div></div>"},"55024":{"type":"graphic_figure","displayName":"Increased incidence of AF in subclinical hyperthyroidism","title":"Increased incidence of atrial fibrillation in subclinical hyperthyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased incidence of atrial fibrillation in subclinical hyperthyroidism</div><div class=\"cntnt\"><img style=\"width:422px; height:240px;\" src=\"images/ENDO/55024_AF_in_subclin_hyperthyroidi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of atrial fibrillation in subjects over age 60 years&nbsp;according to the serum concentration of TSH. The risk of atrial fibrillation was increased almost threefold in the subjects with marked suppression of TSH (left panel) as compared with those who had normal serum TSH concentrations and were presumably euthyroid (right panel); patients with slightly low serum TSH concentrations (middle panel) had a lesser increase in risk.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div class=\"graphic_reference\">Data from: Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.</div><div id=\"graphicVersion\">Graphic 55024 Version 4.0</div></div></div>"},"55026":{"type":"graphic_diagnosticimage","displayName":"Abdomen aorta flow reversal AR","title":"Diastolic flow reversal in the descending abdominal aorta in aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Diastolic flow reversal in the descending abdominal aorta in aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:499px; height:353px;\" src=\"images/CARD/55026_Abdomen_aorta_flow_reversal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using a subcostal window, just to the left of the midline, the pulse wave Doppler (PWD) sample volume from the abdominal aorta (ABAO) viewed in its long axis (panel A). In severe aortic regurgitation, the reverse diastolic flow component is almost equal in size to the forward flow signal (panel B). However, the net forward flow is actually greater than the reversed flow because the diameter of the aorta in systole is much larger than in diastole, due to augmented pulsitility. In the normal subject, diastolic flow in the aorta is minimal (panel C); there is a prominent forward flow signal above the baseline and a small and brief signal of reversed diastolic flow below (arrows).</div><div id=\"graphicVersion\">Graphic 55026 Version 2.0</div></div></div>"},"55029":{"type":"graphic_table","displayName":"Cytokines in rheumatic diseases","title":"Cytokines implicated in rheumatic diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytokines implicated in rheumatic diseases</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Rheumatoid arthritis (macrophage and fibroblast cytokines)</td>\n\n</tr>\n\n<tr>\n<td>IL-1</td>\n\n</tr>\n<tr>\n<td>High TNF-alpha</td>\n\n</tr>\n<tr>\n<td>Chemokines (eg, IL-8)</td>\n\n</tr>\n<tr>\n<td>Growth factors (eg, TGF-beta, PDGF)</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Systemic lupus erythematosus</td>\n\n</tr>\n<tr>\n<td>Low TNF-alpha</td>\n\n</tr>\n<tr>\n<td>Acid labile IFN-alpha</td>\n\n</tr>\n<tr>\n<td>IFN-gamma</td>\n\n</tr>\n<tr>\n<td>IL-6</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Scleroderma</td>\n\n</tr>\n<tr>\n<td>Growth factors (eg, TGF-beta, PDGF, FGF)</td>\n\n</tr>\n<tr>\n<td>IL-6</td>\n\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55029 Version 1.0</div></div></div>"},"55030":{"type":"graphic_figure","displayName":"Six-flap Z-plasty","title":"Six-flap Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Six-flap Z-plasty</div><div class=\"cntnt\"><img style=\"width:484px; height:587px;\" src=\"images/SURG/55030_Six-flap_z-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The six-flap Z-plasty is a four-flap Z-plasty with additional limbs.</div><div id=\"graphicVersion\">Graphic 55030 Version 2.0</div></div></div>"},"55031":{"type":"graphic_picture","displayName":"Arthritis in morphea","title":"Arthritis in morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arthritis in morphea</div><div class=\"cntnt\"><img style=\"width:353px; height:432px;\" src=\"images/DERM/55031_Arthritis_in_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A swollen right knee with effusion (lowest arrow) is present in this patient with morphea (upper arrows).</div><div id=\"graphicVersion\">Graphic 55031 Version 1.0</div></div></div>"},"55032":{"type":"graphic_picture","displayName":"Plexiform neurofibroma in a child with NF1","title":"Plexiform neurofibroma in a child with neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plexiform neurofibroma in a child with neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:442px; height:416px;\" src=\"images/ALLRG/55032_Plexi_neurofib_child_NF1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical picture of a child with plexiform neurofibroma of the thigh in the distribution of the femoral nerve. This patient was subsequently operated on.</div><div class=\"graphic_reference\">Reproduced with permission from: Canavese F, Krajbich JI. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop 2011; 31:303. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55032 Version 9.0</div></div></div>"},"55033":{"type":"graphic_figure","displayName":"Surgical treatment of midpalmar space abscess","title":"Surgical treatment of midpalmar space abscess","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of midpalmar space abscess</div><div class=\"cntnt\"><img style=\"width:548px; height:412px;\" src=\"images/SURG/55033_Surg_tx_midpalm_space_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The surgical approach to a midpalmar space abscess is shown in (A). The debridement of a midpalmar space abscess is shown in (B).</div><div id=\"graphicVersion\">Graphic 55033 Version 3.0</div></div></div>"},"55034":{"type":"graphic_figure","displayName":"Cormack-Lehane grading scheme for laryngoscopy","title":"Cormack-Lehane grading scheme for laryngoscopy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Cormack-Lehane grading scheme for laryngoscopy</div><div class=\"cntnt\"><img style=\"width:541px; height:242px;\" src=\"images/EM/55034_Cormack_Lehane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Difficulty of direct laryngoscopy correlates with the best view of the glottis, as defined by the Cormack-Lehane scale. With this scale, a grade I view connotes a full view of the entire glottic aperture, grade II represents a partial glottic view, grade III represents visualization of the epiglottis only, and grade IV represents inability to visualize even the epiglottis.</div><div id=\"graphicVersion\">Graphic 55034 Version 6.0</div></div></div>"},"55035":{"type":"graphic_table","displayName":"Travel-associated infections, by incubation period - I","title":"Travel-associated infections, by incubation period - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Travel-associated infections, by incubation period - I</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Short incubation (7 to 10 days or less) </td> </tr> <tr> <td>Arboviruses (many)</td> </tr> <tr> <td>Anthrax</td> </tr> <tr> <td>Brucellosis*</td> </tr> <tr> <td>Chikungunya virus</td> </tr> <tr> <td>Dengue fever</td> </tr> <tr> <td>Diphtheria</td> </tr> <tr> <td>Ehrlichiosis*</td> </tr> <tr> <td>Hantavirus infections (eg, hemorrhagic fever with renal syndrome*, hantavirus pulmonary syndrome, others)*</td> </tr> <tr> <td>Histoplasmosis (acute)*</td> </tr> <tr> <td>HIV (acute)*</td> </tr> <tr> <td>Influenza</td> </tr> <tr> <td>Japanese encephalitis</td> </tr> <tr> <td>Lassa and other viruses that cause hemorrhagic fever*</td> </tr> <tr> <td>Legionnaire's disease</td> </tr> <tr> <td>Leptospirosis</td> </tr> <tr> <td>Lyme disease*</td> </tr> <tr> <td>Malaria*</td> </tr> <tr> <td>Measles*</td> </tr> <tr> <td>Melioidosis*</td> </tr> <tr> <td>Meningococcal infections</td> </tr> <tr> <td>Plague</td> </tr> <tr> <td>Psittacosis</td> </tr> <tr> <td>Q fever*</td> </tr> <tr> <td>Rabies*</td> </tr> <tr> <td>Relapsing fever</td> </tr> <tr> <td>Rickettsial infections (multiple)</td> </tr> <tr> <td>Tickborne encephalitis</td> </tr> <tr> <td>Toxoplasmosis*</td> </tr> <tr> <td>Trichinosis*</td> </tr> <tr> <td>Tularemia</td> </tr> <tr> <td>Typhoid and paratyphoid fever* (and nontyphoidal salmonellosis)</td> </tr> <tr> <td>Yellow fever</td> </tr> <tr> <td>Zika virus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Intermediate incubation (within 1 month) </td> </tr> <tr> <td>Amebic liver abscess</td> </tr> <tr> <td>Brucellosis&nbsp;</td> </tr> <tr> <td>Clonorchiasis</td> </tr> <tr> <td>Coccidioidomycosis (acute)</td> </tr> <tr> <td>Cytomegalovirus (CMV)</td> </tr> <tr> <td>Fascioliasis</td> </tr> <tr> <td>Hepatitis A</td> </tr> <tr> <td>Hepatitis C</td> </tr> <tr> <td>Hepatitis E</td> </tr> <tr> <td>Human immunodeficiency virus infection (HIV)</td> </tr> <tr> <td>Leishmaniasis, visceral</td> </tr> <tr> <td>Rubella</td> </tr> <tr> <td>Schistosomiasis (acute)</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Trypanosomiasis, African</td> </tr> <tr> <td>Trypanosomiasis, American</td> </tr> <tr> <td class=\"subtitle1_single\">Long incubation (&#8805;3 months) </td> </tr> <tr> <td>Amebic liver abscess</td> </tr> <tr> <td>Bartonellosis</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Clonorchiasis</td> </tr> <tr> <td>CMV</td> </tr> <tr> <td>Fascioliasis</td> </tr> <tr> <td>Filariasis</td> </tr> <tr> <td>Gnathostomiasis</td> </tr> <tr> <td>Hepatitis B</td> </tr> <tr> <td>Hepatitis C</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td>HIV</td> </tr> <tr> <td>Leishmaniasis, visceral</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td>Melioidosis</td> </tr> <tr> <td>Penicilliosis marneffii</td> </tr> <tr> <td>Rabies</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Trypanosomiasis, African</td> </tr> <tr> <td>Trypanosomiasis, American</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Visceral larva migrans</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Lists are not exhaustive.</div><div class=\"graphic_footnotes\">* Incubation period is commonly longer than 10 days.</div><div class=\"graphic_reference\">Adapted from: Tropical Infectious Diseases: Principles, Pathogens, and Practice (listed as Box 125-3).</div><div id=\"graphicVersion\">Graphic 55035 Version 8.0</div></div></div>"},"55039":{"type":"graphic_table","displayName":"Adding calories to formula","title":"Methods of increasing caloric density of infant formula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods of increasing caloric density of infant formula</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\"><sup></sup>For concentrated formula (40 kcal/oz)*</td> </tr> <tr> <td class=\"subtitle2_single\">Approximate caloric density of final product&nbsp;(kcal/oz)</td> <td class=\"subtitle2_left\">Volume concentrate (oz)</td> <td class=\"subtitle2_left\">Volume water (oz)</td> </tr> <tr> <td class=\"indent1\">20</td> <td>13</td> <td>13</td> </tr> <tr> <td class=\"indent1\">22</td> <td>13</td> <td>10.5</td> </tr> <tr> <td class=\"indent1\">24</td> <td>13</td> <td>8.5</td> </tr> <tr> <td class=\"indent1\">27&nbsp;</td> <td>13</td> <td>6&nbsp;</td> </tr> <tr> <td class=\"indent1\">30</td> <td>13&nbsp;</td> <td>4.5</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\"> <p>For powdered formula (40 kcal/scoop): Consult the manufacturer's website or contact the manufacturer directly<sup>&#182;</sup></p> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Agents that can be added to infant formula</td> </tr> <tr> <td class=\"subtitle2_single\">Agent</td> <td class=\"subtitle2_left\">Kcal/unit</td> <td class=\"subtitle2_left\">Comments</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"3\">Carbohydrate</td> </tr> <tr> <td class=\"indent2\">Maltodextrin (glucose polymer)</td> <td> <p>7.7 kcal per teaspoon</p> 7.7 kcal per 2 g</td> <td>Increases osmolality</td> </tr> <tr> <td class=\"indent2\">Corn syrup</td> <td>3.8 kcal/mL</td> <td>Increases osmolality</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"3\">Fat</td> </tr> <tr> <td class=\"indent2\">Medium chain triglyceride oil (MCT oil)</td> <td>7.7 kcal/mL</td> <td>Nonemulsified</td> </tr> <tr> <td class=\"indent2\">Corn oil</td> <td>8.4 kcal/mL</td> <td>Nonemulsified</td> </tr> <tr> <td class=\"indent2\">Safflower oil</td> <td>8.4 kcal/mL</td> <td>Nonemulsified</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">kcal: kilocalorie; oz: ounce.<br />* Based on the calculation: ((a x b)/c) - a = y.<br />a = volume of concentrated formula to be diluted (ie, 13 oz), b = caloric density of concentrated formula (40 kcal/oz), c = desired caloric density of final product&nbsp;(kcal/oz), and y = amount of water needed.<br />¶ Variability in scoop sizes and household measures precludes provision of a general recipe.<br /></div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Nutrition. Appendix C. Increasing the caloric density of infant formula. In: Pediatric Nutrition, 7<SUP>th</SUP> ed, Kleinman RE, Greer FR (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2014. p.1345.</LI>&#xD;&#xA;<LI>Singla S, Olsson JM. Enteral nutrition. In: Pediatric Hospital Medicine. Textbook of inpatient Management, Perkin RM, Swift JD, Newton DA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. p.812.</LI></OL></div><div id=\"graphicVersion\">Graphic 55039 Version 6.0</div></div></div>"},"55041":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of inconclusive mammographic findings - case 2","title":"Breast MRI of inconclusive mammographic findings - case 2","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Breast MRI of inconclusive mammographic findings - case 2</div><div class=\"cntnt\"><img style=\"width:525px; height:586px;\" src=\"images/SURG/55041_Br_MRI_inconcl_find_case2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be useful for problem solving in cases with inconclusive clinical or imaging findings. Routine screening mammography revealed left breast asymmetry shown by the arrow (A). No abnormality was seen in the right breast. Breast MRI showed a contralateral enhancing mass (arrow) (B). Targeted ultrasound revealed an echogenic, heterogeneous mass (outlined by the calipers) which was biopsied and showed invasive ductal carcinoma on pathology (C).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 55041 Version 6.0</div></div></div>"},"55042":{"type":"graphic_picture","displayName":"Keratoacanthoma - face","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/55042_Keratoacanthoma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crateriform nodule with central hyperkeratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55042 Version 4.0</div></div></div>"},"55043":{"type":"graphic_picture","displayName":"Pathologic skin picking back","title":"Psychogenic excoriations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psychogenic excoriations</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/55043_Pathologic_skin_pick_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excoriated and lichenified lesions with postinflammatory hyperpigmentation. Note the relative sparing of the less accessible scapular areas in typical \"butterfly distribution.\"</div><div id=\"graphicVersion\">Graphic 55043 Version 2.0</div></div></div>"},"55045":{"type":"graphic_diagnosticimage","displayName":"HSG oblique view fibroid","title":"Hysterosalpingogram with an oblique view showing a submucous myoma that disappeared when more dye was injected","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram with an oblique view showing a submucous myoma that disappeared when more dye was injected</div><div class=\"cntnt\"><img style=\"width:468px; height:309px;\" src=\"images/OBGYN/55045_HSG_oblique_view_fibroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 55045 Version 4.0</div></div></div>"},"55046":{"type":"graphic_picture","displayName":"Retinoscope","title":"Retinoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinoscope</div><div class=\"cntnt\"><img style=\"width:297px; height:504px;\" src=\"images/PC/55046_Retinoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retinoscope is used to get an objective measure of refractive error that is not dependent upon patient response.</div><div id=\"graphicVersion\">Graphic 55046 Version 2.0</div></div></div>"},"55047":{"type":"graphic_figure","displayName":"Multiple nerve plexuses A","title":"Multiple nerve plexuses are found in the lower airways","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Multiple nerve plexuses are found in the lower airways</div><div class=\"cntnt\"><img style=\"width:530px; height:535px;\" src=\"images/PULM/55047_multiple_nerve_plexuses_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A composite montage revealing the distribution of nerves and ganglia on the adventitial surface of a segmental bronchus of human fetal lung. Nerves were stained with antisera to protein gene product 9.5 (PGP 9.5). The adventitial nerve plexus can be found in both large and small airways. Parasympathetic ganglia are localized to the adventitial nerve plexus (arrow). Photomicrograph in the inset shows high power magnification of ganglion in the adventitial nerve plexus.</div><div class=\"graphic_reference\">Reproduced with permission from: Sparrow MP, Weichselbaum M, McCray PB. Development of the innervation and airway smooth muscle in human fetal lung. Am J Respir Cell Mol Biol. 1999; 20:550.</div><div id=\"graphicVersion\">Graphic 55047 Version 2.0</div></div></div>"},"55049":{"type":"graphic_diagnosticimage","displayName":"Traction tracheomegaly CT","title":"Traction tracheomegaly","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Traction tracheomegaly</div><div class=\"cntnt\"><img style=\"width:454px; height:320px;\" src=\"images/PULM/55049_Traction_tracheomegaly_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomographic scan showing massive dilation and displacement of the trachea following right pneumonectomy.</div><div id=\"graphicVersion\">Graphic 55049 Version 2.0</div></div></div>"},"55052":{"type":"graphic_table","displayName":"Screening for HBV","title":"Groups that should be screened for hepatitis B virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Groups that&nbsp;should be screened for hepatitis B virus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"indent1\">Individuals born in areas&nbsp;with high*<sup>&#182; </sup>or intermediate <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/hepatitis-b\" spellcheck=\"true\">prevalence rates</a>*<sup>&#916; </sup>for HBV, including immigrants and adopted children<sup>&#9674;&#167;</sup></td> </tr> <tr> <td class=\"indent1\">US-born persons not vaccinated as infants whose parents were born in regions with high <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/hepatitis-b\" spellcheck=\"true\">HBV endemicity </a>(&#8805;8 percent)*</td> </tr> <tr> <td class=\"indent1\">Household and sexual contacts of HBsAg-positive persons<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Persons who have ever injected drugs<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Persons with multiple sexual partners or history of sexually transmitted disease<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Men who have sex with men<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Inmates of correctional facilities<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Individuals with chronically elevated ALT or AST<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Individuals infected with HCV or HIV<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">Patients undergoing renal dialysis<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent1\">All pregnant women</td> </tr> <tr> <td class=\"indent1\">Persons needing immunosuppressive therapy</td> </tr> <tr> <td class=\"indent1\">Blood and tissue donors</td> </tr> <tr> <td class=\"indent1\">Infants born to HBV-infected mothers<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT id=footnote data-bind=\"template: 'footnoteTemplate'\"><FONT jQuery1453831168718=\"2517\">ALT: alanine aminotransferase; AST: aspartate transaminase; HBsAg: hepatitis&nbsp;B surface antigen;&nbsp;HBV: hepatitis B virus; HCV:&nbsp;hepatitis C virus; HIV: human immunodeficiency virus; US: United States.</FONT></FONT><br />* Refer to topic on Epidemiology, transmission, and prevention of hepatitis B virus infection for a description of high and intermediate prevalence areas.<br />¶ HBsAg prevalence ≥8 percent.<br />Δ HBsAg prevalence 2 to 7 percent.<br />◊&nbsp;If HBsAg-positive persons are found in the first generation, subsequent generations should be tested.<br />§&nbsp;Those who are seronegative should receive hepatitis B vaccine.<br />¥ Refer to the topic that discusses HBV immunization in infants.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: Best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017; 167:794.</LI>&#xD;&#xA;<LI>Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57:1.</LI></OL>Adapted with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Copyright © 2009 American Association for the Study of Liver Diseases.</div><div id=\"graphicVersion\">Graphic 55052 Version 14.0</div></div></div>"},"55054":{"type":"graphic_figure","displayName":"Timeline of Campylobacter enteritis","title":"Timeline of a typical attack of Campylobacter enteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timeline of a typical attack of Campylobacter enteritis</div><div class=\"cntnt\"><img style=\"width:309px; height:169px;\" src=\"images/ID/55054_Timeline_Campy_enteritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After a mean incubation period of three days, a febrile prodromal period may be observed for a day prior to the onset of gastrointestinal symptoms.&nbsp;Diarrhea lasts a mean of seven days; abdominal pain may persist slightly longer. Organisms may be shed from the stool for several weeks following symptom resolution.</div><div id=\"graphicVersion\">Graphic 55054 Version 2.0</div></div></div>"},"55057":{"type":"graphic_diagnosticimage","displayName":"MRI of cervical spondylitic myelopathy","title":"MRI of cervical spondylitic myelopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of cervical spondylitic myelopathy</div><div class=\"cntnt\"><img style=\"width:360px; height:362px;\" src=\"images/RADIOL/55057_MRIcervicalspondylosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cervical spondylitic myelopathy. Sagittal T2-weighted MRI of the cervical spine shows spinal canal narrowing due to disc-osteophyte complexes indenting the ventral aspect of the spinal cord (arrows) and abnormal T2 hyperintense cord signal (arrowhead) confirming the diagnosis of myelopathy.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 55057 Version 4.0</div></div></div>"},"55059":{"type":"graphic_picture","displayName":"Intraduct pap mucin neo","title":"Histologic appearance of intraductal papillary mucinous neoplasm, intestinal type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of intraductal papillary mucinous neoplasm, intestinal type</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ONC/55059_Intraduct_pap_mucin_neo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraductal papillary mucinous neoplasm (IPMN) of the intestinal type with intermediate-grade dysplasia. The duct lumen is to the right. Hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 55059 Version 5.0</div></div></div>"},"55060":{"type":"graphic_picture","displayName":"Cholesteatoma tympanic membrane","title":"Cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholesteatoma</div><div class=\"cntnt\"><img style=\"width:286px; height:359px;\" src=\"images/PEDS/55060_Cholesteatoma_tympanic_memb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple white pearls on the lateral surface of the right tympanic membrane.</div><div class=\"graphic_reference\">Reproduced with permission from: Kim, SA, Haupert, MS. Clinical photograph: Congenital cholesteatoma of the tympanic membrane. Otolaryngol Head Neck Surg 2002; 127:359. Copyright &#169; 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 55060 Version 1.0</div></div></div>"},"55061":{"type":"graphic_figure","displayName":"Anatomy of the intra-abdominal esophagus","title":"Anatomy of the intra-abdominal esophagus","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Anatomy of the intra-abdominal esophagus</div><div class=\"cntnt\"><img style=\"width:502px; height:493px;\" src=\"images/SURG/55061_Anatomy-of-the-intra-abdominal-esophagus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the relationship of the intra-abdominal esophagus with the stomach, esophageal hiatus, and gastroesophageal junction.</div><div id=\"graphicVersion\">Graphic 55061 Version 5.0</div></div></div>"},"55062":{"type":"graphic_picture","displayName":"Papulonecrotic tuberculid on penis","title":"Papulonecrotic tuberculid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papulonecrotic tuberculid</div><div class=\"cntnt\"><img style=\"width:245px; height:218px;\" src=\"images/DERM/55062_Papul_tuber_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A purulent ulcer is present on the penis in this patient with papulonecrotic tuberculid.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 55062 Version 1.0</div></div></div>"},"55063":{"type":"graphic_table","displayName":"Referral to gyn oncologist","title":"Referral of women with a pelvic mass to a gynecologic oncologist: ACOG guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Referral of women with a pelvic mass to a gynecologic oncologist: ACOG guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Premenopausal women (refer if any are present)</td> </tr> <tr> <td>Very elevated CA 125 level</td> </tr> <tr> <td>Ascites</td> </tr> <tr> <td>Evidence of abdominal or distant metastases</td> </tr> <tr> <td class=\"subtitle1_single\">Postmenopausal women (refer if any are present)</td> </tr> <tr> <td>Elevated CA 125 level</td> </tr> <tr> <td>Ascites</td> </tr> <tr> <td>Nodular or fixed pelvic mass</td> </tr> <tr> <td>Evidence of abdominal or distant metastases</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ACOG: American Congress of Obstetricians and Gynecologists.</div><div class=\"graphic_reference\">The role of the obstetrician&ndash;gynecologist in the early detection of epithelial ovarian cancer. Committee Opinion No. 477. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011; 117:742.</div><div id=\"graphicVersion\">Graphic 55063 Version 5.0</div></div></div>"},"55067":{"type":"graphic_table","displayName":"Genetics of mitochondrial myopathies","title":"Genetic mutations associated with mitochondrial myopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic mutations associated with mitochondrial myopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mitochondrial DNA mutations</td> </tr> <tr> <td class=\"subtitle2_single\">Mutations in genes encoding respiratory chain proteins</td> </tr> <tr> <td class=\"indent1\">Complex I <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">(ND1 and ND4 cause a pure myopathy; ND5 causes a myopathy with MELAS/LHON/MERRF)</span></td> </tr> <tr> <td class=\"indent1\">Complex III (Cytochrome b causes&nbsp;exercise intolerance/myalgia and&nbsp;rarely causes cardiomyopathy or multisystem disorder)</td> </tr> <tr> <td class=\"indent1\">Complex IV (COX I, COXII, COXIII) causes exercise intolerance/myoglobinuria, but can also cause&nbsp;severe encephalomyopathy (all three), or MELAS (COX III only)</td> </tr> <tr> <td class=\"subtitle2_single\">Mutations affecting protein synthesis</td> </tr> <tr> <td class=\"indent1\">Mutations in transfer RNA most commonly cause MELAS or&nbsp;MERRF, and&nbsp;can also cause isolated myopathy, CPEO, or respiratory muscle weakness</td> </tr> <tr> <td class=\"indent1\">Mutations in ribosomal RNA cause aminoglycoside-related deafness and cardiomyopathy but not skeletal myopathy</td> </tr> <tr> <td class=\"indent1\">Large scale deletions/duplications most often cause sporadic CPEO/Kearns-Sayre syndrome and&nbsp;less commonly cause Pearson syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Nuclear DNA mutations</td> </tr> <tr> <td class=\"subtitle2_single\">Mutations in genes encoding respiratory chain proteins</td> </tr> <tr> <td class=\"indent1\">Coenzyme Q10 deficiency can cause isolated myopathy or rapidly fatal encephalomyopathy of infancy with nephrotic syndrome</td> </tr> <tr> <td class=\"indent1\">Complex I mutations (NDUFS1, 2, 3, 4, 6, 7, 8, NDUFV1, 2, NDUFA1, 2, 11) and complex II mutations (SDHA) can cause autosomal recessive Leigh syndrome</td> </tr> <tr> <td class=\"indent1\">Complex II mutations (SDHB, SDHC, SDHD) can cause paraganglioma and sarcoma</td> </tr> <tr> <td class=\"indent1\">Complex III mutations (UQCRB, UQCRQ) can cause lactic acidosis, hypoglycemia, and psychomotor retardation</td> </tr> <tr> <td class=\"indent1\">Complex IV mutations (COX6B1, COX4I2) can cause infantile encephalopathy, anemia, and pancreatic dysfunction</td> </tr> <tr> <td class=\"subtitle2_single\">Mutations in nuclear genes encoding proteins required for assembly or function of the respiratory chain proteins</td> </tr> <tr> <td class=\"indent1\">Complex I mutations (NDUFAF1, 2, 3, 4, C20orf7, C8orf38, C6orf66) can cause variable disorders including Leigh syndrome and lethal infantile encephalopathy</td> </tr> <tr> <td class=\"indent1\">Complex II mutations (SDHAF1, 2) can cause infantile leukoencephalopathy and paraganglioma</td> </tr> <tr> <td class=\"indent1\">Complex III mutation (BCS1L) can cause GRACILE syndrome</td> </tr> <tr> <td class=\"indent1\">Complex IV mutations (SURF 1, COX10, COX15, SCO1, SCO2) can cause Leigh syndrome and infantile cardioencephalomyopathy</td> </tr> <tr> <td class=\"indent1\">Complex V mutations (ATPAF2, ATP5A1, ATP5E, TMEM70) can cause encephalopathy and 3-methylglutaconic aciduria</td> </tr> <tr> <td class=\"subtitle2_single\">Nuclear gene defects <span class=\"subtitle1_left\">affecting</span> mitochondrial protein synthesis (causing multiple deletions or depletion of mitochondrial DNA)</td> </tr> <tr> <td class=\"indent1\">Mutations in POLG, C10orf2 (encodes twinkle helicase), RRM2B, SLC25A4, POLG2, and DGUOK can cause autosomal dominant or recessive CPEO</td> </tr> <tr> <td class=\"indent1\">Mutations in TK2, SUCLA2, SUCLA2, SUCLG1, RRM2B, and DGUOK can cause congenital encephalomyopathy and muscular dystrophy-like encephalomyopathy; TK2 mutations can also cause a slowly progressive generalized myopathy</td> </tr> <tr> <td class=\"sublist2_start\"><strong class=\"subtitle2_single\">Nuclear <span class=\"subtitle1_left\">gene</span> mutations causing defects of mitochondrial dynamics (fusion/fission)</strong></td> </tr> <tr> <td class=\"indent1\">Mutations in OPA1 can cause bilateral optic neuropathies and may be accompanied by sensorineural hearing loss; MFN2 mutations&nbsp;can cause an axonal form of Charcot-Marie-Tooth disease</td> </tr> <tr> <td class=\"subtitle2_single\">Nuclear gene defects affecting <span class=\"subtitle1_left\">mitochondrial</span> proteins implicated in apoptosis</td> </tr> <tr> <td class=\"indent1\">Mutations in AIF1 can cause multiple mtDNA deletions or mtDNA depletion and present with a mitochondrial encephalomyopathy; FASTKD2 may also present with a mitochondrial encephalomyopathy; APOPT1 mutations can cause a leukodystrophy&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Nuclear gene mutations resulting in defects of the lipid milieu</td> </tr> <tr> <td class=\"indent1\">TAZ mutations can cause Barth syndrome, an X-linked mitochondrial myopathy, cardiomyopathy, neutropenia, and short stature</td> </tr> <tr> <td class=\"indent1\">SERAC1 mutations can cause MEGDEL</td> </tr> <tr> <td class=\"subtitle2_single\">Nuclear gene defects affecting mitochondrial metabolic pathways other than the respiratory chain</td> </tr> <tr> <td class=\"indent1\">Defects of mitochondrial substrate transport include CPT&nbsp;1A deficiency, which results mainly in hepatic disease; CPT 2 deficiency most commonly produces a syndrome of recurrent rhabdomyolysis</td> </tr> <tr> <td class=\"indent1\">Defects in mitochondrial substrate utilization include trifunctional protein deficiency, which causes neuropathy, myopathy, and recurrent rhabdomyolysis</td> </tr> <tr> <td class=\"subtitle2_single\">Nuclear gene mutations causing defects in iron-sulfur cluster assembly/homeostasis<span class=\"subtitle2_single\"></span></td> </tr> <tr> <td class=\"indent1\">Defects in ISCU are associated with myopathy, exercise intolerance, and recurrent rhabdomyolysis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is not all-inclusive but rather lists some of the more common or more important genes associated with mitochondrial disease phenotypes in humans.</div><div class=\"graphic_footnotes\">Barth syndrome: X-linked cardiomyopathy, mitochondrial myopathy and cyclic neutropenia; CPEO: chronic progressive external ophthalmoplegia; GRACILE syndrome: growth retardation, amino aciduria, cholestasis, iron overload, lactic acidosis and early death; Kearns-Sayre syndrome: CPEO with pigmentary retinopathy and onset before age 20; Leigh syndrome: subacute necrotizing encephalomyelopathy; LHON: Leber hereditary optic neuropathy; MEGDEL: 3-methylglutaconic aciduria with deafness, encephalopathy and Leigh-like syndrome; MELAS: mitochondrial encephalopathy with lactic acidosis and stroke-like episodes; MERRF: myoclonic epilepsy with ragged red fibers; Pearson syndrome: sideroblastic anemia and pancreatic dysfunction; RNA: ribonucleic acid;&nbsp;CPT: carnitine palmitoyltransferase;&nbsp;ISCU: iron-sulfur cluster assembly.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<UL>&#xD;&#xA;<LI>DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 2005; 15:276. </LI>&#xD;&#xA;<LI>DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006; 18:636.</LI>&#xD;&#xA;<LI>DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013; 9:429.</LI>&#xD;&#xA;<LI>Lightowlers RN, Taylor RW, Turnbull DM. Mutations causing mitochondrial disease: What is new and what challenges remain? Science 2015; 349:1494.</LI>&#xD;&#xA;<LI>Nardin RA, Johns DR. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001; 24:170.</LI></UL></div><div id=\"graphicVersion\">Graphic 55067 Version 13.0</div></div></div>"},"55071":{"type":"graphic_figure","displayName":"Closure rectovaginal fistula4","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:359px; height:532px;\" src=\"images/OBGYN/55071_Closure_rectovaginal_fist3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Closure of the vaginal mucosa.</div><div id=\"graphicVersion\">Graphic 55071 Version 1.0</div></div></div>"},"55073":{"type":"graphic_figure","displayName":"Bence Jones protein UPEP","title":"Urinary monoclonal protein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary monoclonal protein</div><div class=\"cntnt\"><img style=\"width:372px; height:396px;\" src=\"images/HEME/55073_Bence_Jones_protein_UPEP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel B: This figure illustrates the cellulose acetate electrophoretic pattern of a urine sample. It reveals a dense band of protein with beta mobility. Panel A: Densitometer tracing shows a tall, narrow-based peak of beta mobility. These findings are consistent with a urine monoclonal protein (Bence Jones protein); confirmation of the diagnosis requires demonstration that the protein contains only a lambda or kappa light chain with no heavy chain reactivity.</div><div id=\"graphicVersion\">Graphic 55073 Version 1.0</div></div></div>"},"55074":{"type":"graphic_picture","displayName":"Duane syndrome type 2","title":"Duane syndrome of the left eye (type 2)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Duane syndrome of the left eye (type 2)</div><div class=\"cntnt\"><img style=\"width:504px; height:288px;\" src=\"images/PEDS/55074_Duane_syndrome_type_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Limited adduction and apparently normal abduction.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55074 Version 1.0</div></div></div>"},"55075":{"type":"graphic_figure","displayName":"IVUS catheter insertion","title":"Insertion of the IVUS catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of the IVUS catheter</div><div class=\"cntnt\"><img style=\"width:267px; height:217px;\" src=\"images/CARD/55075_IVUS_catheter_insertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When performing intracoronary ultrasonography (IVUS), the intracoronary catheter is advanced down the coronary artery, past the stenotic lesion. Insert: The artery can be visualized in cross-section, perpendicular to the axis of the catheter.</div><div class=\"graphic_reference\">Courtesy of Neil Weissman, MD.</div><div id=\"graphicVersion\">Graphic 55075 Version 1.0</div></div></div>"},"55076":{"type":"graphic_figure","displayName":"ARMS amplification","title":"Amplification refractory mutation system","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Amplification refractory mutation system</div><div class=\"cntnt\"><img style=\"width:549px; height:375px;\" src=\"images/PC/55076_ARMS_amplification.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This example of amplification refractory mutation system (ARMS) PCR shows how this technique can be used to distinguish between an individual who is homozygous for a normal gene and individuals homozygous or heterozygous for mutation in that gene. In this case separate primers are designed to match the normal gene sequence or the mutant gene sequence. The DNA sequences in red represent the patient DNA; the sequences in green are the primers. The box shows the mutant base and the corresponding altered base on the mutant primer.<br />A an agarose gel is run with the PCR products, and the presence of a band shows whether the normal or mutant DNA sequence was present.<br />Lanes 2 and 3: Individual with the normal gene; only the normal primer gives a PCR product.<br />Lanes 4 and 5: Individual homozygous for the mutation; only the mutant primer gives a PCR product.<br />Lanes 6 and 7: Individual heterozygous for the mutation; both the normal and mutant primers give PCR products.<br />Note: A control DNA product was present in all lanes, verifying that the PCR reaction worked.</div><div class=\"graphic_footnotes\">ARMS: amplification refractory mutation system; PCR: polymerase chain reaction.</div><div id=\"graphicVersion\">Graphic 55076 Version 2.0</div></div></div>"},"55077":{"type":"graphic_picture","displayName":"Apley scratch tests","title":"Apley scratch tests","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Apley scratch tests</div><div class=\"cntnt\"><img style=\"width:540px; height:432px;\" src=\"images/EM/55077_Apley_scratch_tests.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These tests provide a simple way to assess shoulder motion. To assess adduction, the patient is asked to reach across her chest and touch the opposite shoulder (photograph A). To assess external rotation and abduction, the patient is asked to reach behind her head and touch the superior medial tip of the opposite scapula (photograph B). A patient with normal function can reach approximately the level of the T4 spinous process. To assess internal rotation and adduction, the patient is asked to reach behind her back and touch the inferior tip of the opposite scapula (photograph C). A patient with normal function can reach approximately the level of the T8 spinous process.</div><div id=\"graphicVersion\">Graphic 55077 Version 4.0</div></div></div>"},"55078":{"type":"graphic_figure","displayName":"Hip log roll test","title":"Log roll test for evaluation of hip rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Log roll test for evaluation of hip rotation</div><div class=\"cntnt\"><img style=\"width:356px; height:403px;\" src=\"images/EM/55078_Hip_log_roll_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While keeping the leg straight, the foot is manipulated medially (internal rotation of the hip) and laterally (external rotation of the hip). Pain suggests inflammation, infection, or trauma. Synovitis tends to cause pain at extremes of rotation. Significant hip trauma or septic hip joint causes pain despite minimal rotation.</div><div id=\"graphicVersion\">Graphic 55078 Version 1.0</div></div></div>"},"55079":{"type":"graphic_table","displayName":"Therapies for acromegaly","title":"Comparison of treatments for acromegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of treatments for acromegaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp; </td> <td class=\"subtitle1\" colspan=\"2\">Surgery </td> <td class=\"subtitle1\" rowspan=\"2\">Radiotherapy </td> <td class=\"subtitle1\" rowspan=\"2\">Octreotide, lanreotide </td> <td class=\"subtitle1\" rowspan=\"2\">Cabergoline </td> <td class=\"subtitle1\" rowspan=\"2\">Pegvisomant </td> </tr> <tr> <td class=\"subtitle2\">Microadenoma </td> <td class=\"subtitle2\">Macroadenoma </td> </tr> <tr> <td>Normal IGF-1</td> <td>80-90%</td> <td>40%</td> <td>50% at 10 years</td> <td>50%</td> <td>40%</td> <td>95%</td> </tr> <tr> <td>Adenoma shrinkage</td> <td>95%</td> <td>70%</td> <td>95%</td> <td>50%</td> <td>No data</td> <td>Not expected</td> </tr> <tr> <td>Advantages</td> <td>Potential cure reduction</td> <td>Rapid size reduction</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Oral administration</td> <td>&nbsp;</td> </tr> <tr> <td>Disadvantages</td> <td> <p>Recurrence:</p> <p>5-10%</p> </td> <td>Regrowth of adenoma</td> <td>Slow</td> <td>Injection</td> <td>&nbsp;</td> <td>Injection</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Complications </td> </tr> <tr> <td class=\"sublist1\">Hypopituitarism </td> <td class=\"sublist_other\">Rare </td> <td class=\"sublist_other\">15%</td> <td class=\"sublist_other\">50% at 10 years</td> <td class=\"sublist_other\">None</td> <td class=\"sublist_other\">None</td> <td class=\"sublist_other\">None</td> </tr> <tr> <td class=\"sublist1\">Other</td> <td class=\"sublist_other\">Diabetes insipidus, 5%</td> <td class=\"sublist_other\">Diabetes insipidus, 10%</td> <td class=\"sublist_other\">Neurological deficits </td> <td class=\"sublist_other\">GI symptoms, gallstones </td> <td class=\"sublist_other\">Nausea, lassitude </td> <td class=\"sublist_other\">Elevated liver enzymes </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A summary of the advantages, disadvantages, and complications of different treatments for acromegaly.</div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor-1; GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 55079 Version 2.0</div></div></div>"},"55080":{"type":"graphic_figure","displayName":"Cardiac plane definition","title":"Cardiac plane definition","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Cardiac plane definition</div><div class=\"cntnt\"><img style=\"width:519px; height:536px;\" src=\"images/CARD/55080_Cardiac_plane_definition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac plane definition and display for tomographic imaging modalities.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.</div><div id=\"graphicVersion\">Graphic 55080 Version 11.0</div></div></div>"},"55081":{"type":"graphic_table","displayName":"Dietary alternatives to milk","title":"Nutrients to be replaced on a cow's milk avoidance diet and alternative dietary sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutrients to be replaced on a cow's milk avoidance diet and alternative dietary sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutrients in cow's milk</td> <td class=\"subtitle1\">Alternative dietary sources</td> </tr> <tr> <td>Protein</td> <td>Meat, fish, poultry, eggs, soy products, peanut, other legumes, tree nuts, and seeds</td> </tr> <tr> <td>Fat</td> <td>Vegetable oils, margarine, avocado, meats, fish, poultry, peanut, tree nuts, seeds</td> </tr> <tr> <td>Calcium</td> <td>Enriched alternative \"milk\" beverages (soy, rice, oat, almond, hemp, potato), calcium-fortified tofu, calcium-fortified juice</td> </tr> <tr> <td>Vitamin D</td> <td>Enriched alternative \"milk\" beverage, fortified margarine, fortified alternative yogurts, fish oils, salmon, and other fatty fish</td> </tr> <tr> <td>Vitamin B12</td> <td>Meat, fish, poultry, eggs, enriched alternative \"milk\" beverages</td> </tr> <tr> <td>Vitamin A</td> <td> <p>Retinol - Liver, egg yolk, fortified margarine</p> Carotene - Dark green leafy vegetables, deep orange fruits and vegetables, enriched alternative \"milk\" beverages</td> </tr> <tr> <td>Pantothenic acid (vitamin B5)</td> <td>Meat, vegetables, eggs, whole grains, legumes, fish</td> </tr> <tr> <td>Riboflavin</td> <td>Dark green leafy vegetables, enriched and whole grain products</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55081 Version 7.0</div></div></div>"},"55082":{"type":"graphic_table","displayName":"Causes of postop dyspnea","title":"Differential diagnosis of postoperative dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of postoperative dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Cardiac</td>\n</tr>\n<tr>\n<td>Heart failure</td>\n</tr>\n<tr>\n<td>Myocardial infarction</td>\n</tr>\n<tr>\n<td>Unstable angina</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Pulmonary</td>\n</tr>\n<tr>\n<td>Aspiration pneumonitis</td>\n</tr>\n<tr>\n<td>Pneumonia</td>\n</tr>\n<tr>\n<td>Pulmonary embolism</td>\n</tr>\n<tr>\n<td>Fat embolism syndrome</td>\n</tr>\n<tr>\n<td>Asthma</td>\n</tr>\n<tr>\n<td>Chronic obstructive pulmonary disease</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Miscellaneous</td>\n</tr>\n<tr>\n<td>Anemia</td>\n</tr>\n<tr>\n<td>Fever</td>\n</tr>\n<tr>\n<td>Anxiety</td>\n</tr>\n<tr>\n<td>Portal hypertension with ascites</td>\n</tr>\n<tr>\n<td>Deconditioning</td>\n</tr>\n<tr>\n<td>Malnutrition</td>\n</tr>\n<tr>\n<td>Sepsis syndrome</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57814&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_postop_dyspnea.htm</title></head></div><div id=\"graphicVersion\">Graphic 55082 Version 1.0</div></div></div>"},"55083":{"type":"graphic_table","displayName":"Predictive value positive tests","title":"Predictive value of positive test results","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictive value of positive test results</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Prevalence of disease, percent</td>\n<td class=\"subtitle1\">Predictive value of positive test, percent</td>\n</tr>\n<tr>\n<td>0.1</td>\n<td>1.9</td>\n</tr>\n<tr>\n<td>1.0</td>\n<td>16.1</td>\n</tr>\n<tr>\n<td>2.0</td>\n<td>27.9</td>\n</tr>\n<tr>\n<td>5.0</td>\n<td>50.0</td>\n</tr>\n<tr>\n<td>50.0</td>\n<td>95.0</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55083 Version 1.0</div></div></div>"},"55085":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaques PA","title":"Calcified pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified pleural plaques</div><div class=\"cntnt\"><img style=\"width:295px; height:324px;\" src=\"images/PULM/55085_Calcified_pleural_plaques_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral calcified pleural plaques due to previous asbestos exposure and a right-sided malignant mesothelioma. Chest radiographs shows multiple calcifications en face and in tangent, along the rib cage overlying the lung and along the diaphragm. Complete opacification of the right hemithorax with contralateral mediastinal shift is due to the pleural effusion associated with malignant mesothelioma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55085 Version 2.0</div></div></div>"},"55087":{"type":"graphic_table","displayName":"Various types of thromboelastograms","title":"Various types of thromboelastograms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Various types of thromboelastograms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Native TEG</td> <td>Measures clot formation in the absence of a specific activator in either untreated whole blood or in citrated whole blood after recalcification.</td> </tr> <tr> <td>Rapid-TEG (rTEG)</td> <td>Tissue factor is used as the activator inducing clot formation via the extrinsic pathway. Compared with native TEG, rTEG gives a readout of clot characteristics within about 10 minutes. The corresponding RoTEM<sup>&#174;</sup> test is the EXTEM.</td> </tr> <tr> <td>Kaolin-TEG</td> <td>Phospholipid and kaolin are used to induce activation via the intrinsic pathway. The corresponding RoTEM<sup>&#174;</sup> test is the INTEM, which uses phospholipid and ellagic acid as activators.</td> </tr> <tr> <td>Heparinase treatment</td> <td>Simultaneous measurements can be performed comparing heparinase-treated blood with untreated blood to identify the effects of endogenous heparan sulfates, exogenous heparin and heparinoids. The corresponding RoTEM<sup>&#174;</sup> assay is the HEPTEM.</td> </tr> <tr> <td>Platelet mapping</td> <td>Platelet mapping assesses platelet function via the cyclooxygenase and ADP/P2 signaling pathways. The decrement in MA can be measured in the presence of platelet antagonists such as acetylsalicylic acid, dipyridamole, and clopidogrel and compared with the untreated MA.</td> </tr> <tr> <td>Fibrin function testing</td> <td>The RoTEM<sup>&#174;</sup> FIBTEM test activates the extrinsic pathway in the presence of cytochalasin D, which is a cytoskeletal inhibitor of platelet activity. This test qualitatively assesses fibrinogen levels since the clot formation in this test is attributable to fibrin polymerization alone.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TEG: thromboelastogram; ADP/P2: adenosine diphosphate/P2 receptor; MA: maximal amplitude.</div><div id=\"graphicVersion\">Graphic 55087 Version 2.0</div></div></div>"},"55089":{"type":"graphic_figure","displayName":"Muscle displacement","title":"Muscle displacement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscle displacement</div><div class=\"cntnt\"><img style=\"width:306px; height:372px;\" src=\"images/EM/55089_Muscledisplacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The brachioradialis is relaxed in supination but may become a deforming force in pronation.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55089 Version 11.0</div></div></div>"},"55090":{"type":"graphic_figure","displayName":"LH response to pulsatile GnRH","title":"LH response to pulsatile GnRH in GnRH deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LH response to pulsatile GnRH in GnRH deficiency</div><div class=\"cntnt\"><img style=\"width:210px; height:374px;\" src=\"images/ENDO/55090_LH_response_to_pulsatile_Gn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of bolus injections of GnRH (25 ng/kg every two hours) in a GnRH-deficient man on chronic pulsatile GnRH therapy. There is a normal increase in the serum concentrations of LH and the free alpha subunit (FAS) of LH.</div><div class=\"graphic_footnotes\">LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone.</div><div class=\"graphic_reference\">Data from Snyder PJ, Rudenstein RS, Gardner DF,&nbsp;and Rothman JG.&nbsp;J Clin Endocrinol Metab 1979; 48:864.</div><div id=\"graphicVersion\">Graphic 55090 Version 3.0</div></div></div>"},"55091":{"type":"graphic_picture","displayName":"Early esoph ca endoscopy","title":"Early, superficial esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early, superficial esophageal cancer</div><div class=\"cntnt\"><img style=\"width:236px; height:287px;\" src=\"images/GAST/55091_Early_esoph_ca_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early, superficial esophageal cancer seen on endoscopy.</div><div class=\"graphic_reference\">Courtesy of William Brugge, MD.</div><div id=\"graphicVersion\">Graphic 55091 Version 1.0</div></div></div>"},"55092":{"type":"graphic_picture","displayName":"Esophageal Schatzki ring","title":"Esophageal (Schatzki) ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal (Schatzki) ring</div><div class=\"cntnt\"><img style=\"width:274px; height:274px;\" src=\"images/GAST/55092_Schatzki_ring_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of an esophageal (Schatzki) ring, which often cannot be well visualized unless the lower esophagus is widely distended. The ring appears as a thin membrane with a concentric smooth contour that projects into the lumen.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55092 Version 3.0</div></div></div>"},"55093":{"type":"graphic_diagnosticimage","displayName":"Lymphangioleiomyomatosis CT","title":"Lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:343px; height:314px;\" src=\"images/PULM/55093_LymphangioleiomyomatosisCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT scan demonstrates multiple thin-walled cystic airspaces of varying sizes, with loculated pneumothorax on the left (arrows) in a patient with pulmonary lymphangioleiomyomatosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Robert S Crausman, MD and Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 55093 Version 3.0</div></div></div>"},"55095":{"type":"graphic_picture","displayName":"Postural changes in AS","title":"Progression of postural changes with ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Progression of postural changes with ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:507px; height:267px;\" src=\"images/RHEUM/55095_Postural_changes_in_AS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of photographs shows the progressive postural changes of ankylosing spondylitis. The patient had total hip replacements performed in 1972.</div><div class=\"graphic_reference\">Reproduced with permission from: Little, H, Swinson, DR, Cruickshank, B. Upward subluxation of the axis in ankylosing spondylitis: a clinical pathologic report. Am J Med 1976, 60:279. Copyright © 1976 Elsevier.</div><div id=\"graphicVersion\">Graphic 55095 Version 3.0</div></div></div>"},"55096":{"type":"graphic_table","displayName":"Diagnostic criteria for syncope","title":"Diagnostic criteria for syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Level<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>VVS is diagnosed if syncope is precipitated by emotional distress or orthostatic stress and is associated with typical prodrome</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr class=\"divider_bottom\"> <td>Situational syncope is diagnosed if syncope occurs during or immediately after specified triggers</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr class=\"divider_bottom\"> <td>Orthostatic syncope is diagnosed when it occurs after standing up and there is documentation of OH</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"sublist1_start\">Arrhythmia-related syncope is diagnosed by ECG when there is:</td> <td class=\"centered divider_bottom\" rowspan=\"2\">I</td> <td class=\"centered divider_bottom\" rowspan=\"2\">C</td> </tr> <tr> <td class=\"sublist1 divider_bottom\"> <p>- Persistent sinus bradycardia &#60;40 bpm in awake or repetitive sinoartrial block or sinus pauses &#8805;3 s</p> <p>- Mobitz II second or third degree AV block</p> <p>- Alternating left and right BBB</p> <p>- VT or rapid paroxysmal SVT</p> <p>- Non-sustained episodes of polymorphic VT and long or short QT interval</p> - Pacemaker or ICD malfunction with cardiac pauses</td> </tr> <tr class=\"divider_bottom\"> <td>Cardiac ischaemia-related syncope is diagnosed when syncope presents with ECG evidence of acute ischaemia with or without myocardial infarction</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td>Cardiovascular syncope is diagnosed when syncope presents in patients with prolapsing atrial myxoma, severe aortic stenosis, pulmonary hypertension, pulmonary embolus, or acute aortic dissection</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; BBB: bundle branch block; ECG: electrocardiogram; ICD: implantable cardioverter-defibrillator; OH: orthostatic hypotension; SVT: supraventricular tachycardia; VVS: vasovagal syncope; VT: ventricular tachycardia.<br />* Class of recommendation.<br />¶ Level of evidence.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 55096 Version 9.0</div></div></div>"},"55097":{"type":"graphic_figure","displayName":"World map of TB incidence 2016","title":"Estimated tuberculosis incidence rates, by country, 2016","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Estimated tuberculosis incidence rates, by country, 2016</div><div class=\"cntnt\"><img style=\"width:707px; height:385px;\" src=\"images/ID/55097_WorldmapTBincidence2015.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated new tuberculosis cases (all forms) per 100,000 population per year.</div><div class=\"graphic_reference\">Reprinted from Global Tuberculosis Report 2017, World Health Organization, p. 31, Copyright © 2017. Available from: <A href=\"http://apps.who.int/iris/bitstream/10665/259366/1/9789241565516-eng.pdf?ua=1\">http://apps.who.int/iris/bitstream/10665/259366/1/9789241565516-eng.pdf?ua=1</A> (Accessed on December 1, 2017).</div><div id=\"graphicVersion\">Graphic 55097 Version 8.0</div></div></div>"},"55098":{"type":"graphic_picture","displayName":"Verrucous carcinoma aka giant condyloma of Buschke-Lowenstein","title":"Verrucous carcinoma (also known as giant condyloma of Buschke-Lowenstein)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verrucous carcinoma (also known as giant condyloma of Buschke-Lowenstein)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/55098_Verrucous_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55098 Version 4.0</div></div></div>"},"55099":{"type":"graphic_table","displayName":"Ischemic stroke classification","title":"Pathophysiologic ischemic stroke classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiologic ischemic stroke classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Large vessel atherothrombotic stroke</td> </tr> <tr> <td class=\"subtitle2_single\">More common</td> </tr> <tr> <td class=\"indent1\">Bifurcation of the common carotid artery</td> </tr> <tr> <td class=\"indent1\">Siphon portion of the common carotid artery</td> </tr> <tr> <td class=\"indent1\">Middle cerebral artery stem</td> </tr> <tr> <td class=\"indent1\">Intracranial vertebral arteries proximal to middle basilar artery</td> </tr> <tr> <td class=\"indent1\">Origin of the vertebral arteries</td> </tr> <tr> <td class=\"subtitle2_single\">Less common</td> </tr> <tr> <td class=\"indent1\">Origin of the common carotid artery</td> </tr> <tr> <td class=\"indent1\">Posterior cerebral artery stem</td> </tr> <tr> <td class=\"indent1\">Origin of the major branches of the basilar-vertebral arteries</td> </tr> <tr> <td class=\"indent1\">Origin of the branches of the anterior, middle, and posterior cerebral arteries</td> </tr> <tr> <td class=\"subtitle1_single\">Small vessel (lacunar) stroke</td> </tr> <tr> <td class=\"subtitle2_single\">Mechanism</td> </tr> <tr> <td class=\"indent1\">Lipohyalinotic occlusion</td> </tr> <tr> <td class=\"indent1\">Less frequently proximal atherothrombotic occlusion</td> </tr> <tr> <td class=\"indent1\">Least likely embolic occlusion</td> </tr> <tr> <td class=\"subtitle2_single\">Most common locations</td> </tr> <tr> <td class=\"indent1\">Penetrating branches of the anterior, middle, and posterior cerebral and basilar arteries</td> </tr> <tr> <td class=\"subtitle1_single\">Cardioaortic embolic stroke</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac sources definite - antithrombotic therapy generally used</td> </tr> <tr> <td class=\"indent1\">Left atrial thrombus</td> </tr> <tr> <td class=\"indent1\">Left ventricular thrombus</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation and paroxysmal atrial fibrillation</td> </tr> <tr> <td class=\"indent1\">Sustained atrial flutter</td> </tr> <tr> <td class=\"indent1\">Recent myocardial infarction (within&nbsp;one month)</td> </tr> <tr> <td class=\"indent1\">Rheumatic mitral or aortic valve disease</td> </tr> <tr> <td class=\"indent1\">Bioprosthetic and mechanical heart valve</td> </tr> <tr> <td class=\"indent1\">Chronic myocardial infarction with ejection fraction &#60;28 percent</td> </tr> <tr> <td class=\"indent1\">Symptomatic heart failure with ejection fraction &#60;30 percent</td> </tr> <tr> <td class=\"indent1\">Dilated cardiomyopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac sources definite - anticoagulation hazardous</td> </tr> <tr> <td class=\"indent1\">Bacterial endocarditis (exception nonbacterial)</td> </tr> <tr> <td class=\"indent1\">Atrial myxoma</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac sources possible</td> </tr> <tr> <td class=\"indent1\">Mitral annular calcification</td> </tr> <tr> <td class=\"indent1\">Patent foramen ovale</td> </tr> <tr> <td class=\"indent1\">Atrial septal aneurysm</td> </tr> <tr> <td class=\"indent1\">Atrial septal aneurysm with patent foramen ovale</td> </tr> <tr> <td class=\"indent1\">Left ventricular aneurysm without thrombus</td> </tr> <tr> <td class=\"indent1\">Isolated left atrial smoke (no mitral stenosis or atrial fibrillation)</td> </tr> <tr> <td class=\"indent1\">Mitral valve strands</td> </tr> <tr> <td class=\"subtitle2_single\">Ascending aortic atheromatous disease (&#62;4 mm)</td> </tr> <tr> <td class=\"subtitle2_single\">True unknown source embolic stroke</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Dissection</td> </tr> <tr> <td>Moyamoya</td> </tr> <tr> <td>Binswanger's disease</td> </tr> <tr> <td>Primary thrombosis</td> </tr> <tr> <td>Cerebral mass</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55099 Version 3.0</div></div></div>"},"55100":{"type":"graphic_picture","displayName":"Robot surg laparoscope","title":"Robotic surgery laparoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Robotic surgery laparoscope</div><div class=\"cntnt\"><img style=\"width:324px; height:216px;\" src=\"images/OBGYN/55100_Robot_surg_laparoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo courtesy of Intuitive Surgical, Inc, 2008.</div><div id=\"graphicVersion\">Graphic 55100 Version 2.0</div></div></div>"},"55102":{"type":"graphic_picture","displayName":"Alveolar rhabdomyosarcoma","title":"Alveolar rhabdomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Alveolar rhabdomyosarcoma</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PEDS/55102_Alveolarrhabdomyosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical appearance of alveolar rhabdomyosarcoma&nbsp;is that of fibrovascular septae that are lined with densely packed ovoid to round tumor cells and separated by pseudo-alveolar spaces, which vaguely resemble pulmonary alveoli. A tumor must have a predominant (&gt;50%) alveolar component or bear the characteristic translocations t(1;13) or t(2;13) to be subtyped as alveolar (H&amp;E, 200x original magnification).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin. </div><div id=\"graphicVersion\">Graphic 55102 Version 4.0</div></div></div>"},"55105":{"type":"graphic_table","displayName":"WHO clinical staging HIV adult","title":"WHO clinical staging of HIV/AIDS for adults and adolescents with confirmed HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO clinical staging of HIV/AIDS for adults and adolescents with confirmed HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary HIV infection</td> </tr> <tr> <td class=\"indent1\">Asymptomatic</td> </tr> <tr> <td class=\"indent1\">Acute retroviral syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 1</td> </tr> <tr> <td class=\"indent1\">Asymptomatic</td> </tr> <tr> <td class=\"indent1\">Persistent generalized lymphadenopathy (PGL)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 2</td> </tr> <tr> <td class=\"indent1\">Moderate unexplained weight loss (&#60;10 percent of presumed or measured body weight)</td> </tr> <tr> <td class=\"indent1\">Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis)</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> </tr> <tr> <td class=\"indent1\">Angular cheilitis</td> </tr> <tr> <td class=\"indent1\">Recurrent oral ulcerations</td> </tr> <tr> <td class=\"indent1\">Papular pruritic eruptions</td> </tr> <tr> <td class=\"indent1\">Seborrhoeic dermatitis</td> </tr> <tr> <td class=\"indent1\">Fungal nail infections</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 3</td> </tr> <tr> <td class=\"subtitle2_single\">Conditions where a presumptive diagnosis can be made on the basis of clinical signs or simple investigations</td> </tr> <tr> <td class=\"indent1\">Unexplained severe weight loss (&#62;10 percent of presumed or measured body weight)</td> </tr> <tr> <td class=\"indent1\">Unexplained chronic diarrhea for longer than one month</td> </tr> <tr> <td class=\"indent1\">Unexplained persistent fever (above 37.6&#176;C intermittent or constant for longer than one month)</td> </tr> <tr> <td class=\"indent1\">Persistent oral candidiasis</td> </tr> <tr> <td class=\"indent1\">Oral hairy leukoplakia</td> </tr> <tr> <td class=\"indent1\">Pulmonary tuberculosis (current)</td> </tr> <tr> <td class=\"indent1\">Severe bacterial infections (eg, pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteremia)</td> </tr> <tr> <td class=\"indent1\">Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis</td> </tr> <tr> <td class=\"subtitle2_single\">Conditions where confirmatory diagnostic testing is necessary</td> </tr> <tr> <td class=\"indent1\">Unexplained anaemia (&#60;8 g/dL), and/or neutropenia (&#60;500 cells/microL), and/or chronic thrombocytopenia (&#60;50,000/microL) for more than one month</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 4*</td> </tr> <tr> <td class=\"subtitle2_single\">Conditions where a presumptive diagnosis can be made on the basis of clinical signs or simple investigations</td> </tr> <tr> <td class=\"indent1\">HIV wasting syndrome</td> </tr> <tr> <td class=\"indent1\">Pneumocystis pneumonia</td> </tr> <tr> <td class=\"indent1\">Recurrent severe bacterial pneumonia</td> </tr> <tr> <td class=\"indent1\">Chronic herpes simplex infection (orolabial, genital, or anorectal of more than one month's duration)</td> </tr> <tr> <td class=\"indent1\">Esophageal candidiasis</td> </tr> <tr> <td class=\"indent1\">Extrapulmonary tuberculosis</td> </tr> <tr> <td class=\"indent1\">Kaposi's sarcoma</td> </tr> <tr> <td class=\"indent1\">Central nervous system (CNS) toxoplasmosis</td> </tr> <tr> <td class=\"indent1\">HIV encephalopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Conditions where confirmatory diagnostic testing is necessary</td> </tr> <tr> <td class=\"indent1\">Extrapulmonary cryptococcosis, including meningitis</td> </tr> <tr> <td class=\"indent1\">Disseminated non-tuberculous mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy (PML)</td> </tr> <tr> <td class=\"indent1\">Candida of trachea, bronchi, or lungs</td> </tr> <tr> <td class=\"indent1\">Chronic cryptosporidiosis (with diarrhea)</td> </tr> <tr> <td class=\"indent1\">Chronic isosporiasis</td> </tr> <tr> <td class=\"indent1\">Visceral herpes simplex infection</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus (CMV) infection (retinitis or infection of organs other than liver, spleen, or lymph nodes)</td> </tr> <tr> <td class=\"indent1\">Disseminated mycosis (eg, histoplasmosis, coccidiomycosis)</td> </tr> <tr> <td class=\"indent1\">Recurrent non-typhoidal salmonella bacteremia</td> </tr> <tr> <td class=\"indent1\">Lymphoma (cerebral or B cell non-Hodgkin) or other solid HIV-associated tumors</td> </tr> <tr> <td class=\"indent1\">Invasive cervical carcinoma</td> </tr> <tr> <td class=\"indent1\">Atypical disseminated leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Symptomatic HIV-associated nephropathy or symptomatic HIV-associated cardiomyopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some additional specific conditions can also be included in regional classifications (such as reactivation of American trypanosomiasis [meningitis and/or myocarditis] in the WHO region of the Americas, disseminated penicillinosis in Asia, and HIV-associated rectovaginal fistula in Africa).</div><div class=\"graphic_reference\">Updated information from:<br /><ol>&#xD;&#xA;    <li>WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. World Health Organization, Geneva, Switzerland, 2007. Available at: <a href=\"http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf\" target=\"_blank\">http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf</a>.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African Region, 2005. Copyright &copy; 2005 World Health Organization.</div><div id=\"graphicVersion\">Graphic 55105 Version 3.0</div></div></div>"},"55106":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of the tibialis anterior after polio","title":"Ultrasound of the tibialis anterior after polio","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the tibialis anterior after polio</div><div class=\"cntnt\"><img style=\"width:495px; height:434px;\" src=\"images/NEURO/55106_US-tibialis-anterior-polio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an image of the right and left tibialis anterior in a patient with remote polio. The image on the left shows the more severely affected muscle, with greater atrophy; note the distance from the surface to the interosseus membrane (IM), slightly greater hyperechogenicity, loss of bone edge delineation on the tibia (T), and greater loss of heterogeneity. The overall appearance of the muscle tissue, however, is similar to that seen in many myopathic disorders.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 55106 Version 4.0</div></div></div>"},"55107":{"type":"graphic_table","displayName":"VMP for multiple myeloma","title":"Bortezomib (Velcade) plus melphalan and prednisone (VMP) for multiple myeloma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bortezomib (Velcade) plus melphalan and prednisone (VMP) for multiple myeloma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 35 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Bortezomib</strong></td> <td>1.3 mg/m<sup>2</sup> SC<sup>[2] </sup>or IV*</td> <td>Given subcutaneously or as a rapid IV bolus over three to five seconds.</td> <td>Days 1, 8, 15, and 22<sup>&#916;</sup></td> </tr> <tr> <td><strong>Melphalan</strong></td> <td>9 mg/m<sup>2</sup> by mouth, daily</td> <td>Take on an empty stomach (one hour prior to, or two hours after a meal).</td> <td>Cycles 1 through 9: Days 1 through 4</td> </tr> <tr> <td><strong>Prednisone</strong></td> <td>60 mg/m<sup>2</sup> by mouth, daily</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Cycles 1 through 9: Days 1 through 4</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW or VERY LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Routine premedication is not indicated. If a hypersensitivity reaction occurs with melphalan, then neither oral nor IV melphalan should not be readministered.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Antithrombotic prophylaxis:</strong> While patients with multiple myeloma have an increased risk of thrombosis, the risk of thrombosis with the VMP regimen was 1 and 2 percent in two trials<sup>[1,3]</sup>. Routine antithrombotic prophylaxis is not warranted.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VMP. Primary prophylaxis with G-CSF not indicated (rate of severe infection 9 percent)<sup>[1]</sup>. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> The United States Prescribing Information for melphalan provides no specific recommendation for melphalan dose modification in patients with renal dysfunction<sup>[4]</sup>. Some clinicians recommend a 25 percent reduction in the initial dose of oral melphalan for patients with multiple myeloma and a serum creatinine &#62;2 mg/dL to prevent severe myelotoxicity<sup>[5]</sup>. If myelotoxicity does not occur, standard doses should be administered in the subsequent courses. Administer melphalan after hemodialysis in patients undergoing hemodialysis. No dose adjustment for melphalan is necessary in patients with hepatic insufficiency.</p> <p>No dosage adjustment for bortezomib secondary to renal insufficiency is necessary<sup>[6]</sup>. For patients undergoing hemodialysis, bortezomib should be administered after dialysis.</p> <p>Patients with moderate or severe hepatic impairment (serum bilirubin level &#62;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, with further dose modifications based upon patient tolerance. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</p> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle. A CBC should also be performed prior to the day 11 dose of bortezomib during induction therapy and day 15 dose of bortezomib during maintenance therapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Weekly assessment for peripheral neuropathy and/or neuropathic pain.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hypotension during therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> A cycle of VMP should not be started unless the ANC is &#8805;1000 cells/microL and the platelet count is &#8805;70,000/microL<sup>[6]</sup>. If prolonged grade 4 neutropenia (ANC &#60;500 cells/microL), any grade 4 thrombocytopenia (platelet count &#60;25,000/microL), or thrombocytopenia with bleeding are observed, consider a 25 percent reduction of the melphalan dose for subsequent cycles. If platelets are &#60;30,000/microL or ANC is &#60;750 cells/microL on day 15, hold bortezomib. If several doses are held, reduce bortezomib dose by one level (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup> or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>).</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neuropathy:</strong> Dose adjustment guidelines for bortezomib in patients who develop peripheral neuropathy or neuropathic pain are available<sup>[6]</sup>:</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">- Grade 1 (asymptomatic, loss of deep tendon reflexes or paresthesia without pain or loss of function)</td> <td>No action required</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">- Grade 1 (with pain) or Grade 2 (interfering function but not activities of daily living)</td> <td>Reduce to 1 mg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">- Grade 2 (with pain) or Grade 3 (interfering with activities of daily living)</td> <td>Hold until resolution, may reinitiate at 0.7 mg/m<sup>2</sup> once weekly</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">- Grade 4 (life-threatening, disabling, eg, paralysis)</td> <td>Discontinue</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other nonhematological toxicity:</strong> For grade 3 or 4 nonhematologic toxicity other than neuropathy, bortezomib should be held. Once symptoms have resolved to grade 1 or baseline, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>).</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; SC: subcutaneous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Subcutaneous administration is preferred due to a lower risk of neuropathy<SUP>[2]</SUP>.<br />Δ Some investigators administer the first cycle of bortezomib using a twice-weekly schedule, especially in patients in whom a rapid response is needed<SUP>[7]</SUP>: days 1, 4, 8, 11, 22, 25, 29, and 32 of a six week cycle, with melphalan and prednisone administered in the usual dose on days 1 through 4 of that cycle.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Palumbo A, et al. J Clin Oncol 2010; 28:5101. </LI>&#xD;&#xA;<LI>Moreau P, et al. Lancet Oncol 2011; 12:431. </LI>&#xD;&#xA;<LI>San Miguel JF, et al. N Eng J Med 2008; 359:906. </LI>&#xD;&#xA;<LI>Melphalan. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012). </LI>&#xD;&#xA;<LI>Carlson K, et al. Br J Haematol 2005; 128:631. </LI>&#xD;&#xA;<LI>Bortezomib injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012). </LI>&#xD;&#xA;<LI>Mateos MV, et al. Lancet Oncol 2010; 11:934. </LI></OL></div><div id=\"graphicVersion\">Graphic 55107 Version 19.0</div></div></div>"},"55108":{"type":"graphic_diagnosticimage","displayName":"Granulomatous lung involvement in CGD","title":"Granulomatous lung involvement in CGD","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Granulomatous lung involvement in CGD</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/ALLRG/55108_Granulomat_lung_involv_CGD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution computed tomography (HRCT) scan in a patient with chronic granulomatous disease, nonproductive cough, and pleuritic chest pain. Nodular area of consolidation in right middle lobe was persistent for several months despite antibiotic therapy. Lung biopsy revealed granulomatous inflammation. Bilateral areas of decreased vascularity and attenuation are also noted.</div><div class=\"graphic_footnotes\">CGD: chronic granulomatous disease.</div><div class=\"graphic_reference\">From: Godoy MCB, Vos PM, Cooperberg PL, et al. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. AJR Am J Roentgenol 2008; 191:1570. Reprinted with permission from: the American Journal of Roentgenology. Copyright © 2008 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 55108 Version 13.0</div></div></div>"},"55109":{"type":"graphic_table","displayName":"Clinical symptoms in antisocial personality disorder","title":"Clinical symptoms in antisocial personality disorder: Results from a cohort study of 94 patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical symptoms in antisocial personality disorder: Results from a cohort study of 94 patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Men (n = 80)*</td> <td class=\"subtitle1\">Women (n = 14)*</td> <td class=\"subtitle1\">Total (n = 94)*</td> </tr> <tr> <td>Unstable work history</td> <td>82</td> <td>100</td> <td>85</td> </tr> <tr> <td>Arrests</td> <td>81</td> <td>43</td> <td>75</td> </tr> <tr> <td>Financial dependency</td> <td>80</td> <td>71</td> <td>79</td> </tr> <tr> <td>Poor school history (including truancy)</td> <td>79</td> <td>29</td> <td>71</td> </tr> <tr> <td>Alcohol abuse/dependence</td> <td>74</td> <td>64</td> <td>72</td> </tr> <tr> <td>Marital difficulties</td> <td>71</td> <td>93</td> <td>74</td> </tr> <tr> <td>Impulsivity</td> <td>66</td> <td>71</td> <td>67</td> </tr> <tr> <td>Vagrancy</td> <td>65</td> <td>29</td> <td>60</td> </tr> <tr> <td>Belligerence</td> <td>61</td> <td>36</td> <td>58</td> </tr> <tr> <td>\"Wild\" adolescence</td> <td>60</td> <td>71</td> <td>62</td> </tr> <tr> <td>Promiscuous sexual behavior</td> <td>59</td> <td>93</td> <td>64</td> </tr> <tr> <td>Social isolation</td> <td>55</td> <td>64</td> <td>56</td> </tr> <tr> <td>Lack of remorse</td> <td>36</td> <td>64</td> <td>40</td> </tr> <tr> <td>Use of aliases</td> <td>31</td> <td>14</td> <td>29</td> </tr> <tr> <td>Somatic complaints</td> <td>30</td> <td>36</td> <td>31</td> </tr> <tr> <td>Poor military performance</td> <td>28</td> <td>-</td> <td>23</td> </tr> <tr> <td>Pathological lying</td> <td>16</td> <td>14</td> <td>16</td> </tr> <tr> <td>Drug abuse/dependence</td> <td>15</td> <td>14</td> <td>15</td> </tr> <tr> <td>Suicide attempts</td> <td>9</td> <td>21</td> <td>11</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percent of sample.</div><div class=\"graphic_reference\">Data from: Robins LN. Deviant Children Grown Up. Baltimore: Williams and Wilkins, 1966.</div><div id=\"graphicVersion\">Graphic 55109 Version 2.0</div></div></div>"},"55110":{"type":"graphic_table","displayName":"Upper extremity splints","title":"Upper extremity splints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Upper extremity splints</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Splint</td> <td class=\"subtitle1\">Indication</td> </tr> <tr> <td>Figure-of-eight splint</td> <td>Medial clavical fractures</td> </tr> <tr> <td>Sling and swathe</td> <td>Shoulder injuries, humeral injuries</td> </tr> <tr> <td>Velpeau bandage</td> <td>Shoulder injuries, humeral injuries</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Sugar tong splints</td> </tr> <tr> <td class=\"sublist1\">Proximal</td> <td class=\"sublist_other\">Humeral fractures</td> </tr> <tr> <td class=\"sublist1\">Distal </td> <td class=\"sublist_other\">Wrist fractures, distal forearm fractures</td> </tr> <tr> <td class=\"sublist1\">Double</td> <td class=\"sublist_other\">Elbow fractures, forearm fractures </td> </tr> <tr> <td class=\"sublist1\">Reverse</td> <td class=\"sublist_other\">Distal forearm fractures</td> </tr> <tr> <td>Posterior arm splint</td> <td>Stable elbow and forearm injuries</td> </tr> <tr> <td>Colles splint</td> <td>Distal forearm and wrist fractures</td> </tr> <tr> <td>Dorsal or volar splint</td> <td>Wrist fractures or injuries, fractures of second to fifth metacarpals, soft tissue injuries of the hand</td> </tr> <tr> <td>Gutter splint</td> <td>Phalangeal and metacarpal fractures</td> </tr> <tr> <td>Thumb spica splint</td> <td>Scaphoid fractures, extra-articular fractures of the thumb metacarpal, ulnar collateral ligament injuries</td> </tr> <tr> <td>Volar finger splint</td> <td>Fractures of distal phalanges and interphalangeal joints</td> </tr> <tr> <td>Bulky hand compression dressing</td> <td>Closed hand fractures</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55110 Version 2.0</div></div></div>"},"55111":{"type":"graphic_figure","displayName":"Length time bias C","title":"Length-time bias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Length-time bias</div><div class=\"cntnt\"><img style=\"width:342px; height:308px;\" src=\"images/PC/55111_LengthtimebiasC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cases that progress rapidly from onset (O) to symptoms and diagnosis (Dx) are less likely to be detected during a screening examination.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55111 Version 11.0</div></div></div>"},"55114":{"type":"graphic_picture","displayName":"Nodular lymphoid hyperplasia Low","title":"Nodular lymphoid hyperplasia in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphoid hyperplasia in Sj&#246;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:414px; height:274px;\" src=\"images/PULM/55114_Pseudolymphoma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows extensive polyclonal lymphoid infiltration of the lung.</div><div class=\"graphic_reference\">From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 55114 Version 3.0</div></div></div>"},"55115":{"type":"graphic_picture","displayName":"Eosinophils in vessel wall","title":"Eosinophils within blood vessel wall in a patient with the Churg-Strauss syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophils within blood vessel wall in a patient with the Churg-Strauss syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/RHEUM/55115_eosinophils_in_vessel_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This biopsy demonstrates the presence of eosinophils within the blood vessel wall of a patient with eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss). Although eosinophils are the hallmark of EGPA, this biopsy does not show fibrinoid necrosis of the blood vessel wall and hence is not diagnostic of vasculitis.</div><div id=\"graphicVersion\">Graphic 55115 Version 4.0</div></div></div>"},"55116":{"type":"graphic_diagnosticimage","displayName":"Acute cholecystitis US","title":"Acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:364px; height:281px;\" src=\"images/GAST/55116_Acute_cholecystitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of the right upper quadrant in a patient with acute cholecystitis reveals marked thickening of the gallbladder wall (arrow) with fluid surrounding the distended gallbladder (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 55116 Version 2.0</div></div></div>"},"55117":{"type":"graphic_movie","displayName":"Normal TM mobility","title":"Normal tympanic membrane mobility","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal tympanic membrane mobility</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55117_pneumat1conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:266px;\" src=\"images/CARD/55117_pneumat1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A normal tympanic membrane moves briskly in response to both positive and negative pressure. A good seal between the speculum and the external auditory canal is essential.</div><div class=\"graphic_reference\">Courtesy of Ellen R Wald, MD.</div><div id=\"graphicVersion\">Graphic 55117 Version 2.0</div></div></div>"},"55118":{"type":"graphic_picture","displayName":"Local anesthetic block of the lateral femoral cutaneous nerve","title":"Local anesthetic block of the lateral femoral cutaneous nerve","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Local anesthetic block of the lateral femoral cutaneous nerve</div><div class=\"cntnt\"><img style=\"width:512px; height:293px;\" src=\"images/NEURO/55118_Anesthetic_block_meralgia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A local anesthetic block is placed over the lateral femoral cutaneous nerve to distinguish meralgia paresthetica from referred pain from the lumbosacral roots. The patient is placed in a supine position. A 1.5 in (4 cm), 22-gauge needle is inserted perpendicular to the skin, 2.5 cm (1 in)&nbsp;medial and 2.5 cm (1 in) inferior to the anterior superior iliac spine. The depth of injection is&nbsp;1.3 to 3.8 cm (0.5 to 1.5&nbsp;in) to the subcutaneous fat/fascial interface.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55118 Version 2.0</div></div></div>"},"55119":{"type":"graphic_waveform","displayName":"ECG digoxin toxicity in AF 3","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation with further accelerated junctional pacemaker","html":"<div class=\"graphic normal\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial fibrillation with further accelerated junctional pacemaker</div><div class=\"cntnt\"><img style=\"width:537px; height:131px;\" src=\"images/CARD/55119_Digitalis_toxicity_in_AF_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.<br />In this strip, the R-R intervals remain constant with further acceleration of the junctional pacemaker to a rate of 142 beats per minute.</div><div class=\"graphic_reference\">The four electrocardiograms are adapted from: Childers R, Med Clin North Am 1976; 60:3.</div><div id=\"graphicVersion\">Graphic 55119 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"55120":{"type":"graphic_table","displayName":"Prostate CA mortality by PSA DT","title":"Prostate cancer-specific mortality after prostatectomy or radiation therapy: influence of PSA doubling time","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prostate cancer-specific mortality after prostatectomy or radiation therapy: influence of PSA doubling time</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Prostate\ncancer-specific survival</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">PSA-DT &#60;3 mos</td>\n\n      <td class=\"subtitle2\">PSA-DT &#8805;3\nmos</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">3 years</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Surgery</td>\n\n      <td>84.1</td>\n\n      <td>99.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation</td>\n\n      <td>79.1</td>\n\n      <td>99.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">5 years</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Surgery</td>\n\n      <td>68.8</td>\n\n      <td>99.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation</td>\n\n      <td>61.6</td>\n\n      <td>96.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">8 years</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Surgery</td>\n\n      <td>51.5</td>\n\n      <td>98.9</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Radiation</td>\n\n      <td>41.6</td>\n\n      <td>87.6</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PSA-DT: prostate specific antigen-doubling time.</div><div class=\"graphic_reference\">Data from: D'Amico, AV, Moul, JW, Carroll, PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95:1376.</div><div id=\"graphicVersion\">Graphic 55120 Version 1.0</div></div></div>"},"55121":{"type":"graphic_figure","displayName":"Normal ear anatomy PI","title":"Normal ear","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Normal ear</div><div class=\"cntnt\"><img style=\"width:544px; height:505px;\" src=\"images/PI/55121_Normal_ear_anat_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the normal parts of the outer, middle, and inner ear.</div><div id=\"graphicVersion\">Graphic 55121 Version 4.0</div></div></div>"},"55123":{"type":"graphic_table","displayName":"Clinical features of preseptal and orbital cellulitis","title":"Clinical features of preseptal and orbital cellulitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of preseptal and orbital cellulitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Preseptal cellulitis</td> <td class=\"subtitle1\">Orbital cellulitis</td> </tr> <tr> <td>Eyelid swelling with or without erythema</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Eye pain/tenderness</td> <td>May be present</td> <td>Yes; may cause deep eye pain</td> </tr> <tr> <td>Pain with eye movements</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Proptosis</td> <td>No</td> <td>Usually, but may be subtle</td> </tr> <tr> <td>Ophthalmoplegia +/- diplopia</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Vision impairment</td> <td>No</td> <td>May be present*</td> </tr> <tr> <td>Chemosis</td> <td>Rarely present</td> <td>May be present</td> </tr> <tr> <td>Fever</td> <td>May be present</td> <td>Usually present</td> </tr> <tr> <td>Leukocytosis</td> <td>May be present</td> <td>May be present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* An afferent pupillary defect may signal impending visual loss.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566. </li>&#xD;&#xA;    <li>Durand ML. Periocular infections. In: Principles and Practice of Infectious Diseases, 7th ed, Mandell GL, Bennett, et al. (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.1569. </li>&#xD;&#xA;    <li>Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337. </li>&#xD;&#xA;    <li>Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377. </li>&#xD;&#xA;    <li>Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695. </li>&#xD;&#xA;    <li>Sobol SE, Marchand J, Tewfik TL, et al. Orbital complications of sinusitis in children. J Otolaryngol 2002; 31:131. </li>&#xD;&#xA;    <li>Givner LB. Periorbital versus orbital cellulitis. Pediatr Infect Dis J 2002; 21:1157. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55123 Version 3.0</div></div></div>"},"55124":{"type":"graphic_figure","displayName":"Methanol metabolism","title":"Methanol metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Methanol metabolism</div><div class=\"cntnt\"><img style=\"width:239px; height:425px;\" src=\"images/EM/55124_Methanol_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Blocked by ethanol and fomepizole.</div><div id=\"graphicVersion\">Graphic 55124 Version 1.0</div></div></div>"},"55126":{"type":"graphic_table","displayName":"Clinical manifestations of zinc deficiency","title":"Clinical manifestations of zinc deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of zinc deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Abdominal pain</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Alopecia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anorexia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Blepharitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Corneal opacities</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Delayed wound healing</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Depression</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dermatitis (especially around mouth and anus)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Diarrhea</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dysarthria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dysgeusia (impaired taste)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fever</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Glossitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Growth retardation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hypogonadism</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Immune dysfunction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Impaired concentration</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Intention tremor</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Nervousness</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Night blindness</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Nystagmus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Paronychia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pica</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Stomatitis</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from: Goldschmid S, Graham M. Trace element deficiencies in inflammatory bowel disease.&nbsp;Gastroenterol Clin N Am 1989; 18:579.</div><div id=\"graphicVersion\">Graphic 55126 Version 5.0</div></div></div>"},"55127":{"type":"graphic_figure","displayName":"Erythroid maturation sequence","title":"Erythroid maturation","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Erythroid maturation</div><div class=\"cntnt\"><img style=\"width:451px; height:430px;\" src=\"images/HEME/55127_Erythroid_maturation_sequen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proerythroblast, the first identifiable erythroid precursor, has a diameter of 14 to 19 &#181;M, a large, oval homogenously-staining nucleus, indistinct nucleoli, and darkly basophilic cytoplasm. The basophilic normoblast is 12 to 17 &#181;M in diameter with basophilic cytoplasm, and coarsening and prominent clumping of the nuclear chromatin (spoked wheel or cartwheel appearance). Nucleoli are generally not seen. Accumulation of hemoglobin is seen in the polychromatic normoblast by the presence of less basophilic and muddy gray cytoplasm. The last nucleated RBC precursor, the orthochromatic normoblast approaches the diameter of a reticulocyte (8 to 12 &#181;M); the eosinophilic staining cytoplasm contains nearly a full amount of hemoglobin, with a condensed pyknotic nucleus. Extrusion of the nucleus results in the reticulocyte (not shown), a cell slightly larger than a fully mature erythrocyte. The reticulocyte has a fine granular or reticular network of ribosomal RNA observed with supravital stains, such as cresyl blue or methylene blue. Such cells are present in small quantities in the peripheral blood of normal persons (1 to 2 percent), but are increased in response to stress on the erythroid lineage (eg, hemolysis, blood loss, hypoxia).</div><div id=\"graphicVersion\">Graphic 55127 Version 1.0</div></div></div>"},"55130":{"type":"graphic_picture","displayName":"Passive stretch tenosynovitis","title":"Passive stretching sign for active tenosynovitis of the finger (trigger finger)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passive stretching sign for active tenosynovitis of the finger (trigger finger)</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/RHEUM/55130_Passive_stretch_tenosynovit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hands are placed in the palms-up position, and the affected finger is passively stretched in the extended position.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55130 Version 4.0</div></div></div>"},"55131":{"type":"graphic_picture","displayName":"Walk up wall stretch","title":"Walk up wall stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Walk up wall stretch</div><div class=\"cntnt\"><img style=\"width:264px; height:385px;\" src=\"images/RHEUM/55131_Walk_up_wall_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Face a wall about three-quarters of an arm length away from it. Using only your fingers (not your shoulder muscles), raise your arm up to shoulder level. Perform sets of 10 to 20 exercises at each session.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55131 Version 4.0</div></div></div>"},"55132":{"type":"graphic_figure","displayName":"Pressure controlled IRV","title":"Pressure controlled inverse ratio ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure controlled inverse ratio ventilation</div><div class=\"cntnt\"><img style=\"width:383px; height:221px;\" src=\"images/PULM/55132_Pressure_controlled_IRV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of flow and airway pressure characteristics during a pressure limited breath provided by pressure-controlled inverse ratio ventilation (PC-IRV). End-expiratory alveolar pressure is positive at the end of the shortened expiratory period. Airflow has not ceased, and auto-PEEP has developed. A pressure limited breath without inverse ratio ventilation has similar pressure and flow characteristics except that flow has ceased at the end of expiration, and there is no auto-PEEP present.</div><div class=\"graphic_reference\">Redrawn from Marcy, TW, Marini, JJ, Chest 1991; 100:494.</div><div id=\"graphicVersion\">Graphic 55132 Version 1.0</div></div></div>"},"55135":{"type":"graphic_table","displayName":"Gene polymorphism effects","title":"Gene polymorphism effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gene polymorphism effects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gene/polymorphism</td> <td class=\"subtitle1\">Effect/association</td> <td class=\"subtitle1\">Theoretical mechanism</td> <td class=\"subtitle1\">Ref.</td> </tr> <tr> <td><span class=\"highlight\">LTA</span>&nbsp;+ 80</td> <td>Parasitemia reduction</td> <td>Lymphotoxin production</td> <td>[1]</td> </tr> <tr> <td>GNAS</td> <td>Severe malaria</td> <td>Red cell signaling; invasion inhibition</td> <td>[2]</td> </tr> <tr> <td>iNOS</td> <td>Severe malaria</td> <td>Decreased iNOS</td> <td>[3]</td> </tr> <tr> <td>Pyruvate kinase</td> <td>Infection</td> <td>Unknown</td> <td>[4]</td> </tr> <tr> <td>ABO glycosyltransferase</td> <td>Severe malaria anemia</td> <td>Decreased resetting of red blood cells</td> <td>[5]</td> </tr> <tr> <td>Toll-like receptors (TLR-1, -6, and -9)</td> <td>Malaria and high parasitemia</td> <td>Innate immunity</td> <td>[6]</td> </tr> <tr> <td>FLT1</td> <td>Placental malaria</td> <td>Unknown</td> <td>[7]</td> </tr> <tr> <td>TIM1</td> <td>Cerebral malaria</td> <td>Induction of Th2 antiinflammatory responses</td> <td>[8]</td> </tr> <tr> <td>IL-10</td> <td>Severe malaria anemia</td> <td>Antiinflammatory activity of enhanced IL-10 production</td> <td>[9]</td> </tr> <tr> <td>CR-1 (promoter)</td> <td>Cerebral malaria</td> <td>Increased clearance of infected cells</td> <td>[10,11]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LTA: lymphotoxin-alpha; iNOS: inducible nitric oxide synthase; IL: interleukin; CR: complement receptor.</div><div class=\"graphic_reference\">1. &nbsp;Barbier M, et al. Family-based association of a low producing lymphotoxin-alpha allele with reduced Plasmodium falciparum parasitemia. Microbes Infect 2008; 10:673.<br />2. &nbsp;Auburn S, et al. Association of the GNAS locus with severe malaria. Human Genetics 2008; 124:499.<br />3. &nbsp;Dhangadamajhi G, et al. The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection. Parasitology Research.<br />4. &nbsp;Durand PM, Coetzer TM. Pyruvate kinase deficiency protects against malaria in humans. Haematologica 2008; 93:939.<br />5. &nbsp;Fry AE, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 2008; 17:567.<br />6. &nbsp;Leoratti FM, et al. Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria. J Infect Dis 2008; 198:772.<br />7. &nbsp;Muehlenbachs A, et al. Natural selection of FLT1 alleles and their association with malaria resistance in utero. Proc Natl Acad Sci U S A 2008; 105:14488.<br />8. &nbsp;Nuchnoi P, et al. Significant Association Between TIM1 Promoter Polymorphisms and Protection Against Cerebral malaria in Thailand. Annals of Human Genetics 2008; 72:327.<br />9. &nbsp;Ouma C, et al. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 2008; 124:515.<br />10. Cockburn IA, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A 2004; 101:272.<br />11. Teeranaipong P, et al. A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. J Infect Dis 2008; 198:1880.</div><div id=\"graphicVersion\">Graphic 55135 Version 2.0</div></div></div>"},"55136":{"type":"graphic_movie","displayName":"Mitral stenosis as heard at the apex","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55136_msapexconv.mp4\" style=\"width:516px;height:464px\"></div><img style=\"width:508px; height:279px;\" src=\"images/CARD/55136_msapex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of mitral stenosis as heard at the apex. A pre-systolic murmur or rumble of mitral stenosis precedes S1, a result of increased blood flow from atrial contraction. Following S2 (closure of the aortic and pulmonic valves) is the opening of the stenotic mitral valve (snap) and the low pitch mid diastolic murmur or rumble of mitral stenosis.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 55136 Version 3.0</div></div></div>"},"55138":{"type":"graphic_picture","displayName":"Radinduced angiosarc chest","title":"Radiation-induced angiosarcoma on chest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation-induced angiosarcoma on chest</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/ONC/55138_Radinduced_angiosarc_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A multiple skin lesions on right chest wall with edema and modest discoloration. Biopsy findings revealed radiation-induced angiosarcoma.</div><div id=\"graphicVersion\">Graphic 55138 Version 4.0</div></div></div>"},"55139":{"type":"graphic_table","displayName":"HBV immunoprophylaxis for infants with BW less than 2 kg","title":"Recommended schedule of hepatitis B immunoprophylaxis for preterm infants with birth weight <2 kg","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended schedule of hepatitis B immunoprophylaxis for preterm infants with birth weight &lt;2 kg</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal HBsAg status</td> <td class=\"subtitle1\" colspan=\"2\">Single antigen vaccine*</td> <td class=\"subtitle1\" colspan=\"2\">Single antigen&nbsp;plus combination vaccine*</td> </tr> <tr> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Age</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Age</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Positive<sup>&#182;</sup></td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> </tr> <tr> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)</td> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)</td> </tr> <tr> <td>2</td> <td>1 month*</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>2 to 3 months</td> <td>3</td> <td>4 months</td> </tr> <tr class=\"divider_bottom\"> <td>4</td> <td>6 months<sup>&#9674;</sup><sup>&#167;</sup></td> <td>4</td> <td>6 months<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Unknown</td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> <td>1</td> <td>Birth (&#8804;12 hours)*</td> </tr> <tr> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)*</td> <td>HBIG<sup>&#916;</sup></td> <td>Birth (&#8804;12 hours)</td> </tr> <tr> <td>2</td> <td>1 month*</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>2 to 3 months</td> <td>3</td> <td>4 months</td> </tr> <tr class=\"divider_bottom\"> <td>4</td> <td>6 months<sup>&#9674;</sup></td> <td>4</td> <td>6 months<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"4\">Negative</td> <td>1</td> <td>Hospital discharge or age 1 month*</td> <td>1</td> <td>Hospital discharge or age 1 month*</td> </tr> <tr> <td>2</td> <td>2 months</td> <td>2</td> <td>2 months</td> </tr> <tr> <td>3</td> <td>6 to 18 months<sup>&#9674;</sup></td> <td>3</td> <td>4 months</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>6 months<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immune globulin; anti-HBs: antibody to HBsAg.<br />* Single-antigen vaccines (ie, Recombivax HB or Engerix-B) should be used for the birth dose. Combination vaccines (eg, Pediarix) cannot be administered at birth or before age 6 weeks.<br />¶ Infants born to HBsAg-positive mothers should receive immunoprophylaxis as recommended whether or not their mother received antiviral therapy during the third trimester.<br />Δ HBIG (0.5 mL) administered intramuscularly at a separate site (ie, different leg) from vaccine.<br /><FONT class=lozenge>◊</FONT> The final dose in the vaccine series should not be administered before age 24 weeks (164 days).<br />§ These infants should be tested for anti-HBs and HBsAg at age 9 to 12 months or&nbsp;one to&nbsp;two months after the last dose of hepatitis B vaccine. Testing should not be performed before age 9 months nor within&nbsp;four weeks of the most recent vaccine dose.</div><div class=\"graphic_reference\">Adapted from: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.</div><div id=\"graphicVersion\">Graphic 55139 Version 12.0</div></div></div>"},"55141":{"type":"graphic_picture","displayName":"Guttate psoriasis 1","title":"Guttate psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Guttate psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55141_Guttate_psoriasis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous, scaly papules are present in this patient with guttate psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55141 Version 4.0</div></div></div>"},"55142":{"type":"graphic_picture","displayName":"McGrath video laryngoscope","title":"McGrath","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">McGrath</div><div class=\"cntnt\"><img style=\"width:284px; height:504px;\" src=\"images/EM/55142_McGrath_video_laryngoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aircraft Medical. Copyright ©2008 Aircraft Medical.</div><div id=\"graphicVersion\">Graphic 55142 Version 4.0</div></div></div>"},"55144":{"type":"graphic_table","displayName":"Fibrinogen disorders","title":"Classification of fibrinogen disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of fibrinogen disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Quantitative abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Afibrinogenemia (uncommon, autosomal recessive)</td> </tr> <tr> <td class=\"indent1\">Hypofibrinogenemia (autosomal dominant)</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Hypofibrinogenemia (eg, liver disease, consumptive coagulopathies such as disseminated intravascular coagulation)</td> </tr> <tr> <td class=\"indent1\">Hyperfibrinogenemia (eg, inflammation, neoplasia, pregnancy)</td> </tr> <tr> <td class=\"indent1\">Medications (eg, fibrinolytic agents, L-asparaginase, valproic acid)</td> </tr> <tr> <td class=\"subtitle1_single\">Qualitative abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Dysfibrinogenemia (autosomal dominant)</td> </tr> <tr> <td class=\"indent1\">Hypodysfibrinogenemia (autosomal dominant)</td> </tr> <tr> <td class=\"subtitle2_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Malignancies (eg, renal carcinoma, hepatoma)</td> </tr> <tr> <td class=\"indent1\">Antifibrinogen antibodies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for details of the pathophysiology, clinical manifestations, diagnosis, and management of fibrinogen disorders.</div><div id=\"graphicVersion\">Graphic 55144 Version 6.0</div></div></div>"},"55146":{"type":"graphic_figure","displayName":"UPJ obstruction schematic drawing","title":"Ureteropelvic junction obstruction (UPJ)","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Ureteropelvic junction obstruction (UPJ)</div><div class=\"cntnt\"><img style=\"width:452px; height:558px;\" src=\"images/PEDS/55146_UPJobstructionschema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of ureteropelvic obstruction that demonstrates the location of a functional or anatomical abnormality resulting in renal pelvic dilatation.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55146 Version 12.0</div></div></div>"},"55147":{"type":"graphic_picture","displayName":"Palpation of the elbow medial epicondyle","title":"Palpation of the elbow medial epicondyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the elbow medial epicondyle</div><div class=\"cntnt\"><img style=\"width:432px; height:382px;\" src=\"images/EM/55147_Palpation_medial_epicondyle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial epicondyle is palpated for tenderness with the elbow flexed at 90 degrees. Local tenderness is a hallmark feature of medial epicondylitis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55147 Version 4.0</div></div></div>"},"55148":{"type":"graphic_figure","displayName":"Tumor bronchus relationships","title":"Schematic representations of tumor-bronchus relationships","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representations of tumor-bronchus relationships</div><div class=\"cntnt\"><img style=\"width:382px; height:211px;\" src=\"images/PULM/55148_Tumor_bronchus_relationship.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research- Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 55148 Version 1.0</div></div></div>"},"55149":{"type":"graphic_figure","displayName":"Posterior approach to open repair of popliteal aneurysm","title":"Posterior approach to open repair of popliteal aneurysm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Posterior approach to open repair of popliteal aneurysm</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/55149_Pop_repair_post.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right lower extremity popliteal artery aneursym repair: With the posterior approach, a vein or prosthetic graft is used to reconstruct the popliteal artery. A ‘lazy’ S-shaped incision is started superior and medial to the popliteal fossa&nbsp;and carried&nbsp;inferiorly and laterally to minimize problems with scar contracture (A). After gaining vascular control, the popliteal artery is&nbsp;opened and the graft sutured to normal artery proximally and distally (B). Upon completion of the repair, the aneurysm sac is closed over the repair, provided enough arterial wall remains (similar to other aneurysm repairs) (C).</div><div id=\"graphicVersion\">Graphic 55149 Version 3.0</div></div></div>"},"55150":{"type":"graphic_diagnosticimage","displayName":"Osteochondroma knee Xray","title":"Osteochondroma of the distal femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondroma of the distal femur</div><div class=\"cntnt\"><img style=\"width:248px; height:432px;\" src=\"images/RHEUM/55150_Osteochondroma_knee_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal radiograph of the knee demonstrates a metaphyseal femoral pedunculated bone lesion, oriented away from the joint, consistent with an osteochondroma (arrow).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 55150 Version 2.0</div></div></div>"},"55154":{"type":"graphic_movie","displayName":"Parasternal long axis color Doppler aortic valve endocarditis ","title":"Parasternal long axis echocardiogram with color Doppler showing aortic valve endocarditis with severe aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram with color Doppler showing aortic valve endocarditis with severe aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55154_laxcdaveconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:241px; height:443px;\" src=\"images/CARD/55154_laxcdave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from a&nbsp;two-dimensional (2D)&nbsp;echocardiogram shows marked left ventricular dilatation and severe aortic regurgitation resulting from aortic valve endocarditis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 55154 Version 5.0</div></div></div>"},"55155":{"type":"graphic_table","displayName":"E coli adhesins","title":"Escherichia coli virulence factors: Adhesins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Escherichia coli virulence factors: Adhesins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Bacterial structure</td> <td class=\"subtitle1\" colspan=\"2\">Cellular receptor</td> </tr> <tr> <td class=\"subtitle2\">Adhesin</td> <td class=\"subtitle2\">Pilin (fimbria)</td> <td class=\"subtitle2\">Operon</td> <td class=\"subtitle2\">Biochemical nature</td> <td class=\"subtitle2\">Hemagglutination</td> </tr> <tr> <td>PAP G</td> <td>P fimbriae</td> <td>pap</td> <td>Alpha-D-gal-(1-4)-beta-D-gal</td> <td>Human P blood group</td> </tr> <tr> <td>SFA</td> <td>S fimbriae</td> <td>sfa</td> <td>Alpha-sialyl-(2-3)-beta-gal</td> <td>Human and bovine erythrocytes</td> </tr> <tr> <td>AFA</td> <td>Not associated with fimbriae</td> <td>afa</td> <td>Decay accelerating factor + unknown</td> <td>Human erythrocytes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Characteristics of different adhesins expressed by strains of Escherichia coli that are uropathogenic.</div><div class=\"graphic_reference\">Adapted from: Archambaud M, Courcoux P, Labigne-Roussel A, Ann Inst Pasteur/Microbiol 1988; 139:575, and from Le Bouguenec C, Lalioui L, du Merle L et al. Characterization of AfAE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. J Clin Microbiol 2001; 39:1738.</div><div id=\"graphicVersion\">Graphic 55155 Version 2.0</div></div></div>"},"55156":{"type":"graphic_table","displayName":"Criteria for outpatient management of PPROM","title":"Suggested criteria for home management of women with PPROM","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested criteria for home management of women with PPROM</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Reliable patient</td> </tr> <tr> <td>Dependable transportation and telephone service</td> </tr> <tr> <td>Lives near hospital</td> </tr> <tr> <td>Evaluation in hospital for 72 hours before discharge home</td> </tr> <tr> <td>Patient to check her pulse and temperature every 6 hours and notify clinician if temperature &#62;98.6<span style=\"font-size: 13px; font-family: Verdana;\">&#176;</span>F (37<span style=\"font-size: 13px; font-family: Verdana;\">&#176;</span>C) or pulse &#62;100 beats/minute</td> </tr> <tr> <td>Fetal kick counts daily and notify clinician if fewer than 10 fetal movements in a 2-hour period</td> </tr> <tr> <td>Nonstress test and complete blood count twice a week</td> </tr> <tr> <td>Weekly ultrasound</td> </tr> <tr> <td>Cephalic presentation</td> </tr> <tr> <td>No evidence of infection or labor</td> </tr> <tr> <td>Presence of a vertical amniotic fluid pocket &#62;2 cm on ultrasound</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&nbsp;Bartfield MC, Carlan SJ. The home management of preterm premature ruptured membranes. Clin Obstet Gynecol 1998; 41:503.</div><div id=\"graphicVersion\">Graphic 55156 Version 6.0</div></div></div>"},"55159":{"type":"graphic_table","displayName":"The localization of abducens nerve lesions","title":"The localization of abducens nerve lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The localization of abducens nerve lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Structure involved</td> <td class=\"subtitle1\">Clinical presentation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nuclear lesions</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Abducens nucleus</td> <td>Horizontal gaze palsy</td> </tr> <tr> <td>M&#246;bius syndrome (gaze palsy with facial diplegia)</td> </tr> <tr> <td>Duane retraction syndrome (gaze palsy with globe retraction and narrowing of palpebral fissure with adduction)</td> </tr> <tr> <td class=\"indent1\">Dorsolateral pons</td> <td>Foville syndrome (ipsilateral gaze palsy, facial paresis, dysmetria occasionally with contralateral hemiparesis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lesions of the abducens fascicle</td> </tr> <tr> <td class=\"indent1\">Abducens fascicle</td> <td>Isolated CN VI palsy</td> </tr> <tr> <td class=\"indent1\">Anterior paramedial pons</td> <td>Ipsilateral CN VI palsy, ipsilateral CN VII palsy, contralateral hemiparesis (Millard-Gubler)</td> </tr> <tr> <td class=\"indent1\">Prepontine cistern</td> <td>May have contralateral hemiparesis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lesion of abducens nerve (subarachnoid, petrous)</td> </tr> <tr> <td class=\"indent1\">Petrous apex (Dorello canal)</td> <td>CN VI palsy, deafness, facial (especially retroorbital) pain (Gradenigo)</td> </tr> <tr> <td><strong>Cavernous sinus</strong></td> <td>Isolated CN VI palsy; CN VI palsy plus Horner syndrome; also may affect CN III, IV, V1</td> </tr> <tr> <td><strong>Superior orbital fissure syndrome</strong></td> <td>CN VI palsy with varible affection of CN III, IV, V1; proptosis</td> </tr> <tr> <td><strong>Orbit</strong></td> <td>CN VI palsy; visual loss; variable proptosis, chemosis, lid swelling</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Brazis PW, Masdeu JC, Biller J. Localization in Clinical Neurology, Fourth Edition. Lippincott Williams &amp; Wilkins, 2001.</div><div id=\"graphicVersion\">Graphic 55159 Version 2.0</div></div></div>"},"55160":{"type":"graphic_picture","displayName":"Invasion of inflammatory cells into center of myofiber in IBM","title":"Invasion of inflammatory cells into center of myofiber in IBM","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Invasion of inflammatory cells into center of myofiber in IBM</div><div class=\"cntnt\"><img style=\"width:480px; height:348px;\" src=\"images/RHEUM/55160_Invasion_inflam_IBM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep invasion of inflammatory cells into the center of a non-necrotic myofiber in inclusion body myositis.</div><div class=\"graphic_reference\">Courtesy of Steven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 55160 Version 1.0</div></div></div>"},"55162":{"type":"graphic_figure","displayName":"Control of gastric motility","title":"Control of gastric motility","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Control of gastric motility</div><div class=\"cntnt\"><img style=\"width:481px; height:278px;\" src=\"images/GAST/55162_Control_of_gastric_motility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The motor function of the gut is controlled at three main levels: extrinsic neural control (vagal and sympathetic); intrinsic neural control; and excitability of smooth muscle cells controlled by transmitters.</div><div class=\"graphic_reference\">Adapted from: Camilleri M, Prather CM. In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia 1998. p.572.</div><div id=\"graphicVersion\">Graphic 55162 Version 4.0</div></div></div>"},"55164":{"type":"graphic_picture","displayName":"PUPPP hives and plaques","title":"PUPPP hives and plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PUPPP hives and plaques</div><div class=\"cntnt\"><img style=\"width:392px; height:258px;\" src=\"images/ALLRG/55164_PUPPP_hives_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PUPPP: pruritic urticarial papules and plaques of pregnancy.</div><div id=\"graphicVersion\">Graphic 55164 Version 5.0</div></div></div>"},"55165":{"type":"graphic_figure","displayName":"Cytotoxicity assays I","title":"Flow cytometry based cytotoxicity assay","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Flow cytometry based cytotoxicity assay</div><div class=\"cntnt\"><img style=\"width:514px; height:544px;\" src=\"images/ALLRG/55165_Cytotoxicity_assays_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target cells (K562 cell line) are fluorescently labeled and incubated with increasing ratios of individual's peripheral blood mononuclear cells&nbsp;(PBMCs). Cytotoxicity is measured by staining of the labeled target cells with 7-AAD, an indicator of cell death, and cell size which decreases upon apoptosis.</div><div class=\"graphic_footnotes\">HLH: hemophagocytic lymphohistiocytosis; %: percent; 7-AAD: 7-aminoactinomycin D.</div><div id=\"graphicVersion\">Graphic 55165 Version 2.0</div></div></div>"},"55168":{"type":"graphic_diagnosticimage","displayName":"Idiopathic pulm fibrosis PA I","title":"Idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:349px; height:347px;\" src=\"images/PULM/55168_Idiopathic_pulm_fibrosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows fine, partially confluent small reticular opacities with small lung volumes, due to longstanding disease and restrictive physiology.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55168 Version 3.0</div></div></div>"},"55169":{"type":"graphic_figure","displayName":"Spigelian hernia 4","title":"Spigelian hernia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Spigelian hernia</div><div class=\"cntnt\"><img style=\"width:590px; height:287px;\" src=\"images/SURG/55169_Spigelian_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spigelian hernia. A) Usual site of occurrence. B) Transverse section of abdominal wall showing site of defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55169 Version 1.0</div></div></div>"},"55170":{"type":"graphic_table","displayName":"B virus postexposure ppx","title":"Recommendations for postexposure prophylaxis for persons exposed to B virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for postexposure prophylaxis for persons exposed to B virus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Prophylaxis recommended</td> </tr> <tr> <td>Skin exposure* (with loss of skin integrity) or mucosal exposure (with or without injury) to a high-risk source (eg, a macaque that is ill, immunocompromised, or known to be shedding virus or that has lesions compatible with B virus disease)</td> </tr> <tr> <td>Inadequately cleaned skin exposure (with loss of skin integrity) or mucosal exposure (with or without injury)</td> </tr> <tr> <td>Laceration of the head, neck, or torso</td> </tr> <tr> <td>Deep puncture bite</td> </tr> <tr> <td>Needlestick associated with tissue or fluid from the nervous system, lesions suspicious for B virus, eyelids, or mucosa</td> </tr> <tr> <td>Puncture or laceration after exposure to objects (a) contaminated either with fluid from monkey oral or genital lesions or with nervous system tissues or (b) known to contain B virus</td> </tr> <tr> <td>A postcleansing culture is positive for B virus</td> </tr> <tr> <td class=\"subtitle1_single\">Prophylaxis considered</td> </tr> <tr> <td>Mucosal splash that has been adequately cleaned</td> </tr> <tr> <td>Laceration (with loss of skin integrity) that has been adequately cleaned</td> </tr> <tr> <td>Needlestick involving blood from an ill or immunocompromised macaque</td> </tr> <tr> <td>Puncture or laceration occurring after exposure to (a) objects contaminated with body fluid (other than that from a lesion) or (b) potentially infected cell culture</td> </tr> <tr> <td class=\"subtitle1_single\">Prophylaxis not recommended</td> </tr> <tr> <td>Skin exposure in which the skin remains intact</td> </tr> <tr> <td>Exposure associated with nonmacaque species of nonhuman primates</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Exposures include macaque bites; macaque scratches; or contact with ocular, oral, or genital secretions, nervous system tissue, or material contaminated by macaques (eg, cages or equipment).</div><div class=\"graphic_reference\">Reproduced with permission from: Cohen JI, Davenport DS, Stewart JA, et al. Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine Herpesvirus 1). Clin Infect Dis 2002; 35:1191. Copyright © 2002 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 55170 Version 2.0</div></div></div>"},"55176":{"type":"graphic_picture","displayName":"Parallelogram mastectomy","title":"Parallelogram mastectomy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Parallelogram mastectomy</div><div class=\"cntnt\"><img style=\"width:463px; height:692px;\" src=\"images/SURG/55176_Parallelogrammastect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parallelogram partial mastectomy, upper pole cancer preoperative, and intraoperative images.<br> (A) Preoperative target marking and placement of parallelogram.<br> (B) Intraoperative marking with patient in supine position.<br> (C) Initial skin incision revealing wide exposure over target lesion.<br> (D) Full-thickness dissection posteriorly to chest wall to facilitate delivery of target lesion.<br> (E) Inked resected specimen.<br> (F) Deep ﬁbroglandular closure using mastopexy advancement technique to close breast tissue over exposed muscle.<br> (G) Final wound closure.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55176 Version 7.0</div></div></div>"},"55178":{"type":"graphic_diagnosticimage","displayName":"Colorectal lymphoma barium enema","title":"Non-Hodgkin's lymphoma of the colon and terminal ileum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-Hodgkin's lymphoma of the colon and terminal ileum</div><div class=\"cntnt\"><img style=\"width:220px; height:239px;\" src=\"images/GAST/55178_Colorectal_lymphoma_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-evacuation film from a barium enema shows diffuse nodularity of the ileum and entire colon. Histology was consistent with a non-Hodgkin's lymphoma.</div><div id=\"graphicVersion\">Graphic 55178 Version 3.0</div></div></div>"},"55180":{"type":"graphic_figure","displayName":"X-linked recessive--pedigree","title":"Example of a pedigree showing X-linked recessive inheritance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing X-linked recessive inheritance</div><div class=\"cntnt\"><img style=\"width:444px; height:242px;\" src=\"images/PC/55180_X-linked_recessive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">X-linked recessive. Features of X-linked recessive inheritance seen here include: male-affected status&nbsp;bias, lack of father-son transmission; 50% affected status rate among sons of female carriers.</div><div id=\"graphicVersion\">Graphic 55180 Version 6.0</div></div></div>"},"55183":{"type":"graphic_picture","displayName":"Parathyroid adenoma","title":"Parathyroid adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parathyroid adenoma</div><div class=\"cntnt\"><img style=\"width:391px; height:391px;\" src=\"images/SURG/55183_Parathyroid_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parathyroid adenoma.<br />(A) External (top) and cross-section views (bottom) show a tan, fleshy tumor.<br />(B) The tumor consists of sheets of neoplastic chief cells and is separated from normal parenchyma by a thin capsule.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin, R, Strayer, DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55183 Version 3.0</div></div></div>"},"55184":{"type":"graphic_figure","displayName":"Dissection for occult left parathyroid gland","title":"Dissection for occult left parathyroid gland","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Dissection for occult left parathyroid gland</div><div class=\"cntnt\"><img style=\"width:539px; height:328px;\" src=\"images/SURG/55184_Path of dissection for occult left parathyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the cross-sectional anatomy at the second tracheal ring. The dotted line corresponds to the lateral approach for a reoperative case, exposing the prevertebral fascia behind the carotid sheath.</div><div id=\"graphicVersion\">Graphic 55184 Version 3.0</div></div></div>"},"55185":{"type":"graphic_figure","displayName":"Component separation technique rectus muscle elevation","title":"Component separation technique rectus muscle elevation","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Component separation technique rectus muscle elevation</div><div class=\"cntnt\"><img style=\"width:453px; height:259px;\" src=\"images/SURG/55185_CST-rectus-muscle-elevation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When additional advancement is needed while performing the component separation technique, the rectus muscle can be elevated from the posterior sheath in its entirety. The anterior rectus fascia remains intact.</div><div class=\"graphic_reference\">Nguyen, VT, and Shestak, KC. Separation of anatomic components method of abdominal wall reconstruction--clinical outcome analysis and an update of surgical modifications using the technique. Clin Plast Surg. 2006; 33:247.</div><div id=\"graphicVersion\">Graphic 55185 Version 5.0</div></div></div>"},"55186":{"type":"graphic_figure","displayName":"Derivation great vessels","title":"Origin of great vessels and ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Origin of great vessels and ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:424px; height:379px;\" src=\"images/CARD/55186_Derivation_great_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the morphologic derivation of proximal pulmonary and aortic vessels at birth. The main pulmonary artery (MPA) comes from the fused ventral VI<SUP>th</SUP> arterial arch (FV-VI) while the right (RPA) and left pulmonary arteries (LPA) come from the right (RV-VI) and left ventral VI<SUP>th</SUP> arterial arches (LV-VI). The ascending aorta (AAo) and right brachiocephalic artery (RBCA) are derived from the right ventral IV<SUP>th</SUP> arterial arch (RV-IV), while the aortic arch (Ao arch) comes from the left ventral IV<SUP>th</SUP> arterial arch (LV-IV). The ductus arteriosus (DA) is derived from the left dorsal VI<SUP>th </SUP>arch (LD-VI).</div><div class=\"graphic_footnotes\">LSA: left subclavian artery; LCA: left carotid artery; RSA: right subclavian artery; RCA: right carotid artery.</div><div class=\"graphic_reference\">With permission from Skidmore FD, Ann R Coll Surg Engl 1975; 57:186.</div><div id=\"graphicVersion\">Graphic 55186 Version 2.0</div></div></div>"},"55189":{"type":"graphic_figure","displayName":"Lymph nodes head neck PI","title":"Lymph nodes of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Lymph nodes of the head and neck</div><div class=\"cntnt\"><img style=\"width:568px; height:480px;\" src=\"images/PI/55189_Lymph_nodes_head_neck_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing schematically depicts the major lymph nodes in the head and neck area that are likely to be enlarged on physical examination in patients with various local or systemic diseases. The major nodal groups are shown here in bold, with the areas draining into these nodal groups noted when appropriate. While enlargement of both the left and right supraclavicular lymph nodes may reflect disease in the thorax, left supraclavicular nodal enlargement, because of its drainage pattern, may also reflect the presence of abdominal involvement (ie, Virchow's node).</div><div id=\"graphicVersion\">Graphic 55189 Version 1.0</div></div></div>"},"55190":{"type":"graphic_table","displayName":"Diagnosis of DiGeorge syndrome","title":"Diagnostic criteria for DiGeorge syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for DiGeorge syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis* </td> </tr> <tr> <td class=\"sublist1_start\">Male or female patient with reduced numbers of CD3+ T cells (less than 500/mm<sup>3</sup>) and two of the three following characteristics:</td> </tr> <tr> <td class=\"sublist1\">1. Conotruncal cardiac defect (truncus arteriosus, tetrology of Fallot, interrupted aortic arch, or aberrant right subclavian).</td> </tr> <tr> <td class=\"sublist1\">2. Hypocalcemia of greater than&nbsp;three weeks' duration that requires therapy.</td> </tr> <tr> <td class=\"sublist1\">3. Deletion of chromosome 22q11.2.</td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis* </td> </tr> <tr> <td>Male or female patient with reduced numbers of CD3+ T cells (less than 1500/mm<sup>3</sup>) and a deletion of chromosome 22q11.2.</td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis* </td> </tr> <tr> <td class=\"sublist1_start\">Male or female patient with reduced numbers of CD3+ T cells (less than 1500/mm<sup>3</sup>) and at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Cardiac defect.</td> </tr> <tr> <td class=\"sublist1\">2. Hypocalcemia of greater than&nbsp;three weeks' duration that requires therapy.</td> </tr> <tr> <td class=\"sublist1\">3. Dysmorphic facies or palatal abnormalities.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.<br /></div><div class=\"graphic_reference\">From Conley ME, Notarangelo LD, Etzioni A. Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 55190 Version 2.0</div></div></div>"},"55191":{"type":"graphic_picture","displayName":"Pediculosis pubis","title":"Pediculosis pubis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis pubis</div><div class=\"cntnt\"><img style=\"width:386px; height:264px;\" src=\"images/PC/55191_Pediculosis_pubis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous lice and nits located around the pubic hair.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 55191 Version 1.0</div></div></div>"},"55196":{"type":"graphic_table","displayName":"Risk of child with CF based on parental screening results","title":"Risk that both partners carry a CFTR mutation and the risk they will have a child with CF based on their test results and race/ethnicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk that both partners carry a CFTR mutation and the risk they will have a child with CF based on their test results and race/ethnicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Carrier frequency in population and proportion of CF identified by carrier screening (23 mutation panel)</td> <td class=\"subtitle1\" colspan=\"3\">Results of partner screening</td> <td class=\"subtitle1\" rowspan=\"2\"> <p>Risk that both parents are carriers</p> <p>1 in</p> </td> <td class=\"subtitle1\" rowspan=\"2\"> <p>Risk of child with CF</p> <p>1 in</p> </td> </tr> <tr> <td class=\"subtitle2\">Not tested</td> <td class=\"subtitle2\">Negative</td> <td class=\"subtitle2\">Positive</td> </tr> <tr> <td rowspan=\"6\">Ashkenazi Jewish (1/23.8, 94.04 percent)</td> <td>XX</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>570</td> <td>2270</td> </tr> <tr> <td>&nbsp;</td> <td>XX</td> <td>&nbsp;</td> <td>147,000</td> <td>490,000</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>XX</td> <td>1</td> <td>4</td> </tr> <tr> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>9140</td> <td>36,600</td> </tr> <tr> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>23.8</td> <td>95.2</td> </tr> <tr> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>384</td> <td>1540</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Non-Hispanic Caucasian (1/25.0, 88.29 percent)</td> <td>XX</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>625</td> <td>2500</td> </tr> <tr> <td>&nbsp;</td> <td>XX</td> <td>&nbsp;</td> <td>42,400</td> <td>170,000</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>XX</td> <td>1</td> <td>4</td> </tr> <tr> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>5150</td> <td>20,600</td> </tr> <tr> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>25</td> <td>100</td> </tr> <tr> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>206</td> <td>824</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">African American (1/61.4, 64.46 percent)</td> <td>XX</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>3770</td> <td>15,100</td> </tr> <tr> <td>&nbsp;</td> <td>XX</td> <td>&nbsp;</td> <td>29,200</td> <td>117,000</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>XX</td> <td>1</td> <td>4</td> </tr> <tr> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>10,500</td> <td>42,000</td> </tr> <tr> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>61.4</td> <td>246</td> </tr> <tr> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>171</td> <td>684</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Hispanic Caucasian (1/58.2, 71.72 percent)</td> <td>XX</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>3380</td> <td>13,500</td> </tr> <tr> <td>&nbsp;</td> <td>XX</td> <td>&nbsp;</td> <td>41,200</td> <td>165,000</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>XX</td> <td>1</td> <td>4</td> </tr> <tr> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>11,800</td> <td>47,200</td> </tr> <tr> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>58.1</td> <td>232</td> </tr> <tr> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>203</td> <td>812</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Asian American (1/93.7, 48.93 percent)</td> <td>XX</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>8780</td> <td>35,100</td> </tr> <tr> <td>&nbsp;</td> <td>XX</td> <td>&nbsp;</td> <td>33,500</td> <td>134,000</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>XX</td> <td>1</td> <td>4</td> </tr> <tr> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>17,100</td> <td>68,600</td> </tr> <tr> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>93.7</td> <td>375</td> </tr> <tr> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>183</td> <td>732</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">4/3/2009--Requested permission (JD). 9/30/2009--Permission granted; figure to Terrence (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43899&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">This table is intended for use in&nbsp;cystic fibrosis&nbsp;screening of reproductive couples who have no family history of cystic fibrosis. For individuals with a family history of cystic fibrosis, the calculations would be different and would be based upon pedigree information.</div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis conductance transmembrane regulator; X: the result for one of the partners.</div><div class=\"graphic_reference\">Reproduced with permission from: American College of Medical Genetics. Technical Standards and Guidelines for CFTR Mutation Testing. 2006 Edition. Available at: http://www.acmg.net/Pages/ACMG_Activities/stds-2002/cf.htm. Copyright © 2006 American College of Medical Genetics.</div><div id=\"graphicVersion\">Graphic 55196 Version 5.0</div></div></div>"},"55198":{"type":"graphic_figure","displayName":"Split S2","title":"Splitting of the second heart sound","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Splitting of the second heart sound</div><div class=\"cntnt\"><img style=\"width:542px; height:462px;\" src=\"images/CARD/55198_Split_S2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wide splitting of second heart sound (S2) may be due to delayed closure of pulmonic valve as in right bundle branch block, pulmonic stenosis, and atrial septal defect, or to early closure of aortic valve as in mitral regurgitation and ventricular septal defect. In atrial septal defect, splitting is both wide and fixed.</div><div class=\"graphic_footnotes\">S1: first heart sound; A2: aortic valve closure sound; P2: pulmonic valve closure sound; T1: tricuspid valve closure sound; M1: mitral valve closure sound.</div><div class=\"graphic_reference\">Reprinted with permission from: Shaver JA, Leonard JJ, Leon DF. Auscultation of the Heart. Examination of the Heart, Part 4. American Heart Association, Dallas 1990. Copyright ©1990, American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 55198 Version 11.0</div></div></div>"},"55200":{"type":"graphic_table","displayName":"Mechanisms thyroid autoimmunity","title":"Mechanisms of thyroid autoimmunity with an emphasis on Grave's disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of thyroid autoimmunity with an emphasis on Grave's disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Mediating mechanisms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Molecular mimicry</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bystander activation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thyroid cell HLA antigen expression</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Precipitating causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Genetic susceptibility</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Thyroid injury</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Radiation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stress</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sex steroids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnancy and fetal microchimerism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Iodine</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55200 Version 1.0</div></div></div>"},"55201":{"type":"graphic_figure","displayName":"Blood flow erection PI","title":"Penile blood flow in erection","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Penile blood flow in erection</div><div class=\"cntnt\"><img style=\"width:494px; height:317px;\" src=\"images/PI/55201_Blood_flow_erection_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-section of corpora cavernosae illustrating penile blood flow in the flaccid and erect state. As intracavernosal pressure rises, emissary veins are occluded to maintain erectile function.</div><div id=\"graphicVersion\">Graphic 55201 Version 1.0</div></div></div>"},"55203":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CXR II","title":"Cystic hygroma involving right axilla and mediastinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma involving right axilla and mediastinum</div><div class=\"cntnt\"><img style=\"width:360px; height:306px;\" src=\"images/PULM/55203_Cystic_hygroma_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph demonstrates a large right-sided mediastinal mass displacing the trachea to the left.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55203 Version 2.0</div></div></div>"},"55205":{"type":"graphic_picture","displayName":"Palpation of internal pterygoid","title":"Palpation of internal pterygoid muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of internal pterygoid muscle</div><div class=\"cntnt\"><img style=\"width:238px; height:359px;\" src=\"images/RHEUM/55205_Palpation_of_internal_ptery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with temporomandibular disorder, the internal pterygoid muscle may be tender on the affected side. The muscle is palpated on the inner aspect of the ramus of the mandible, between the tonsillar pillars. Each side is compared for pain reproduction.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 55205 Version 3.0</div></div></div>"},"55206":{"type":"graphic_diagnosticimage","displayName":"Osteoarthritis following ankle fracture","title":"Osteoarthritis following ankle fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis following ankle fracture</div><div class=\"cntnt\"><img style=\"width:238px; height:504px;\" src=\"images/EM/55206_Osteoart_ank_frac_arrows_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankle osteoarthritis developed in this 41-year-old male after an ankle injury with ligamentous damage and distal fibular fracture. Callus at the distal fibular fracture site, several centimeters above the joint line (upper arrow), and medial joint line narrowing with sclerotic changes (lower arrow), suggestive of osteoarthritis, can be seen.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 55206 Version 4.0</div></div></div>"},"55207":{"type":"graphic_diagnosticimage","displayName":"Aortogram showing descending thoracic aortic dissection","title":"Aortogram showing descending thoracic aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram showing descending thoracic aortic dissection</div><div class=\"cntnt\"><img style=\"width:281px; height:358px;\" src=\"images/CARD/55207_Aortic_dissection_aortogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This aortogram demonstrates dissection of the descending thoracic aorta, arising immediately distal to the origin of the left subclavian artery. An oblique lucency is noted within the lumen of the aorta, which is a diagnostic feature (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 55207 Version 3.0</div></div></div>"},"55210":{"type":"graphic_table","displayName":"Causes ischemic stroke children and young adults","title":"Causes of ischemic stroke in children and young adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of ischemic stroke in children and young adults</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td>Congenital heart disease</td> </tr> <tr> <td>Patent foramen ovale</td> </tr> <tr> <td>Atrial septal aneurysm</td> </tr> <tr> <td>Atrial myxoma</td> </tr> <tr> <td>Atrial fibrillation</td> </tr> <tr> <td>Other arrhythmia</td> </tr> <tr> <td>Cardiomyopathy</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Cardiac surgery</td> </tr> <tr> <td>Cardiac catheterization</td> </tr> <tr> <td>Extracorporeal membrane oxygenation (ECMO)</td> </tr> <tr> <td>Endocarditis</td> </tr> <tr> <td>Rheumatic heart disease</td> </tr> <tr> <td>Prosthetic valve</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td>Sickle cell disease and iron deficiency anemias</td> </tr> <tr> <td class=\"sublist1_start\">Inherited prothrombotic states</td> </tr> <tr> <td class=\"sublist1\">Protein C deficiency</td> </tr> <tr> <td class=\"sublist1\">Protein S deficiency</td> </tr> <tr> <td class=\"sublist1\">Antithrombin III deficiency</td> </tr> <tr> <td class=\"sublist1\">Factor V Leiden gene mutation (associated with activated protein C resistance)</td> </tr> <tr> <td class=\"sublist1\">Prothrombin gene mutation</td> </tr> <tr> <td class=\"sublist1\">Elevated homocysteine</td> </tr> <tr> <td class=\"sublist1\">Elevated lipoprotein(a)</td> </tr> <tr> <td class=\"sublist1\">Polycythemia vera</td> </tr> <tr> <td class=\"sublist1_start\">Acquired prothrombotic states</td> </tr> <tr> <td class=\"sublist1\">Antiphospholipid antibody syndrome</td> </tr> <tr> <td class=\"sublist1\">L-asparaginase</td> </tr> <tr> <td class=\"sublist1\">Pregnancy</td> </tr> <tr> <td class=\"sublist1\">Oral contraceptives</td> </tr> <tr> <td class=\"sublist1\">Protein-losing enteropathy</td> </tr> <tr> <td class=\"sublist1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"sublist1\">Leukemia and other malignancies</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"subtitle2_single\">Noninflammatory</td> </tr> <tr> <td class=\"indent1\">Arterial dissection</td> </tr> <tr> <td class=\"indent1\">Spontaneous</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> </tr> <tr> <td class=\"indent1\">Secondary to connective tissue disease (Ehlers-Danlos, Marfan)</td> </tr> <tr> <td class=\"indent1\">Fibromuscular dysplasia</td> </tr> <tr> <td class=\"indent1\">Transient cerebral arteriopathy</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Radiation vasculopathy</td> </tr> <tr> <td class=\"sublist2_start\">Moyamoya</td> </tr> <tr> <td class=\"sublist2\">Primary moyamoya disease</td> </tr> <tr> <td class=\"sublist2\">Secondary moyamoya syndrome</td> </tr> <tr> <td class=\"sublist3\">Sickle cell disease</td> </tr> <tr> <td class=\"sublist3\">Neurofibromatosis type 1</td> </tr> <tr> <td class=\"sublist3\">Down syndrome</td> </tr> <tr> <td class=\"sublist3\">Williams syndrome</td> </tr> <tr> <td class=\"sublist3\">Cranial radiation</td> </tr> <tr> <td class=\"sublist3\">Fibromuscular dysplasia</td> </tr> <tr> <td class=\"sublist3\">Young women who smoke and use oral contraceptives</td> </tr> <tr> <td class=\"sublist3\">Vasculitis and postinfectious vasculopathy</td> </tr> <tr> <td class=\"sublist3\">Viral or bacterial infection</td> </tr> <tr> <td class=\"sublist3\">Congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Vasospasm following subarachnoid hemorrhage</td> </tr> <tr> <td class=\"indent1\">Congenital vessel hypoplasia</td> </tr> <tr> <td class=\"indent1\">Migraine</td> </tr> <tr> <td class=\"subtitle2_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Takayasu arteritis</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Vasculitis associated with rheumatologic disease</td> </tr> <tr> <td class=\"indent1\">Primary central nervous system angiitis</td> </tr> <tr> <td class=\"sublist2_start\">Infectious/postinfectious vasculitis</td> </tr> <tr> <td class=\"sublist2\">Human Immunodeficiency Virus (HIV)</td> </tr> <tr> <td class=\"sublist2\">Varicella</td> </tr> <tr> <td class=\"sublist2\">Bacterial meningitis</td> </tr> <tr> <td class=\"sublist2\">Syphilis</td> </tr> <tr> <td class=\"sublist2\">Tuberculosis</td> </tr> <tr> <td class=\"sublist2\">Fungal</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</td> </tr> <tr> <td>Fabry disease</td> </tr> <tr> <td>Homocystinuria</td> </tr> <tr> <td>Menkes' disease</td> </tr> <tr> <td>Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)</td> </tr> <tr> <td class=\"subtitle1_single\">Ingestion</td> </tr> <tr> <td>Cocaine, methamphetamine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55210 Version 3.0</div></div></div>"},"55211":{"type":"graphic_table","displayName":"Consequences of labor pain","title":"Potential effects of severe labor pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential effects of severe labor pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Increased oxygen consumption</td>\n</tr>\n<tr>\n<td>Hyperventilation leading to hypocarbia and respiratory alkalosis</td>\n</tr>\n<tr>\n<td>Gastric inhibition</td>\n</tr>\n<tr>\n<td>Increased gastric acidity</td>\n</tr>\n<tr>\n<td>Lipolysis</td>\n</tr>\n<tr>\n<td>Increased peripheral vascular resistance, cardiac output, blood pressure</td>\n</tr>\n<tr>\n<td>Decreased placental perfusion</td>\n</tr>\n<tr>\n<td>Incoordinate uterine activity</td>\n</tr>\n<tr>\n<td>Postpartum psychological effects, such as posttraumatic stress disorder</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42406&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Consequences_of_labor_pain.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Brownridge, P. Eur J Obstet Gynecol Reprod Biol 1995; 59 Suppl:S9.</div><div id=\"graphicVersion\">Graphic 55211 Version 2.0</div></div></div>"},"55212":{"type":"graphic_table","displayName":"Drug doses for oral treatment of hypertension in pregnancy","title":"Drug doses for oral treatment of hypertension in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug doses for oral treatment of hypertension in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Usual effective dose range</td> <td class=\"subtitle1\">Maximum total daily dose</td> </tr> <tr> <td>Methyldopa</td> <td>Centrally acting alpha-agonist</td> <td>250 mg two to three times daily, increase every two days as needed*</td> <td>250 to 1000 mg in two to three divided doses</td> <td>3000 mg</td> </tr> <tr> <td>Labetalol</td> <td>Combined alpha- and beta-blocker</td> <td>100 mg two times daily, increase by 100 mg twice daily every two to three days as needed</td> <td>200 to 800 mg in two divided doses</td> <td>2400 mg</td> </tr> <tr> <td>Nifedipine extended release<sup>&#8226;</sup></td> <td>Calcium channel blocker</td> <td>30 to 60 mg once daily as an extended release tablet, increase at 7 to 14 day intervals</td> <td>30 to 90 mg once daily</td> <td>120 mg</td> </tr> <tr> <td> <p>Hydralazine</p> <strong>NOTE:</strong> Due to reflex tachycardia, monotherapy with oral hydralazine is not recommended; hydralazine may be combined with methyldopa or labetalol if needed as add-on therapy</td> <td>Peripheral vasodilator</td> <td>Begin with 10 mg four times per day, increase by 10 to 25 mg/dose every 2 to 5 days</td> <td>50 to 100 mg in two to four divided doses</td> <td>200 mg<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The full hypotensive effect of an initial dose or adjustment of methylodopa may not occur until after 2 to 3 days of continuous use.<br /><span class=\"bullet\">&bull;</span> Use of immediate release nifedipine (oral or sublingual) is not recommended because it may cause significant rapid decreases in blood pressure.<br />&Delta; Chronic hydralazine doses above 100 mg daily are associated with an increased risk for developing lupus erythematosus, particularly in women and slow acetylators; ascertainment of acetylator status is recommended before increasing dose above 100 mg per day in many countries.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Seely EW, Ecker J. Chronic hypertension in pregnancy. N Engl J Med 2011; 365:439.</LI>&#xD;&#xA;<LI>Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 2001; 24:457.</LI></OL></div><div id=\"graphicVersion\">Graphic 55212 Version 8.0</div></div></div>"},"55214":{"type":"graphic_figure","displayName":"Sinus node pacemaker sites","title":"Location of pacemaker sites in the human sinus node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of pacemaker sites in the human sinus node</div><div class=\"cntnt\"><img style=\"width:406px; height:402px;\" src=\"images/CARD/55214_Sinus_node_pacemaker_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Filled circles represent the location of sites under autonomic control, while the open circles are &quot;escape&quot; sites that are not under the control of the autonomic nervous system and are capable of generating ectopic impulses. There is a predominant clustering of all sites along the sulcus terminalis and superior vena caval (SVC)-right atrial (RA) junction in the upper posterior right atrium; a few escape sites are also located in the left atrium, below the pulmonary vein (PV). Stimulation of the parasympathetic nervous system shifts the dominant pacemaker site to a more caudal region of the sinus complex, while sympathetic stimulation shifts the site to a more cranial location.</div><div class=\"graphic_footnotes\">LAA: left atrial appendage; RAA: right atrial appendage.</div><div class=\"graphic_reference\">From Boineau, JP, Canavan, TE, Schuessler, RB, et al Circulation 1988; 77:1221.</div><div id=\"graphicVersion\">Graphic 55214 Version 1.0</div></div></div>"},"55215":{"type":"graphic_figure","displayName":"VISA questionnaire","title":"The VISA questionnaire: An index of severity of symptoms in patients with jumper's knee (patellar tendinosis)","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">The VISA questionnaire: An index of severity of symptoms in patients with jumper's knee (patellar tendinosis)</div><div class=\"cntnt\"><img style=\"width:570px; height:762px;\" src=\"images/EM/55215_VISA_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Visentini, PJ, Khan, KM, Cook, JL, et al. The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1998; 1:22. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55215 Version 2.0</div></div></div>"},"55216":{"type":"graphic_figure","displayName":"Metformin in type 2 DM I","title":"Metformin in overweight patients with type 2 diabetes mellitus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metformin in overweight patients with type 2 diabetes mellitus</div><div class=\"cntnt\"><img style=\"width:412px; height:304px;\" src=\"images/ENDO/55216_Metformin_in_type_2_DM_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plots of any diabetes-related endpoint in 753 overweight patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to either intensive therapy with metformin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L) Another 951 overweight patients received intensive therapy with a sulfonylurea or insulin and are included in the analysis. Metformin was associated with a 32 percent reduction in any diabetes-related endpoint compared to conventional therapy (P = 0.002) and had the same relative benefit compared to intensive therapy with other therapy (P = 0.003).</div><div class=\"graphic_reference\">Data from UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352:854.</div><div id=\"graphicVersion\">Graphic 55216 Version 1.0</div></div></div>"},"55217":{"type":"graphic_figure","displayName":"Preimplantation development","title":"Preimplantation developmental time-line in humans","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Preimplantation developmental time-line in humans</div><div class=\"cntnt\"><img style=\"width:537px; height:308px;\" src=\"images/OBGYN/55217_Preimplantation_development.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cleavage stage embryos range from the two-cell stage to the 8- to 16-cell morula. The blastocyst consists of an inner cell mass (which becomes the embryo) and an outer cell mass (cytotrophoblastic shell, which will become the placenta).</div><div class=\"graphic_reference\">Courtesy of Catherine Racowsky, PhD.</div><div id=\"graphicVersion\">Graphic 55217 Version 3.0</div></div></div>"},"55219":{"type":"graphic_table","displayName":"Delayed clinical toxicity agents","title":"Toxic time bombs (delayed clinical toxicity)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxic time bombs (delayed clinical toxicity)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Pennyroyal oil</td> </tr> <tr> <td>Carbon tetrachloride</td> </tr> <tr> <td class=\"sublist1_start\">Mushrooms</td> </tr> <tr> <td class=\"sublist1\">Amanita (amatoxin)</td> </tr> <tr> <td class=\"sublist1\">Lepiota (amatoxin)</td> </tr> <tr> <td class=\"sublist1\">Gyromitra (gyromitrin)</td> </tr> <tr> <td class=\"sublist1\">Cortinarius (orellanine/orelline)</td> </tr> <tr> <td class=\"sublist1_start\">Toxic alcohols</td> </tr> <tr> <td class=\"sublist1\">Ethylene glycol</td> </tr> <tr> <td class=\"sublist1\">Methanol</td> </tr> <tr> <td class=\"sublist1_start\">Sustained-release preparations</td> </tr> <tr> <td class=\"sublist1\">Calcium-channel blockers</td> </tr> <tr> <td class=\"sublist1\">Beta-blockers</td> </tr> <tr> <td class=\"sublist1\">Lithium</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1_start\">Enteric-coated preparations</td> </tr> <tr> <td class=\"sublist1\">Aspirin</td> </tr> <tr> <td>Monoamine oxidase inhibitors</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Drug packet ingestion (heroin, cocaine)</td> </tr> <tr> <td>Oral hypoglycemic agents</td> </tr> <tr> <td>Diphenoxylate</td> </tr> <tr> <td>Methylene chloride</td> </tr> <tr> <td>Paraquat/diquat</td> </tr> <tr> <td>Cyanogenic glycosides</td> </tr> <tr> <td>Flouride</td> </tr> <tr> <td class=\"sublist1_start\">Warfarin/superwarfarin</td> </tr> <tr> <td class=\"sublist1\">Brodifacoum</td> </tr> <tr> <td>Neurotoxic snake envenomation</td> </tr> <tr> <td class=\"sublist1_start\">Antimetabolites</td> </tr> <tr> <td class=\"sublist1\">Colchicine</td> </tr> <tr> <td class=\"sublist1\">Methotrexate</td> </tr> <tr> <td class=\"sublist1\">Alkylating agents</td> </tr> <tr> <td>Fat-soluble organophosphate insecticides</td> </tr> <tr> <td>Ergotamines</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Lead</td> </tr> <tr> <td class=\"sublist1\">Thallium</td> </tr> <tr> <td class=\"sublist1\">Mercury</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55219 Version 5.0</div></div></div>"},"55220":{"type":"graphic_table","displayName":"Increased upper airway resist","title":"Conditions leading to increased upper airway resistance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions leading to increased upper airway resistance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Obesity (increased fat deposition)</td>\n</tr>\n<tr>\n<td>Nasal obstruction</td>\n</tr>\n<tr>\n<td>Micrognathia and retrognathia</td>\n</tr>\n<tr>\n<td>Tonsillar hypertrophy</td>\n</tr>\n<tr>\n<td>Uvular hypertrophy</td>\n</tr>\n<tr>\n<td>Hypothyroidism</td>\n</tr>\n<tr>\n<td>Acromegaly</td>\n</tr>\n<tr>\n<td>Macroglossia</td>\n</tr>\n<tr>\n<td>Tissue edema or fibrosis</td>\n</tr>\n<tr>\n<td>Other craniofacial abnormalities (eg, high arched palate)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55220 Version 1.0</div></div></div>"},"55221":{"type":"graphic_figure","displayName":"Anatomy of the radial artery","title":"Anatomy of the radial artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the radial artery</div><div class=\"cntnt\"><img style=\"width:421px; height:629px;\" src=\"images/SURG/55221_Anatomy_of_the_radial_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the arterial supply to the ventral surface of the hand. Collateral circulation to the radial artery is provided by the ulnar artery through the deep and superficial volar arterial arches.</div><div id=\"graphicVersion\">Graphic 55221 Version 5.0</div></div></div>"},"55222":{"type":"graphic_picture","displayName":"Oral ulcer Behçet’s syndrome PI","title":"Oral ulcer Behçet’s syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral ulcer Behçet’s syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:326px;\" src=\"images/PI/55222_Oral_ulcer_Behcets_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 55222 Version 4.0</div></div></div>"},"55223":{"type":"graphic_table","displayName":"Secondary prophylaxis for rheumatic fever - Duration of therapy","title":"Secondary prophylaxis for rheumatic fever - Duration of therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary prophylaxis for rheumatic fever - Duration of therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Duration after last attack </td> </tr> <tr> <td> <p>Rheumatic fever with carditis and residual heart disease </p> <p>(persistent valvular disease*)</p> </td> <td> <p>10 years or until 40 years of age (whichever is longer) </p> <p>Sometimes lifelong prophylaxis (refer to UpToDate topics&nbsp;on treatment and prevention of acute rheumatic fever and management and prevention of rheumatic heart disease)</p> </td> </tr> <tr> <td> <p>Rheumatic fever with carditis but no residual heart disease </p> <p>(no valvular disease*)</p> </td> <td> <p>10 years or until 21 years of age</p> <p>(whichever is longer)</p> </td> </tr> <tr> <td>Rheumatic fever without carditis</td> <td> <p>5 years or until 21 years of age</p> <p>(whichever is longer)</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical or echocardiographic evidence.</div><div class=\"graphic_reference\">Modified with permission from: Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009; 119(11):1541-51. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55223 Version 11.0</div></div></div>"},"55226":{"type":"graphic_picture","displayName":"Electron micrograph showing membranous nephropathy","title":"Electron micrograph showing membranous nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:387px; height:248px;\" src=\"images/NEPH/55226_Membranous_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows stage II membranous nephropathy. Electron-dense deposits (D) are present in the subepithelial space across the glomerular basement membrane (GBM) and under the epithelial cells (Ep). New basement membrane is growing between the deposits, leading to a spike appearance on silver stain.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 55226 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"55227":{"type":"graphic_diagnosticimage","displayName":"CAA perivascular inflammation","title":"CAA-related perivascular inflammation","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">CAA-related perivascular inflammation</div><div class=\"cntnt\"><img style=\"width:532px; height:631px;\" src=\"images/NEURO/55227_CAA_perivascular_inflammati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T2 weighted axial MR image shows periventricular white matter hyperintensity in a patient who presented with memory difficulties.<br />(B) Gradient echo MR image from the same patient shows multiple low intensity foci (arrows) consistent with microhemorrhages, which are not seen on the T2 weighted image (A). The microhemorrhages are located peripherally, as opposed to hypertensive related hemorrhages that may occur centrally.<br />(C) FLAIR MR image demonstrates patchy and confluent periventricular white matter hyperintensity.</div><div class=\"graphic_footnotes\">CAA: cerebral amyloid angiopathy; MR: magnetic resonance; FLAIR: fluid-attenuated inversion recovery.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 55227 Version 3.0</div></div></div>"},"55229":{"type":"graphic_picture","displayName":"Juvenile spring eruption 1","title":"Juvenile spring eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile spring eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/55229_Juvenile_spring_eruption_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pruritic, erythematous vesicles and crusted papules occurred on the ears of this seven-year-old boy after sun-exposure in the early spring.</div><div class=\"graphic_reference\">Copyright © Eric Ehrsam, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 55229 Version 6.0</div></div></div>"},"55231":{"type":"graphic_table","displayName":"Diagnostic value of BAL in ILD","title":"Diagnostic features of bronchoalveolar lavage in interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic features of bronchoalveolar lavage in interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease category</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Findings in BAL fluid</td> </tr> <tr> <td rowspan=\"3\">Malignancy</td> <td>Lymphangitic carcinomatosis</td> <td>Malignant cells</td> </tr> <tr> <td>Bronchioloalveolar cell carcinoma</td> <td>Malignant cells</td> </tr> <tr> <td>Pulmonary lymphoma</td> <td>Malignant cells</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Diseases due to inhaled (exogenous) material</td> <td rowspan=\"2\">Lipoid pneumonia</td> <td>Fat globules in macrophages (oil-red-O-stain)</td> </tr> <tr> <td>Multinucleated giant cells</td> </tr> <tr> <td>Asbestosis</td> <td>Ferruginous bodies</td> </tr> <tr> <td>Silicosis</td> <td>Dust particles seen by polarized microscopy</td> </tr> <tr> <td>Berylliosis</td> <td>Positive lymphocyte transformation test to beryllium salts</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Inflammatory</td> <td rowspan=\"3\">Diffuse alveolar hemorrhage</td> <td>Large numbers of erythrocytes</td> </tr> <tr> <td>Hemosiderin-laden macrophages (iron stain)</td> </tr> <tr> <td>Sequential lavages progressively more hemorrhagic</td> </tr> <tr> <td>Chronic eosinophilic pneumonia</td> <td>Eosinophils &#8805;40 percent</td> </tr> <tr> <td>Idiopathic acute eosinophilic pneumonia</td> <td>Eosinophils &#8805;25 percent</td> </tr> <tr> <td>Pulmonary alveolar proteinosis</td> <td>Lipoproteinaceous material (periodic acid-Schiff stain)</td> </tr> <tr> <td rowspan=\"3\">Pulmonary Langerhans cell histiocytosis (Histiocytosis X)</td> <td>Monoclonal antibody (T6) positive histiocytes</td> </tr> <tr> <td>CD1 positive Langerhans cells &#62;5 percent</td> </tr> <tr> <td>Birbeck granules in lavaged macrophages (seen by electron microscopy)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div id=\"graphicVersion\">Graphic 55231 Version 5.0</div></div></div>"},"55232":{"type":"graphic_figure","displayName":"Mechanisms cough reflex","title":"Simplified schematic diagram of the cough reflex","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Simplified schematic diagram of the cough reflex</div><div class=\"cntnt\"><img style=\"width:538px; height:230px;\" src=\"images/PULM/55232_Mechanisms_cough_reflex.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Cough receptors include rapid acting receptors (RAR), slow acting receptors (SAR), C fibers, and other cough receptors. Some receptors are mechanosensitive and others are chemosensitive. Impulses from these receptors are all carried by the vagus nerve.</div><div id=\"graphicVersion\">Graphic 55232 Version 1.0</div></div></div>"},"55233":{"type":"graphic_diagnosticimage","displayName":"Pulm bronchogenic cyst CXR","title":"Infected intrapulmonary cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected intrapulmonary cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/55233_Pulm_bronchogenic_cyst_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows cystic lesion in right middle lobe with two gas-liquid levels.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55233 Version 2.0</div></div></div>"},"55234":{"type":"graphic_table","displayName":"Symptoms of GE reflux","title":"Symptoms of gastroesophageal reflux in patients with asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of gastroesophageal reflux in patients with asthma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Esophageal symptoms</td>\n</tr>\n<tr>\n<td>Heartburn</td>\n</tr>\n<tr>\n<td>Regurgitation</td>\n</tr>\n<tr>\n<td>Water brash</td>\n</tr>\n<tr>\n<td>Dysphagia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Extraesophageal symptoms</td>\n</tr>\n<tr>\n<td>Sore throat</td>\n</tr>\n<tr>\n<td>Choking</td>\n</tr>\n<tr>\n<td>Hoarseness</td>\n</tr>\n<tr>\n<td>Dental erosions</td>\n</tr>\n<tr>\n<td>Chest pain</td>\n</tr>\n<tr>\n<td>Cervical pain</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Worsened asthma symptoms with</td>\n</tr>\n<tr>\n<td>Eating</td>\n</tr>\n<tr>\n<td>Alcohol</td>\n</tr>\n<tr>\n<td>Reflux symptoms</td>\n</tr>\n<tr>\n<td>Supine position</td>\n</tr>\n<tr>\n<td>Theophylline</td>\n</tr>\n<tr>\n<td>Systemic beta-adrenergic agonists</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Clinically silent</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55234 Version 1.0</div></div></div>"},"55235":{"type":"graphic_figure","displayName":"Flow volume loop in RPC","title":"Flow-volume loop in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-volume loop in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:368px; height:279px;\" src=\"images/RHEUM/55235_Flow_volume_loop_in_RPC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume loop in relapsing polychondritis showing a very low flow rate during expiration due to severe expiratory flow obstruction.</div><div id=\"graphicVersion\">Graphic 55235 Version 2.0</div></div></div>"},"55237":{"type":"graphic_picture","displayName":"Rim pattern IF MPGN","title":"Rim immunofluorescent pattern in membranoproliferative glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rim immunofluorescent pattern in membranoproliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:395px; height:253px;\" src=\"images/NEPH/55237_MPGN_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in membranoproliferative glomerulonephritis reveals complement deposition in a rim pattern outlining the glomerular capillary wall.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 55237 Version 3.0</div></div></div>"},"55238":{"type":"graphic_diagnosticimage","displayName":"Axial MRI LSS","title":"Axial MRI in lumbar spinal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial MRI in lumbar spinal stenosis</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/NEURO/55238_Axial_MRI_LSS.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 55238 Version 4.0</div></div></div>"},"55239":{"type":"graphic_picture","displayName":"Traumatic neuroma","title":"Traumatic neuroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic neuroma</div><div class=\"cntnt\"><img style=\"width:302px; height:497px;\" src=\"images/NEURO/55239_Traumaticneuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-power micrograph of a traumatic neuroma of the superficial branch of the right median nerve. The white arrow shows the parent nerve giving rise to the disorganized proliferation of axons, Schwann cells, and perineural cells within a collagenous stroma that makes up the neuroma. H&amp;E stain, 40x. <br />(B) Higher-power micrograph demonstrating the haphazard arrangement of the nerve fiber bundles, both cut longitudinally (white arrow) and in cross-section (black arrow). As noted previously, the neuroma is collagen rich (blue arrow). H&amp;E stain, 200x.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 55239 Version 3.0</div></div></div>"},"55243":{"type":"graphic_picture","displayName":"Pulmonary LAM HMB 45","title":"Microscopic features of lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microscopic features of lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:250px; height:223px;\" src=\"images/PULM/55243_Pulmonary_LAM_HMB_45.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification photomicrograph showing immunohistochemical staining for the melanogenesis-associated marker HMB-45. This unique phenotype is an important diagnostic characteristic in difficult cases.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 55243 Version 1.0</div></div></div>"},"55245":{"type":"graphic_table","displayName":"Fatty acid oxidation enzymes","title":"Fatty acid oxidation enzymes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fatty acid oxidation enzymes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>1. Short-chain acyl-CoA dehydrogenase (SCAD)</td>\n</tr>\n<tr>\n<td>2. Medium-chain acyl-CoA dehydrogenase (MCAD)</td>\n</tr>\n<tr>\n<td>3. Long-chain acyl-CoA dehydrogenase (LCAD)</td>\n</tr>\n<tr>\n<td>4. Very long-chain acyl-CoA dehydrogenase (VLCAD)</td>\n</tr>\n<tr>\n<td>5. Enoyl-CoA hydratase (crotonase)</td>\n</tr>\n<tr>\n<td>6. Long-chain enoyl-CoA hydratase</td>\n</tr>\n<tr>\n<td>7. Short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD)</td>\n</tr>\n<tr>\n<td>8. Long-chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD)</td>\n</tr>\n<tr>\n<td>9. Acetyoacetyl-CoA thiolase</td>\n</tr>\n<tr>\n<td>10. Long-chain 3-ketoacyl-CoA thiolase</td>\n</tr>\n<tr>\n<td>11. Trifunctional enzyme (combines activities of 6, 8, and 10)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55245 Version 1.0</div></div></div>"},"55247":{"type":"graphic_picture","displayName":"Molluscum on face","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:420px; height:337px;\" src=\"images/DERM/55247_Molluscum_face_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple dome-shaped papules with a central core are present on the face of this child with molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55247 Version 3.0</div></div></div>"},"55250":{"type":"graphic_movie","displayName":"Whooping cough no whoop","title":"Sound of a child with whooping cough without whooping","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sound of a child with whooping cough without whooping</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55250_Whoopcoughnowhoopconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:252px; height:372px;\" src=\"images/CARD/55250_Whoopingcoughnowhoop.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: http://www.whoopingcough.net/symptoms.htm. Copyright © 2010 Dr. Doug Jenkinson.</div><div id=\"graphicVersion\">Graphic 55250 Version 2.0</div></div></div>"},"55251":{"type":"graphic_diagnosticimage","displayName":"Ureteral obstruction","title":"Ureteral obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral obstruction</div><div class=\"cntnt\"><img style=\"width:320px; height:457px;\" src=\"images/NEPH/55251_Ureteral_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential transverse images from a noncontrast CT scan. Panel A shows hydronephrosis in the lower pole of the right kidney and a dilated ureter (arrow). The stone obstructing the ureter is visible (arrow) in Panel B.</div><div class=\"graphic_reference\">Courtesy of Deborah A Baumgarten, MD, MPH.</div><div id=\"graphicVersion\">Graphic 55251 Version 2.0</div></div></div>"},"55254":{"type":"graphic_diagnosticimage","displayName":"Medial epicondylar fracture  with entrapment","title":"Medial epicondylar fracture with entrapment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial epicondylar fracture with entrapment</div><div class=\"cntnt\"><img style=\"width:260px; height:396px;\" src=\"images/EM/55254_Entrappedmedepicondylefx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entrapment of fracture fragment in medial epicondylar fracture with posterolateral elbow dislocation.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55254 Version 14.0</div></div></div>"},"55255":{"type":"graphic_diagnosticimage","displayName":"Oblique view of fifth metatarsal fracture nonunion","title":"Oblique view of a fifth metatarsal avulsion fracture nonunion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique view of a fifth metatarsal avulsion fracture nonunion</div><div class=\"cntnt\"><img style=\"width:402px; height:466px;\" src=\"images/EM/55255_Oblique_nonunion_fifth_meta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oblique view of this radiograph demonstrates a nonunion of a fifth metatarsal avulsion fracture (arrow). Note the widened fracture line and sclerosis of the fractured edges.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 55255 Version 5.0</div></div></div>"},"55259":{"type":"graphic_table","displayName":"Damage control surgery for liver injury","title":"Damage control surgery for liver injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Damage control surgery for liver injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"3\"><strong>Phase I</strong></td> <td>Exploratory laparotomy</td> </tr> <tr> <td>Control of bleeding and contamination</td> </tr> <tr> <td>Packing and temporary abdominal closure</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Phase II</strong></td> <td>Aggressive ICU resuscitation</td> </tr> <tr> <td>Rewarming</td> </tr> <tr> <td>Correction of coagulopathy</td> </tr> <tr> <td>Optimization of blood volume and oxygen delivery</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Phase III</strong></td> <td>Planned reoperation</td> </tr> <tr> <td>Packing change</td> </tr> <tr> <td>Evacuation of blood clot</td> </tr> <tr> <td>Definitive repair of injuries</td> </tr> <tr> <td>Abdominal closure</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55259 Version 2.0</div></div></div>"},"55261":{"type":"graphic_picture","displayName":"CD1a stain LCH","title":"Lymph node biopsy in Langerhans cell histiocytosis CD1a stain","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Lymph node biopsy in Langerhans cell histiocytosis CD1a stain</div><div class=\"cntnt\"><img style=\"width:584px; height:224px;\" src=\"images/HEME/55261_CD1astainLCH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The lesion fills and expands lymph node sinuses, and the Langerhans cells are associated with eosinophils and giant cells. Hematoxylin-eosin stain.<br> (B) Immunostain for CD1a highlights numerous Langerhans cells. Immunochemistry with hematoxylin counterstain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Dendritic cell neoplasms. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55261 Version 8.0</div></div></div>"},"55262":{"type":"graphic_table","displayName":"Dystrophic epidermolysis bullosa variants","title":"Genotypic and phenotypic variants of dystrophic epidermolysis bullosa<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genotypic and phenotypic variants of dystrophic epidermolysis bullosa<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subtype</td> <td class=\"subtitle1\"> <p>Inheritance</p> <p>Mutated gene</p> <p>Targeted gene product</p> </td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dominant DEB</td> </tr> <tr> <td class=\"indent1\">Dominant DEB, generalized</td> <td> <p>Autosomal dominant</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized blistering from birth, atrophic scarring, dystrophic (or absent) nails; alopecia </li> <li>\"Albopapuloid\" lesions (small, grouped, hypopigmented papules usually on the lower back) </li> <li>Involvement of oral cavity, gastrointestinal and, rarely, genitourinary tract </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dominant DEB, acral</td> <td> <p>Autosomal dominant, autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Predilection of blistering for hands and feet from early infancy, milia, atrophic scarring, dystrophic (or absent) nails </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dominant DEB, pretibial</td> <td> <p>Autosomal dominant, autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Pretibial blistering from birth or early infancy, involvement of hands and feet, milia, atrophic scarring; dystrophic nails </li> <li>Lichen planus-like skin lesions&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dominant DEB, pruriginosa</td> <td> <p>Autosomal dominant, autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized or localized erosions, blisters, milia, and atrophic scars from infancy or later; dystrophic nails </li> <li>Pronounced pruritus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dominant DEB, nails only</td> <td> <p>Autosomal dominant</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Nail dystrophy or loss at birth or infancy without skin involvement </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dominant DEB, bullous dermolysis of the newborn</td> <td> <p>Autosomal dominant, autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized blistering from birth or early infancy that improves dramatically over time </li> <li>Milia, atrophic scarring; dystrophic nails </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Recessive DEB</td> </tr> <tr> <td class=\"indent1\">Recessive DEB, generalized severe (formerly recessive DEB-Hallopeau-Siemens)</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized blistering from birth, atrophic scarring, milia; sparse hair with scarring alopecia; dystrophic or absent nails </li> <li>Acral pseudosyndactyly and contractures </li> <li>Involvement of oral cavity (blisters, erosions, scarring, excessive caries, smooth tongue without papillae), gastrointestinal (protein losing enteropathy) and genitourinary tract (glomerulonephritis, IgA nephropathy, chronic renal failure), conjunctivae </li> <li>Tremendous risk for development of squamous cell carcinomas </li> <li>Cardiomyopathy, osteoporosis, anemia, impaired growth, delayed puberty </li> <li>Shortened life expectancy&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, generalized intermediate</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized blistering at birth, continue to develop throughout life; atrophic scarring, milia; nail dystrophy; scarring alopecia </li> <li>Pseudosyndactyly </li> <li>Increased risk for development of squamous cell carcinomas </li> <li>Involvement of oral cavity, gastrointestinal and genitourinary tract, conjunctivae </li> <li>Anemia, growth retardation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, inversa</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Blistering predominantly located in intertriginous lumbosacral, acral, and axial areas; milia, atrophic scarring; nail dystrophy; </li> <li>Involvement of oral cavity (caries), gastrointestinal and genitourinary tract </li> <li>Stenosis of meatus acusticus externus </li> <li>Anemia, growth retardation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, pretibial</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Pretibial blistering at birth or early infancy, involvement of hands and feet; milia; atrophic scarring; nail dystrophy </li> <li>Lichen planus-like skin lesions </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, localized</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Blistering on hands and feet from early infancy, milia, atrophic scarring; nail dystrophy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, pruriginosa</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized or localized erosions, blisters, milia, and atrophic scars from infancy; dystrophic nails </li> <li>Excessive pruritus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, centripetalis</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Pretibial and acral blistering at birth or from early infancy, milia, atrophic scarring; nail dystrophy </li> <li>Involvement of oral mucosa </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recessive DEB, bullous dermolysis of the newborn</td> <td> <p>Autosomal recessive</p> <p><em>COL7A1</em></p> <p>Type VII collagen</p> </td> <td> <ul> <li>Generalized blistering from birth or early infancy that improves dramatically over time </li> <li>Milia, atrophic scarring; dystrophic nails </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DEB: dystrophic epidermolysis bullosa; IgA: immunoglobulin A.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations with dystrophic epidermolysis bullosa. Exp Dermatol 2008; 17:553.</LI>&#xD;&#xA;<LI>Kim J, Loh CH, Murrell DF. Epidermolysis bullosa pruriginosa triggered by scabies infestation. J Dermatol 2013; 40:562.</LI>&#xD;&#xA;<LI>Fine JD, Bruckner-Tuderman L, Eady RA. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103.</LI></OL></div><div id=\"graphicVersion\">Graphic 55262 Version 4.0</div></div></div>"},"55263":{"type":"graphic_figure","displayName":"Reoperation rates for arterial versus venous grafts","title":"Reoperation rates for arterial versus venous grafts","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Reoperation rates for arterial versus venous grafts</div><div class=\"cntnt\"><img style=\"width:509px; height:335px;\" src=\"images/CARD/55263_Bypass_graft_reop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compared to the use of mammary arterial grafts at the time of first bypass surgery, the need for reoperation is greater when only vein grafts are used. This difference increases over time.</div><div class=\"graphic_reference\">Data from Loop FD, Lytle BW, Cosgrove DM, et al. N Engl J Med 1986; 314:1.</div><div id=\"graphicVersion\">Graphic 55263 Version 3.0</div></div></div>"},"55266":{"type":"graphic_picture","displayName":"Micrograph schwannoma","title":"Micrograph schwannoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph schwannoma</div><div class=\"cntnt\"><img style=\"width:268px; height:417px;\" src=\"images/NEURO/55266_Micrographschwannoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Photomicrograph of an intracranial schwannoma removed from the vestibular nerve. The tumor cell nuclei are spindle shaped. At the top and bottom of the figure are areas of compact tissue (Antoni A pattern), while the middle of the figure consists of loose-textured tissue (Antoni B pattern). H&amp;E stain, 100x. <br />(B) Photomicrograph of a spinal schwannoma removed from the L2-3 nerve root. Palisading of nuclear and cytoplasmic processes of the tumor cells is shown in the center of the figure. This is a Verocay body. H&amp;E stain, 600x.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 55266 Version 3.0</div></div></div>"},"55268":{"type":"graphic_picture","displayName":"Angiogram cerebellar hemangio","title":"Cerebellar hemangioblastoma: Angiogram","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Cerebellar hemangioblastoma: Angiogram</div><div class=\"cntnt\"><img style=\"width:553px; height:335px;\" src=\"images/ONC/55268_Angiogram_cerebellar_hemang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional angiogram of the cerebellar hemangioma pictured in radiograph 1, showing the extensive vascularity and typical tumor blush following contrast injection (left panel). Therapeutic embolization of the feeder vessels lessens potential bleeding complications during surgery. Following therapeutic embolization, the tumor blush is substantially reduced (right panel, red arrow).</div><div class=\"graphic_reference\">Courtesy of Eric T Wong, MD.</div><div id=\"graphicVersion\">Graphic 55268 Version 3.0</div></div></div>"},"55269":{"type":"graphic_picture","displayName":"Spiration intrabronchial valve","title":"Intrabronchial valve appearance and nomenclature","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Intrabronchial valve appearance and nomenclature</div><div class=\"cntnt\"><img style=\"width:573px; height:396px;\" src=\"images/PULM/55269_Spiration_intrabr_valve_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Wood DE, McKenna RJ, Yusen RD, et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thorac Cardiovasc Surg 2007; 133:65. Illustration reproduced with permission from Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55269 Version 1.0</div></div></div>"},"55270":{"type":"graphic_diagnosticimage","displayName":"CT with extraluminal contrast from perforated ulcer","title":"Perforated duodenal ulcer","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Perforated duodenal ulcer</div><div class=\"cntnt\"><img style=\"width:477px; height:468px;\" src=\"images/GAST/55270_CT_extraluminal_contrast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decubitus computed tomographic scan shows marked thickening and inflammation of the duodenal wall (white arrows) with extraluminal contrast material and air (black arrows) due to a perforated duodenal ulcer.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55270 Version 3.0</div></div></div>"},"55271":{"type":"graphic_picture","displayName":"Calf raise PI","title":"Calf raise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calf raise</div><div class=\"cntnt\"><img style=\"width:259px; height:424px;\" src=\"images/PI/55271_Calf_raise_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand behind a chair, holding onto the chair. Slowly rise up and stand on the balls of the feet and toes. Hold for 5 seconds then slowly roll down onto the entire foot. Rest as needed. Repeat 10 to 15 times (one set). Increase the difficulty of this exercise by rising higher, holding longer, or moving up and down more quickly. Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 55271 Version 4.0</div></div></div>"},"55272":{"type":"graphic_diagnosticimage","displayName":"Oriental cholangiohepatitis CT","title":"Recurrent pyogenic cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recurrent pyogenic cholangitis</div><div class=\"cntnt\"><img style=\"width:369px; height:276px;\" src=\"images/GAST/55272_Oriental_cholangiohepatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image of a patient with recurrent pyogenic cholangitis showing a massively dilated left hepatic system and numerous stones (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Hannah M Lee, MD.</div><div id=\"graphicVersion\">Graphic 55272 Version 4.0</div></div></div>"},"55273":{"type":"graphic_diagnosticimage","displayName":"Vascular malformation 9c","title":"Coronal view of pelvic MR","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Coronal view of pelvic MR</div><div class=\"cntnt\"><img style=\"width:493px; height:467px;\" src=\"images/OBGYN/55273_Vascular_malformation_9c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal view of pelvic MR shows flow void (arrow) in the uterine fundus suggesting a rapid arteriovenous connection.</div><div id=\"graphicVersion\">Graphic 55273 Version 2.0</div></div></div>"},"55274":{"type":"graphic_picture","displayName":"Tear drop cells","title":"Teardrop-shaped red blood cells (dacrocytes)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Teardrop-shaped red blood cells (dacrocytes)</div><div class=\"cntnt\"><img style=\"width:305px; height:288px;\" src=\"images/HEME/55274_Tear_drop_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This peripheral smear from a patient with bone marrow fibrosis shows numerous teardrop-shaped red cells (arrows). Note that the teardrops are pointed in several different directions, ruling out an artifact due to preparation of the smear.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 55274 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"55275":{"type":"graphic_picture","displayName":"Lichen sclerosus child","title":"Lichen sclerosus in a 4-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus in a 4-year-old child</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/EM/55275_Lichen_sclerosus_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the subepithelial hemorrhages located proximally at the edge of the right labia minora and the V-shaped bilateral distribution of hypopigmentation lateral to the labia minora extending to the posterior fourchette. The hymen is crescentic in configuration with smooth, even borders.</div><div class=\"graphic_reference\">Courtesy of Celeste Wilson, MD.</div><div id=\"graphicVersion\">Graphic 55275 Version 2.0</div></div></div>"},"55276":{"type":"graphic_form","displayName":"NAS assessment scoring and treatment","title":"Johns Hopkins Bayview Medical Center neonatal abstinence scoring sheet and initiation of treatment*","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Johns Hopkins Bayview Medical Center neonatal abstinence scoring sheet and initiation of treatment*</div><div class=\"cntnt\"><img style=\"width:661px; height:1067px;\" src=\"images/PEDS/55276_NAS_assessment_score.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NAS: neonatal abstinence syndrome.<br />* This protocol is based on the Finnegan scoring system, which is optimally employed in the perinatal period for term infants. NAS expression differs in preterm infants compared with term infants<sup>[1]</sup>; however, currently there are no standardized scoring protocols for preterm infants.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35:344.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />From: Jansson LM, Velez M, Harrow C: The opioid-exposed newborn: Assessment and pharmacologic management. J Opioid Manag. 2009; 5(1):47-55. Reprinted with permission from Journal of Opioid Management, Vol. 5, No. 1: 47-55. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 55276 Version 11.0</div></div></div>"},"55277":{"type":"graphic_waveform","displayName":"Intermediate case 6 with answer","title":"Atrial tachycardia with 2:1 block","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Atrial tachycardia with 2:1 block</div><div class=\"cntnt\"><img style=\"width:464px; height:99px;\" src=\"images/CARD/55277_Intermediate_case_6_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial tachycardia with 2:1 atrioventricular (AV) block. The atrial rate is about 160 beats/min while the ventricular rate is about 80 beats/min. The nonconducted P waves (arrows) are superimposed on the ST-T segments. The P waves have a similar morphology to normal P waves suggesting that the ectopic site is near to the sinoatrial node. This arrhythmia may be an important sign of digitalis toxicity, but can also occur in other settings.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 55277 Version 2.0</div></div></div>"},"55279":{"type":"graphic_diagnosticimage","displayName":"Obstructive emphysema B","title":"Obstructive emphysema in a child following foreign body aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obstructive emphysema in a child following foreign body aspiration</div><div class=\"cntnt\"><img style=\"width:270px; height:378px;\" src=\"images/PULM/55279_Obstructive_emphysema_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inspiratory and expiratory chest&nbsp;radiographs in a child following right-sided foreign body aspiration.<br /> Top panel: The inspiratory film appears normal. <br />Bottom panel: The expiratory film demonstrates hyperlucency of the right lung, indicating obstructive emphysema. </div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 55279 Version 6.0</div></div></div>"},"55283":{"type":"graphic_figure","displayName":"Echo in Fabry disease with LVH","title":"Echocardiography in Fabry disease with left ventricular hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Echocardiography in Fabry disease with left ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:514px; height:366px;\" src=\"images/CARD/55283_EchoinFabrydiseasewith.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiography in four-chamber apical view and left ventricular endomyocardial biopsy from a patient with Fabry disease cardiomyopathy with left ventricular hypertrophy (panels A and C) and from a patient with left ventricular hypertrophy due to hypertrophic cardiomyopathy (panels B and D). Panel A shows two major findings: a thickened hyperechogenic layer, which represents intracellular glycosphingolipid deposition in the endocardium (End) and subendocardial myocardium (SM) (panel C); and a hypoechogenic middle layer (ML) of the myocardium that appears partially spared. This echocardiographic pattern is absent in hypertrophic cardiomyopathy (panel B), despite a similar thickening of the endocardium (panel D).</div><div class=\"graphic_reference\">Reproduced from Pieroni M, Chimenti C, De Cobelli F, et al. J Am Coll Cardiol 2006; 47:1663. Copyright © 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 55283 Version 3.0</div></div></div>"},"55284":{"type":"graphic_picture","displayName":"Grade II infiltrating carcinoma of the breast","title":"Grade II infiltrating carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Grade II infiltrating carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:588px; height:239px;\" src=\"images/ONC/55284_Grade_2_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of a moderately differentiated breast carcinoma shows tumor cells infiltrating as solid nests with some glandular differentiation.<br />(Panel B) High power view demonstrates some nuclear pleomorphism in the tumor cells.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 55284 Version 3.0</div></div></div>"},"55287":{"type":"graphic_table","displayName":"Steroidogenic enzymes","title":"Nomenclature used for steroidogenic enzymes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nomenclature used for steroidogenic enzymes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gene symbol</td> <td class=\"subtitle1\">Prior designation</td> <td class=\"subtitle1\">Trivial name</td> </tr> <tr> <td>CYP11A1</td> <td>P450scc</td> <td>Cholesterol side-chain cleavage enzyme; desmolase</td> </tr> <tr> <td>HSD3B2</td> <td>3-beta-hydroxysteroid dehydrogenase</td> <td>3-beta-hydroxysteroid dehydrogenase</td> </tr> <tr> <td>CYP17</td> <td>P450c17</td> <td>17 alpha-hydroxylase/17, 20-lyase</td> </tr> <tr> <td>CYP21A2</td> <td>P450c21</td> <td>21-hydroxylase</td> </tr> <tr> <td>CYP11B1</td> <td>P450c11</td> <td>11-beta-hydroxylase</td> </tr> <tr> <td>CYP11B2</td> <td>P450c11as</td> <td>Aldosterone synthase, corticosterone methyl oxidase</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55287 Version 2.0</div></div></div>"},"55289":{"type":"graphic_table","displayName":"Prevalence of syncope I","title":"Causes of syncope in pooled data from five population-based studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of syncope in pooled data from five population-based studies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Cause</td>\n\n      <td class=\"subtitle1\">Mean prevalence, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Neurally mediated</td>\n      \n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Vasovagal </td>\n\n      <td class=\"sublist_other\">18</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Situational (eg, cough, micturition, defecation, swallow) </td>\n\n      <td class=\"sublist_other\">5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Carotid sinus syncope</td>\n\n      <td class=\"sublist_other\">1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Orthostatic hypotension</td>\n\n      <td>8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Medications</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Psychiatric</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neurologic</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Cardiac</td>\n      \n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Organic heart disease</td>\n\n      <td class=\"sublist_other\">4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Arrhythmia</td>\n\n      <td class=\"sublist_other\">14</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unknown</td>\n\n      <td>34</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Linzer M, Yang EH, Estes M, et al. Ann Intern Med 1997; 126:989. Includes 1002 unselected patients with syncope, including those from hospital-based referrals, emergency departements, and outpatient clinics between 1984 and 1990.</div><div id=\"graphicVersion\">Graphic 55289 Version 2.0</div></div></div>"},"55290":{"type":"graphic_picture","displayName":"Melomental folds","title":"Melomental folds (marionette lines)","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Melomental folds (marionette lines)</div><div class=\"cntnt\"><img style=\"width:500px; height:338px;\" src=\"images/DERM/55290_Melomental_folds_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial lines extending from the corners of the mouth to the mandible are melomental folds.</div><div id=\"graphicVersion\">Graphic 55290 Version 3.0</div></div></div>"},"55291":{"type":"graphic_diagnosticimage","displayName":"MRI showing osteochondral injury talus","title":"MRI showing osteochondral injury of the talus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI showing osteochondral injury of the talus</div><div class=\"cntnt\"><img style=\"width:418px; height:418px;\" src=\"images/EM/55291_Osteochondral_injury_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This MRI scan demonstrates an osteochondral injury of the talus (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 55291 Version 3.0</div></div></div>"},"55297":{"type":"graphic_table","displayName":"Definition of accuracy","title":"Definition of accuracy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of accuracy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Disease present</td> <td class=\"subtitle1\">Disease absent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test positive</strong></td> <td class=\"centered\"><strong>A</strong></td> <td class=\"centered\"><strong>B</strong></td> </tr> <tr> <td><strong>Test negative</strong></td> <td class=\"centered\"><strong>C</strong></td> <td class=\"centered\"><strong>D</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Accuracy = The number of true positives plus the number of true negatives expressed as a percentage (ie, [A + D]/[A + B + C + D]).</div><div id=\"graphicVersion\">Graphic 55297 Version 2.0</div></div></div>"},"55298":{"type":"graphic_picture","displayName":"Felon","title":"Felon of the fingertip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Felon of the fingertip</div><div class=\"cntnt\"><img style=\"width:200px; height:151px;\" src=\"images/PC/55298_Felon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented with three days of increased swelling, redness, and severe pain of the fingertip.</div><div class=\"graphic_reference\">Reproduced with permission from: Anthony J Viera, MD. Copyright &#169; Anthony J Viera, MD.</div><div id=\"graphicVersion\">Graphic 55298 Version 2.0</div></div></div>"},"55299":{"type":"graphic_table","displayName":"Treatment of conjunctivitis","title":"Therapy of conjunctivitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapy of conjunctivitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Empiric approach</td> </tr> <tr> <td class=\"indent1\">Erythromycin 5 mg/gram ophthalmic ointment</td> <td>One-half inch (1.25 cm) four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Trimethoprim-polymyxin B 0.1%-10,000 units/mL ophthalmic drops</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Ofloxacin 0.3% ophthalmic drops (preferred agent in contact lens wearer)</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ciprofloxacin 0.3% ophthalmic drops (preferred agent in contact lens wearer)</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Specific approach</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Bacterial conjunctivitis</td> </tr> <tr> <td class=\"indent2\">Erythromycin 5 mg/gram ophthalmic ointment</td> <td>One-half inch (1.25 cm) four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Trimethoprim-polymyxin B 0.1%-10,000 units/mL ophthalmic drops</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Bacitracin-polymyxin B 500 units-10,000 units/gram ophthalmic ointment</td> <td>One-half inch (1.25 cm) four to six times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Bacitracin 500 units/gram ophthalmic ointment</td> <td>One-half inch (1.25 cm) four to six times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Ofloxacin 0.3% (preferred agent in contact lens wearers)</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin 0.3% ophthalmic drops (preferred agent in contact lens wearer)</td> <td>1 to 2 drops four times daily for 5 to 7 days</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Azithromycin 1% ophthalmic drops</td> <td>1 drop twice a day for 2 days; then 1 drop daily for 5 days</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Viral conjunctivitis</td> </tr> <tr> <td class=\"indent2\">Antihistamine/decongestant drops (OTC)</td> <td>1 to 2 drops four times daily as needed for no more than three weeks</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Allergic conjunctivitis</td> </tr> <tr> <td class=\"indent2\">Antihistamine/decongestant drops (OTC)</td> <td>1 to 2 drops four times daily as needed for no more than three weeks</td> </tr> <tr> <td class=\"indent2\">Mast cell stabilizer/antihistamine drops</td> <td>Generally, 1 to 2 drops one to three times daily (regimens vary by medication)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Non-specific conjunctivitis</td> </tr> <tr> <td class=\"indent2\">Eye lubricant drops (OTC)</td> <td>1 to 2 drops every 1 to 6 hours as needed</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>AND/OR</strong></td> </tr> <tr> <td class=\"indent2\">Eye lubricant ointment (OTC)</td> <td>One-half inch (1.25 cm) at bedtime or four times daily as needed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OTC: over-the-counter (available without a prescription in the United States).</div><div class=\"graphic_reference\">Courtesy of Deborah S. Jacobs, MD with additional data from: ​The Wills Eye Manual, Chapter 5, \"Conjunctiva/Sclera/Iris/External Disease,\" 4th ed, Kunimoto DY, Kanitkar KD, and Makar MS, eds, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2004.</div><div id=\"graphicVersion\">Graphic 55299 Version 8.0</div></div></div>"},"55301":{"type":"graphic_picture","displayName":"Cocci lung stain B","title":"<EM>Coccidioides </EM>spp in lung tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Coccidioides </EM>spp in lung tissue</div><div class=\"cntnt\"><img style=\"width:430px; height:324px;\" src=\"images/ID/55301_Cocci_lung_stain_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Methenamine silver stain of a pleural biopsy specimen, showing small spherules (white arrow), clumps of endospores (blue arrow), and hyphal forms (black arrows; original magnification, x400).</div><div class=\"graphic_reference\">Reproduced with permission from: Nicolasora N, Cinti SK, Riddell IV J, Kauffman CA. Photo quiz. A 53-year-old man with a large air bubble in his chest. Clin Infect Dis 2008; 47:823. Copyright © 2008 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 55301 Version 3.0</div></div></div>"},"55308":{"type":"graphic_figure","displayName":"Anatomic location VSD","title":"Anatomic locations of ventricular septal defects","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Anatomic locations of ventricular septal defects</div><div class=\"cntnt\"><img style=\"width:559px; height:363px;\" src=\"images/CARD/55308_Anatomic_location_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: The ventricular septum, viewed from the right ventricular side (left panel), is made up of four components: the inlet (I) extends from the tricupid annulus to attachments of the tricuspid valve; the trabecular septum (T) extends from inlet out to apex and up to smooth-walled outlet; the outlet (O) or infundibular septum extends up to the pulmonary valve; and the membranous septum. Right panel: The anatomic location of ventricular septal defects.</div><div class=\"graphic_footnotes\">a: outlet defect; b: papillary muscle of the conus; c: perimembranous defect; d: marginal muscular defects; e: central muscular defects; f: inlet defect; g: apical muscular defects.</div><div class=\"graphic_reference\">Courtesy of Thomas Graham, MD.</div><div id=\"graphicVersion\">Graphic 55308 Version 1.0</div></div></div>"},"55309":{"type":"graphic_figure","displayName":"Pacemaker congenital CHB","title":"Timing of pacemaker implantation according to age at diagnosis of congenital CHB","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timing of pacemaker implantation according to age at diagnosis of congenital CHB</div><div class=\"cntnt\"><img style=\"width:425px; height:294px;\" src=\"images/CARD/55309_Pacemaker_congenital_CHB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 102 cases of congenital complete heart block (CHB), most patients ultimately had a pacemaker inserted, regardless of the time of onset of the syndrome. By 20 years of age, only 11 percent of neonatal and 12 percent of childhood cases had not required pacemaker implantation.</div><div class=\"graphic_reference\">Data from Jaeggi ET, Hamilton RM, Silverman ED, et al, J Am Coll Cardiol 2002; 39:130.</div><div id=\"graphicVersion\">Graphic 55309 Version 2.0</div></div></div>"},"55310":{"type":"graphic_diagnosticimage","displayName":"Quadriceps tendon tear","title":"Quadriceps tendon tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Quadriceps tendon tear</div><div class=\"cntnt\"><img style=\"width:334px; height:396px;\" src=\"images/RHEUM/55310_Chronic_quad_tendon_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the knee demonstrates low position of the patella (arrow) secondary to chronic tear of the quadriceps tendon. A small suprapatellar effusion is also noted (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 55310 Version 4.0</div></div></div>"},"55311":{"type":"graphic_figure","displayName":"Single incision fasciotomy lower leg","title":"Single incision fasciotomy of the lower leg","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Single incision fasciotomy of the lower leg</div><div class=\"cntnt\"><img style=\"width:532px; height:708px;\" src=\"images/SURG/55311_Single-incision-fasciotomy-lower-leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single-incision technique uses a generous lateral leg incision 1 cm anterior to the fibula. Extensive flaps expose the anterior and lateral compartments. Longitudinal fascial incisions are made in anterior and lateral compartment fascia, taking care to avoid injury to the common, superficial and deep (fibular) peroneal nerves near the fibular head. The lateral flap is extended posteriorly to expose the superficial posterior compartment. Once the gastrocnemius is identified, its fascia is incised longitudinally. The deep posterior compartment is accessed in the plane between the lateral and superficial posterior compartment which exposes the posterior margin of the fibula. The soleus is dissected from the posterior aspect of the fibula beginning distally. During the peri-fibular dissection, the fibular (peroneal) vessels are retracted posteriorly to avoid injury.</div><div id=\"graphicVersion\">Graphic 55311 Version 3.0</div></div></div>"},"55315":{"type":"graphic_diagnosticimage","displayName":"CPAM prenatal ultrasound_length","title":"Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:432px; height:357px;\" src=\"images/PEDS/55315_CCAM_prenat_USG_leng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The calipers are used to measure the longest dimension of the lesion (L).</div><div class=\"graphic_footnotes\">* CPAM&nbsp;was previously known as congenital cystic adenomatoid malformation, CCAM.</div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, MD and Andrew P Schuller, RDMS.</div><div id=\"graphicVersion\">Graphic 55315 Version 6.0</div></div></div>"},"55316":{"type":"graphic_diagnosticimage","displayName":"Enchondroma malignant transformation","title":"Solitary enchondroma to chondrosarcoma: Malignant degeneration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary enchondroma to chondrosarcoma: Malignant degeneration</div><div class=\"cntnt\"><img style=\"width:420px; height:549px;\" src=\"images/PEDS/55316_Enchondroma_malignant_tran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Observe the grossly expansile, primarily lytic lesion of the metaphysis and proximal diaphysis of the femur. There is characteristic stippled matrix calcification throughout the lesion (arrows). There is disruption of the cortex with the presence of a soft tissue mass on the medial surface of the femur (arrowheads). The radiographic signs of cortical disruption, a poor zone of transition surrounding the lesion, and a large soft tissue mass support the biopsy diagnosis of malignant degeneration of a pre-existing benign enchondroma to a secondary chondrosarcoma. Malignant degeneration of benign cartilaginous tumors occurs in bones closest to the axial skeleton and is much more common in the long tubular bones than in the small bones of the hands or feet.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55316 Version 3.0</div></div></div>"},"55317":{"type":"graphic_table","displayName":"Indications pacing modes II","title":"Indications for different pacing modes - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for different pacing modes - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mode</td> <td class=\"subtitle1\">Generally agreed upon indications</td> <td class=\"subtitle1\">Controversial indications</td> <td class=\"subtitle1\">Contraindicated</td> </tr> <tr> <td>DVI*</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>VDD<sup>&#182;</sup></td> <td> <p>Congenital AV block</p> AV block when sinus node function can be proven normal</td> <td>&nbsp;</td> <td> <p>Sinus node dysfunction</p> <p>AV block when accompanied by sinus node dysfunction</p> <p>When adequate atrial sensing cannot be attained</p> AV block when accompanied by paroxysmal supraventricular tachycardias</td> </tr> <tr> <td>VDDR<sup>&#916;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular<br />* DVI as a stand-alone pacing mode (ie, a pacemaker capable of DVI as the only dual-chamber mode of operation) is obsolete. All primary uses of this mode should be considered individually.<br />¶ VDD as a stand-alone pacing mode (ie, a pacemaker capable of VDD as the only dual-chamber mode of operation) is currently used primarily as a single-lead VDD system. If a dual-lead system is implanted, then the capability of DDD pacing is desirable.<br />Δ In current single-lead VDDR pacemakers, P-wave tracking occurs as long as the sinus rate is appropriate. However, in the presence of sinus bradycardia or chronotropic incompetence, the pacemaker operates in the VVIR mode.</div><div id=\"graphicVersion\">Graphic 55317 Version 3.0</div></div></div>"},"55318":{"type":"graphic_picture","displayName":"Hyperpigmentation","title":"Hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:297px; height:396px;\" src=\"images/PC/55318_Hyperpigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmentation following sclerotherapy</div><div class=\"graphic_reference\">Reproduced with permission from: New Zealand Dermatological Society Incorporated (DermNetNZ.org). Copyright &#169;2009 DermNet NZ.</div><div id=\"graphicVersion\">Graphic 55318 Version 1.0</div></div></div>"},"55319":{"type":"graphic_figure","displayName":"Prevalence of polyps with age","title":"Prevalence of adenomatous colonic polyps increases with age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevalence of adenomatous colonic polyps increases with age</div><div class=\"cntnt\"><img style=\"width:415px; height:256px;\" src=\"images/PC/55319_Prevalence_of_polyps_with_a.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adenomatous colonic polyps are found in about 25 percent of people by the age of 50; the prevalence continues to increase with increasing age.</div><div class=\"graphic_reference\">Data from: Williams AR, Balasooriya BA, Day DW, Gut 1982; 123:835.</div><div id=\"graphicVersion\">Graphic 55319 Version 2.0</div></div></div>"},"55320":{"type":"graphic_table","displayName":"Causes central airway obstruct","title":"Conditions associated with central airway obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with central airway obstruction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignant</td> </tr> <tr> <td class=\"indent1\"><strong>Primary endoluminal malignancy</strong></td> </tr> <tr> <td class=\"indent2\">Bronchogenic</td> </tr> <tr> <td class=\"indent2\">Adenoid cystic</td> </tr> <tr> <td class=\"indent2\">Mucoepidermoid</td> </tr> <tr> <td class=\"indent2\">Carcinoid</td> </tr> <tr> <td class=\"indent2\">Plasmacytoma</td> </tr> <tr> <td class=\"indent1\"><strong>Metastatic carcinoma to the airway</strong></td> </tr> <tr> <td class=\"indent2\">Bronchogenic</td> </tr> <tr> <td class=\"indent2\">Renal cell</td> </tr> <tr> <td class=\"indent2\">Breast</td> </tr> <tr> <td class=\"indent2\">Thyroid</td> </tr> <tr> <td class=\"indent2\">Colon</td> </tr> <tr> <td class=\"indent2\">Sarcoma</td> </tr> <tr> <td class=\"indent2\">Melanoma</td> </tr> <tr> <td class=\"indent1\"><strong>Laryngeal and nasopharyngeal carcinoma</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Esophageal carcinoma</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Mediastinal tumors</strong></td> </tr> <tr> <td class=\"indent2\">Thymic carcinoma</td> </tr> <tr> <td class=\"indent2\">Thyroid carcinoma</td> </tr> <tr> <td class=\"indent2\">Germ cell tumors (eg, teratoma)</td> </tr> <tr> <td class=\"indent1\"><strong>Lymphadenopathy</strong></td> </tr> <tr> <td class=\"indent2\">Associated with any of the above malignancies</td> </tr> <tr> <td class=\"indent2\">Lymphoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nonmalignant</td> </tr> <tr> <td class=\"indent1\"><strong>Benign airway tumors</strong></td> </tr> <tr> <td class=\"indent2\">Squamous cell papilloma</td> </tr> <tr> <td class=\"indent2\">Hamartoma</td> </tr> <tr> <td class=\"indent1\"><strong>Lymphadenopathy</strong></td> </tr> <tr> <td class=\"indent2\">Sarcoidosis</td> </tr> <tr> <td class=\"indent2\">Infectious (ie, tuberculosis)</td> </tr> <tr> <td class=\"indent1\"><strong>Vascular</strong></td> </tr> <tr> <td class=\"indent2\">Vascular ring</td> </tr> <tr> <td class=\"indent2\">Vascular aneurysm</td> </tr> <tr> <td class=\"indent1\"><strong>Cartilage</strong></td> </tr> <tr> <td class=\"indent2\">Relapsing polychondritis</td> </tr> <tr> <td class=\"indent1\"><strong>Granulation tissue</strong></td> </tr> <tr> <td class=\"indent2\">Endotracheal tubes</td> </tr> <tr> <td class=\"indent2\">Tracheostomy tubes</td> </tr> <tr> <td class=\"indent2\">Airway stents</td> </tr> <tr> <td class=\"indent2\">Foreign bodies</td> </tr> <tr> <td class=\"indent2\">Surgical anastomosis (eg, post resection or transplant)</td> </tr> <tr> <td class=\"indent2\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent2\">Rhinoscleroma (klebsiella infection)</td> </tr> <tr> <td class=\"indent1\"><strong>Pseudotumor</strong></td> </tr> <tr> <td class=\"indent2\">Endobronchial pseudotumor</td> </tr> <tr> <td class=\"indent1\"><strong>Hyperdynamic</strong></td> </tr> <tr> <td class=\"indent2\">Tracheomalacia</td> </tr> <tr> <td class=\"indent2\">Bronchomalacia</td> </tr> <tr> <td class=\"indent1\"><strong>Webs</strong></td> </tr> <tr> <td class=\"indent2\">Idiopathic progressive subglottic stenosis</td> </tr> <tr> <td class=\"indent2\">Tuberculosis</td> </tr> <tr> <td class=\"indent2\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent2\">Goiter</td> </tr> <tr> <td class=\"indent2\">Mucus plug</td> </tr> <tr> <td class=\"indent2\">Vocal cord paralysis</td> </tr> <tr> <td class=\"indent2\">Airway hematoma</td> </tr> <tr> <td class=\"indent2\">Burn/smoke injury</td> </tr> <tr> <td class=\"indent2\">Epiglottitis</td> </tr> <tr> <td class=\"indent2\">Blood clot</td> </tr> <tr> <td class=\"indent2\">Amyloid</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278. Copyright &copy; 2004 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 55320 Version 4.0</div></div></div>"},"55323":{"type":"graphic_figure","displayName":"Uterine distension and PTB","title":"Uterine distension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine distension</div><div class=\"cntnt\"><img style=\"width:311px; height:303px;\" src=\"images/OBGYN/55323_Uterine_distension_and_PTB.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 55323 Version 1.0</div></div></div>"},"55324":{"type":"graphic_picture","displayName":"Bulky foot compression dressing","title":"Bulky foot compression dressing","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Bulky foot compression dressing</div><div class=\"cntnt\"><img style=\"width:535px; height:287px;\" src=\"images/EM/55324_Bulky_foot_compression_dres.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bulky foot compression dressing is used to treat calcaneal fractures and foot injuries. Sheet wadding in several layers is applied after cotton fluffs are placed between the toes, and elastic bandage is used to wrap the foot. The elastic wrap should be looser around the leg than the ankle, providing a pressure gradient to facilitate drainage for edema.</div><div id=\"graphicVersion\">Graphic 55324 Version 2.0</div></div></div>"},"55325":{"type":"graphic_picture","displayName":"Morning glory disc","title":"Morning glory disc anomaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morning glory disc anomaly</div><div class=\"cntnt\"><img style=\"width:353px; height:289px;\" src=\"images/PEDS/55325_Morning_glory_disc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The disc is large and there is a central, white tuft of glial tissue. The retinal vessels proceed radially from the disc.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 55325 Version 1.0</div></div></div>"},"55327":{"type":"graphic_table","displayName":"Unfavorable prognostic factors early HL","title":"Unfavorable prognostic factors in early (stage I/II) Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unfavorable prognostic factors in early (stage I/II) Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">European Organization for the Research and Treatment of Cancer (EORTC)</td> </tr> <tr> <td> <ul> <li>Large mediastinal adenopathy (&#62;1/3 maximum transverse thoracic diameter) </li> <li>Involvement of four or more lymph node regions </li> <li>Age &#8805;50 years at diagnosis </li> <li>A defined combination of B symptoms* and elevated ESR: B symptoms and an ESR over 30 mm/hour or an ESR over 50 mm/hour without B symptoms </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">German Hodgkin's Study Group (GHSG)</td> </tr> <tr> <td> <ul> <li>Large mediastinal adenopathy (&#62;1/3 maximum transverse thoracic diameter) </li> <li>Three or more lymph node sites of involvement </li> <li>A defined combination of B symptoms and elevated ESR: B symptoms and an ESR over 30 mm/hour; an ESR over 50 mm/hour without B symptoms </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Groupe d'Etudes des Lymphomes de l'Adulte (GELA)</td> </tr> <tr> <td> <ul> <li>Age 45 years or older </li> <li>Male gender </li> <li>Extranodal disease </li> <li>Hemoglobin 10.5 g/dL or less </li> <li>Absolute lymphocyte count of 600 mg/microL or less </li> <li>Elevated ESR </li> <li>B symptoms </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">National Cancer Institute of Canada (NCIC)/Eastern Cooperative Oncology Group (ECOG)</td> </tr> <tr> <td> <ul> <li>Large mediastinal adenopathy (&#62;1/3 maximum transverse thoracic diameter) </li> <li>Involvement of four or more sites </li> <li>Age &#8805;40 years at diagnosis </li> <li>ESR &#62;50 mm/hour </li> <li>Mixed cellularity histology </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Once the diagnosis of Hodgkin lymphoma has been established, therapy and prognosis are based upon the stage of the disease. Among patients with stage I-II disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Stratification of patients with early stage disease into favorable and unfavorable subsets varies by region.</div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate.<BR>* B symptoms are systemic symptoms of significant unexplained fever, night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis.</div><div id=\"graphicVersion\">Graphic 55327 Version 2.0</div></div></div>"},"55328":{"type":"graphic_figure","displayName":"Allergen-specific IgE production and dissemination","title":"Allergen-specific IgE production and dissemination","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Allergen-specific IgE production and dissemination</div><div class=\"cntnt\"><img style=\"width:484px; height:712px;\" src=\"images/ALLRG/55328_Allergen-sensitization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergens (in this figure, aeroallergens)&nbsp;enter the tonsils within which they are taken up and degraded by antigen-presenting cells (APCs). APCs then&nbsp;interact with T helper type 2&nbsp;(Th2) cells and B cells in the lymph nodes, leading to allergen-specific IgE production. The IgE&nbsp;enters the blood stream and then diffuses&nbsp;through tissues (especially the skin and&nbsp;mucosal tissues of the respiratory and&nbsp;gastrointestinal tracts).&nbsp;The IgE&nbsp;binds to high-affinity Fc receptors (Fc-epsilon-RI) on the surface of the tissue mast cells and circulating basophils. When these IgE-coated cells encounter that specific aeroallergen subsequently, they become activated, leading to the release of inflammatory mediators, which results in the signs and symptoms of IgE-mediated allergic reactions.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 55328 Version 8.0</div></div></div>"},"55329":{"type":"graphic_table","displayName":"Sexual maturity rating of secondary sexual characteristics","title":"Sexual maturity rating (Tanner stages) of secondary sexual characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sexual maturity rating (Tanner stages) of secondary sexual characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Boys&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><strong>&ndash;</strong></span> Development of external genitalia</td> </tr> <tr> <td class=\"indent1\">Stage 1: Prepubertal</td> </tr> <tr> <td class=\"indent1\">Stage 2: Enlargement of testes and scrotum; scrotal skin reddens and changes in texture</td> </tr> <tr> <td class=\"indent1\">Stage 3: Enlargement of penis (length at first); further growth of testes</td> </tr> <tr> <td class=\"indent1\">Stage 4: Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotal skin darker</td> </tr> <tr> <td class=\"indent1\">Stage 5: Adult genitalia</td> </tr> <tr> <td class=\"subtitle1_single\">Girls&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><strong>&ndash;</strong></span> Breast development</td> </tr> <tr> <td class=\"indent1\">Stage 1: Prepubertal</td> </tr> <tr> <td class=\"indent1\">Stage 2: Breast bud stage with elevation of breast and papilla; enlargement of areola</td> </tr> <tr> <td class=\"indent1\">Stage 3: Further enlargement of breast and areola; no separation of their contour</td> </tr> <tr> <td class=\"indent1\">Stage 4: Areola and papilla form a secondary mound above level of breast</td> </tr> <tr> <td class=\"indent1\">Stage 5: Mature stage: Projection of papilla only, related to recession of areola</td> </tr> <tr> <td class=\"subtitle1_single\">Boys and girls&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><strong>&ndash;</strong></span> Pubic hair</td> </tr> <tr> <td class=\"indent1\">Stage 1: Prepubertal (the pubic area may have vellus&nbsp;hair,&nbsp;similar to that of forearms)</td> </tr> <tr> <td class=\"indent1\">Stage 2: Sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia</td> </tr> <tr> <td class=\"indent1\">Stage 3: Darker, coarser, and more curled hair, spreading sparsely over junction of pubes</td> </tr> <tr> <td class=\"indent1\">Stage 4: Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs</td> </tr> <tr> <td class=\"indent1\">Stage 5: Adult in type and quantity, with horizontal upper border</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55329 Version 10.0</div></div></div>"},"55330":{"type":"graphic_figure","displayName":"Transperineal fistula repair6","title":"Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex</div><div class=\"cntnt\"><img style=\"width:420px; height:462px;\" src=\"images/OBGYN/55330_Transperineal_fistula_rep5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The puborectalis fibers are reapproximated in the midline, providing an additional reinforcing layer between the anterior rectal and posterior vaginal walls.</div><div id=\"graphicVersion\">Graphic 55330 Version 1.0</div></div></div>"},"55331":{"type":"graphic_picture","displayName":"Leukemia cutis forearms","title":"Leukemia cutis forearms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukemia cutis forearms</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/HEME/55331_Leukemia_cutis_forearms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leukemia cutis: extensor forearms.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright ©2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55331 Version 2.0</div></div></div>"},"55332":{"type":"graphic_picture","displayName":"Corneal ulcers fluorescein","title":"Corneal infiltrates or ulcers with fluorescein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal infiltrates or ulcers with fluorescein</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PC/55332_Corneal_ulcers_fluorescein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two small corneal areas of fluorescein staining (indicated by the arrows) that are either infiltrates or ulcers are shown with illumination using a cobalt blue filter.</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 55332 Version 2.0</div></div></div>"},"55334":{"type":"graphic_figure","displayName":"Axillary artery anatomy","title":"Axillary artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Axillary artery anatomy</div><div class=\"cntnt\"><img style=\"width:513px; height:602px;\" src=\"images/SURG/55334_Axillary_artery_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axillary artery is palpated within the axilla when the arm is abducted and externally rotated.</div><div class=\"graphic_reference\">Adapted from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 55334 Version 4.0</div></div></div>"},"55335":{"type":"graphic_picture","displayName":"Peutz-Jeghers syndrome lip pigmentation","title":"Peutz-Jeghers syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peutz-Jeghers syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/55335_Peutz-Jeghers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pigmented macules are present on the lips.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55335 Version 3.0</div></div></div>"},"55336":{"type":"graphic_picture","displayName":"Lichenoid chronic GVHD","title":"Chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:373px;\" src=\"images/DERM/55336_Lichenoid_chronic_GVHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous papules and plaques, many with a reticulated appearance, are present on the trunk and extremities.</div><div id=\"graphicVersion\">Graphic 55336 Version 1.0</div></div></div>"},"55337":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound images of umbilical cord insertion sites","title":"Prenatal ultrasound images of umbilical cord insertion sites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound images of umbilical cord insertion sites</div><div class=\"cntnt\"><img style=\"width:316px; height:514px;\" src=\"images/OBGYN/55337_Umbil_cord_insert_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilical cord insertion sites in the second trimester.<br> (A) Transverse view of the fetal abdomen shows the normal fetal umbilical cord insertion into the anterior abdominal wall.<br> (B) Normal cord insertion into the placental mass.</div><div id=\"graphicVersion\">Graphic 55337 Version 2.0</div></div></div>"},"55338":{"type":"graphic_table","displayName":"Supportive care variceal bleed","title":"Supportive care of patients with active variceal hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supportive care of patients with active variceal hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hemodynamic resuscitation</td> </tr> <tr> <td>Packed red cell transfusion to keep hemoglobin between 7&nbsp;and 8&nbsp;g/dL</td> </tr> <tr> <td>Crystalloids to keep urine volume &#62;50 mL/h</td> </tr> <tr> <td>Correct coagulopathy and thrombocytopenia as indicated</td> </tr> <tr> <td>Avoid volume overload</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary resuscitation</td> </tr> <tr> <td>Monitor airway integrity and oxygen saturation</td> </tr> <tr> <td>Protect airway if mental status obtunded or if active hemetemesis present</td> </tr> <tr> <td class=\"subtitle1_single\">Infection prophylaxis and detection</td> </tr> <tr> <td>Antibiotic prophylaxis for patients with ascites</td> </tr> <tr> <td>Monitor closely for signs of sepsis</td> </tr> <tr> <td class=\"subtitle1_single\">Renal management</td> </tr> <tr> <td>Avoid transfusion mismatch</td> </tr> <tr> <td>Avoid aminoglycosides and other nephrotoxic drugs</td> </tr> <tr> <td>Maintain euvolemia</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Monitor for alcohol withdrawal</td> </tr> <tr> <td>Thiamine replacement if suspected deficiency</td> </tr> <tr> <td>Monitor for hypokalemia, hypophosphatemia, and acid-base balance</td> </tr> <tr> <td>Monitor for acid-base balance and correct as necessary</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55338 Version 3.0</div></div></div>"},"55340":{"type":"graphic_table","displayName":"Arbovirus CNS infections","title":"Clinically significant arboviruses causing CNS infections in humans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically significant arboviruses causing CNS infections in humans</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Viral taxonomy\n   </td>\n   <td  class=\"subtitle1\">\n   Vectors\n   </td>\n   <td  class=\"subtitle1\">\n   Incubation period, days\n   </td>\n   <td  class=\"subtitle1\">\n   Geographic distribution\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">\n   Togaviridae\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Eastern equine encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>3 to 10</td>\n   <td>East United States and Canada, South America</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Western equine encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>2 to 10</td>\n   <td>West United States and Canada, South America</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Venezuelan equine encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>1 to 4</td>\n   <td>Central and South America</td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">\n   Flaviviridae\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   St. Louis encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>4 to 14</td>\n   <td>United States</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Powassan virus\n   </td>\n   <td>Ticks</td>\n   <td>4 to 18</td>\n   <td>North United States</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   West Nile virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>5 to 15</td>\n   <td>United States, southern Europe, Asia, Africa</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Japanese encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>4 to 14</td>\n   <td>Asia</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Murray Valley encephalitis virus\n   </td>\n   <td>Mosquitoes</td>\n   <td>4 to 14</td>\n   <td>Australia and New Guinea</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Tick-borne encephalitis virus\n   </td>\n   <td>Ticks</td>\n   <td>8 to 14</td>\n   <td>Europe</td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">\n   Bunyaviridae\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2_start\">\n   California encephalitis viruses\n   </td>\n   <td  colspan=\"1\" rowspan=\"4\">\n   Mosquitoes\n   </td>\n   <td  colspan=\"1\" rowspan=\"4\">\n   5 to 15\n   </td>\n   <td>West United States, Europe, Asia</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Snowshoe hare\n   </td>\n   <td  class=\"sublist_other\">\n   North United States\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Jamestown Canyon\n   </td>\n   <td  class=\"sublist_other\">\n   United States\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   La Crosse\n   </td>\n   <td  class=\"sublist_other\">\n   Midwest, east, south United States\n   </td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 55340 Version 1.0</div></div></div>"},"55341":{"type":"graphic_table","displayName":"Most common medial elbow throwing injury by skeletal maturity","title":"Most common medial elbow throwing injury by skeletal maturity level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common medial elbow throwing injury by skeletal maturity level</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Maturity level</td>\n\n      <td class=\"subtitle1\">Skeletal maturity</td>\n\n      <td class=\"subtitle1\">Most common injury</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Childhood</td>\n\n      <td>From birth to the appearance of all secondary ossification centers</td>\n\n      <td>Medial epcondyle apophysitis</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Adolescence</td>\n\n      <td>From the appearance of all to the fusion of all the secondary ossification centers</td>\n\n      <td>Medial epicondyle avulsion fracture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Young adulthood</td>\n\n      <td>From the end of adolescence to the attainment of all bone growth and muscular form</td>\n\n      <td>Ulnar collateral ligament tear</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51430&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DDx_medial_elbow_injury.htm</title></head></div><div id=\"graphicVersion\">Graphic 55341 Version 2.0</div></div></div>"},"55342":{"type":"graphic_table","displayName":"Eval adolescent WLS","title":"Recommended evaluation of an adolescent considering bariatric surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended evaluation of an adolescent considering bariatric surgery</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Anthropometrics</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Systolic and diastolic blood pressure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Waist circumference</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Weight</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Height</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tanner Stage (criteria for surgery is Tanner stage 4 or more)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Laboratory testing</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fasting lipid profile</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fasting insulin and glucose</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Oral glucose tolerance test</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hemoglobin A1C</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver profile</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>TSH</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Diagnostic evaluations</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Polysomnography</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Echocardiogram</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Electrocardiogram</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Urea breath test or endoscopy to exclude helicobacter pylori infection</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bone age if needed to assess skeletal maturity (criteria for surgery is attainment of &#8805;95 percent of predicted adult height)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Comprehensive psychological evaluation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Evaluation by pediatric psychologist or psychiatrist to screen for cognitive and psychiatric disorders, assess emotional maturity, decisional capacity and family support</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 55342 Version 2.0</div></div></div>"},"55343":{"type":"graphic_table","displayName":"Risk of spine injury in children","title":"Factors producing increased mobility and risk of injury to the pediatric spine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors producing increased mobility and risk of injury to the pediatric spine</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Large size of head in comparison to neck and trunk, increasing flexion, extension, and shearing forces on the cervical spine</td>\n   </tr>\n   <tr>\n   <td>Underdevelopment of paraspinous muscles</td>\n   </tr>\n   <tr>\n   <td>Shallow, horizontally oriented facet joints</td>\n   </tr>\n   <tr>\n   <td>Increased elasticity of facet joint ligaments</td>\n   </tr>\n   <tr>\n   <td>Incompletely ossified vertebrae</td>\n   </tr>\n   <tr>\n   <td>High water content and elasticity of intervertebral disks, increasing vertical loading effect</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from Akbarnia, BA. Orthop Clin North Am 1999; 30:521; Thomas, NH, Robinson, L, Evans, A, Bullock, P. Pediatr Neurosurg 1995; 23:188; and Rooks, VJ, Sisler, C, Burton, B. Pediatr Radiol 1998; 28:193.</div><div id=\"graphicVersion\">Graphic 55343 Version 2.0</div></div></div>"},"55344":{"type":"graphic_table","displayName":"Fallop tube cancer FIGO surv","title":"Carcinoma of the Fallopian tube: FIGO stage and five-year survival for patients treated in 1999-2001","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carcinoma of the Fallopian tube: FIGO stage and five-year survival for patients treated in 1999-2001</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">FIGO stage</td> <td class=\"subtitle1\">Number of patients (n)</td> <td class=\"subtitle1\">Five-year survival (percent)</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">51</td> <td class=\"centered\">81.3</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">40</td> <td class=\"centered\">66.9</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">67</td> <td class=\"centered\">41.3</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">12</td> <td class=\"centered\">33.3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original table modified for this publication. From: Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the fallopian tube. Int J Gynaecol Obstet 2006; 95:S145. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55344 Version 11.0</div></div></div>"},"55347":{"type":"graphic_figure","displayName":"Third nerve palsy","title":"Third nerve palsy of the left eye","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Third nerve palsy of the left eye</div><div class=\"cntnt\"><img style=\"width:542px; height:265px;\" src=\"images/PEDS/55347_Third_nerve_palsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical features of third nerve palsy may include ptosis and pupillary dilation (all images); exotropia and hypotropia in neutral gaze (central image); limited adduction (left column); limited elevation (top row); and limited depression (bottom row).</div><div id=\"graphicVersion\">Graphic 55347 Version 6.0</div></div></div>"},"55348":{"type":"graphic_diagnosticimage","displayName":"Cervical osteoarthritis radiograph","title":"Cervical spine osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical spine osteoarthritis</div><div class=\"cntnt\"><img style=\"width:337px; height:524px;\" src=\"images/PC/55348_Cervicalosteoarthritisxra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view from a cervical spine plain film series of a 77-year-old who complained of neck stiffness. He denied radicular symptoms or loss of strength in the upper extremities. Neck rotation measured 60 to 65 degrees (30% loss) with end-point stiffness. The Spurling maneuver was normal as was the neurologic examination. Imaging demonstrates exaggerated cervical lordosis and narrowed and irregular disk spaces (arrows). The posterior aspects of the vertebral bodies and facet joints are hypertrophic and sclerotic. Foraminal encroachment by osteophytes (arrowheads) is also noted.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55348 Version 4.0</div></div></div>"},"55350":{"type":"graphic_figure","displayName":"Diagnosis and reporting grid for NSF scoring system","title":"Diagnosis and reporting grid for nephrogenic systemic fibrosis (NSF) scoring system","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Diagnosis and reporting grid for nephrogenic systemic fibrosis (NSF) scoring system</div><div class=\"cntnt\"><img style=\"width:519px; height:248px;\" src=\"images/NEPH/55350_Diag_report_grid_NSF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Using grid:</strong><br />Clinical score is located across top row of grid, whereas histologic score is located along left vertical column. Intersection of these two values within chart results in one of six diagnostic possibilities. For epidemiologic purposes, those in green should be scored as confirmed nephrogenic systemic fibrosis (NSF) cases. Those in yellow should be closely re-examined and perhaps rebiopsied. Until more compelling evidence is obtained, these will not have satisfied criteria for NSF and should be considered nondiagnostic of NSF. Those in red are ruled out either for lack of criteria or because another Dx can be made.<br /><strong>Caveats:</strong><br /><ol>&#xD;&#xA;    <li>Absence of documentable renal disease: in the unlikely event the final patient score falls into NSF box, yet current or prior renal disease cannot be established, the most certain Dx that should be rendered is \"suggestive of NSF.\" Consultants with extensive NSF experience should evaluate any such case, as it would represent a highly unusual occurence.</li>&#xD;&#xA;    <li>Postmortem evaluation of suspected NSF: the histological assessment of NSF in the postmortem setting is not difficult, provided the diagnosis is suspected clinically and generous samples of contiguous skin, fascia, and underlying muscle are obtained. This type of specimen is not gathered during a routine postmortem examination, however, so the pathologist must be made aware of the suspected diagnosis in advance to assure appropriate sampling. The clinical examination is much more challenging as neither induration nor range of motion can be appropriately assessed, and livedoid patterning may occur as a normal postmortem finding. Scleral plaques in persons younger than 45 years of age, if combined with excellent histology and a good physician-documented corroborative medical record, may enable a definitive diagnosis in the postmortem setting.</li>&#xD;&#xA;</ol></div><div class=\"graphic_reference\">Reproduced from: Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55350 Version 3.0</div></div></div>"},"55351":{"type":"graphic_figure","displayName":"Accessory paths in Mahaim tachy","title":"AV connections in Mahaim fiber tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AV connections in Mahaim fiber tachycardia</div><div class=\"cntnt\"><img style=\"width:175px; height:280px;\" src=\"images/CARD/55351_Accessory_paths_in_Mahaim_t.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two types of accessory atrioventricular (AV) pathways are associated with a Mahaim fiber tachycardia. The most common is an atriofascicular tract (AFT) that arises at the AV annulus and inserts in the apical portion of the right ventricle. The second is an atrioventricular tract (AVT) that arises from the same location, but inserts into the proximal right ventricle, near the annulus.</div><div id=\"graphicVersion\">Graphic 55351 Version 1.0</div></div></div>"},"55352":{"type":"graphic_diagnosticimage","displayName":"Whales tail EUS","title":"Celiac artery bifurcation seen on endoscopic ultrasound (whale's tail sign)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac artery bifurcation seen on endoscopic ultrasound (whale's tail sign)</div><div class=\"cntnt\"><img style=\"width:340px; height:605px;\" src=\"images/GAST/55352_Whales_tail_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: Radial EUS image showing the celiac artery (CA) bifurcating into the hepatic artery (HA) and the splenic artery (SA), or the so-called &quot;whale's tail&quot; sign. Bottom: Simplification of top image.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 55352 Version 3.0</div></div></div>"},"55353":{"type":"graphic_figure","displayName":"Number of risk factors and CVD risk","title":"Additive effects of risk factors on cardiovascular disease at five years","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Additive effects of risk factors on cardiovascular disease at five years</div><div class=\"cntnt\"><img style=\"width:575px; height:383px;\" src=\"images/NEPH/55353_Numberofriskfactorsand.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative absolute risk of CVD at five years according to systolic blood pressure and specified levels of other risk factors. The reference category is a non-diabetic, non-smoking 50-year-old woman with a serum TC of 154 mg/dL (4.0 mmol/L) and HDL cholesterol of 62 mg/dL (1.6 mmol/L). The CVD risks are given for systolic blood pressure levels of 110, 130, 150, and 170 mmHg. In the other categories, the additional risk factors are added consecutively. As an example, the diabetes category is a 50-year-old diabetic man who is a smoker and has a TC of 270 mg/dL (7 mmol/L) and HDL cholesterol of 39 mg/dL (1 mmol/L).</div><div class=\"graphic_footnotes\">BP: blood pressure; CVD: cardiovascular disease; HDL: high-density lipoprotein; TC: total cholesterol.</div><div class=\"graphic_reference\">Adapted from: Jackson R, Lawes CM, Bennett DA, et al. Lancet 2005; 365:434.</div><div id=\"graphicVersion\">Graphic 55353 Version 11.0</div></div></div>"},"55354":{"type":"graphic_picture","displayName":"Myelomeningocele newborn","title":"Myelomeningocele defect in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myelomeningocele defect in a newborn infant</div><div class=\"cntnt\"><img style=\"width:360px; height:246px;\" src=\"images/PEDS/55354_Meningomyelocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A myelomeningocele in a newborn infant.</div><div class=\"graphic_reference\">Courtesy of Marvin A Fishman, MD.</div><div id=\"graphicVersion\">Graphic 55354 Version 3.0</div></div></div>"},"55355":{"type":"graphic_table","displayName":"UGI versus US in pyloric stenosis","title":"Comparison of ultrasonography and upper gastrointestinal contrast study in the diagnosis of pyloric stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of ultrasonography and upper gastrointestinal contrast study in the diagnosis of pyloric stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Ultrasonography</td>\n\n\n      <td class=\"subtitle1\">Upper GI contrast study</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Cost</td>\n\n\n      <td>Variable</td>\n\n\n      <td>Variable</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Radiation exposure</td>\n\n\n      <td>None </td>\n\n\n      <td>Present</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Diagnostic differentiation</td>\n\n\n      <td>Can only demonstrate IHPS if present</td>\n\n\n      <td>Demonstrates IHPS, other causes of obstruction, and anatomic variation</td>\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n      <td>Risk of aspiration</td>\n\n\n      <td>None</td>\n\n\n      <td>Present but small</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Dependence on skill of technician</td>\n\n\n      <td>High</td>\n\n\n      <td>Low</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">IHPS: infantile hypertrophic pyloric stenosis.</div><div class=\"graphic_reference\">Adapted from: <BR>1. Mandell GA, Wolfson PJ, Adkins ES, et al, Pediatrics 1999; 103:1198.<BR>2. Hulka F, Campbell JR, Harrison MW, Campbell TJ, J Pediatric Surg 1997; 32:1604.<BR>3. Godbole P, Sprigg A, Dickson JA, Lin PC, Arch Dis Child 1996; 75:335.</div><div id=\"graphicVersion\">Graphic 55355 Version 2.0</div></div></div>"},"55357":{"type":"graphic_picture","displayName":"Angular cheilitis","title":"Angular cheilitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angular cheilitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/55357_Angular_cheilitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and fissures are present at the corners of the mouth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55357 Version 3.0</div></div></div>"},"55358":{"type":"graphic_picture","displayName":"Mushroom spore print","title":"Mushroom spore print","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mushroom spore print</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/EM/55358_Mushroom_spore_print.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This mushroom cap was placed upon the paper several hours ago and was kept in a room without significant wind or drafts. The resulting print is highly specific to the genus and species of the mushroom but should be interpreted by a professional mycologist.</div><div class=\"graphic_reference\">Courtesy of Paul Dengler.</div><div id=\"graphicVersion\">Graphic 55358 Version 1.0</div></div></div>"},"55359":{"type":"graphic_picture","displayName":"Gastric folds","title":"Gastric folds","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Gastric folds</div><div class=\"cntnt\"><img style=\"width:461px; height:459px;\" src=\"images/GAST/55359_Gastric_folds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric folds seen upon passage of an upper endoscope into the stomach during esophagogastroduodenoscopy.</div><div id=\"graphicVersion\">Graphic 55359 Version 1.0</div></div></div>"},"55361":{"type":"graphic_picture","displayName":"Proper movement avoid twisting","title":"Proper mechanics: Move entire body forward and avoid twisting at the waist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper mechanics: Move entire body forward and avoid twisting at the waist</div><div class=\"cntnt\"><img style=\"width:269px; height:382px;\" src=\"images/RHEUM/55361_prop_move_avoid_twist.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 55361 Version 1.0</div></div></div>"},"55362":{"type":"graphic_table","displayName":"IMWG response criteria","title":"2016 International Myeloma Working Group uniform response criteria for multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2016 International Myeloma Working Group uniform response criteria for multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Response criteria*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">IMWG MRD criteria (requires a complete response as defined below)</td> </tr> <tr> <td class=\"indent1\">Sustained MRD-negative</td> <td>MRD negativity in the marrow (NGF or NGS, or both) and by imaging as defined below, confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify the duration of negativity (eg, MRD-negative at 5 years).<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Flow MRD-negative</td> <td>Absence of phenotypically aberrant clonal plasma cells by NGF<sup>&#916;</sup> on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10<sup>5</sup> nucleated cells or higher.</td> </tr> <tr> <td class=\"indent1\">Sequencing MRD-negative</td> <td>Absence of clonal plasma cells by NGS on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10<sup>5</sup> nucleated cells<sup>&#9674;</sup> or higher.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Imaging plus MRD-negative</td> <td>MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less than the mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue.<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Standard IMWG response criteria<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Stringent complete response</td> <td>Complete response as defined below plus normal FLC ratio<sup>&#135;</sup> and absence of clonal cells in bone marrow biopsy by immunohistochemistry (&#954;/&#955; ratio &#8804;4:1 or &#8805;1:2 for &#954; and &#955; patients, respectively, after counting &#8805;100 plasma cells).<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Complete response</td> <td>Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &#60;5% plasma cells in bone marrow aspirates.</td> </tr> <tr> <td class=\"indent1\">Very good partial response</td> <td>Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &#8805;90% reduction in serum M-protein plus urine M-protein level &#60;100 mg per 24 hours.</td> </tr> <tr> <td class=\"indent1\">Partial response</td> <td>&#8805;50% reduction of serum M-protein plus reduction in 24 hour urinary M-protein by &#8805;90% or to &#60;200 mg per 24 hours. If the serum and urine M-protein are unmeasurable, a &#8805;50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, &#8805;50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was &#8805;30%. In addition to these criteria, if present at baseline, a &#8805;50% reduction in the size (SPD)** of soft tissue plasmacytomas is also required.</td> </tr> <tr> <td class=\"indent1\">Minimal response</td> <td>&#8805;25% but &#8804;49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50 to 89%. In addition to the above listed criteria, if present at baseline, a &#8805;50% reduction in the size (SPD)** of soft tissue plasmacytomas is also required.</td> </tr> <tr> <td class=\"indent1\">Stable disease</td> <td>Not recommended for use as an indicator of response; stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.</td> </tr> <tr> <td class=\"indent1\">Progressive disease<sup>&#182;&#182;,</sup><sup>&#916;&#916;</sup></td> <td>Any one or more of the following criteria: <ul class=\"decimal_heading\"> <li>Increase of 25% from lowest confirmed response value in one or more of the following criteria: <ul> <li>Serum M-protein (absolute increase must be &#8805;0.5 g/dL); </li> <li>Serum M-protein increase &#8805;1 g/dL, if the lowest M component was &#8805;5 g/dL; </li> <li>Urine M-protein (absolute increase must be &#8805;200 mg/24 hours); </li> <li>In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase must be &#62;10 mg/dL); </li> <li>In patients without measurable serum and urine M-protein levels and without measurable involved FLC levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be &#8805;10%); </li> </ul> </li> <li>Appearance of a new lesion(s), &#8805;50% increase from nadir in SPD** of &#62;1 lesion, or &#8805;50% increase in the longest diameter of a previous lesion &#62;1 cm in short axis; </li> <li>&#8805;50% increase in circulating plasma cells (minimum of 200 cells per microL) if this is the only measure of disease. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Clinical relapse</td> <td>Clinical relapse requires one or more of the following criteria: <ul class=\"decimal_heading\"> <li>Direct indicators of increasing disease and/or end organ dysfunction (CRAB features) related to the underlying clonal plasma-cell proliferative disorder. It is not used in calculation of time to progression or progression-free survival but is listed as something that can be reported optionally or for use in clinical practice; </li> <li>Development of new soft tissue plasmacytomas or bone lesions (osteoporotic fractures do not constitute progression); </li> <li>Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and &#8805;1 cm) increase as measured serially by the SPD** of the measurable lesion; </li> <li>Hypercalcemia (&#62;11 mg/dL); </li> <li>Decrease in hemoglobin of &#8805;2 g/dL not related to therapy or other non-myeloma-related conditions; </li> <li>Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma; </li> <li>Hyperviscosity related to serum paraprotein. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Relapse from complete response (to be used only if the end point is disease-free survival)</td> <td>Any one or more of the following criteria: <ul class=\"decimal_heading\"> <li>Reappearance of serum or urine M-protein by immunofixation or electrophoresis; </li> <li>Development of &#8805;5% plasma cells in the bone marrow; </li> <li>Appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcemia [refer to 'clinical relapse' above]). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Relapse from MRD negative (to be used only if the end point is disease-free survival)</td> <td>Any one or more of the following criteria: <ul class=\"decimal_heading\"> <li>Loss of MRD negative state (evidence of clonal plasma cells on NGF or NGS, or positive imaging study for recurrence of myeloma); </li> <li>Reappearance of serum or urine M-protein by immunofixation or electrophoresis; </li> <li>Development of &#8805;5% clonal plasma cells in the bone marrow; </li> <li>Appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcemia). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For MRD assessment, the first bone marrow aspirate should be sent to MRD (not for morphology) and this sample should be taken in one draw with a volume of minimally 2 mL (to obtain sufficient cells), but maximally 4 to 5 mL to avoid hemodilution. Special attention should be given to the emergence of a different monoclonal protein following treatment, especially in the setting of patients having achieved a conventional complete response, often related to oligoclonal reconstitution of the immune system. These bands typically disappear over time and in some studies have been associated with a better outcome. Also, appearance of monoclonal IgG &kappa; in patients receiving monoclonal antibodies should be differentiated from the therapeutic antibody.</div><div class=\"graphic_footnotes\">IMWG: International Myeloma Working Group; MRD: minimal residual disease; NGF: next-generation flow; NGS: next-generation sequencing; PET: positron emission tomography; CT: computed tomography; SUV: standardized uptake value; FLC: free light chain; M-protein: myeloma protein; SPD: sum of the products of the maximal perpendicular diameters of measured lesions; CRAB features: calcium elevation, renal failure, anemia, lytic bone lesions; FCM: flow cytometry; SUV<sub>max</sub>: maximum standardized uptake value; MFC: multiparameter flow cytometry; <sup>18</sup>F-FDG PET: <sup>18</sup>F-fluorodeoxyglucose PET; ASCT: autologous stem cell transplantation.<br />* All response categories require two consecutive assessments made any time before starting any new therapy; for MRD there is no need for two consecutive assessments, but information on MRD after each treatment stage is recommended (eg, after induction, high-dose therapy/ASCT, consolidation, maintenance). MRD tests should be initiated only at the time of suspected complete response. All categories of response and MRD require no known evidence of progressive or new bone lesions if radiographic studies were performed. However, radiographic studies are not required to satisfy these response requirements except for the requirement of FDG PET if imaging MRD-negative status is reported.<br />&para; Sustained MRD negativity when reported should also annotate the method used (eg, sustained flow MRD-negative, sustained sequencing MRD-negative).<br />&Delta; Bone marrow MFC should follow NGF guidelines.<sup>[1]</sup> The reference NGF method is an eight-color two-tube approach, which has been extensively validated. The two-tube approach improves reliability, consistency, and sensitivity because of the acquisition of a greater number of cells. The eight-color technology is widely available globally and the NGF method has already been adopted in many flow laboratories worldwide. The complete eight-color method is most efficient using a lyophilized mixture of antibodies which reduces errors, time, and costs. 5 million cells should be assessed. The FCM method employed should have a sensitivity of detection of at least 1 in 10<sup>5</sup> plasma cells.<br /><span class=\"lozenge\">&loz;</span> DNA sequencing assay on bone marrow aspirate should use a validated assay such as LymphoSIGHT (Sequenta).<br />&sect; Criteria used by Zamagni and colleagues,<sup>[2]</sup> and expert panel (Italian Myeloma criteria for PET Use [IMPetUs]).<sup>[3,4]</sup> Baseline positive lesions were identified by presence of focal areas of increased uptake within bones, with or without any underlying lesion identified by CT and present on at least two consecutive slices. Alternatively, an SUV<sub>max</sub> = 2.5 within osteolytic CT areas &gt;1 cm in size, or SUV<sub>max</sub> = 1.5 within osteolytic CT areas &le;1 cm in size were considered positive. Imaging should be performed once MRD negativity is determined by MFC or NGS.<br />&yen; Derived from international uniform response criteria for multiple myeloma.<sup>[5]</sup> Minor response definition and clarifications derived from Rajkumar and colleagues.<sup>[6]</sup> When the only method to measure disease is by serum FLC levels: Complete response can be defined as a normal FLC ratio of 0.26 to 1.65 in addition to the complete response criteria listed previously. Very good partial response in such patients requires a &ge;90% decrease in the difference between involved and uninvolved FLC levels. All response categories require two consecutive assessments made at any time before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions or extramedullary plasmacytomas if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments do not need to be confirmed. Each category, except for stable disease, will be considered unconfirmed until the confirmatory test is performed. The date of the initial test is considered as the date of response for evaluation of time dependent outcomes such as duration of response.<br />&Dagger; All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on results obtained with the validated Freelite test (Binding Site, Birmingham, UK).<br />&dagger; Presence/absence of clonal cells on immunohistochemistry is based upon the &kappa;/&lambda;/L ratio. An abnormal &kappa;/&lambda; ratio by immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is &kappa;/&lambda; of &gt;4:1 or &lt;1:2.<br />** Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT scans where applicable. For patients with only skin involvement, skin lesions should be measured with a ruler. Measurement of tumor size will be determined by the SPD.<br />&para;&para; Positive immunofixation alone in a patient previously classified as achieving a complete response will not be considered progression. For purposes of calculating time to progression and progression-free survival, patients who have achieved a complete response and are MRD-negative should be evaluated using criteria listed for progressive disease. Criteria for relapse from a complete response or relapse from MRD should be used only when calculating disease-free survival.<br />&Delta;&Delta; In the case where a value is felt to be a spurious result per physician discretion (eg, a possible laboratory error), that value will not be considered when determining the lowest value.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Paiva B, Gutierrez NC, Rosinol L, et al, for the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119:687.</LI>&#xD;&#xA;<LI>Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the defi nition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 2015; 21:4384.</LI>&#xD;&#xA;<LI>Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fl uoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 2013; 121:1819.</LI>&#xD;&#xA;<LI>Nanni C, Zamagni E, Versari A, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 2015; 43:414.</LI>&#xD;&#xA;<LI>Durie BG, Harousseau JL, Miguel JS, et al, for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467.</LI>&#xD;&#xA;<LI>Rajkumar SV, Harousseau JL, Durie B, et al, for the International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117:4691.</LI></OL>Reproduced from: Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17:e328. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55362 Version 4.0</div></div></div>"},"55363":{"type":"graphic_figure","displayName":"Abdom incisions PI","title":"Incisions for abdominal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Incisions for abdominal hysterectomy</div><div class=\"cntnt\"><img style=\"width:495px; height:361px;\" src=\"images/PI/55363_Abdom_incisions_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55363 Version 1.0</div></div></div>"},"55364":{"type":"graphic_picture","displayName":"Bacterial tracheitis - Endoscopy","title":"Bacterial tracheitis: Endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial tracheitis: Endoscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:352px;\" src=\"images/PEDS/55364_Bacterial_tracheitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the adherent mucopurulent membranes within the trachea.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 55364 Version 3.0</div></div></div>"},"55366":{"type":"graphic_figure","displayName":"Hilgenreiner Perkins lines","title":"Hilgenreiner and Perkins lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hilgenreiner and Perkins lines</div><div class=\"cntnt\"><img style=\"width:365px; height:235px;\" src=\"images/PEDS/55366_Hilgenreiner_Perkins_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hilgenreiner line is a horizontal line through the upper margin of the radiolucent triradiate cartilage. Perkins line is a vertical line drawn from the most lateral ossified margin of the roof of the acetabulum and perpendicular to Hilgenreiner line. In the normal hip, the medial end of the ossified upper femoral metaphysis lies medial to Perkins line and inferior to Hilgenreiner line. In the subluxated hip, it lies lateral to Perkins line. In the dislocated hip, the medial end of the ossific metaphysis of the femoral neck lies lateral to Perkins line and superior to Hilgenreiner line.</div><div class=\"graphic_footnotes\">DDH: developmental dysplasia of the hip.</div><div id=\"graphicVersion\">Graphic 55366 Version 1.0</div></div></div>"},"55367":{"type":"graphic_table","displayName":"Newborn resuscitation drugs","title":"Medications used in neonatal resuscitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used in neonatal resuscitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Action</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Dose and route</td> </tr> <tr class=\"divider_bottom\"> <td>Epinephrine</td> <td>Increases cardiac output by increasing the heart rate and myocardial contractility, increases blood pressure by causing peripheral vasoconstriction</td> <td>Heart rate &#60;60 per minute despite adequate ventilation and chest compressions</td> <td> <p>0.1 to 0.3 mL/kg <strong>IV</strong> using 0.1 mg/mL epinephrine (also labeled 1:10,000)</p> 0.3 to 1 mL/kg <strong>ET</strong> using 0.1 mg/mL epinephrine (also labeled 1:10,000)</td> </tr> <tr class=\"divider_bottom\"> <td>Isotonic saline</td> <td>Increases intravascular volume</td> <td>Suspected hypovolemia</td> <td>10 mL/kg of 0.9 percent saline solution IV over 5 to 10 minutes</td> </tr> <tr> <td>Sodium bicarbonate</td> <td>Corrects metabolic acidosis</td> <td>Not recommended for routine use. Has been used in cases of metabolic acidosis, and should only be given after adequate ventilation and circulation have been established.</td> <td>1 or 2 mEq/kg slow IV administration at a rate no faster than 1 mEq/kg per minute</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; ET: endotracheal.</div><div id=\"graphicVersion\">Graphic 55367 Version 6.0</div></div></div>"},"55368":{"type":"graphic_table","displayName":"Management of status epilepticus in children","title":"Initial management of status epilepticus in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial management of status epilepticus in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Timeline*</td> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\">Supportive care</td> <td class=\"subtitle1\">Seizure therapy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">0 to 5 minutes</td> <td>Obtain initial vital signs, including temperature</td> <td> <p>Open airway</p> <p>Suction secretions</p> Administer 100% O2</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p><strong>Benzodiazepine:</strong></p> <p>Lorazepam 0.1 mg/kg IV or IO, maximum 4 mg</p> <p>OR</p> <p>Diazepam 0.2 mg/kg IV or IO, maximum 8 mg</p> <p>IV or IO access not achieved within 3 minutes:</p> <p>Buccal midazolam 0.2 mg/kg, maximum 10 mg</p> <p>OR</p> <p>IM midazolam 0.1 to 0.2 mg/kg, maximum 10 mg</p> <p>OR</p> Rectal diazepam (Diastat gel or injection solution given rectally) 0.5 mg/kg, maximum 20 mg</td> </tr> <tr> <td>Identify airway obstruction and hypoxemia</td> <td>Place continuous cardiorespiratory monitors and pulse oximetry</td> </tr> <tr> <td>Identify impaired oxygenation or ventilation</td> <td> <p>Perform bag-valve-mask ventilation, as needed</p> Prepare for RSI*</td> </tr> <tr> <td>Obtain rapid bedside blood glucose and other studies, as indicated<sup>&#182;</sup></td> <td>Establish IV or IO access</td> </tr> <tr> <td>Evaluate for signs of sepsis/meningitis</td> <td>Treat hypoglycemia (IV dextrose 0.25 to 0.5 g/kg)</td> </tr> <tr class=\"divider_bottom\"> <td>Evaluate for signs of head trauma</td> <td>Treat fever (acetaminophen 15 mg/kg rectally)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">5 to 10 minutes</td> <td>Reevaluate vital signs, airway, breathing, and circulation</td> <td>Maintain monitoring, ventilatory support, and vascular access</td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Benzodiazepine: second dose</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Evaluate for signs of trauma, sepsis, meningitis, or encephalitis</td> <td>Give antibiotics if signs of sepsis or meningitis<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">10 to 15 minutes</td> <td class=\"divider_bottom\" rowspan=\"3\">Reevaluate vital signs, airway, breathing, and circulation</td> <td>Maintain monitoring, ventilatory support, and vascular access</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p><strong>Fosphenytoin:</strong></p> <p>20 mg PE per kg IV or IO<sup>&#9674;</sup></p> <p><strong>OR</strong>, if toxin-induced seizure,</p> <p><strong>Phenobarbital:</strong></p> 20 mg/kg IV or IO, maximum 1 g, (expect respiratory depression with apnea)<sup>&#167;</sup></td> </tr> <tr> <td>Place second IV</td> </tr> <tr class=\"divider_bottom\"> <td>RSI potentially indicated*</td> </tr> <tr> <td rowspan=\"2\">15 to 30 minutes</td> <td>Reevaluate vital signs, airway, breathing, and circulation</td> <td rowspan=\"2\">Maintain monitoring, ventilatory support, and vascular access</td> <td rowspan=\"2\"> <p><strong>Phenobarbital:</strong></p> <p>20 mg/kg IV or IO, maximum 1 g, (10 mg/kg if phenobarbital already given)<sup>&#167;</sup></p> <p><strong>OR</strong></p> <p><strong>Valproic acid</strong> 20 to 40 mg/kg IV or IO</p> <p><strong>OR</strong></p> <p><strong>Levetiracetam</strong> 20 to 60 mg/kg IV or IO</p> <p><strong>AND</strong></p> <p>Pyridoxine 100 mg IV or IO in infants &#60;1 year of age</p> <p>Pyridoxine 70 mg/kg IV or IO, maximum 5 g, if INH poisoning suspected</p> <strong>Obtain pediatric neurology consultation<sup>&#165;</sup></strong></td> </tr> <tr> <td>Obtain continuous EEG monitoring, if available</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IO: intraosseous; IM: intramuscular; O2: oxygen; RSI: rapid sequence endotracheal intubation; PE: phenytoin equivalents; EEG: electroencephalogram; INH: isoniazid.<br />* Rapid sequence intubation should be performed if airway, ventilation, or oxygenation cannot be maintained and if the seizure becomes prolonged.<br />¶ For ancillary studies to obtain in children with status epilepticus, refer to UpToDate topics on status epilepticus in children.<br />Δ Empiric antibiotic regimens vary depending on patient susceptibility and likely pathogen.<br /><FONT class=lozenge>◊</FONT> Do not exceed 3 mg/kg per minute (maximum rate: 150 mg per minute). Fosphenytoin may be ineffective for toxin-induced seizures and may intensify seizures caused by cocaine and other local anesthetics, theophylline, or lindane. If fosphenytoin not available, may use phenytoin 20 mg/kg IV, do not exceed 1 mg/kg per minute (maximum rate: 50 mg per minute) with ECG monitoring.<br />§ Do not exceed 1 mg/kg per minute.<br />¥ In patients with ongoing seizure activity despite two initial doses of benzodiazepine and a second-line antiseizure drug, preparation for a continuous infusion of midazolam, propofol, or pentobarbital should occur simultaneously with administration of a third-line antiseizure drug.</div><div id=\"graphicVersion\">Graphic 55368 Version 15.0</div></div></div>"},"55370":{"type":"graphic_figure","displayName":"Algorithm eval rx CPP adol","title":"Protocol for evaluation and treatment of adolescent pelvic pain/endometriosis","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Protocol for evaluation and treatment of adolescent pelvic pain/endometriosis</div><div class=\"cntnt\"><img style=\"width:519px; height:658px;\" src=\"images/OBGYN/55370_Algorithm_eval_rx_CPP_adol.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAIDS: Nonsteroidal anti-inflammatory drugs; CHT: combination hormonal therapy (oral contraceptive pills, estrogen/progestin patch, estrogen/progestin vaginal ring); Progestins: norethindrone acetate, medroxyprogesterone acetate; GnRH: gonadotropin-releasing hormone agonist; add-back: estrogen + progestin or norethindrone acetate alone.</div><div class=\"graphic_reference\">Adapted with permission from: Laufer, MR, Sanfilippo, J, Rose, G. Adolescent endometriosis: diagnosis and treatment approaches. J Pediatr Adolesc Gynecol 2003; 16(3 Suppl):S3-11. Copyright &#169;2003 North American Society for Pediatric and Adolescent Gynecology.</div><div id=\"graphicVersion\">Graphic 55370 Version 1.0</div></div></div>"},"55373":{"type":"graphic_figure","displayName":"Prevalence of atrial fibrillation in CKD pts","title":"Prevalence of atrial fibrillation in chronic kidney disease patients","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Prevalence of atrial fibrillation in chronic kidney disease patients</div><div class=\"cntnt\"><img style=\"width:564px; height:310px;\" src=\"images/NEPH/55373_Prevalence_atrial_fib.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prevalence (percent) of atrial fibrillation in the general population and different cohorts of patients with CKD are shown: While patients with peritoneal dialysis appear to suffer less frequently from atrial fibrillation, in those on hemodialysis, the prevalence was observed to be 10- to 20-fold higher than in the general population. Age was in all groups a key factor.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright © 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 55373 Version 5.0</div></div></div>"},"55374":{"type":"graphic_diagnosticimage","displayName":"Pulmonary regurgitation","title":"Pulmonary regurgitation","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Pulmonary regurgitation</div><div class=\"cntnt\"><img style=\"width:572px; height:399px;\" src=\"images/CARD/55374_Pulmonary_regurgitation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous wave Doppler signal showing pulmonary regurgitation. The velocity of the regurgitant jet at the end of diastole (after the a wave) represents the end-diastolic pressure gradient between pulmonary artery and right ventricle. Adding right atrial pressure gives an estimate of pulmonary artery diastolic pressure.</div><div id=\"graphicVersion\">Graphic 55374 Version 2.0</div></div></div>"},"55375":{"type":"graphic_picture","displayName":"Adult chronic atopic dermatitis","title":"Adult chronic atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Adult chronic atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55375_Adultatopicdermatitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichenified, hyperpigmented plaque in the elbow flexure of a 35-year-old woman with atopic dermatitis.</div><div class=\"graphic_reference\">Copyright © Yusoff Saifuzzaman, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 55375 Version 5.0</div></div></div>"},"55376":{"type":"graphic_figure","displayName":"Roux-en-Y limb inversion following Roux-en-Y bypass procedure","title":"Roux-en-Y limb inversion","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Roux-en-Y limb inversion</div><div class=\"cntnt\"><img style=\"width:533px; height:623px;\" src=\"images/SURG/55376_Rouxlimbinversion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55376 Version 1.0</div></div></div>"},"55377":{"type":"graphic_table","displayName":"Graded prognostic assessment brain metastases from lung cancer","title":"Graded prognostic assessment for brain metastases from lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Graded prognostic assessment for brain metastases from lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle1\" colspan=\"3\">Scoring criteria</td> <td class=\"subtitle1\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">0.5</td> <td class=\"subtitle2\">1.0</td> </tr> <tr> <td>Age in years</td> <td class=\"centered\">&#62;60</td> <td class=\"centered\">50 to 60</td> <td class=\"centered\">&#60;50</td> <td>&nbsp;</td> </tr> <tr> <td>Karnofsky performance score</td> <td class=\"centered\">&#60;70</td> <td class=\"centered\">70 to 80</td> <td class=\"centered\">90 to 100</td> <td>&nbsp;</td> </tr> <tr> <td>Extracranial metastases</td> <td class=\"centered\">Present</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Absent</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Number of brain metastases</td> <td class=\"centered\">&#62;3</td> <td class=\"centered\">2 to 3</td> <td class=\"centered\">1</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"4\" align=\"right\"><strong>Total:</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Median survival (months) by score: 0 to 1.0 = 3.0; 1.5 to 2.0 = 5.5; 2.5 to 3.0 = 9.4; 3.5 to 4.0 = 14.8.</div><div class=\"graphic_reference\">From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55377 Version 4.0</div></div></div>"},"55378":{"type":"graphic_picture","displayName":"Fungating gastric cancer Endosc","title":"Gastric tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric tumor</div><div class=\"cntnt\"><img style=\"width:324px; height:316px;\" src=\"images/GAST/55378_Fungating_gastric_cancer_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of an ulcerated gastric adenacarcinoma.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 55378 Version 1.0</div></div></div>"},"55383":{"type":"graphic_picture","displayName":"Invade panc duct adenoCA","title":"Pancreatic ductal adenocarcinoma with duodenal submucosa and muscularis invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic ductal adenocarcinoma with duodenal submucosa and muscularis invasion</div><div class=\"cntnt\"><img style=\"width:261px; height:334px;\" src=\"images/ONC/55383_Invade_panc_duct_adenoCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic ductal adenocarcinoma invading the duodenal submucosa (top) and muscularis (bottom). Duodenal mucosa is shown at top right. The carcinoma is moderately differentiated (Grade 2). Hematoxylin and Eosin.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 55383 Version 2.0</div></div></div>"},"55385":{"type":"graphic_table","displayName":"PTCL path","title":"Histology, immunophenotype, and genetic features of the peripheral T cell lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histology, immunophenotype, and genetic features of the peripheral T cell lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features</td> </tr> <tr class=\"divider_bottom\"> <td>Angioimmunoblastic T cell lymphoma</td> <td>Polymorphous infiltrate of small to large atypical lymphocytes with prominent arborizing high endothelial venules. Expanded populations of follicular dendritic cells can be detected with CD21 staining.</td> <td> <p>Express CD3 and CD4; sometimes express BCL-6 and CD10.</p> May lose a subset of pan-T cell antigens (ie, CD2, CD3, CD5, CD7).</td> <td>TCR genes are rearranged in 75 to 90%; immunoglobulin heavy chains are rearranged in 25%. Epstein-Barr virus and human herpes virus-6 genomes may be present in reactive B cells.</td> </tr> <tr class=\"divider_bottom\"> <td>Enteropathy-associated T cell lymphoma*</td> <td> <p>Tumor cells are of variable size and morphology. The adjacent \"normal\" mucosa often demonstrates signs of celiac disease.</p> </td> <td> <p>Typically express CD3 and do not express CD4; most cases also CD8 negative. Large cells within the tumor infiltrate are frequently CD30 positive.</p> </td> <td> <p>TCR beta gene is clonally rearranged. Many patients have an HLA haplotype associated with celiac disease. 50 to 60% have complex segmental amplification of the 9q34 region.</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Extranodal NK/T cell lymphoma; nasal type</td> <td>Polymorphous lymphoid infiltrate of variable morphology that invades the vascular walls, often producing extensive fibrinoid necrosis.</td> <td>Express CD2, cytoplasmic CD3, CD56, and cytotoxic granule proteins, and are negative for surface CD3.</td> <td>Clonal Epstein-Barr virus genomes are virtually always present. TCR and immunoglobulin genes are usually germline, consistent with a natural killer cell origin.</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatosplenic T cell lymphoma*</td> <td>Malignant cells accumulate within the sinusoids of the liver, spleen, or bone marrow.</td> <td>Express CD2, surface CD3, CD7, and CD16, and do not express CD4, CD5, or CD8. Express gamma/delta TCR or alpha/beta TCR.</td> <td>Cytogenetics demonstrating isochrome 7q supports the diagnosis, but is not essential.</td> </tr> <tr class=\"divider_bottom\"> <td>Subcutaneous panniculitis-like T cell lymphoma*</td> <td>Subcutaneous infiltrate of atypical lymphocytes involving the fat lobules, but typically sparing the septae, overlying dermis, and epidermis.</td> <td>Express CD3, CD8, and the alpha/beta TCR, but are negative for CD4, CD56, and TCR gamma. Strong expression of the cytotoxic granule proteins. Expression of CD2, CD5, and/or CD7 is variable.</td> <td>Clonal TCR rearrangements are present.</td> </tr> <tr class=\"divider_bottom\"> <td>Anaplastic large cell lymphoma T/null cell type</td> <td>Composed of large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm. Often shows a cohesive growth pattern.</td> <td>Homogeneous and strong expression of CD30 in a membrane and golgi pattern. Usually express one or more T cell antigens (ie, CD2, CD3, CD5, CD7).</td> <td>Two distinct subtypes: ALK positive (detected by immunostains or molecular genetics) and ALK negative.</td> </tr> <tr> <td>Peripheral T cell lymphoma; not otherwise specified</td> <td>Mixture of small and large atypical cells.</td> <td>Varies greatly from case to case, but always demonstrates expression of one or more of the pan-T antigens (ie, CD2, CD3, CD5, CD7). Roughly half of cases lose a T cell antigen (ie, CD2, CD3, CD5, CD7).</td> <td>While the majority have cytogenetic abnormalities, none is specific.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TCR: T cell receptor.<br />* NOTE: Each of these entities includes tumors expressing alpha-beta T cell receptors and gamma-delta T cell receptors; in general, it appears that tumors expressing gamma-delta T cell receptors have more aggressive natural histories and worse prognoses.</div><div id=\"graphicVersion\">Graphic 55385 Version 5.0</div></div></div>"},"55386":{"type":"graphic_table","displayName":"LV structure and function in chronic heart failure","title":"Left ventricular structure and function in chronic heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Left ventricular structure and function in chronic heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\"><span style=\"font-size: 16px; font-family: Times New Roman; background-color: #ffffff;\"></span></td> <td class=\"subtitle1\">&nbsp;Heart failure with&nbsp; <p>reduced ejection fraction (HFrEF)</p> </td> <td class=\"subtitle1\">Heart failure with<br /> preserved ejection fraction (HFpEF)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">LV remodeling</td> </tr> <tr> <td class=\"indent1\">End-diastolic volume</td> <td class=\"centered\">&#8593; (May be normal in acute heart failure)</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"indent1\">End-systolic volume</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"indent1\">Mass</td> <td class=\"centered\">&#8593; (May be normal in acute heart failure)</td> <td class=\"centered\">Normal or &#8593;</td> </tr> <tr> <td class=\"indent1\">Geometry</td> <td class=\"centered\">Eccentric</td> <td class=\"centered\">Normal or Concentric</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">LV systolic properties</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Performance</td> </tr> <tr> <td class=\"indent2\">Stroke volume</td> <td class=\"centered\">&#8595; (or normal)</td> <td class=\"centered\">Normal (or &#8595;)*</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Function</td> </tr> <tr> <td class=\"indent2\">Longitudinal strain</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;&nbsp;</td> </tr> <tr> <td class=\"indent2\">Ejection fraction</td> <td class=\"centered\">&#8595; (&#8804;40 percent)</td> <td class=\"centered\">Normal or near normal (&#8805;50)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Contractility</td> </tr> <tr> <td class=\"indent2\">End-systolic elastance</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">Normal (or &#8593;)</td> </tr> <tr> <td class=\"indent2\">Stress shortening</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td class=\"subtitle3_left\">Preload reserve</td> <td class=\"centered\">Exhausted</td> <td class=\"centered\">Limited</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">LV diastolic properties</td> </tr> <tr> <td class=\"indent1\">End-diastolic pressure</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td class=\"indent1\">Tau</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td class=\"indent1\">Chamber stiffness</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td class=\"indent1\">Myocardial stiffness</td> <td class=\"centered\">Normal (or &#8593;)</td> <td class=\"centered\">&#8593;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In patients with heart failure with preserved ejection fraction, stroke volume is often impaired with exercise. </div><div class=\"graphic_reference\">Original table provided courtesy of Dr. Michael Zile and modified by Dr. Barry Borlaug.</div><div id=\"graphicVersion\">Graphic 55386 Version 8.0</div></div></div>"},"55387":{"type":"graphic_picture","displayName":"Parallel pattern","title":"Dermoscopic structures seen in melanocytic lesions: Parallel pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures seen in melanocytic lesions: Parallel pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55387_Parallel_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parallel pattern is typically seen in palmar and plantar melanocytic lesions.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 55387 Version 2.0</div></div></div>"},"55388":{"type":"graphic_picture","displayName":"FAST pleural examination probe position","title":"FAST: Pleural examination probe position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Pleural examination probe position</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/EM/55388_FAST_pleural_exam_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper probe positioning to look for signs of a pneumothorax.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 55388 Version 1.0</div></div></div>"},"55389":{"type":"graphic_figure","displayName":"Q angle","title":"Q angle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Q angle</div><div class=\"cntnt\"><img style=\"width:380px; height:477px;\" src=\"images/EM/55389_Q_angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although the Q angle is often&nbsp;mentioned, research suggests its role in conditions such as patellofemoral pain syndrome and patellar instability is&nbsp;of little importance.&nbsp;</div><div id=\"graphicVersion\">Graphic 55389 Version 4.0</div></div></div>"},"55390":{"type":"graphic_figure","displayName":"Swan neck deformity","title":"Swan neck deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swan neck deformity</div><div class=\"cntnt\"><img style=\"width:310px; height:556px;\" src=\"images/EM/55390_Swan_neck_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Posterior view of normal dorsal extensor expansion. The extensor expansion near the proximal interphalangeal joint splits into three parts; a central part, which is inserted into the base of the middle phalanx, and two lateral parts, which converge to be inserted into the base of the distal phalanx. B) Mallet or baseball finger. The insertion of the extensor expansion into the base of the distal phalanx ruptured; sometimes a flake of bone on the base of the phalanx is pulled off. C) Boutonniere deformity. The insertion of the extensor expansion into the base of the middle phalanx is ruptured. The arrows indicate the direction of the pull of the muscles and the deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott, Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 55390 Version 2.0</div></div></div>"},"55391":{"type":"graphic_algorithm","displayName":"Management of thrombotic mesenteric arterial occlusion","title":"Management of thrombotic mesenteric arterial occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of thrombotic mesenteric arterial occlusion</div><div class=\"cntnt\"><img style=\"width:400px; height:940px;\" src=\"images/SURG/55391_Mng_thrmbtc_msnt_artr_occls.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Diagnosis is typically made on CT angiography.<br />¶ In the absence of contraindications to thrombolysis.<br />Δ May include thromboendarterectomy, mesenteric bypass, retrograde mesenteric stenting, or a combination.<br />​</div><div id=\"graphicVersion\">Graphic 55391 Version 3.0</div></div></div>"},"55392":{"type":"graphic_diagnosticimage","displayName":"T2 T1 MRI panc adeno","title":"Pancreatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:350px; height:541px;\" src=\"images/ONC/55392_T2_T1_MRI_panc_adeno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted (A) and T1-weighted (B) fat saturated magnetic resonance (MR) images of a patient with pancreatic adenocarcinoma. Panels A and B both demonstrate atrophy of the pancreatic tail parenchyma, with dilatation of the main pancreatic duct (A arrow). The pancreatic cancer is best visualized on the T1-weighted image as a hypointense solid tumor (B arrow) in the body of the pancreas.</div><div class=\"graphic_reference\">Courtesy of Dr. Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 55392 Version 2.0</div></div></div>"},"55393":{"type":"graphic_figure","displayName":"SCFE metaphyseal blurring","title":"Blurring of the metaphyseal-growth plate junction","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Blurring of the metaphyseal-growth plate junction</div><div class=\"cntnt\"><img style=\"width:473px; height:221px;\" src=\"images/PEDS/55393_SCFE_metaphyseal_blurring.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Bloomberg, TJ, Nuttall, J, Stoker, DJ. Clin Radiol 1978; 29:657. Copyright &#169; 1978 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 55393 Version 1.0</div></div></div>"},"55394":{"type":"graphic_figure","displayName":"Risk of dementia by ethnicity","title":"Risk of dementia by ethnicity and family history","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Risk of dementia by ethnicity and family history</div><div class=\"cntnt\"><img style=\"width:564px; height:354px;\" src=\"images/PC/55394_Risk_of_dementia_by_ethnici.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The data illustrates the cumulative risk of dementia in first- degree biological relatives of Alzheimer disease probands, stratified by relatives' sex and ethnicity. First-degree relatives of African Americans with Alzheimer disease had a higher cumulative risk of dementia than relatives of whites.</div><div class=\"graphic_reference\">Data from Green, RC, Cupples, LA, Go, R, et al. JAMA 2002; 287:329</div><div id=\"graphicVersion\">Graphic 55394 Version 2.0</div></div></div>"},"55397":{"type":"graphic_picture","displayName":"Diffuse anterior scleritis","title":"Diffuse anterior scleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse anterior scleritis</div><div class=\"cntnt\"><img style=\"width:330px; height:213px;\" src=\"images/RHEUM/55397_Diffuse_anterior_scleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior sclera reveals diffuse redness and vascular engorgement.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 55397 Version 4.0</div></div></div>"},"55399":{"type":"graphic_table","displayName":"Phenytoin interactions with other antiseizure drugs","title":"Some interactions between phenytoin or fosphenytoin and other antiseizure drugs*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some interactions between phenytoin or fosphenytoin and other antiseizure drugs*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Interacting drugs</td> <td class=\"subtitle1\">Effects (probable mechanism)</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Phenytoin or fosphenytoin, with:</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Brivaracetam</td> <td>Decreased brivaracetam effect (increased metabolism by CYP2C19)</td> <td>Monitor clinical status</td> </tr> <tr class=\"divider_bottom\"> <td>Possible phenytoin toxicity (decreased metabolism by CYP2C19)</td> <td>Monitor clinical status and phenytoin concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Carbamazepine</td> <td>Decreased carbamazepine effect (increased metabolism)</td> <td class=\"divider_bottom\" rowspan=\"2\">Monitor carbamazepine and phenytoin concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Altered phenytoin effect may include decreased or increased phenytoin levels (mechanism not established)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Clonazepam</td> <td>Decreased clonazepam effect (increased metabolism)</td> <td>Monitor clinical status</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Monitor phenytoin concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Eslicarbazepine</td> <td>Decreased eslicarbazepine concentrations (increased metabolism)</td> <td>Monitor clinical status; eslicarbazepine dose may need to be increased</td> </tr> <tr class=\"divider_bottom\"> <td>Possible phenytoin toxicity (decreased metabolism by CYP2C19)</td> <td>Monitor clinical status and phenytoin concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Felbamate</td> <td>Decreased felbamate effect (increased metabolism)</td> <td>Monitor felbamate effect; dose may need to be increased</td> </tr> <tr class=\"divider_bottom\"> <td>Possible phenytoin toxicity (mechanism not established)</td> <td>Phenytoin dose reduction may be needed; refer to Lexicomp for detail. Monitor clinical status and phenytoin concentrations.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lamotrigine</td> <td>Decreased lamotrigine serum concentrations (increased metabolism; induction of glucuronidation by phenytoin)</td> <td>Monitor clinical status and lamotrigine serum concentrations; lamotrigine dose may need to be adjusted</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Levetiracetam</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Possible decreased levetiracetam concentrations (increased metabolism)</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Monitor clinical effect</span></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Oxcarbazepine</td> <td>Possible decreased oxcarbazepine effect (increased metabolism)</td> <td>Monitor clinical status and oxcarbazepine concentration</td> </tr> <tr class=\"divider_bottom\"> <td>Possible phenytoin toxicity with oxcarbazepine doses of 1200 mg/day or higher (decreased metabolism by CYP2C19)</td> <td>Monitor phenytoin concentrations especially when oxcarbazepine dosage is 1200 mg/day or higher; reduction of phenytoin dose may be needed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Perampanel</td> <td>Decreased perampanel effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status; perampanel dose may need to be adjusted</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tiagabine</td> <td>Decreased tiagabine effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Topiramate</td> <td>Possible decreased topiramate effect (increased metabolism)</td> <td>Monitor clinical status; may need to increase topiramate dose</td> </tr> <tr class=\"divider_bottom\"> <td>Possible phenytoin toxicity (decreased metabolism by CYP2C19) with high doses of topiramate</td> <td>Monitor clinical status and phenytoin concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Valproate</td> <td>Possible phenytoin toxicity (displacement from binding and decreased metabolism, complex time course)</td> <td>Monitor clinical status and phenytoin concentrations (unbound concentrations may be more helpful than total)</td> </tr> <tr class=\"divider_bottom\"> <td>Possible decreased valproate effect and increased toxicity (increased metabolism and formation of toxic metabolite)</td> <td>Monitor clinical status and valproate serum concentrations</td> </tr> <tr> <td class=\"indent1\">Zonisamide</td> <td>Decreased zonisamide effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status and zonisamide concentrations; zonisamide dose may need to be adjusted</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The pharmacokinetics of phenytoin are distinctive in that its metabolism by CYP2C9 and 2C19 is saturable and half-life variable (ie, from 12 hours to up to 10 days or more) depending upon serum levels. The magnitude of effect due to a drug interaction can vary widely based upon phenytoin serum level, and a new steady-state phenytoin level may not occur until 2 to 3 weeks following an alteration of therapy. Refer to accompanying text.</div><div class=\"graphic_footnotes\">CYP: Cytochrome P450.<br /><br />* <STRONG>Not all potential interactions are listed.</STRONG> Additional interactions of antiseizure drugs and management suggestions may be determined using the drug interactions&nbsp;program included within UpToDate. </div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 55399 Version 11.0</div></div></div>"},"55403":{"type":"graphic_picture","displayName":"Vascular invasion","title":"Vascular invasion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vascular invasion</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/55403_Vascular_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular invasion by urothelial carcinoma.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55403 Version 1.0</div></div></div>"},"55404":{"type":"graphic_figure","displayName":"Central triangle of the face","title":"Central triangle of the face","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central triangle of the face</div><div class=\"cntnt\"><img style=\"width:420px; height:496px;\" src=\"images/ID/55404_Central-triangle-of-the-face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rarely, infections involving the medial third of the face (ie, the areas around the eyes and nose) can be complicated by septic cavernous thrombosis, since the veins in this region are valveless.</div><div id=\"graphicVersion\">Graphic 55404 Version 4.0</div></div></div>"},"55405":{"type":"graphic_picture","displayName":"Endosc GOO prepylorus PUD","title":"Gastric outlet obstruction due to peptic ulcer disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric outlet obstruction due to peptic ulcer disease</div><div class=\"cntnt\"><img style=\"width:288px; height:317px;\" src=\"images/GAST/55405_Endosc_GOO_prepylorus_PUD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the pre-pylorus in a patient with acute on chronic peptic ulcer disease and associated gastric outlet obstruction. The black arrow indicates the narrowed pylorus.</div><div class=\"graphic_reference\">Courtesy of Derek Frederickson, MD.</div><div id=\"graphicVersion\">Graphic 55405 Version 2.0</div></div></div>"},"55408":{"type":"graphic_figure","displayName":"Incision for sigmoid colostomy","title":"Incision for sigmoid colostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision for sigmoid colostomy</div><div class=\"cntnt\"><img style=\"width:228px; height:172px;\" src=\"images/OBGYN/55408_Incision_for_sigmoid_colost.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutting disc of skin for colostomy.</div><div id=\"graphicVersion\">Graphic 55408 Version 2.0</div></div></div>"},"55409":{"type":"graphic_picture","displayName":"Megakaryocytes","title":"Bone marrow megakaryocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow megakaryocytes</div><div class=\"cntnt\"><img style=\"width:349px; height:266px;\" src=\"images/HEME/55409_Megakaryocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate shows two megakaryocytes with multilobulated nuclei and voluminous cytoplasm. A normal neutrophil (arrow) next to the megakaryocyte illustrates the large size of these cells.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 55409 Version 2.0</div></div></div>"},"55410":{"type":"graphic_figure","displayName":"Generation of the P wave","title":"Generation of the P wave","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Generation of the P wave</div><div class=\"cntnt\"><img style=\"width:490px; height:277px;\" src=\"images/CARD/55410_Generation_of_the_P_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With normal sinus rhythm, the atrial depolarization vector is directed from the right atrium to the left atrium and downward towards the AV junction (arrow). As a result, the P wave will normally be upright in lead II and negative in lead aVR.</div><div id=\"graphicVersion\">Graphic 55410 Version 1.0</div></div></div>"},"55411":{"type":"graphic_picture","displayName":"Hypertrophic scar","title":"Injection of kenalog in a hypertrophic scar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Injection of kenalog in a hypertrophic scar</div><div class=\"cntnt\"><img style=\"width:385px; height:263px;\" src=\"images/PC/55411_Hypertrophic_scar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appearance of the hypertrophic scar is similar to that of keloids, but does not extend beyond the margin of the scar. The scar is being injected with kenalog.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 55411 Version 3.0</div></div></div>"},"55413":{"type":"graphic_picture","displayName":"Histiocytosis X High power","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/PULM/55413_Histiocytosis_X_High_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cellular infiltrate of pulmonary Langerhans cell histiocytosis is characterized by Langerhans cells, eosinophils, lymphocytes, neutrophils, and alveolar macrophages.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 55413 Version 1.0</div></div></div>"},"55415":{"type":"graphic_picture","displayName":"Acute paronychia lateral nail fold","title":"Acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Acute paronychia</div><div class=\"cntnt\"><img style=\"width:548px; height:367px;\" src=\"images/SURG/55415_Acute_parony_lat_nail_fold.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute paronychia is a bacterial infection of the lateral nail fold and can result from nail biting, hangnail, poor manicure technique, minor trauma, and, in children, thumb sucking.</div><div id=\"graphicVersion\">Graphic 55415 Version 2.0</div></div></div>"},"55417":{"type":"graphic_table","displayName":"Staph IE medical Rx in IDU","title":"Medical management of <EM>Staphylococcus aureus </EM>infective endocarditis in injection drug users","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical management of <EM>Staphylococcus aureus </EM>infective endocarditis in injection drug users</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Number with IE</td> <td class=\"subtitle1\">Valve involved</td> <td class=\"subtitle1\">Antimicrobial regimen</td> <td class=\"subtitle1\">Outcomes/comments</td> </tr> <tr> <td>Abrams et al, 1979</td> <td>25 </td> <td>Right sided (20), left sided (2), both (3)</td> <td>Beta-lactam x 4 weeks versus beta-lactam x 4 weeks plus gentamicin x 2 weeks</td> <td>No treatment failures in either group</td> </tr> <tr> <td>Parker et al, 1980</td> <td>33 (29 with IDU)</td> <td>Right sided (29), left sided (4)</td> <td>Multiple IV regimens (mean duration 16 days), then multiple single PO regimens (mean duration 26 days) </td> <td>100 percent cure rate at 6 months; all patients male; mean total duration of therapy 42 days</td> </tr> <tr> <td>Chambers et al, 1988 </td> <td>53</td> <td>Right sided</td> <td>Nafcillin plus tobramycin x 2 weeks (vancomycin instead of nafcillin in 3 penicillin-allergic patients)</td> <td>47 of 50 (94 percent) cured at 2 weeks with nafcillin/tobramycin, 1 of 3 (33 percent) with vancomycin</td> </tr> <tr> <td>Dworkin et al, 1989 </td> <td>14</td> <td>Right sided</td> <td>Ciprofloxacin (IV, then PO) plus rifampin x 4 weeks</td> <td>10 of 14 completed therapy, all cured at 4 weeks of follow-up</td> </tr> <tr> <td>Markowitz et al, 1992</td> <td>23 </td> <td>Right sided</td> <td>TMP-SMX versus vancomycin</td> <td>7 of 11 (64 percent) cured with TMP-SMX versus 11 of of 12 (92 percent) with vancomycin; no treatment failures for MRSA</td> </tr> <tr> <td>Torres-Tortosa et al, 1994 </td> <td>139</td> <td>Right sided</td> <td>Cloxacillin plus amikacin x 2 weeks; chosen for good prognosis</td> <td>67 of 72 (93 percent) cured; 24 percent mortality in those with poor prognosis</td> </tr> <tr> <td>Fortun et al, 1995</td> <td>16</td> <td>Right sided</td> <td>Cloxacillin plus gentamicin x 2 weeks versus teicoplanin x 28 days </td> <td>Study stopped early due to high rate of failure in teicoplanin arm</td> </tr> <tr> <td>Heldman et al, 1996</td> <td>85</td> <td>Right sided</td> <td>Ciprofloxacin PO plus rifampin x 4 weeks versus oxacillin or vancomycin x 28 days plus gentamicin x 5 days</td> <td>Only 44 patients available for test of cure, bacteriologic cure in 18 of 19 (95 percent) with PO regimen, 22 of 25 (88 percent) with IV; definite IE in 15 patients</td> </tr> <tr> <td rowspan=\"2\">Ribera et al, 1996</td> <td rowspan=\"2\">90</td> <td rowspan=\"2\">Right sided</td> <td rowspan=\"2\">Cloxacillin x 2 weeks versus cloxacillin x 2 weeks plus gentamicin x 7 days</td> <td><strong>Intention-to-treat analysis:</strong> 34 to 45 (76 percent) cured with cloxacillin versus 31 to 45 (69 percent) with cloxacillin/gentamicin</td> </tr> <tr> <td><strong>Efficacy analysis:</strong> 34 to 38 (89 percent) cure rate with monotherapy versus 31 of 36 (86 percent) with combination regimen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IDU: injection drug use; IV: intravenous: PO: by mouth; TMP-SMX: trimethoprim-sulfamethoxazole; MRSA: methicillin-resistant <EM innerHtml>S. aureus<STRONG></STRONG></EM>.</div><div id=\"graphicVersion\">Graphic 55417 Version 2.0</div></div></div>"},"55418":{"type":"graphic_table","displayName":"Canada guide heart disease kidney transplantation","title":"Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiac disease</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">1. All patients should be assessed for the presence of IHD before kidney transplantation. The minimum required investigations include history, physical examination, ECG, and a chest radiograph (Grade A).</td> </tr> <tr> <td class=\"sublist2_start\">2. Further testing for IHD depends on the pretest probability of CAD. The following patients should have further noninvasive testing:</td> </tr> <tr> <td class=\"indent2\">I. Symptomatic patients or patients with a prior history of CAD including <ul class=\"decimal_heading\"> <li>Previous history of myocardial infarction (Grade A) </li> <li>Symptoms of angina (Grade A) </li> <li>Signs or symptoms of heart failure (Grade A) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">II. Asymptomatic patients with <ul class=\"decimal_heading\"> <li>Diabetes (type 1 or type 2) (Grade B) </li> <li>Multiple risk factors for CAD (three or more) (Grade B) <ul> <li>Age &#62;50 years </li> <li>Prolonged duration of chronic kidney disease </li> <li>Family history of CAD (first-degree relative) </li> <li>Significant smoking history </li> <li>Dyslipidemia (high-density lipoprotein level &#60;0.9 mmol/L or total cholesterol &#62;5.2 mmol/L), BMI &#8805;30 kg/m<sup>2</sup> </li> <li>History of hypertension </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">3. All patients with a positive noninvasive test should be assessed by a cardiologist with a view to undergoing angiography (Grade B).</td> </tr> <tr> <td class=\"indent1\">4. Very high-risk patients should be considered for angiography even with a negative noninvasive test (Grade C).</td> </tr> <tr> <td class=\"indent1\">5. Patients with IHD should be eligible for kidney transplantation if they fall into one of the following categories: <ul class=\"decimal_heading\"> <li>Low-risk asymptomatic patients (Grade A) </li> <li>Asymptomatic patients with negative noninvasive testing (Grade B) </li> <li>Patients who have undergone successful intervention (Grade B) </li> <li>Patients who on angiography have noncritical disease and are on appropriate medical therapy (Grade C) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">6. Kidney transplantation is contraindicated in patients with IHD in the following situations: <ul class=\"decimal_heading\"> <li>Patients with progressive symptoms of angina (Grade A) </li> <li>Patients with a myocardial infarction within six months (Grade A) </li> <li>Patients without an appropriate cardiac work-up (Grade C) </li> <li>Patients with severe diffuse disease, especially with positive noninvasive tests in whom intervention is not possible and in whom expected survival is sufficiently compromised so that transplantation is not reasonable (Grade C) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">7. Patients with IHD should be reevaluated on a regular basis. <ul class=\"decimal_heading\"> <li>Reevaluation should include history, physical examination, ECG, and noninvasive testing (Grade C) </li> <li>Reevaluation should occur any time a patient becomes symptomatic (Grade A) </li> <li>Reevaluation should occur annually in all patients who are at high risk (see previous recommendation for high-risk groups) (Grade C) </li> <li>A repeat angiogram may be considered in patients with known IHD before transplantation if waiting time has been prolonged and it is known that a transplant is likely within the next year (Grade C) </li> <li>All high-risk patients on the waiting list should be treated aggressively with risk-factor reduction strategies (Grade A) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">8. LV dysfunction is not necessarily a contraindication to kidney transplantation. LV function should be evaluated in all patients being assessed for transplantation with history, physical examination, ECG, and chest radiography (Grade A). An echocardiogram should be performed in patients with evidence of LV dysfunction (Grade B) or in patients at high risk for LV dysfunction (patients with diabetes, CAD, longstanding hypertension, longstanding kidney disease, or known valvular heart disease) (Grade C).</td> </tr> <tr> <td class=\"indent1\">9. Uremic LV dysfunction may improve after transplantation; thus, it is not necessarily a contraindication to waitlisting (Grade B).</td> </tr> <tr> <td class=\"indent1\">10. Patients with severe irreversible (nonuremic) cardiac dysfunction should not be listed for kidney transplantation alone. Selected patients may be candidates for combined heart-kidney transplants (Grade C).</td> </tr> <tr> <td class=\"indent1\">11. Children with evidence of cardiomyopathy on echocardiography or with congenital heart disease should be evaluated for transplantation in consultation with a pediatric cardiologist (Grade C).</td> </tr> <tr> <td class=\"indent1\">12. All patients should be monitored for aortic stenosis by history, physical examination, and echocardiogram where clinical suspicion is high (Grade C).</td> </tr> <tr> <td class=\"indent1\">13. Patients with aortic stenosis should have regular follow-up echocardiograms, and consideration should be given to early surgical intervention as the disease is accelerated in renal failure (Grade C).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The strength of evidence supporting each recommendation was graded using the system developed by the Canadian Task Force on Preventive Health Care as follows:<br /><ul class=\"decimal_heading\">&#xD;&#xA;    <li>Grade A - There is good evidence to support</li>&#xD;&#xA;    <li>Grade B - There is fair evidence to support</li>&#xD;&#xA;    <li>Grade C - The existing evidence is conflicting, but other factors may influence decision making</li>&#xD;&#xA;    <li>Grade D - There is fair evidence to recommend against</li>&#xD;&#xA;    <li>Grade E - There is good evidence to recommend against</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">IHD: ischemic heart disease; ECG: electrocardiogram; CAD: coronary artery disease; BMI: body mass index; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from: Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:S1. Copyright &copy; 2005 CMA Media Inc.</div><div id=\"graphicVersion\">Graphic 55418 Version 4.0</div></div></div>"},"55419":{"type":"graphic_diagnosticimage","displayName":"CT scan showing retroperitoneal fibrosis","title":"CT scan showing retroperitoneal fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing retroperitoneal fibrosis</div><div class=\"cntnt\"><img style=\"width:372px; height:258px;\" src=\"images/NEPH/55419_RP_fibrosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of a patient with biopsy-proven retroperitoneal fibrosis. The right kidney is hydronephotic and the left kidney is small. In addition, there is circumferential encasement of the aorta and vena cava by tissue (arrowheads), with attenuation numbers similar to that of adjacent psoas muscle.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan R Diamond, MD.</div><div id=\"graphicVersion\">Graphic 55419 Version 4.0</div></div></div>"},"55420":{"type":"graphic_table","displayName":"Testing in rapidly progressive dementia","title":"Rapidly progressive dementia: Potential diagnostic testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapidly progressive dementia: Potential diagnostic testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">In all patients:</td> </tr> <tr> <td class=\"indent1\">Brain MRI, including FLAIR and DWI, with and without gadolinium enhancement</td> </tr> <tr> <td class=\"indent1\">Serum electrolytes, liver, renal, and thyroid function tests</td> </tr> <tr> <td class=\"indent1\">Vitamin B12, homocysteine</td> </tr> <tr> <td class=\"indent1\">Urinalysis, culture</td> </tr> <tr> <td class=\"subtitle1_single\">In most patients:</td> </tr> <tr> <td class=\"indent1\">Lumbar puncture, cell count and differential, protein, glucose, syphilis serology</td> </tr> <tr> <td class=\"indent1\">EEG</td> </tr> <tr> <td class=\"subtitle1_single\">In selected patients (based on abnormalities in above tests or suggestive clinical features):</td> </tr> <tr> <td class=\"sublist2_start\">CSF</td> </tr> <tr> <td class=\"sublist2\">Cryptococcal antigen</td> </tr> <tr> <td class=\"sublist2\">Bacterial fungal AFB stains and cultures</td> </tr> <tr> <td class=\"sublist2\">Cytology</td> </tr> <tr> <td class=\"sublist2\">Viral PCRs and cultures</td> </tr> <tr> <td class=\"sublist2\">Lyme serology</td> </tr> <tr> <td class=\"sublist2\">14-3-3 protein</td> </tr> <tr> <td class=\"sublist2_start\">Blood</td> </tr> <tr> <td class=\"sublist2\">Rheumatological screen (ESR, ANA, CRP)</td> </tr> <tr> <td class=\"sublist2\">Antithyroglobulin, anti-thyroperoxidase antibodies</td> </tr> <tr> <td class=\"sublist2\">HIV</td> </tr> <tr> <td class=\"sublist2\">Lyme</td> </tr> <tr> <td class=\"sublist2\">Paraneoplastic antibodies</td> </tr> <tr> <td class=\"sublist2\">Copper, ceruloplasmin</td> </tr> <tr> <td class=\"sublist2\">Whipples PCR</td> </tr> <tr> <td class=\"indent1\">Urine copper, heavy metal screen</td> </tr> <tr> <td class=\"indent1\">Further imaging (angiography, PET, SPECT)</td> </tr> <tr> <td class=\"indent1\">Brain biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; DWI: diffusion weighted imaging; PET: positron emission tomography; SPECT: single photon emission computed tomography; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibodies; CRP: C-reactive protein.</div><div id=\"graphicVersion\">Graphic 55420 Version 5.0</div></div></div>"},"55422":{"type":"graphic_figure","displayName":"Lymph node regions lymphoma","title":"Lymph node regions in lymphoma","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Lymph node regions in lymphoma</div><div class=\"cntnt\"><img style=\"width:476px; height:707px;\" src=\"images/HEME/55422_Lymph_node_regions_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node regions used to determine stage in lymphoma.</div><div id=\"graphicVersion\">Graphic 55422 Version 3.0</div></div></div>"},"55424":{"type":"graphic_picture","displayName":"Atopic dermatitis papular","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/DERM/55424_Atopic_dermatitis_pap_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous papules are present on the hands of this patient with atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55424 Version 5.0</div></div></div>"},"55425":{"type":"graphic_figure","displayName":"HRT and hip fracture WHI","title":"Estrogen-progestin therapy reduces hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estrogen-progestin therapy reduces hip fracture</div><div class=\"cntnt\"><img style=\"width:392px; height:219px;\" src=\"images/ENDO/55425_HRT_and_hip_fracture_WHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Women's Health Initiative, combined estrogen-progestin replacement therapy was associated with significant reduction in hip fracture (five fewer hip fractures per 10,000 person-years; HR 0.7, unadjusted 95% CI 0.4-1.0).</div><div class=\"graphic_footnotes\">HR: hazard ratio.</div><div class=\"graphic_reference\">Data from: Rossouw JE, Anderson GL, Prentice RL, et al.&nbsp;Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.</div><div id=\"graphicVersion\">Graphic 55425 Version 4.0</div></div></div>"},"55426":{"type":"graphic_figure","displayName":"Weight loss with orlistat","title":"Weight loss with orlistat","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Weight loss with orlistat</div><div class=\"cntnt\"><img style=\"width:524px; height:298px;\" src=\"images/ENDO/55426_Weight_loss_orlistat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weight loss (means &#177; SEM) during four years of treatment with orlistat plus lifestyle changes or placebo plus lifestyle changes in obese patients.</div><div class=\"graphic_reference\">Reproduced with permission of the American Diabetes Association. From: Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155. Copyright © 2004; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 55426 Version 6.0</div></div></div>"},"55429":{"type":"graphic_figure","displayName":"Cross sectional area of airways","title":"The total cross-sectional area of the air passages at different generations of the airways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The total cross-sectional area of the air passages at different generations of the airways</div><div class=\"cntnt\"><img style=\"width:427px; height:309px;\" src=\"images/PULM/55429_Resp_cross_sectional_area.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the minimum cross-sectional area is at generation 3 (lobar to segment bronchi). The total cross-sectional area becomes very large in the smaller air passeges, approaching a square meter in the alveolar ducts.</div><div id=\"graphicVersion\">Graphic 55429 Version 2.0</div></div></div>"},"55430":{"type":"graphic_figure","displayName":"Mouth anatomy PI","title":"Inside the mouth","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Inside the mouth</div><div class=\"cntnt\"><img style=\"width:514px; height:486px;\" src=\"images/PI/55430_OP_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are the different parts of the mouth.</div><div id=\"graphicVersion\">Graphic 55430 Version 1.0</div></div></div>"},"55431":{"type":"graphic_figure","displayName":"Rates of recovery in hibernating myocardium","title":"Rates of recovery in hibernating myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rates of recovery in hibernating myocardium</div><div class=\"cntnt\"><img style=\"width:369px; height:336px;\" src=\"images/CARD/55431_Recovery_rates_hibern_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the possible range of acute, subacute, and chronic myocardial hibernation, based on the rate of recovery of ventricular function after increasing coronary artery blood flow. The role of stunned myocardium (S) and structural changes (SC) in the myocardium can also be seen.</div><div class=\"graphic_reference\">Redrawn from: Rahimtoola SH. Am J Cardiol 1995; 75:16E.</div><div id=\"graphicVersion\">Graphic 55431 Version 4.0</div></div></div>"},"55432":{"type":"graphic_picture","displayName":"Acromioclavicular joint cross body adduction test","title":"Acromioclavicular joint cross body adduction test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular joint cross body adduction test</div><div class=\"cntnt\"><img style=\"width:432px; height:348px;\" src=\"images/EM/55432_ACjointcrossbodyadduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain elicited by passively adducting the patient's arm, thereby compressing the AC joint, is suggestive of AC pathology.</div><div class=\"graphic_footnotes\">AC: acromioclavicular.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 55432 Version 2.0</div></div></div>"},"55433":{"type":"graphic_movie","displayName":"Thoracic ultrasound - Lung sliding","title":"Thoracic ultrasound: Lung sliding","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound: Lung sliding</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/55433_ThoracUSslidinglungconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:271px;\" src=\"images/PULM/55433_ThoracicUSslidinglung.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55433 Version 2.0</div></div></div>"},"55434":{"type":"graphic_picture","displayName":"Cat bite","title":"Cat bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cat bite</div><div class=\"cntnt\"><img style=\"width:389px; height:583px;\" src=\"images/SURG/55434_Cat_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cat bites often result in multiple small puncture wounds and are likely to cause infection because cats have sharp teeth that inoculate bacteria deeply in the tissue. The photographs demonstrate a subcutaneous abscess of the right thumb following a cat bite. The arrows point to the puncture wounds.</div><div id=\"graphicVersion\">Graphic 55434 Version 2.0</div></div></div>"},"55435":{"type":"graphic_table","displayName":"Drugs for GERD in children","title":"Drugs demonstrated to be effective for gastroesophageal reflux disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs demonstrated to be effective for gastroesophageal reflux disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of medication</td> <td class=\"subtitle1\">Recommended oral dose</td> <td class=\"subtitle1\">Adverse effects/precautions<sup>&#916;</sup></td> <td class=\"subtitle1\">Useful dose forms for children<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Proton pump inhibitors (PPIs)<sup>&#167;&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> <td> <p>Infants 1 to 11 months (daily):</p> <p class=\"indent1\">3 to &#60;5 kg: 2.5 mg </p> <p class=\"indent1\">5 to &#60;10 kg: 5 mg </p> <p class=\"indent1\">&#8805; 10 kg: 10 mg&nbsp;&nbsp;</p> <p>&nbsp;</p> <p>Children &#8805;1 year: 1 mg/kg daily, given 30 minutes before meal(s)*</p> <p>May increase to 1 mg/kg twice daily if needed for symptomatic improvement</p> Adults: 20 or 40 mg once daily</td> <td> <p>Safety data for long-term use of PPIs in children are in general reassuring<sup>&#916;</sup></p> <p>Frequent (2 to 14 percent): Headache, diarrhea, abdominal pain, nausea, rash, constipation</p> <p>Infrequent or rare: Increased risk of C. difficile and other enteric infections; increased risk for lower respiratory tract infections in infants (pediatric reports). Malabsorption of magnesium, calcium, and to a lesser extent, vitamin B12 and iron (adult reports).</p> United States FDA approval is for use in pediatric patients 1&nbsp;month and older</td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food (10, 20, 40 mg) </li> <li>Flavored oral suspension (2 mg/mL) </li> <li>Granules for oral suspension (2.5 and 10 mg) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Omeprazole and sodium bicarbonate</td> <td>Similar to omeprazole</td> <td> <p>Similar to other PPIs<sup>&#916;</sup></p> <p>Avoid using in patients on sodium restricted diets; contains 303 mg [13 mmol] sodium per 20 or 40 mg capsule; 460 mg (20 mmol) sodium per 20 or 40 mg packet</p> United States FDA approval is for adults 18 years and older</td> <td> <ul> <li>Capsules should not be opened (20 and 40 mg capsules) </li> <li>Powder for oral suspension should be dissolved in water only (20 or 40 mg packets) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Esomeprazole</td> <td> <p>Infants 1 to 11 months (daily):</p> <p class=\"indent1\">3 to 5 kg: 2.5 mg</p> <p class=\"indent1\">5 to 7.5 kg: 5 mg</p> <p class=\"indent1\">7.5 to 12 kg: 10 mg</p> <br /> <p>Children 1 to 11 years (daily, given 30 minutes before first meal each day):</p> <p class=\"indent1\">Weight &#60;20 kg: 10 mg</p> <p class=\"indent1\">Weight &#62;20 kg: 10 mg or 20 mg*</p> <br /> Children &#8805;12 years and adults: 20 or 40 mg daily</td> <td> <p>Similar to other PPIs<sup>&#916;</sup></p> Indication in infants is for erosive esophagitis due to acid-mediated GERD</td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food (20, 40 mg) </li> <li>Granules for oral suspension (2.5, 5, 10, 20 and 40 mg packets) </li> <li>Intravenous formulation available<sup>&#135; </sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lansoprazole</td> <td> <p>1 mg/kg daily, given 30 minutes before meal(s)*</p> <p>May increase to 1 mg/kg twice daily if needed for symptomatic improvement</p> Adult dose: 15 to 30 mg once daily</td> <td>Similar to other PPIs<sup>&#916;</sup></td> <td> <ul> <li>Capsules can be opened and sprinkled on soft food, or give via NG or other enteral tube suspended in apple juice (15, 30 mg capsules) </li> <li>Flavored oral suspension (3 mg/mL) </li> <li>Orally disintegrating tablets can be dissolved in the mouth or suspended in water and given by oral syringe or NG or other enteral tube (15, 30 mg tablets) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dexlansoprazole&nbsp;</td> <td>Children &#8805;12 years and adults: 30 mg once daily&nbsp;</td> <td>Similar to other PPIs<sup>&#916;</sup>&nbsp;</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Capsules can be opened and sprinkled on applesauce and consumed immediately or suspended in water and given by oral syringe (30 mg capsules) </li> <li>Orally disintegrating tablets can be dissolved in the mouth or suspended in water and given by oral syringe or NG or other enteral tube (30 mg tablets) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pantoprazole</td> <td> <p>Children &#8805;5 years:</p> <p class=\"indent1\"><span class=\"indent1\">weight 15 to &#60;40 kg: 20 mg</span></p> <p class=\"indent1\"><span class=\"indent1\">weight &#8805;40 kg: 40 mg</span></p> <p>Adult dose: 40 mg once daily</p> </td> <td>Similar to other PPIs<sup>&#916;</sup></td> <td> <ul> <li>Oral tablets should be swallowed whole (20, 40 mg) </li> <li>Granules for oral suspension (40 mg packets) </li> <li>Intravenous formulation available<sup>&#135;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Rabeprazole</td> <td> <p>Children &#8805;12 years and adults:</p> 20 mg once daily, given 30 minutes before the first meal each day</td> <td>Similar to other PPIs<sup>&#916;</sup></td> <td> <ul> <li>Oral tablets should be swallowed whole (20 mg) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Histamine<sub>2</sub> receptor antagonists (H<sub>2</sub>RAs)<sup>&#167;&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Cimetidine</td> <td> <p>Children: 30 to 40 mg/kg per day divided in four doses*</p> Adult dose: 400 to 800 mg twice daily</td> <td> <p>Safety data for the use of H2RAs in children are in general reassuring. H2RAs produce less profound acid suppression than PPIs, which may be an advantage in some clinical scenarios.<sup>&#916;</sup></p> <p>Tachyphylaxis (tolerance) commonly develops with chronic use (ie, &#62;6 weeks)</p> <p>Frequent: Headache, dizziness, diarrhea, abdominal pain, somnolence (adult reports)</p> <p>Infrequent or rare: CNS disturbance, gynecomastia, idiosyncratic or immune-mediated hypersensitivity including organ toxicity (liver, kidney) and hematologic abnormalities (myelosuppression, thrombocytopenia, neutropenia, anemia, pancytopenia) (mostly adult reports). Rapid IV administration has been associated with bradycardia and hypotension. Increased risk of C. difficile and other enteric infections (pediatric and adult reports).</p> Cimetidine is a moderate inhibitor of CYP metabolism, and can increase levels of some co-administered medications, such as theophylline, SSRIs, warfarin and cisapride. For specific interactions, use the Lexi-Interact program included with UpToDate.</td> <td> <ul> <li>Oral tablets may be crushed (200, 300, 400, 800 mg) </li> <li>Flavored oral solution (300 mg/5 mL) </li> <li>Intravenous formulation available<sup>&#135;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Nizatidine</td> <td> <p>Children: 10 mg/kg/day divided into two doses*</p> Adults: 150 mg/dose twice daily or 300 mg once daily at bedtime</td> <td>Similar to cimetidine, except that nizatidine <strong>lacks</strong> anti-androgenic activity (gynecomastia) and does <strong>not</strong> inhibit CYP metabolism or alter co-administered drugs metabolized by CYP<sup>&#916;</sup></td> <td> <ul> <li>Oral tablets may be crushed (150, 300 mg) </li> <li>Flavored oral solution (15 mg/mL) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ranitidine</td> <td> <p>Children: 5 to 10 mg/kg per day, divided into two to three doses*</p> Adults: 150 mg/dose twice daily</td> <td>Similar to cimetidine, except that ranitidine <strong>lacks</strong> anti-androgenic activity (gynecomastia) and does <strong>not</strong> inhibit CYP metabolism or alter co-administered drugs metabolized by CYP<sup>&#916;</sup></td> <td> <ul> <li>Oral tablets may be crushed (75, 150, 300 mg) </li> <li>Capsules (150, 300 mg) </li> <li>Flavored oral syrup (15 mg/mL) </li> <li>Intravenous formulation available<sup>&#135;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Famotidine</td> <td> <p>Children: 1 mg/kg per day, divided into two doses*</p> Adults: 20 mg/dose twice daily</td> <td>Similar to cimetidine, except that famotidine <strong>lacks</strong> anti-androgenic activity (gynecomastia) and does <strong>not</strong> inhibit CYP metabolism or alter co-administered drugs metabolized by CYP<sup>&#916;</sup></td> <td> <ul> <li>Tablets may be crushed (10, 20, 40 mg) </li> <li>Flavored powder for suspension (40 mg/5 mL) </li> <li>Intravenous formulation available<sup>&#135;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Prokinetics&#134;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Cisapride<sup>&#182;&#182;</sup></td> <td rowspan=\"3\"> <p>Children: 0.6 to 0.8 mg/kg per day, divided into four doses, given 30 minutes before each meal and at bedtime. Maximum 10 mg per dose.</p> Adults dose range: 5 to 20 mg four times daily</td> <td>Cisapride is not available in the United States. The only way that US physicians can obtain cisapride is through a limited access program developed by Janssen Pharmaceuticals, and the United States FDA.<sup>&#182;&#182;</sup></td> <td rowspan=\"3\">Restricted availability in the United States<sup>&#182;&#182;</sup></td> </tr> <tr> <td>Infrequent or rare: <ul class=\"decimal_heading\"> <li><span class=\"red\">Infants and children may be at increased risk for developing potentially fatal ventricular arrhythmias due to QT prolongation.</span> </li> <li><span class=\"red\">If prescribed, requires assessment of risk factors for cardiac arrhythmias, including ECG and serum electrolytes<sup>**</sup> and close attention to avoiding co-administration of drugs that can elevate cisapride blood levels and/or also prolong the QT interval, including macrolide antibiotics, azole antifungals, and protease inhibitors. Drug interactions may be evaluated by using the Lexi-Interact program included with UpToDate.</span> </li> <li>Hypersensitivity reactions (rash, bronchospasm), convulsions, dystonic reactions (mostly adult reports). </li> </ul> </td> </tr> <tr> <td>Frequent: Abdominal pain, diarrhea, headache, dizziness</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; FDA: Food and Drug Administration; H2RAs: histamine<SUB>2</SUB> receptor antagonist; NG: nasogastric; CNS: central nervous system; SSRI: selective serotonin reuptake inhibitor; ECG: electrocardiogram.<br />* In general, the pediatric dose should not exceed the higher end of the adult dose. On a milligram per kilogram basis, doses of some of the PPIs needed to obtain a similar degree of acid suppression in children are greater than those for adolescents and adults. Optimally, PPIs are given once daily about 30 minutes before the first meal of the day, or if given twice daily prior to the first meal and the evening meal.<br />Δ For additional information about adverse effects, refer to separate UpToDate topic reviews of proton pump inhibitors in the treatment of acid-related disorders and the pharmacology of anti-ulcer medications. Additional information is available in the Lexicomp individual drug topics.<br /><FONT class=lozenge>◊</FONT> Preparations shown in the table are those available in the United States and some other countries.<br />§ Acid suppression with PPIs or H2RAs may be a risk factor for lower respiratory tract infections, particularly in infants and young children.<br />¥ Relative potency varies among PPIs. Bioequivalent doses for acid suppression are pantoprazole 0.23; lansoprazole 0.9; omeprazole 1.0; esomeprazole 1.6; rabeprazole 1.8.<SUP>[4]</SUP> <br />‡ Intravenous formulations are available for some PPIs and H2RAs, and may be used when oral therapy is inappropriate or not possible (eg, patients in intensive care for stress ulcer prophylaxis). Further information on intravenous preparations and dosing is available in the Lexicomp individual drug topics.<br />†&nbsp;Dose adjustment of H2RAs is needed in the setting of renal insufficiency.<br />**&nbsp;Systematic reviews have not supported the use of metoclopramide, cisapride, erythromycin or domperidone for treatment of GERD. These drugs should be considered for use only in carefully selected patients who have delayed gastric emptying because of gastric dysmotility (gastroparesis), contributing to GERD. Refer to UpToDate topic on treatment of gastroparesis.&nbsp;<br />¶¶ In the United States, prescriptions for cisapride can only be filled through an investigational limited access program from the manufacturer, after providing documentation of the need for cisapride and assessment of risk factors for cardiac arrhythmias in the individual patient (eg, a QTc &gt;450 ms). Cisapride is available in several other countries. Refer to topic on acquired long QT syndrome for details.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lightdale JR, Gremse DA and the section on Gastroenterology, Hepatology and Nutrition. Gastroesophageal reflux: Management guidance for the pediatrician. Pediatrics 2013; 131:e1684.</LI>&#xD;&#xA;<LI>Vandenplas Y, Rudolph D, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.</LI>&#xD;&#xA;<LI>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2018.</LI>&#xD;&#xA;<LI>Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65:19.</LI></OL></div><div id=\"graphicVersion\">Graphic 55435 Version 18.0</div></div></div>"},"55436":{"type":"graphic_table","displayName":"Signs symptoms exposure to intimate partner violence","title":"Signs and symptoms of childhood exposure to intimate partner violence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of childhood exposure to intimate partner violence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infants and toddlers</td> </tr> <tr> <td>Disrupted sleep patterns</td> </tr> <tr> <td>Disrupted feeding routines</td> </tr> <tr> <td>Failure to thrive</td> </tr> <tr> <td>Excessive screaming</td> </tr> <tr> <td>Developmental delays</td> </tr> <tr> <td class=\"subtitle1_single\">Pre-schoolers</td> </tr> <tr> <td>Behavioral problems</td> </tr> <tr> <td>Posttraumatic stress symptoms</td> </tr> <tr> <td>Aggressive behavior</td> </tr> <tr> <td>Anxiety symptoms</td> </tr> <tr> <td>Regressive behaviors such as bed-wetting, thumb-sucking</td> </tr> <tr> <td>Nightmares</td> </tr> <tr> <td class=\"subtitle1_single\">School-age</td> </tr> <tr> <td>Problems concentrating and focusing</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Behavioral problems such as conduct disorders or mood disorders</td> </tr> <tr> <td>Bullying/aggressive behavior</td> </tr> <tr> <td>Poor academic performance</td> </tr> <tr> <td>Somatic complaints such as chronic headache or abdominal pain</td> </tr> <tr> <td class=\"subtitle1_single\">Adolescents</td> </tr> <tr> <td>Substance abuse problems</td> </tr> <tr> <td>Sexual promiscuity</td> </tr> <tr> <td>Teen pregnancy</td> </tr> <tr> <td>Sexually transmitted infections</td> </tr> <tr> <td>School failure/truancy</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: <br /><ol>&#xD;&#xA;    <li>Evans SE, Davies C, DiLillo D. Exposure to domestic violence: A meta-analysis of child and adolescent outcomes. Aggression and Violent Behavior 2008; 13:131.</li>&#xD;&#xA;    <li>Holt S, Buckley H, Whelan S. The impact of exposure to domestic violence on children and young people: A review of the literature. Child Abuse &amp; Negl 2008; 32:797.</li>&#xD;&#xA;    <li>Knapp JF. The impact of children witnessing violence. Pediatric Clinics of North America 1998; 45:355.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55436 Version 7.0</div></div></div>"},"55437":{"type":"graphic_table","displayName":"Causes of heavy or prolonged menses","title":"Causes of heavy or prolonged menses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of heavy or prolonged menses</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Coagulopathy</td> </tr> <tr> <td class=\"indent1\">von Willebrand disease</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia (due to idiopathic thrombocytopenic purpura, hypersplenism, chronic renal failure)</td> </tr> <tr> <td class=\"indent1\">Acute leukemia</td> </tr> <tr> <td class=\"indent1\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Advanced liver disease</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasm</td> </tr> <tr> <td class=\"indent1\">Endometrial hyperplasia or carcinoma</td> </tr> <tr> <td class=\"indent1\">Uterine sarcoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Structural lesion</td> </tr> <tr> <td class=\"indent1\">Uterine leiomyomas (fibroids)</td> </tr> <tr> <td class=\"indent1\">Adenomyosis</td> </tr> <tr> <td class=\"indent1\">Endometrial polyps</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Endometritis</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Intrauterine device</td> </tr> <tr> <td class=\"indent1\">Hyperestrogenism</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55437 Version 4.0</div></div></div>"},"55438":{"type":"graphic_table","displayName":"Indications for ECT","title":"Indications for electroconvulsive therapy (ECT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for electroconvulsive therapy (ECT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitely effective</td> </tr> <tr> <td class=\"sublist2_start\">Unipolar major depression</td> </tr> <tr> <td class=\"sublist2\">Refractory or resistant to antidepressant therapy</td> </tr> <tr> <td class=\"sublist2\">Need exists for rapid treatment response, such as in pregnancy, persistent suicidal intent, or food refusal leading to dehydration or nutritional compromise</td> </tr> <tr> <td class=\"sublist2\">Medical comorbidities prevent the use of antidepressant medication</td> </tr> <tr> <td class=\"sublist2\">Previous response to ECT</td> </tr> <tr> <td class=\"sublist2\">Psychotic features (eg, delusions or hallucinations)</td> </tr> <tr> <td class=\"sublist2\">Catatonia</td> </tr> <tr> <td class=\"sublist2\">Persistent suicidal intent</td> </tr> <tr> <td class=\"indent1\">Bipolar depression or mania</td> </tr> </tbody></table></div><div class=\"graphic_reference\">American Psychiatric Association. Am J Psychiatry 2000; 157:1.</div><div id=\"graphicVersion\">Graphic 55438 Version 3.0</div></div></div>"},"55439":{"type":"graphic_table","displayName":"Drug and toxin related temperature change","title":"Drug- and toxin-induced temperature abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced temperature abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hyperthermia</td> </tr> <tr> <td class=\"subtitle2_single\">Increased heat production</td> </tr> <tr> <td class=\"indent1\">Muscular hyperactivity/rigidity</td> </tr> <tr> <td class=\"sublist3_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist3\">Cocaine</td> </tr> <tr> <td class=\"sublist3\">Amphetamines</td> </tr> <tr> <td class=\"sublist3\">Phenylpropanolamine</td> </tr> <tr> <td class=\"sublist3\">Ephedrine</td> </tr> <tr> <td class=\"sublist3\">Cathinones</td> </tr> <tr> <td class=\"indent2\">Anticholinergics</td> </tr> <tr> <td class=\"indent2\">Drug withdrawal states</td> </tr> <tr> <td class=\"indent2\">Lithium</td> </tr> <tr> <td class=\"sublist3_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist3\">Phencyclidine</td> </tr> <tr> <td class=\"sublist3\">Lysergic acid diethylamide (LSD)</td> </tr> <tr> <td class=\"sublist3\">Designer amphetamines (MDMA, MDEA)</td> </tr> <tr> <td class=\"sublist3\">Synthetic cannabinoids</td> </tr> <tr> <td class=\"sublist3_start\">Drugs causing recurrent seizures</td> </tr> <tr> <td class=\"sublist3\">Isoniazid</td> </tr> <tr> <td class=\"sublist3\">Theophylline</td> </tr> <tr> <td class=\"indent2\">Strychnine</td> </tr> <tr> <td class=\"indent2\">Neuroleptic malignant syndrome</td> </tr> <tr> <td class=\"indent2\">Serotonin syndrome</td> </tr> <tr> <td class=\"indent2\">MAO inhibitors</td> </tr> <tr> <td class=\"indent2\">Malignant hyperthermia</td> </tr> <tr> <td class=\"subtitle2_single\">Impaired heat dissipation</td> </tr> <tr> <td class=\"indent1\">Impaired sweating</td> </tr> <tr> <td class=\"sublist3_start\">Anticholinergic agents</td> </tr> <tr> <td class=\"sublist3\">Antihistamines</td> </tr> <tr> <td class=\"sublist3\">Phenothiazines</td> </tr> <tr> <td class=\"sublist3\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"subtitle2_single\">Increased metabolic rate</td> </tr> <tr> <td class=\"sublist2_start\">Uncoupled oxidative phosphorylation</td> </tr> <tr> <td class=\"sublist2\">Salicylates</td> </tr> <tr> <td class=\"sublist2\">Dinitrophenol, pentachlorophenol</td> </tr> <tr> <td class=\"indent1\">Thyroid hormone</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypothermia</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td class=\"sublist1_start\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td class=\"sublist1\">Alcohols</td> </tr> <tr> <td class=\"sublist1_start\">Sympatholytics</td> </tr> <tr> <td class=\"sublist1\">Beta blockers</td> </tr> <tr> <td class=\"sublist1\">Clonidine</td> </tr> <tr> <td class=\"sublist1\">Alpha-adrenergic antagonists</td> </tr> <tr> <td>Hypoglycemic agents</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td>General anesthetic agents</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Drugs which cause flaccid coma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55439 Version 8.0</div></div></div>"},"55440":{"type":"graphic_figure","displayName":"Lung volume and capacities","title":"Pulmonary function tests: Lung volumes and capacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary function tests: Lung volumes and capacities</div><div class=\"cntnt\"><img style=\"width:313px; height:208px;\" src=\"images/PULM/55440_Lung_vol_capacities_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are boundaries of lung volume within which tidal volume can vary. A lung capacity is a combination of more than one lung volume. TLC, for example, is the combination of FRC plus IC (or the combination of RV, ERV, VT, and IRV). TLC, RV, and their ratio provide the most information about restrictive lung disease and help differentiate between restrictive and obstructive disorders. However, TLC and RV are effort-dependent, so an evaluation of strength and/or effort is needed. In contrast, the FRC is effort-independent.</div><div class=\"graphic_footnotes\">IRV: inspiratory reserve volume; VT: tidal volume; ERV: expiratory reserve volume; RV: residual volume; IC: inspiratory capacity; FRC: functional residual capacity; TLC: total lung capacity; VC: vital capacity.</div><div id=\"graphicVersion\">Graphic 55440 Version 7.0</div></div></div>"},"55441":{"type":"graphic_waveform","displayName":"Type I atrial flutter","title":"Type I atrial flutter","html":"<div class=\"graphic normal\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Type I atrial flutter</div><div class=\"cntnt\"><img style=\"width:537px; height:85px;\" src=\"images/CARD/55441_Atrial_flutter_1_1_conducti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 1:1 AV conduction was induced by quinidine which both slowed the flutter wave and, via its vagolytic effect, enhanced conduction through the AV node.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 55441 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"55443":{"type":"graphic_picture","displayName":"L monocytogenes motility","title":"<em>Listeria monocytogenes</em> motility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Listeria monocytogenes</em> motility</div><div class=\"cntnt\"><img style=\"width:206px; height:366px;\" src=\"images/ID/55443_L_monocytogenes_motility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Test for motility of <EM>Listeria monocytogenes </EM>in semi-solid agar.<EM> L. monocytogenes </EM>is motile, as can be seen by the growth spreading outward from the central stab.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 55443 Version 2.0</div></div></div>"},"55446":{"type":"graphic_figure","displayName":"McDonald cerclage","title":"McDonald cerclage","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">McDonald cerclage</div><div class=\"cntnt\"><img style=\"width:508px; height:691px;\" src=\"images/OBGYN/55446_McDonald_cerclage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each pass should be deep into the cervical stroma, and should avoid entering the endocervical canal or impacting the uterine vessels.</div><div id=\"graphicVersion\">Graphic 55446 Version 3.0</div></div></div>"},"55447":{"type":"graphic_picture","displayName":"Pill esophagitis II CPC Endosc","title":"Medication-induced esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medication-induced esophagitis</div><div class=\"cntnt\"><img style=\"width:249px; height:256px;\" src=\"images/GAST/55447_Pill_esophagitis_II_CPC_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy revealed superficial ulcerations with bleeding localized in the proximal esophagus at the level of the aortic arch. The mid and distal esophageal mucosa appeared normal.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.</div><div id=\"graphicVersion\">Graphic 55447 Version 3.0</div></div></div>"},"55448":{"type":"graphic_picture","displayName":"Pratt and Hegar cervical dilators","title":"Pratt and Hegar cervical dilators","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Pratt and Hegar cervical dilators</div><div class=\"cntnt\"><img style=\"width:575px; height:252px;\" src=\"images/OBGYN/55448_Cervicaldilators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pratt dilator.<br />(B) Hegar dilator.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 55448 Version 4.0</div></div></div>"},"55449":{"type":"graphic_table","displayName":"Diagnosis of vulvar pruritus","title":"Differential diagnosis of vulvar pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of vulvar pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr><td class=\"subtitle1_single\">Mild</td></tr><tr>\n\n      \n\n      <td>Condylomata</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Squamous cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Vulvar intraepithelial neoplasia</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Syringoma</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Angioma</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Acrochordon</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Polyp</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Seborrheic keratosis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Perimenopausal atrophy</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Irritants</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Allergens</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Sexually transmitted diseases</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle1_single\">Moderate</td></tr><tr>\n\n      \n\n      <td>Irritants</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Allergens</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Candidiasis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Seborrheic dermatitis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Vulvodynia</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle1_single\">Severe</td></tr><tr>\n\n      \n\n      <td>Lichen simplex chronicus</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Lichen sclerosus</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Lichen planus</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Psoriasis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Pemphigus</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Vulvodynia</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Severe contact dermatitis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Severe candidiasis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Pediculosis pubis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55449 Version 1.0</div></div></div>"},"55451":{"type":"graphic_figure","displayName":"RBC membrane protein abnormalities","title":"RBC membrane protein abnormalities and sites of the responsible gene mutations in hereditary spherocytosis, hereditary elliptocytosis, and hereditary pyropoikilocytosis","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">RBC membrane protein&nbsp;abnormalities and sites of the responsible gene mutations&nbsp;in hereditary spherocytosis, hereditary elliptocytosis, and hereditary pyropoikilocytosis</div><div class=\"cntnt\"><img style=\"width:568px; height:458px;\" src=\"images/HEME/55451_RBC_membrane_protein_mutati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The domain structure of these proteins is shown, with positions of known mutations causing HS and HE/HPP indicated beneath each protein. <br />(B) The structure of the spectrin tetramer is shown, illustrating the triple helical coiled-coil repeats of the spectrin peptides, the head-to-head spectrin self-association sites, and the nucleation sites that initiate the side-to-side interaction between alpha- and beta-spectrin chains.</div><div class=\"graphic_footnotes\">RBC: red blood cell; HS: hereditary spherocytosis; HE: hereditary elliptocytosis; HPP: hereditary pyropoikilocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol 1999; 104:2. Copyright 1999 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 55451 Version 5.0</div></div></div>"},"55452":{"type":"graphic_figure","displayName":"TEE abnormalities stroke risk","title":"Left atrial abnormalities and complex aortic plaque correlate with the risk of thromboembolism in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial abnormalities and complex aortic plaque correlate with the risk of thromboembolism in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:419px; height:437px;\" src=\"images/CARD/55452_TEEabnormalitiesstrokeri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Correlation of clinical risk for thromboembolism (TE) and transesophageal echocardiographic (TEE) findings in 786 patients with atrial fibrillation. Patients were deemed to be at high risk if they had one or more of the following clinical features: prior TE, women &gt;75 years of age, systolic blood pressure &gt;160 mmHg, and heart failure or poor left ventricular function. Patients with none of these features were either at low risk or, if they had a history of hypertension, moderate risk. Panel A: There was an increasing incidence of a left atrial appendage (LAA) abnormality (thrombus, dense spontaneous echo contrast, or flow velocity ≤20 cm/s) or a complex aortic plaque risk with increasing clinical risk of TE. Panel B: The frequency of LAA abnormalities and complex aortic plaque in patients with a single high risk factor.</div><div class=\"graphic_reference\">Redrawn from: Zabalgoitia M, Halperin JL, Pearce LA, et al. for the Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31:1622.</div><div id=\"graphicVersion\">Graphic 55452 Version 3.0</div></div></div>"},"55455":{"type":"graphic_picture","displayName":"Starting position for straight leg raise","title":"Starting position for straight leg raise","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Starting position for straight leg raise</div><div class=\"cntnt\"><img style=\"width:463px; height:259px;\" src=\"images/EM/55455_Straight_leg_raise_prep.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 55455 Version 2.0</div></div></div>"},"55456":{"type":"graphic_table","displayName":"Causes of hypothyroidism in children","title":"Causes of hypothyroidism in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypothyroidism in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Chronic autoimmune (Hashimoto's) thyroiditis</td> </tr> <tr> <td class=\"sublist1_start\">Iodine</td> </tr> <tr> <td class=\"sublist1\">Deficiency</td> </tr> <tr> <td class=\"sublist1\">Excess ingestion (eg, nutritional supplements, drugs [amiodarone, expectorants])</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Antithyroid drugs (eg, methimazole, propylthiouracil)</td> </tr> <tr> <td class=\"sublist1\">Anticonvulsant drugs (eg, phenytoin, phenobarbital, valproate)</td> </tr> <tr> <td class=\"sublist1\">Tyrosine kinase inhibitors</td> </tr> <tr> <td class=\"sublist1\">Interferon alfa</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid injury</td> </tr> <tr> <td class=\"sublist1\">External radiation therapy</td> </tr> <tr> <td class=\"sublist1\">Radioactive iodine treatment</td> </tr> <tr> <td class=\"sublist1\">Thyroidectomy</td> </tr> <tr> <td class=\"sublist1\">Infiltrative diseases</td> </tr> <tr> <td class=\"sublist2\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"sublist2\">Cystinosis</td> </tr> <tr> <td>Late-onset congenital hypothyroidism</td> </tr> <tr> <td>Williams syndrome</td> </tr> <tr> <td>Hemangiomas</td> </tr> <tr> <td>Thyroid hormone resistance</td> </tr> <tr> <td>Central hypothyroidism (hypothalamic-pituitary disease)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55456 Version 9.0</div></div></div>"},"55459":{"type":"graphic_figure","displayName":"Dyspnea post LVRS","title":"Respondent score changes in modified Medical Research Council dyspnea scale after LVRS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respondent score changes in modified Medical Research Council dyspnea scale after LVRS</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/PULM/55459_Dyspnea_post_LVRS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Ciccone, AM, Meyers, BR, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.</div><div id=\"graphicVersion\">Graphic 55459 Version 1.0</div></div></div>"},"55460":{"type":"graphic_figure","displayName":"Spirometry technique","title":"Technique for performing spirometry","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Technique for performing spirometry</div><div class=\"cntnt\"><img style=\"width:454px; height:350px;\" src=\"images/PULM/55460_Spirometry_technique.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unlike most other medical tests in which the patient remains passive, accurate spirometry requires a coordinated maximum effort. The technician should instruct and encourage the patient to perform the breathing maneuvers in three phases: Phase 1: coach the patient to take as deep a breath as possible; Phase 2: loudly prompt the patient to BLAST out the air into the spirometer; Phase 3: encourage the patient to continue exhaling for several more seconds.</div><div id=\"graphicVersion\">Graphic 55460 Version 1.0</div></div></div>"},"55461":{"type":"graphic_table","displayName":"Quick Inventory of Depressive Symptomatology","title":"The Quick Inventory of Depressive Symptomatology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Quick Inventory of Depressive Symptomatology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\"><br /> Name or ID: ________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: _____________ </td> </tr> <tr class=\"divider_top\"> <td colspan=\"3\"><strong>Check the one response to each item that best describes you for the past seven days.</strong></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">During the past seven days...</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">1. Falling asleep</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I never take longer than 30 minutes to fall asleep.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I take at least 30 minutes to fall asleep, less than half the time.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I take at least 30 minutes to fall asleep, more than half the time.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I take more than 60 minutes to fall asleep, more than half the time.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">2. Sleep during the night</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I do not wake up at night.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I have a restless, light sleep with a few brief awakenings each night.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I wake up at least once a night, but I go back to sleep easily.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I awaken more than once a night and stay awake for 20 minutes or more, more than half the time.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">3. Waking up too early</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>Most of the time, I awaken no more than 30 minutes before I need to get up.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>More than half the time, I awaken more than 30 minutes before I need to get up.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I almost always awaken at least one hour or so before I need to, but I go back to sleep eventually.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I awaken at least one hour before I need to, and can't go back to sleep.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">4. Sleeping too much</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I sleep no longer than 7-8 hours/night, without napping during the day.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I sleep no longer than 10 hours in a 24-hour period including naps.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I sleep no longer than 12 hours in a 24-hour period including naps.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I sleep longer than 12 hours in a 24-hour period including naps.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">5. Feeling sad</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I do not feel sad.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I feel sad less than half the time.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I feel sad more than half the time.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I feel sad nearly all of the time.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"3\">Please complete either 6 or 7 (not both).</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">6. Decreased appetite</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>There is no change in my usual appetite.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I eat somewhat less often or lesser amounts of food than usual.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I eat much less than usual and only with personal effort.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I rarely eat within a 24-hour period, and only with extreme personal effort or when others persuade me to eat.</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">7. Increased appetite</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>There is no change from my usual appetite.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I feel a need to eat more frequently than usual.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I regularly eat more often and/or greater amounts of food than usual.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I feel driven to overeat both at mealtime and between meals.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"3\">Please complete either 8 or 9 (not both).</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">8. Decreased weight (within the last two weeks)</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I have not had a change in my weight.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I feel as if I have had a slight weight loss.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I have lost 2 pounds or more.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I have lost 5 pounds or more.</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">9. Increased weight (within the last two weeks)</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I have not had a change in my weight.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I feel as if I have had a slight weight gain.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I have gained 2 pounds or more.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I have gained 5 pounds or more.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_single\" colspan=\"3\">10. Concentration/decision making</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>There is no change in my usual capacity to concentrate or make decisions.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I occasionally feel indecisive or find that my attention wanders.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>Most of the time, I struggle to focus my attention or to make decisions.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I cannot concentrate well enough to read or cannot make even minor decisions.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">11. View of myself:</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I see myself as equally worthwhile and deserving as other people.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I am more self-blaming than usual.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I largely believe that I cause problems for others.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I think almost constantly about major and minor defects in myself.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">12. Thoughts of death or suicide</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I do not think of suicide or death.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I feel that life is empty or wonder if it's worth living.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I think of suicide or death several times a week for several minutes.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I think of suicide or death several times a day in some detail, or I have made specific plans for suicide or have actually tried to take my life.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">13. General interest</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>There is no change from usual in how interested I am in other people or activities.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I notice that I am less interested in people or activities.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I find I have interest in only one or two of my formerly pursued activities.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I have virtually no interest in formerly pursued activities.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">14. Energy level</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>There is no change in my usual level of energy.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I get tired more easily than usual.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I have to make a big effort to start or finish my usual daily activities (for example, shopping, homework, cooking, or going to work).</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I really cannot carry out most of my usual daily activities because I just don't have the energy.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">15. Feeling slowed down</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I think, speak, and move at my usual rate of speed.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I find that my thinking is slowed down or my voice sounds dull or flat.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>It takes me several seconds to respond to most questions and I'm sure my thinking is slowed.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>I am often unable to respond to questions without extreme effort.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">16. Feeling restless</td> </tr> <tr> <td class=\"indent1\">____&nbsp;0</td> <td>I do not feel restless.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;1</td> <td>I'm often fidgety, wringing my hands, or need to shift how I am sitting.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;2</td> <td>I have impulses to move about and am quite restless.</td> </tr> <tr> <td class=\"indent1\">____&nbsp;3</td> <td>At times, I am unable to stay seated and need to pace around.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=92361&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from the UT Southwestern Medical Center at Dallas. For more information, please visit <a href=\"http://www.ids-qids.org/\">www.ids-qids.org</a>. Copyright © 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55461 Version 2.0</div></div></div>"},"55462":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum - histopathology dermis","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/55462_Pyoderm_gangr_histo_dermis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dense neutrophil-predominant inflammatory infiltrate is present in the dermis.</div><div id=\"graphicVersion\">Graphic 55462 Version 2.0</div></div></div>"},"55465":{"type":"graphic_figure","displayName":"Anatomy VIII cranial nerve","title":"Anatomy of the auditory nerve (cranial nerve VIII)","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anatomy of the auditory nerve (cranial nerve VIII)</div><div class=\"cntnt\"><img style=\"width:539px; height:415px;\" src=\"images/ONC/55465_Anatomy_VIII_cranial_nerve.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55465 Version 2.0</div></div></div>"},"55467":{"type":"graphic_table","displayName":"DMD during anesthesia","title":"Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the management of patients with Duchenne muscular dystrophy (DMD) during general anesthesia or procedural sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the management of patients with Duchenne muscular dystrophy (DMD) during general anesthesia or procedural sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Consider use of a total intravenous anesthesia technique for induction and maintenance of general anesthesia (eg, propofol and short-acting opioids)</td> </tr> <tr> <td class=\"sublist1\">&#8226; The use of depolarizing muscle relaxants such as succinylcholine is absolutely contraindicated because of the risk of fatal reactions</td> </tr> <tr> <td class=\"sublist1_start\">Optimize the medical setting and personnel in attendance when patients with DMD undergo general anesthesia or procedural sedation, and have an intensive care unit available for postprocedure care</td> </tr> <tr> <td class=\"sublist1_start\">Options for providing respiratory support during maintenance of general anesthesia or procedural sedation for patients with DMD include:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Endotracheal intubation, with use of noninvasive positive pressure ventilation (NPPV) to facilitate extubation for selected patients</td> </tr> <tr> <td class=\"sublist1\">&#8226; Laryngeal mask airway</td> </tr> <tr> <td class=\"sublist1\">&#8226; Mechanical ventilation via a mouthpiece with leak-proof seal</td> </tr> <tr> <td class=\"sublist1\">&#8226; Manual or mechanical ventilation (using conventional ventilators or bilevel positive pressure ventilators designed for noninvasive respiratory support) delivered via a full face mask or nasal mask interface</td> </tr> <tr> <td class=\"sublist1_start\">Application of ventilation in the assisted or controlled modes should be considered for patients with DMD and a forced vital capacity (FVC) &#60;50 percent of predicted, and strongly considered for those with an FVC &#60;30 percent of predicted, during induction of and recovery from general anesthesia and throughout procedural sedation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Options for respiratory support during induction of and recovery from general anesthesia or procedural sedation include manual ventilation using a flow-inflated manual resuscitation bag (standard \"anesthesia bag\") with a full face or nasal mask interface, and mechanical support using a conventional or noninvasive positive pressure ventilator via a full face or nasal mask</td> </tr> <tr> <td class=\"sublist1_start\">Intraoperatively, continuously monitor oxyhemoglobin saturation measured by pulse oximetry and, whenever possible, blood or end-tidal carbon dioxide levels</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Birnkrant, DJ, Panitch, HB, Benditt, JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.</div><div id=\"graphicVersion\">Graphic 55467 Version 2.0</div></div></div>"},"55468":{"type":"graphic_table","displayName":"Joint exam child","title":"Joint examination of a child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Joint examination of a child</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lower limbs: Patient lying down </td> </tr> <tr> <td class=\"sublist1_start\">1. Inspection.</td> </tr> <tr> <td class=\"sublist2\">a. Symmetry.</td> </tr> <tr> <td class=\"sublist2\">b. Size (limb length, muscle wasting, joint enlargement).</td> </tr> <tr> <td class=\"sublist2\">c. Skin (scars, color, warmth, vascular pattern and vascular malformations).</td> </tr> <tr> <td class=\"sublist2\">d. Postural deformity (flexion, valgus).</td> </tr> <tr> <td class=\"sublist1_start\">2. Palpation.</td> </tr> <tr> <td class=\"sublist2\">a. Soles of feet, insertions of tendon into bone (enthesitis).</td> </tr> <tr> <td class=\"sublist2\">b. Joint margins (metatarsal squeeze, anterior ankle, medial knee).</td> </tr> <tr> <td class=\"sublist2\">c. Palpate joint enlargement (is it bony, soft tissue, or fluid?).</td> </tr> <tr> <td>3. Active movement: Curl toes, dorsiflex ankles, bend knees and hips, watch for subtle compensatory movements.</td> </tr> <tr> <td>4. Passive movement: Joint range of movement (note both increased range [hypermobility] and reduced range [restriction]). Forefoot and hindfoot inversion/eversion, relaxed passive extension of knees, internal rotation of hips (knees and hips flexed to 90%). Watch for subtle guarding and compensatory movements.</td> </tr> <tr> <td class=\"subtitle1_single\">Upper limbs: Patient sitting up </td> </tr> <tr> <td>1. Inspection similar to evaluation for lower limbs: Symmetry, size, scars, wasting, enlargement, nails.</td> </tr> <tr> <td>2. Palpation: Joint margins (metacarpal squeeze, dorsal wrist, anterior glenohumeral), palpate bony enlargements, warmth.</td> </tr> <tr> <td>3. Active movement: Finger extension, fist, tuck, wrist extension (prayer position), arms straight up then behind head then behind lower back, neck extension and rotation (chin to shoulder), beware compensatory movements (especially elbow lift on wrist flexion, lateral flexion of spine on shoulder abduction).</td> </tr> <tr> <td>4. Passive movement: Joint range of movement, wrist flexion and extension (watch for subtle guarding and compensatory movements).</td> </tr> <tr> <td class=\"subtitle1_single\">Axial skeleton: Patient standing up </td> </tr> <tr> <td>1. Inspect symmetry from behind: Especially posterior ankles, pelvic position, spine.</td> </tr> <tr> <td>2. Spinal movements: Scoliosis, lumbar mobility (lumbar curve on forward flexion, lumbar pain on hyperextension), cervical spine extension and lateral rotation.</td> </tr> <tr> <td>3. Gait: Normal, tip toes, heels.</td> </tr> <tr> <td>4. Muscle power: Gowers test, Trendelenberg gait.</td> </tr> <tr> <td>5. Temporo-mandibular joint.</td> </tr> <tr> <td>6. Sacroiliac joints: Direct palpation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Yukiko Kimura, MD and Taunton R Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH.</div><div id=\"graphicVersion\">Graphic 55468 Version 4.0</div></div></div>"},"55472":{"type":"graphic_figure","displayName":"Coronary flow abnormalities with myocardial bridging","title":"Coronary flow abnormalities with myocardial bridging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary flow abnormalities with myocardial bridging</div><div class=\"cntnt\"><img style=\"width:391px; height:473px;\" src=\"images/CARD/55472_Coronary_flow_myoc_bridging.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The contrasting patterns of variation in vessel area (VA) and coronary flow velocity (CFV) in a normal vessel (N) and in a muscle bridge segment (B). The end of the QRS (black line) represents the start of isometric contraction of the left ventricle and point of opening of aortic valve and the end of the T-wave (red line) represents the end of systole and the point of closure of aortic valve. In the bridged segment, vessel area falls markedly during systole and increases during diastole with a marked early peak in diastolic coronary flow velocity (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from Ge J, Erbel R, Rupprecht HJ, et al. Circulation 1994; 89:1725.</div><div id=\"graphicVersion\">Graphic 55472 Version 3.0</div></div></div>"},"55473":{"type":"graphic_figure","displayName":"Effect of blood flow on urea clearance during hemodialysis","title":"Figure showing the effect of blood flow on urea clearance during hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Figure showing the effect of blood flow on urea clearance during hemodialysis</div><div class=\"cntnt\"><img style=\"width:426px; height:280px;\" src=\"images/NEPH/55473_Urea_clearance_in_hemodialy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of increasing Qb on Kd in hemodialysis for a given KoA approximately 1000. Increasing flow raises Kd by delivering more blood with a high urea concentration, thereby maintaining a favorable concentration gradient for urea diffusion across the dialysis membrane. There is a relative plateau above 500 mL/min due to limitations of the dialysis membrane. A similar relationship is seen between dialysate flow and Kd; in this setting, the concentration gradient is maintained as dialysate flow rises by the supply of new dialysate containing no urea.</div><div class=\"graphic_footnotes\">Qb: dialyzer blood flow; Kd: urea clearance; KoA: area-permeability product.</div><div id=\"graphicVersion\">Graphic 55473 Version 4.0</div></div></div>"},"55474":{"type":"graphic_diagnosticimage","displayName":"Fetal spine limb body wall defect","title":"Limb-body wall complex 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Limb-body wall complex 2</div><div class=\"cntnt\"><img style=\"width:399px; height:241px;\" src=\"images/OBGYN/55474_Spine_limb_body_wall_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal spine limb body wall defect. Note that the spine is twisted out of the plane of the image at the left side. Arrow points to herniated abdominal contents.</div><div class=\"graphic_reference\">Courtesy of Wendy Shaffer, RDMS and Joshua A. Copel, MD, Yale University School of Medicine.</div><div id=\"graphicVersion\">Graphic 55474 Version 4.0</div></div></div>"},"55475":{"type":"graphic_table","displayName":"Nasal vs oronasal masks","title":"Nasal versus oronasal masks: Advantages and disadvantages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nasal versus oronasal masks: Advantages and disadvantages</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variables</td> <td class=\"subtitle1\">Nasal</td> <td class=\"subtitle1\">Oronasal</td> </tr> <tr> <td>Comfort</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td>Claustrophobia</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Rebreathing</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Lowers CO<sub>2</sub></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Permits expectoration*</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td>Permits speech<sup>&#182;</sup></td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td>Permits eating<sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Function if nose obstructed</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+: possible; ++: most likely; &ndash;: not possible.&#xD;&#xA;* Expectoration is possible but requires the assistance of a respiratory therapist with oronasal mask.<br />&para; Speech is possible but may vary depending on the degree of respiratory failure.<br />&Delta; Eating necessitates oronasal mask removal and may be contraindicated in patients with severe respiratory failure.</div><div class=\"graphic_reference\">Reproduced with permission from: Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003; 124:699. Copyright &copy; 2003 American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 55475 Version 4.0</div></div></div>"},"55476":{"type":"graphic_picture","displayName":"Centruroides exilicauda 2","title":"Centruroides exilicauda (sculpturatus) or bark scorpion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centruroides exilicauda (sculpturatus) or bark scorpion</div><div class=\"cntnt\"><img style=\"width:396px; height:295px;\" src=\"images/EM/55476_C_exilicauda_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.</div><div id=\"graphicVersion\">Graphic 55476 Version 2.0</div></div></div>"},"55477":{"type":"graphic_picture","displayName":"Polymorphic light eruption A","title":"Polymorphic light eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphic light eruption</div><div class=\"cntnt\"><img style=\"width:360px; height:314px;\" src=\"images/ALLRG/55477_Polymorphic_light_eruptionA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clusters of confluent, extremely pruritic papules and vesicles on the exposed chest occurred the day following the first sun exposure of the season. The eruption involved the dorsum of the arms, but spared the face and dorsal hands.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick T, Johnson R, Wolff K, et al. Color atlas and synopsis of clinical dermatology: Common and Serious Diseases, Third Edition, McGraw Hill, New York, 1997. Copyright © 1997 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 55477 Version 16.0</div></div></div>"},"55479":{"type":"graphic_table","displayName":"Antibiotics C diff diarrhea","title":"Antimicrobial agents that may induce <EM>Clostridium difficile </EM>diarrhea and colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial agents that may induce <EM>Clostridium difficile </EM>diarrhea and colitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Frequently associated </td> </tr> <tr> <td>Fluoroquinolones</td> </tr> <tr> <td>Clindamycin</td> </tr> <tr> <td>Cephalosporins (broad spectrum)</td> </tr> <tr> <td>Penicillins (broad spectrum)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Occasionally associated </td> </tr> <tr> <td>Macrolides</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rarely associated </td> </tr> <tr> <td>Aminoglycosides</td> </tr> <tr> <td>Tetracyclines</td> </tr> <tr> <td>Metronidazole</td> </tr> <tr> <td>Vancomycin</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55479 Version 6.0</div></div></div>"},"55486":{"type":"graphic_picture","displayName":"Thin basement membrane EM","title":"Thin basement membrane disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thin basement membrane disease</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/55486_Thin_basement_membrane_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph comparing the thickness of the normal glomerular basement membrane (GBM) (left panel) to the much thinner GBM in thin basement membrane disease (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 55486 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"55487":{"type":"graphic_table","displayName":"Objective physical signs of substance abuse","title":"Objective physical signs to look for in substance abusers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Objective physical signs to look for in substance abusers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Body system </td> <td class=\"subtitle1\">Findings </td> </tr> <tr> <td>Dermatologic</td> <td>Abscesses, rashes, cellulitis, thrombosed veins, jaundice, scars, track marks, pock marks from skin popping</td> </tr> <tr> <td>Eye, ear, nose, and throat</td> <td>Pupils pinpoint or dilated, yellow sclera, conjunctivitis ruptured eardrums, otitis media, discharge from ears, rhinorrhea, rhinitis, excoriation or perforation of nasal septum, epistaxis, sinusitis, hoarseness or laryngitis</td> </tr> <tr> <td>Mouth</td> <td>Poor dentition, gum disease, abscesses</td> </tr> <tr> <td>Cardiovascular</td> <td>Murmurs, arrhythmias</td> </tr> <tr> <td>Respiratory</td> <td>Asthma, dyspnea, rales, chronic cough, hematemesis</td> </tr> <tr> <td>Musculoskeletal&nbsp;and extremities</td> <td>Pitting edema, broken bones, traumatic amputations, burns on fingers</td> </tr> <tr> <td>Gastrointestinal</td> <td>Hepatomegaly, hernias</td> </tr> <tr> <td>Chest/breasts</td> <td>Lumps, abscesses, scars, track marks in mammary vessels, enlarged lymph nodes in axilla</td> </tr> <tr> <td>Pelvic exam</td> <td>Assess uterus, cervix, cesarean delivery scars, labial tears or rectal contusions, sexually transmitted infections</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55487 Version 4.0</div></div></div>"},"55488":{"type":"graphic_figure","displayName":"Yellow fever Africa PI","title":"Areas in Africa where yellow fever is present","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Areas in Africa where yellow fever is present</div><div class=\"cntnt\"><img style=\"width:413px; height:417px;\" src=\"images/PI/55488_Yellow_fever_Africa_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55488 Version 2.0</div></div></div>"},"55489":{"type":"graphic_diagnosticimage","displayName":"M mode tricuspid valve","title":"M-mode echocardogram of tricuspid valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardogram of tricuspid valve</div><div class=\"cntnt\"><img style=\"width:285px; height:188px;\" src=\"images/CARD/55489_M_mode_tricuspid_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transducer is at the left parasternal area and two of the tricuspid valve leaflets are seen. The movement of the valves is similar to that of the mitral valve.</div><div id=\"graphicVersion\">Graphic 55489 Version 2.0</div></div></div>"},"55490":{"type":"graphic_table","displayName":"Neurotransmitters airway","title":"Neurotransmitters found in nerve fibers innervating the airways: Origin, colocalization and effects on airway function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurotransmitters found in nerve fibers innervating the airways: Origin, colocalization and effects on airway function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurotransmitters*</td> <td class=\"subtitle1\">Origin<sup>&#182;</sup></td> <td class=\"subtitle1\">Cotransmitters<sup>&#916;</sup></td> <td class=\"subtitle1\">Vasculature</td> <td class=\"subtitle1\">Glands</td> <td class=\"subtitle1\">Airway smooth muscle</td> </tr> <tr> <td>Acetylcholine</td> <td>Parasympathetic</td> <td>Carbon monoxide</td> <td>Vasodilatation</td> <td>Secretion</td> <td>Contraction</td> </tr> <tr> <td>VIP<sup>&#9674;</sup></td> <td>Parasympathetic</td> <td>NO, PACAP</td> <td>Vasodilatation</td> <td>Secretion</td> <td>Relaxation</td> </tr> <tr> <td>Nitric Oxide (NO)<sup>&#167;</sup></td> <td>Parasympathetic</td> <td>VIP, PACAP</td> <td>Vasodilatation</td> <td>No effect</td> <td>Relaxation</td> </tr> <tr> <td>Carbon monoxide<sup>&#165;</sup></td> <td>Parasympathetic</td> <td>Acetylcholine</td> <td>Vasodilatation</td> <td>Not assessed</td> <td>Relaxation</td> </tr> <tr> <td>Norepinephrine</td> <td>Sympathetic</td> <td>Neuropeptide Y</td> <td>Vasoconstriction</td> <td>No effect</td> <td>Relaxation</td> </tr> <tr> <td>Neuropeptide Y</td> <td>Sympathetic</td> <td>Norepinephrine</td> <td>Vasoconstriction</td> <td>No effect</td> <td>No effect</td> </tr> <tr> <td>CGRP<sup>&#135;</sup></td> <td>Afferent</td> <td>SP, NKA</td> <td>Vasodilatation</td> <td>No effect</td> <td>No effect</td> </tr> <tr> <td>Substance P (SP)**</td> <td>Afferent</td> <td>NKA, CGRP</td> <td>Vasodilatation</td> <td>Secretion </td> <td>Contraction</td> </tr> <tr> <td>Neurokinin A (NKA)</td> <td>Afferent</td> <td>SP, CGRP</td> <td>Vasodilatation</td> <td>Secretion</td> <td>Contraction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other putative neurotransmitters have been localized to nerve fibers in the airways (eg, ATP, dynorphin, enkephalin, GABA, galanin, gastrin releasing peptide, glutamate, nociceptin, serotonin (5-HT), somatostatin). However, their function in the airways is poorly characterized.<br />¶ Several neurotransmitters (e.g. neuropeptide Y, VIP) localized to nerve fibers innervating the airways are found in both sympathetic and parasympathetic nerves. Their primary origin is listed above.<br />Δ Multiple neurotransmitters are frequently localized to the same nerves. Such transmitters are known as cotransmitters. The most commonly colocalized neurotransmitters in the airways are listed above. Other examples of cotransmission (eg. galanin with VIP, dynorphin with substance P and neurokinin A) have been noted.<br /><FONT class=lozenge>◊</FONT> Vasoactive intestinal peptide and related peptides (peptide histidine isoleucine (PHI), peptide histidine methionine (PHM), pituitary adenylate cyclase activating peptide (PACAP), helodermin, helospectin).<br />§ Synthesized from arginine by nitric oxide synthase (NO synthase or NOS).<br />¥ Synthesized from heme by heme oxygenase-2.<br />‡ Calcitonin gene-related peptide.<br />** Substance P has also been localized to a subset of airway parasympathetic ganglia neurons.</div><div id=\"graphicVersion\">Graphic 55490 Version 2.0</div></div></div>"},"55491":{"type":"graphic_diagnosticimage","displayName":"Distal fibular fracture - Adult","title":"Distal fibula fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal fibula fracture</div><div class=\"cntnt\"><img style=\"width:217px; height:360px;\" src=\"images/RHEUM/55491_Distal_fibular_fracture_adu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a fracture of the distal fibula.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 55491 Version 3.0</div></div></div>"},"55492":{"type":"graphic_figure","displayName":"Penis aspiration","title":"Glans penis aspiration for reduction of paraphimosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glans penis aspiration for reduction of paraphimosis</div><div class=\"cntnt\"><img style=\"width:405px; height:218px;\" src=\"images/EM/55492_Penis_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penis aspiration is an invasive method for paraphimosis reduction and is usually performed by an urologist but can also be performed by a knowledgeable physician if no urologist is available and emergency reduction is needed (eg, glans penis necrosis or complete urinary obstruction). After local anesthesia and, in young children or otherwise uncooperative patients, procedural sedation are performed,&nbsp;a 20 gauge needle is&nbsp;attached to a 10 mL syringe&nbsp;and advanced parallel to the urethra as shown. After aspiration of blood, the foreskin is reduced over the decompressed glans penis similar to manual reduction (Refer to UpToDate topics on treatment of paraphimosis).</div><div id=\"graphicVersion\">Graphic 55492 Version 3.0</div></div></div>"},"55493":{"type":"graphic_picture","displayName":"Carcinoid flush","title":"Carcinoid flush","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid flush</div><div class=\"cntnt\"><img style=\"width:288px; height:275px;\" src=\"images/ENDO/55493_Carcinoid_flush.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked facial flushing in a patient with the carcinoid syndrome.</div><div class=\"graphic_reference\">Courtesy of Stephen E Goldfinger, MD.</div><div id=\"graphicVersion\">Graphic 55493 Version 2.0</div></div></div>"},"55494":{"type":"graphic_picture","displayName":"Anal condyloma","title":"Anal condyloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anal condyloma</div><div class=\"cntnt\"><img style=\"width:334px; height:252px;\" src=\"images/GAST/55494_Anal_condyloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph shows the characteristic verrucous, pink or skin-colored, papilliform appearance of anal condyloma accuminata.&nbsp;By contrast, anal squamous cell carcinoma has a smooth and pearly appearance and may contain areas of hemorrhage and necrosis.</div><div class=\"graphic_reference\">Reproduced by permission from the American Society of Colon and Rectal Surgeons.</div><div id=\"graphicVersion\">Graphic 55494 Version 2.0</div></div></div>"},"55496":{"type":"graphic_figure","displayName":"Sensory nerve conduction study","title":"Sensory nerve conduction study","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Sensory nerve conduction study</div><div class=\"cntnt\"><img style=\"width:528px; height:466px;\" src=\"images/NEURO/55496_Sensory_nerve_action_potent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recording of the sensory action potential is helpful in determining the site of nerve injury particularly in those with lesions resulting in sensory symptoms. This illustration depicts a sensory nerve conduction study of the ulnar nerve. Normal latency is seen with lesions of the central nervous system or those that are proximal to the dorsal root ganglion (arrowhead number 1). A more distal lesion (arrowhead number 2) results in a decreased amplitude but normal conduction velocity. Either a compressive mononeuropathy (arrowhead number 3) or generalized demyelinating peripheral neuropathy results in a decrease in both amplitude and conduction velocity.</div><div class=\"graphic_reference\">Courtesy of Shahram Khoshbin, MD.</div><div id=\"graphicVersion\">Graphic 55496 Version 2.0</div></div></div>"},"55497":{"type":"graphic_picture","displayName":"Toe towel curls","title":"Toe towel curls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toe towel curls</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/RHEUM/55497_Toe_towel_curls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The toes are curled around a towel as pictured. The toes should be alternately curled and straightened. This exercise is performed for one to two minutes, twice daily.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 55497 Version 1.0</div></div></div>"},"55499":{"type":"graphic_picture","displayName":"Acropustulosis of infancy 2","title":"Acropustulosis of infancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acropustulosis of infancy</div><div class=\"cntnt\"><img style=\"width:432px; height:291px;\" src=\"images/DERM/55499_Acropustulosis_of_infancy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small pustules are present on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55499 Version 4.0</div></div></div>"},"55500":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step eight","title":"Standard cricothyrotomy step eight","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step eight</div><div class=\"cntnt\"><img style=\"width:372px; height:303px;\" src=\"images/EM/55500_Cric_standard_step_eight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red><FONT color=black>Replace the inner cannula and inflate the cuff.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 55500 Version 2.0</div></div></div>"},"55501":{"type":"graphic_movie","displayName":"Pulmonary hypertension four chamber echocardiogram","title":"Pulmonary hypertension four chamber echocardiographic view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension four chamber echocardiographic view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55501_4chpulhyconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:225px; height:411px;\" src=\"images/CARD/55501_4chpulhy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram shows marked enlargement of the right atrium and ventricle which is also hypokinetic as a result of elevated pressures due to pulmonary hypertension.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 55501 Version 4.0</div></div></div>"},"55504":{"type":"graphic_figure","displayName":"HR BP response tilt table test","title":"Heart rate and blood pressure patterns observed in head-up tilt-table testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart rate and blood pressure patterns observed in head-up tilt-table testing</div><div class=\"cntnt\"><img style=\"width:419px; height:620px;\" src=\"images/CARD/55504_HR_BP_response_tilt_table_t.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the heart rate and blood pressure responses seen during tilt-table testing in patients with various etiologies of syncope including classic neurocardiogenic syncope, pure autonomic failure, or postural orthostatic tachycardia syndrome (POTS).</div><div class=\"graphic_reference\">Reproduced with permission from: Grubb, BP. Neurocardiogenic syncope. In: Syncope: Mechanisms and Management, Grubb, BP, Olshansky, B (Eds), Furtura Publishing Co., Armonk, NY, 1997. p. 73-166. Copyright © 1997 Futura Publishing Co.</div><div id=\"graphicVersion\">Graphic 55504 Version 2.0</div></div></div>"},"55505":{"type":"graphic_table","displayName":"Helpful clues in recognizing HP","title":"Helpful clues in the recognition of hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful clues in the recognition of hypersensitivity pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>History of recurrent atypical pneumonia, particularly if there is regularity to the illness (eg, only in spring or fall, only certain time of week or following certain events)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Symptoms developed after moving to new job or home</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patient or any family member has pets (especially birds), even if the patient denies contact with the pets</td>\n\n    </tr>\n\n    <tr>\n\n      <td>History of water damage to home or office, particularly to crawl space, basement, roof, ceiling tiles, carpet (even if previously cleaned)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Use of hot tub, sauna, swimming pool</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other people have similar symptoms or have left work because of recurrent symptoms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patient feels better when away from home or work (such as after a vacation)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 55505 Version 1.0</div></div></div>"},"55507":{"type":"graphic_table","displayName":"Extrinsic causes of shoulder pain","title":"Extrinsic causes of shoulder pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extrinsic causes of shoulder pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Cervical nerve root compression (C5, C6)</td> </tr> <tr> <td>Suprascapular nerve compression</td> </tr> <tr> <td>Brachial plexus lesions</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Spinal cord lesion</td> </tr> <tr> <td>Cervical spine disease</td> </tr> <tr> <td class=\"subtitle1_single\">Abdominal</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> <tr> <td>Diaphragmatic irritation (eg, splenic injury, ruptured ectopic pregnancy, perforated viscus)</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Myocardial ischemia</td> </tr> <tr> <td>Axillary vein thrombosis</td> </tr> <tr> <td>Thoracic outlet syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Thoracic</td> </tr> <tr> <td>Upper lobe pneumonia</td> </tr> <tr> <td>Apical lung tumor</td> </tr> <tr> <td>Pulmonary embolus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55507 Version 3.0</div></div></div>"},"55508":{"type":"graphic_diagnosticimage","displayName":"Complex thyroid nodule echo","title":"Complex thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex thyroid nodule</div><div class=\"cntnt\"><img style=\"width:317px; height:331px;\" src=\"images/ENDO/55508_Complex_thyroid_nodule_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right lobe of the thyroid gland in the transverse plane that shows a large complex thyroid mass.</div><div class=\"graphic_footnotes\">H: region of cystic/hemorrhagic degeneration; L: solid portion of the nodule.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 55508 Version 3.0</div></div></div>"},"55513":{"type":"graphic_table","displayName":"ACAAI ACOG chronic asthma preg","title":"Preferred pharmacologic step therapy of asthma during pregnancy: NAEPP update 2004","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred pharmacologic step therapy of asthma during pregnancy: NAEPP update 2004</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Step therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Mild intermittent</td> <td>Inhaled short-acting beta2 agonist* as needed (for all categories)</td> </tr> <tr class=\"divider_bottom\"> <td>Mild persistent</td> <td>Low dose inhaled glucocorticoid<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Moderate persistent</td> <td>Medium dose inhaled glucocorticoid<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong></td> </tr> <tr> <td>Low dose inhaled glucocorticoid<sup>&#182;</sup> plus long-acting beta agonist<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Medium dose inhaled glucocorticoid<sup>&#182;</sup> plus long-acting beta agonist<sup>&#916;</sup>, if needed</td> </tr> <tr> <td rowspan=\"2\">Severe persistent</td> <td>High dose inhaled glucocorticoid<sup>&#182;</sup> plus long-acting beta agonist<sup>&#916;</sup></td> </tr> <tr> <td>Prednisone if needed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Albuterol is preferred inhaled short acting beta2 agonist during pregnancy.<br />&para; Budesonide is preferred inhaled corticosteroid during pregnancy.<br />&Delta; Salmeterol is preferred long-acting beta agonist during pregnancy.</div><div class=\"graphic_reference\">Based on data from: Quick Reference. NAEPP Expert Panel Report Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment-Update 2004. US Dept of Health and Human Services, Bethesda, MD. NIH Publication No. 04-5246, March, 2004.</div><div id=\"graphicVersion\">Graphic 55513 Version 6.0</div></div></div>"},"55515":{"type":"graphic_table","displayName":"Etravirine susceptibility","title":"Weighted scores for etravirine susceptibility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weighted scores for etravirine susceptibility</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Monogram</td> <td class=\"subtitle1\" colspan=\"2\">Janssen Therapeutics (Tibotec)</td> </tr> <tr> <td class=\"subtitle2\">Weight</td> <td class=\"subtitle2\">Mutations</td> <td class=\"subtitle2\">Weight</td> <td class=\"subtitle2\">Mutations</td> </tr> <tr> <td>4</td> <td>100I, 101P, 181C/I</td> <td>3</td> <td>181I/V</td> </tr> <tr> <td>3</td> <td>138A/G, 179E, 190Q, 230L, 238N</td> <td>2.5</td> <td>101P, 100I, 181C, 230L</td> </tr> <tr> <td>2</td> <td>101E, 106A, 138K, 179L, 188L</td> <td>1.5</td> <td>138A, 106I, 190S, 179F</td> </tr> <tr class=\"divider_bottom\"> <td>1</td> <td> <p>90I, 101H, 106M, 138Q, 179D/F/M, 181F,</p> 190E/T, 221Y, 225H, 238T</td> <td>1</td> <td>90I, 179D, 101E, 101H, 98G, 179T, 190A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Total score*:</td> <td class=\"subtitle2_left\" colspan=\"2\">Total score<sup>&#182;</sup>:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\" colspan=\"2\">&#8805;4 = reduced susceptibility</td> <td class=\"indent1\" colspan=\"2\">0-2: Susceptible</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">2.5-3.5: Intermediate</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8805;4: Resistant</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Weighted scoring systems for determining etravirine susceptibility based on genotype analysis. The score is determined by adding the weights for each mutation present.</div><div class=\"graphic_footnotes\">* The Monogram system (left) predicts phenotypic susceptibility.<br />¶ The Janssen Therapeutics (Tibotec) system (right) predicts virologic response in the DUET trials: &#xD;&#xA;<UL>&#xD;&#xA;<LI>0-2 = 74 percent response.</LI>&#xD;&#xA;<LI>2.5-3.5 = 52 percent response.</LI>&#xD;&#xA;<LI>≥4 = 38 percent response.</LI></UL></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Tibotec system: Vingerhoets, J, Peeters, M, Azijn, H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 24. </li>&#xD;&#xA;    <li>Monogram system: Benhamida, J, Chappey, C, Coakley, E, Parkin, NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 130. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55515 Version 6.0</div></div></div>"},"55516":{"type":"graphic_diagnosticimage","displayName":"MRI diffuse meningeal enhancement","title":"Brain MRI showing diffuse meningeal enhancement with low cerebrospinal fluid pressure headache","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Brain MRI showing diffuse meningeal enhancement with low cerebrospinal fluid pressure headache</div><div class=\"cntnt\"><img style=\"width:507px; height:370px;\" src=\"images/NEURO/55516_MRI_DME.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of a patient with low cerebrospinal fluid pressure headache. Contrast (gadolinium) enhanced T1-weighted images in axial (A) and coronal (B) planes show diffuse pachymeningeal enhancement (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Images provided courtesy of Dr. Simon Edelstein, Department of Radiology, Mount Sinai Medical Center, New York.</div><div id=\"graphicVersion\">Graphic 55516 Version 3.0</div></div></div>"},"55517":{"type":"graphic_figure","displayName":"VF congr inf quadrantanopia","title":"Visual fields: Congruous inferior quadrantanopia","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Visual fields: Congruous inferior quadrantanopia</div><div class=\"cntnt\"><img style=\"width:521px; height:439px;\" src=\"images/NEURO/55517_VF_congr_inf_quadrantanopia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field showing a left congruous inferior quadrantic homonymous scotoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55517 Version 11.0</div></div></div>"},"55518":{"type":"graphic_figure","displayName":"Bell clapper deformity","title":"Bell clapper deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bell clapper deformity</div><div class=\"cntnt\"><img style=\"width:404px; height:493px;\" src=\"images/PEDS/55518_Bell_clapper_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the &quot;bell clapper&quot; deformity, the testis lies horizontally and the tunica vaginalis extends up over the spermatic cord so that the testis is suspended within the tunica vaginalis by the spermatic cord.</div><div id=\"graphicVersion\">Graphic 55518 Version 4.0</div></div></div>"},"55519":{"type":"graphic_picture","displayName":"Temporal segmental atrophy","title":"Temporal segmental optic disc atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temporal segmental optic disc atrophy</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/PEDS/55519_Temporal_segmental_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporal segmental optic disc atrophy in a patient with dominant optic atrophy.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 55519 Version 1.0</div></div></div>"},"55521":{"type":"graphic_figure","displayName":"Capillaria hepatica life cycle","title":"<em>Capillaria hepatica</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\"><em>Capillaria hepatica</em> life cycle</div><div class=\"cntnt\"><img style=\"width:570px; height:442px;\" src=\"images/ID/55521_Capillaria_hepat_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Capillaria hepatica</EM> has a direct life cycle that requires only one host. Adult worms invade the liver of the host (usually rodents but may also be pigs, carnivores, and primates, including humans) and lay hundreds of eggs in the surrounding parenchyma <STRONG>(1)</STRONG>. The eggs are not passed in the feces of the host and remain in the liver until the animal dies and decomposes <STRONG>(2)</STRONG> or is eaten by a predator or scavenger <STRONG>(3)</STRONG>. Eggs ingested by such an animal are unembryonated, are not infectious, and are passed in the feces, providing an efficient mechanism to release eggs into the environment <STRONG>(4)</STRONG>. Cannibalism has been reported as an important role in transmission among rodent populations. Eggs embryonate in the environment <STRONG>(5)</STRONG>, where they require air and damp soil to become infective. Under optimal conditions, this takes about 30 days. The cycle continues when embryonated eggs are eaten by a suitable mammalian host <STRONG>(6)</STRONG>. Infective eggs hatch in the intestine, releasing larvae. The larvae migrate via the portal vein to the liver. Larvae take about four weeks to mature into adults and mate. Humans are usually infected after ingesting embryonated eggs in fecal-contaminated food, water, or soil <STRONG>(7)</STRONG>. Occasionally in humans, larvae will migrate to the lungs, kidneys, or other organs. The presence of <EM>C. hepatica</EM> eggs in human stool during routine ova-and-parasite (O&amp;P) examinations indicates spurious passage of ingested eggs and not a true infection. Diagnosis in humans is usually achieved by finding adults and eggs in biopsy or autopsy specimens.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hepatic capillariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/hepaticCapillariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/hepaticCapillariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 55521 Version 5.0</div></div></div>"},"55523":{"type":"graphic_diagnosticimage","displayName":"Type I supracondylar fracture","title":"Nondisplaced supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:280px;\" src=\"images/EM/55523_TypeIsupracondylarfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 4-year-old girl fell on her right arm and was diagnosed with a nursemaid's elbow. Close review of the radiograph shows the presence of a posterior fat pad (arrowheads) that is due to an effusion and suggests a high likelihood of a fracture. In addition, a subtle cortical defect is visible (arrow) on the anterior surface of the distal humeral metaphysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of pediatric emergency medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 55523 Version 16.0</div></div></div>"},"55524":{"type":"graphic_table","displayName":"Drug reactions RUCAM","title":"Method for causality assessment of adverse drug reactions (RUCAM) (CIOMS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Method for causality assessment of adverse drug reactions (RUCAM) (CIOMS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Hepatocellular</td> <td class=\"subtitle1\" colspan=\"3\">Cholestatic or mixed</td> </tr> <tr> <td class=\"subtitle2\">Exposure</td> <td class=\"subtitle2\">Initial</td> <td class=\"subtitle2\">Subsequent</td> <td class=\"subtitle2\">Points</td> <td class=\"subtitle2\">Initial</td> <td class=\"subtitle2\">Subsequent</td> <td class=\"subtitle2\">Points</td> </tr> <tr> <td class=\"indent1\">Time from drug start (days)</td> <td class=\"centered\"> <p>5 to 90</p> &#60;5 or &#62;90</td> <td class=\"centered\"> <p>1 to 15</p> &#62;15</td> <td class=\"centered\"> <p>+2</p> +1</td> <td class=\"centered\"> <p>5 to 90</p> &#60;5 or &#62;90</td> <td class=\"centered\"> <p>1 to 90</p> &#62;90</td> <td class=\"centered\"> <p>+2</p> +1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Time from drug stop (days)</td> <td class=\"centered\">&#8804;15</td> <td class=\"centered\">&#8804;15</td> <td class=\"centered\">+1</td> <td class=\"centered\">&#8804;30</td> <td class=\"centered\">&#8804;30</td> <td class=\"centered\">+1</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"3\">Difference between peak ALT and ULN</td> <td class=\"subtitle2\" colspan=\"3\">Difference between peak AP (or bilirubin) and ULN</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Course after stopping drug</td> <td colspan=\"2\">Decrease &#8805;50 percent in 8 days</td> <td class=\"centered\">+3</td> <td colspan=\"2\">Decrease &#8805;50 percent in &#60;180 days</td> <td class=\"centered\">+2</td> </tr> <tr> <td colspan=\"2\">Decrease &#8805;50 percent in 30 days</td> <td class=\"centered\">+2</td> <td colspan=\"2\">Decrease &#60;50 percent in &#60;180 days</td> <td class=\"centered\">+1</td> </tr> <tr> <td colspan=\"2\">Decrease &#8805;50 percent in &#62;30 days</td> <td class=\"centered\">0</td> <td colspan=\"2\">Persistence or increase or no information</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Decrease &#60;50 percent in &#62;30 days</td> <td class=\"centered\">-2</td> <td colspan=\"2\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Risk factor</td> <td colspan=\"2\">Ethanol: yes</td> <td class=\"centered\">+1</td> <td colspan=\"2\">Ethanol or pregnancy: yes</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Ethanol: no</td> <td class=\"centered\">0</td> <td colspan=\"2\">Ethanol or pregnancy: no</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Age</td> <td colspan=\"2\">&#8805;55 years</td> <td class=\"centered\">+1</td> <td colspan=\"2\">&#8805;55 years</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&#60;55 years</td> <td class=\"centered\">0</td> <td colspan=\"2\">&#60;55 years</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Other drugs</td> <td colspan=\"2\">None or no information</td> <td class=\"centered\">0</td> <td colspan=\"2\">None or no information</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">Drug with suggestive timing</td> <td class=\"centered\">-1</td> <td colspan=\"2\">Drug with suggestive timing</td> <td class=\"centered\">-1</td> </tr> <tr> <td colspan=\"2\">Known hepatotoxin with suggestive timing</td> <td class=\"centered\">-2</td> <td colspan=\"2\">Known hepatotoxin with suggestive timing</td> <td class=\"centered\">-2</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Drug with other evidence for a role (eg, + rechallenge)</td> <td class=\"centered\">-3</td> <td colspan=\"2\">Drug with other evidence for a role (eg, + rechallenge)</td> <td class=\"centered\">-3</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"5\">Competing causes</td> <td colspan=\"2\">All group I* &#38; II<sup>&#182;</sup> ruled out</td> <td class=\"centered\">+2</td> <td colspan=\"2\">All group I* &#38; II<sup>&#182;</sup> ruled out</td> <td class=\"centered\">+2</td> </tr> <tr> <td colspan=\"2\">All of group I ruled out</td> <td class=\"centered\">+1</td> <td colspan=\"2\">All of group I ruled out</td> <td class=\"centered\">+1</td> </tr> <tr> <td colspan=\"2\">4 to 5 of group I ruled out</td> <td class=\"centered\">0</td> <td colspan=\"2\">4 to 5 of group I ruled out</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">&#60;4 of group I ruled out</td> <td class=\"centered\">-2</td> <td colspan=\"2\">&#60;4 of group I ruled out</td> <td class=\"centered\">-2</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Nondrug cause highly probable</td> <td class=\"centered\">-3</td> <td colspan=\"2\">Nondrug cause highly probable</td> <td class=\"centered\">-3</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Previous information</td> <td colspan=\"2\">Reaction in product label</td> <td class=\"centered\">+2</td> <td colspan=\"2\">Reaction in product label</td> <td class=\"centered\">+2</td> </tr> <tr> <td colspan=\"2\">Reaction published; no label</td> <td class=\"centered\">+1</td> <td colspan=\"2\">Reaction published; no label</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Reaction unknown</td> <td class=\"centered\">0</td> <td colspan=\"2\">Reaction unknown</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Rechallenge</td> <td colspan=\"2\">Positive</td> <td class=\"centered\">+3</td> <td colspan=\"2\">Positive</td> <td class=\"centered\">+3</td> </tr> <tr> <td colspan=\"2\">Compatible</td> <td class=\"centered\">+1</td> <td colspan=\"2\">Compatible</td> <td class=\"centered\">+1</td> </tr> <tr> <td colspan=\"2\">Negative</td> <td class=\"centered\">-1</td> <td colspan=\"2\">Negative</td> <td class=\"centered\">-1</td> </tr> <tr> <td colspan=\"2\">Not done or not interpretable</td> <td class=\"centered\">0</td> <td colspan=\"2\">Not done or not interpretable</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If incompatible, then case \"unrelated.\"<br />If information not available, then case \"insufficiently documented.\"<br /><strong>Scoring:</strong><br />&le;0: Relationship with the drug excluded<br />1 to 2: Unlikely<br />3 to 5: Possible<br />6 to 8: Probable<br />&gt;8: Highly probable</div><div class=\"graphic_footnotes\">RUCAM: Roussel Uclaf Causality Assessment Method; ALT: alanine aminotransferase; ULN: upper limit of normal; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; CMV: cytomegalovirus; EBV: Epstein-Barr virus.<br />* Group I: HAV, HBV, HCV (acute), biliary obstruction, alcoholism, recent hypotension (shock liver).<br />¶ Group II: CMV, EBV, herpes virus infection.</div><div class=\"graphic_reference\">Modified with permission from: Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009; 29:348. Copyright &copy; 2009 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 55524 Version 5.0</div></div></div>"},"55525":{"type":"graphic_figure","displayName":"Uterus didelphys and vag sept","title":"Uterus didelphys, bicollis, with complete vaginal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus didelphys, bicollis, with complete vaginal septum</div><div class=\"cntnt\"><img style=\"width:347px; height:271px;\" src=\"images/OBGYN/55525_Uterusdidelphysandvagse.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55525 Version 10.0</div></div></div>"},"55527":{"type":"graphic_diagnosticimage","displayName":"Contarinis condition CT","title":"Contarini's condition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contarini's condition</div><div class=\"cntnt\"><img style=\"width:360px; height:305px;\" src=\"images/PULM/55527_Contarinis_condition_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with a right sided transudate from left ventricular failure and with a left sided empyema that is loculated, adjacent to a focus of pneumonia with air bronchograms in the subjacent lung. This is also called Contarini's condition and refers to bilateral pleural effusions of differing etiologies.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55527 Version 2.0</div></div></div>"},"55529":{"type":"graphic_waveform","displayName":"Old lateral MI tutorial","title":"Chronic lateral wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Chronic lateral wall myocardial infarction</div><div class=\"cntnt\"><img style=\"width:530px; height:179px;\" src=\"images/CARD/55529_Old_lateral_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chronic lateral wall infarction is characterized by the presence of initial Q waves which are deep and broad in leads 1 and aVL.</div><div id=\"graphicVersion\">Graphic 55529 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"55530":{"type":"graphic_figure","displayName":"Human genome","title":"Autosomes, sex-chromosomes, mitochondrial genomes","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Autosomes, sex-chromosomes, mitochondrial genomes</div><div class=\"cntnt\"><img style=\"width:517px; height:285px;\" src=\"images/PC/55530_Autosomes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The human genome is DNA organized as 23 chromosomes including 22 autosomes (named 1-22), and one sex chromosome (either X or Y). Humans are diploid, with each somatic cell consisting of two sets of 23 chromosomes, one paternally inherited (blue) and one maternally inherited (pink). The Y chromosome is necessarily paternally inherited. The mitochondrial genome (mt) is derived solely from mitochondria in the ova and therefore exhibits exclusive matrilineal inheritance.</div><div id=\"graphicVersion\">Graphic 55530 Version 3.0</div></div></div>"},"55531":{"type":"graphic_picture","displayName":"Endoscopic diverticulectomy","title":"Endoscopic diverticulectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic diverticulectomy</div><div class=\"cntnt\"><img style=\"width:438px; height:400px;\" src=\"images/GAST/55531_Endoscopic_diverticulectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image of the final stage of endoscopic diverticulectomy using argon plasma coagulation, which has been delivered by the blue catheter. In the upper part of image, the esophageal lumen, with a nasogastric tube, can be observed. In the middle of the image, the remnant of the diverticular bridge with clearly visible muscle fibers can be seen. The Zenker's diverticulum was at the lower part of the image.</div><div class=\"graphic_reference\">Courtesy of Chris J J Mulder, MD, and Stijn J B van Weyenberg, MD.</div><div id=\"graphicVersion\">Graphic 55531 Version 1.0</div></div></div>"},"55533":{"type":"graphic_picture","displayName":"Rash of primary varicella","title":"Primary varicella lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary varicella lesions</div><div class=\"cntnt\"><img style=\"width:382px; height:252px;\" src=\"images/ID/55533_Rash_of_primary_varicella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicular lesions on an erythematous base are characteristic of chickenpox. The lesions occur in crops and are present in a variety of stages from maculopapular to vesicular or even pustular. Central necrosis and early crusting is also visible.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 55533 Version 5.0</div></div></div>"},"55534":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber color flow Doppler MR II","title":"Apical four chamber view showing color flow Doppler of mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four chamber view showing color flow Doppler of mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:286px; height:460px;\" src=\"images/CARD/55534_Color_flow_Doppler_MR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A is an apical four chamber view in systole showing color jets of mild mitral regurgitation (MR) and mild tricuspid regurgitation (TR). The jets are central and do not penetrate the left atrium (LA) on right atrium (RA) beyond the mid cavity. Panel B shows an apical four chamber view in patients with severe MR; the arrows outline the course of a jet during systole that adheres to and follows the contour of the LA. Such wall hugging jets are typical of severe regurgitation. Since their area is smaller than central jets, the use of wall hugging jet area as a sign of MR severity is not recommended.</div><div class=\"graphic_footnotes\">LV: left ventricle; RA: right atrium; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 55534 Version 5.0</div></div></div>"},"55535":{"type":"graphic_picture","displayName":"Equipment for vacuum delivery","title":"Vacuum delivery equipment","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Vacuum delivery equipment</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/OBGYN/55535_Equipment_for_vacuum_delive.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 55535 Version 1.0</div></div></div>"},"55537":{"type":"graphic_figure","displayName":"Course of uncomplicated viral upper respiratory infection (URI)","title":"Course of uncomplicated viral upper respiratory infection (URI)","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Course of uncomplicated viral upper respiratory infection (URI)</div><div class=\"cntnt\"><img style=\"width:479px; height:283px;\" src=\"images/PEDS/55537_Course_uncomplicated_URI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The course of most uncomplicated viral URIs is 5 to 10 days. Most patients with viral URIs are afebrile. If fever is present, it tends to occur on the first&nbsp;2 days of illness, in concert with constitutional symptoms (eg, headache, myalgia). As fever and/or constitutional symptoms resolve, respiratory symptoms become more prominent, peaking in severity on days&nbsp;3 to&nbsp;6 of illness. Respiratory symptoms may continue to be present on day 10 of illness, but are less severe than earlier in the course.</div><div id=\"graphicVersion\">Graphic 55537 Version 2.0</div></div></div>"},"55539":{"type":"graphic_picture","displayName":"E-C clamp technique","title":"E-C clamp technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">E-C clamp technique</div><div class=\"cntnt\"><img style=\"width:290px; height:430px;\" src=\"images/EM/55539_E-C_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is positioned so that the little, ring, and&nbsp;middle fingers are spread over the mandible from the angle of the jaw forward towards the chin in the configuration of the letter \"E\". The jaw is then lifted, pulling the face into the mask. The thumb and forefinger are placed over the mask in the shape of the letter \"C\". The mask is squeezed onto the face and a seal is formed between the mask and the face.</div><div id=\"graphicVersion\">Graphic 55539 Version 6.0</div></div></div>"},"55540":{"type":"graphic_table","displayName":"Opioid intoxication in adults - Rapid overview","title":"Opioid intoxication (adult): Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid intoxication (adult): Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>Altered mental status ranging from mild euphoria or lethargy to coma</td> </tr> <tr> <td>Miotic pupils</td> </tr> <tr> <td>Decreased bowel sounds</td> </tr> <tr> <td>Low to normal heart rate and blood pressure</td> </tr> <tr> <td>Hypoventilation</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Obtain rapid bedside serum glucose concentration, to exclude hypoglycemia as cause of coma.</td> </tr> <tr> <td>Obtain creatine kinase (if history indicates prolonged immobilization).</td> </tr> <tr> <td>Obtain chest radiograph (if physical examination suggests acute lung injury or aspiration).</td> </tr> <tr> <td>Obtain serum acetaminophen concentration (if opioid was taken with intent of self-harm or in opioid/acetaminophen combination product).</td> </tr> <tr> <td>Obtain electrocardiogram (if methadone or&nbsp;loperamide toxicity&nbsp;is suspected).</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Ensure adequate ventilation. If respiratory rate is &#8805;12 breaths/minute and O2 saturation &#62;90 percent on room air, observe the patient in a monitored setting and reassess frequently. End-tidal CO2 monitoring using capnography is an excellent means to monitor ventilation.</td> </tr> <tr> <td>If the O2 saturation is &#60;90 percent on room air but the patient is breathing spontaneously, administer supplemental oxygen followed by intravenous naloxone, 0.05 mg. In absence of IV access, naloxone can be given intramuscularly. Repeat until ventilation is adequate. The goal of treatment is adequate ventilation, <strong>NOT</strong> normal mental status. If the response is inadequate after 5 to 10 mg, reconsider the diagnosis.</td> </tr> <tr> <td>If the patient is apneic, ventilate using a bag-valve mask attached to supplemental oxygen and administer naloxone in doses of 0.2 to 1 mg IV or IM. If no response occurs after a total of 5 to 10 mg of naloxone, reconsider the diagnosis and perform tracheal intubation.</td> </tr> <tr> <td>If hypoventilation recurs following the initial naloxone bolus, give additional bolus doses to restore adequate ventilation. When ventilation is adequate, a naloxone infusion can be instituted in lieu of frequent rebolusing. Begin the infusion rate at 2/3 of the total dose of naloxone needed to restore breathing, delivered every hour.</td> </tr> <tr> <td>If the patient develops respiratory depression despite a naloxone infusion, administer a naloxone bolus (using half the original bolus dose) and repeat if necessary until adequate ventilation returns, then increase the infusion rate.</td> </tr> <tr> <td>If the patient develops signs of opioid withdrawal, stop the infusion. If respiratory depression returns, start the infusion at half the original rate.</td> </tr> <tr> <td>The patient is medically stable for transfer or discharge when their mental status and ventilation remain normal for more than one hour after cessation of naloxone.</td> </tr> <tr> <td>Psychiatry consultation may be required to assess suicidality.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55540 Version 11.0</div></div></div>"},"55541":{"type":"graphic_diagnosticimage","displayName":"Osteosarcoma in Paget","title":"Paget osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paget osteosarcoma</div><div class=\"cntnt\"><img style=\"width:259px; height:288px;\" src=\"images/ENDO/55541_Osteosarcoma_in_Paget.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph in a patient with known Paget disease shows osteosarcoma arising in a pagetic area of the distal right femur. There is soft tissue swelling and destruction of the distal femoral cortex (arrow). Marked trabecular thickening consistent with Paget disease is also seen.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 55541 Version 3.0</div></div></div>"},"55542":{"type":"graphic_picture","displayName":"Malignant stricture EGD","title":"Malignant stricture of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant stricture of the esophagus</div><div class=\"cntnt\"><img style=\"width:239px; height:252px;\" src=\"images/GAST/55542_Malignant_stricture_EGD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tumor mass is not readily evident because it is predominantly infiltrating the esophageal wall.</div><div class=\"graphic_reference\">Courtesy of William Brugge, MD.</div><div id=\"graphicVersion\">Graphic 55542 Version 1.0</div></div></div>"},"55543":{"type":"graphic_picture","displayName":"Tonsillar epith bacteria","title":"Epithelial surface of tonsils","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epithelial surface of tonsils</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/GAST/55543_Tonsillar_epith_bacteria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Healthy tonsillar epithelium free of bacteria. B) Superficial adherence of bacteria to the tonsillar surface. Bacteria are attached to the surface and mixed with an inflammatory infiltrate. Insertion b) DAPI stain of the same microscopic field reveals the DNA structures. Bacteria are enveloped by a lymphatic infiltrate (large blue nuclei of leukocytes). C) Fissure filled with bacteria. D) Microabscess. Bacteria are hybridized with universal Eub338 Cy3 probe, x400 orange fluorescence. (Magnification x400).</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 55543 Version 2.0</div></div></div>"},"55544":{"type":"graphic_diagnosticimage","displayName":"RCDP type 2","title":"Rhizomelic chondrodysplasia punctata type 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rhizomelic chondrodysplasia punctata type 2</div><div class=\"cntnt\"><img style=\"width:319px; height:504px;\" src=\"images/PEDS/55544_RCDP_type_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 5-year-old female is one of twins with rhizomelic chondrodysplasia punctata type 2. This X-linked disorder is characterized by midface hypoplasia, high arched palate, ocular abnormalities and symmetric or asymmetric shortening of the long bones. The epiphyses and vertebral bodies are stippled. In this example, severe abnormalities of the cervical vertebral bodies have lead to occipitalization of C1, C2 instability and kyphosis of C5-6.</div><div class=\"graphic_reference\">Copyright &copy; Jeanne Chow, MD.</div><div id=\"graphicVersion\">Graphic 55544 Version 3.0</div></div></div>"},"55545":{"type":"graphic_table","displayName":"Agents responsible for RADS","title":"Agents responsible for reactive airways dysfunction syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents responsible for reactive airways dysfunction syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Type of investigation</td> <td class=\"subtitle1\">Evidence</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td rowspan=\"2\">Acetic acid</td> <td>Epidemiological</td> <td>H, S, BHR</td> <td>Am Rev Respir Dis 1991; 144:1058</td> </tr> <tr> <td>Case report</td> <td>H, S, P</td> <td>Br J Ind Med 1989; 46:67</td> </tr> <tr class=\"divider_top\"> <td>Chloridic acid</td> <td>Case report</td> <td>H, S, BHR</td> <td> <p>Chest 1988; 94:476</p> Chest 1990; 98:928</td> </tr> <tr class=\"divider_top\"> <td>Sulfuric acid</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1988; 94:476</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Various acids</td> <td>Case report</td> <td>H, S, BHR, P</td> <td>Chest 1994; 105:1895</td> </tr> <tr> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1989; 96:297</td> </tr> <tr class=\"divider_top\"> <td>Bleaching agent</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1988; 94:476</td> </tr> <tr class=\"divider_top\"> <td>Cleaning agents</td> <td>Case report</td> <td>H, S</td> <td>Chest 1976; 69:372</td> </tr> <tr class=\"divider_top\"> <td>Sealing agents</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1985; 88:376</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Ammonia</td> <td>Case report</td> <td>H, S</td> <td>Mayo Clin Proc 1983; 58:389</td> </tr> <tr> <td>Case report</td> <td>H, S, P</td> <td>Thorax 1992; 47:755</td> </tr> <tr class=\"divider_top\"> <td>Phtalic anhydride</td> <td>Case report</td> <td>H, S, BHR</td> <td>Rev Pneumol Clin 1993; 49:247</td> </tr> <tr class=\"divider_top\"> <td>Bromochlorodifluoromethane (Halon 1211)</td> <td>Case report</td> <td>H, S, BHR</td> <td>Occup Env Med 2004; 61:712</td> </tr> <tr class=\"divider_top\"> <td>Bromotrifluoromethane (Halon 1301)</td> <td>Case report</td> <td>H, S</td> <td>Eur Respir J 1999; 13:1192</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Chlorine</td> <td>Epidemiological</td> <td>H, S, BHR</td> <td>Occup Env Med 1994; 51:225</td> </tr> <tr> <td>Clinical study</td> <td>H, S, BHR, P</td> <td> <p>J Allergy Clin Immunol 1994; 93:12</p> Eur Respir J 1997; 10:241</td> </tr> <tr class=\"divider_top\"> <td>Chlorofluorocarbons (CFC)</td> <td>Clinical study</td> <td>H, S, BHR, P</td> <td>Scand J Work Environ Health 2003; 29:71</td> </tr> <tr class=\"divider_top\"> <td>Chloropicrin</td> <td>Experimental</td> <td>P</td> <td>Toxicol Appl Pharm 1984; 74:417</td> </tr> <tr class=\"divider_top\"> <td>Metal coat remover</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1985; 88:376</td> </tr> <tr class=\"divider_top\"> <td>Diesel</td> <td>Case report</td> <td>H, S, BHR</td> <td>J Occup Med 1993; 35:149</td> </tr> <tr class=\"divider_top\"> <td>Diethylaminoethanol</td> <td>Epidemiological</td> <td>H, S</td> <td>J Occup Med 1994; 36:623</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Sulfur dioxide</td> <td>Case report</td> <td>H, S, BHR, P</td> <td> <p>Chest 1990; 98:928</p> Am Rev Respir Dis 1979; 119:555</td> </tr> <tr> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1989; 96:297</td> </tr> <tr class=\"divider_top\"> <td>Epichlorohydrin</td> <td>Experimental</td> <td>P</td> <td>Toxicol Appl Pharm 1984; 74:417</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Fire/smoke</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1988; 94:476</td> </tr> <tr> <td>Case report</td> <td>H, S</td> <td>J Occup Med 1991; 33:458</td> </tr> <tr class=\"divider_top\"> <td>Formalin</td> <td>Case report</td> <td>H, S</td> <td>Lancet 1975; 2:603</td> </tr> <tr class=\"divider_top\"> <td>Formaldehyde</td> <td>Case report</td> <td>H, S, BHR</td> <td>Allergy 2004; 59:115</td> </tr> <tr class=\"divider_top\"> <td>Hydrazin</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1985; 88:376</td> </tr> <tr class=\"divider_top\"> <td>Iodine</td> <td>Case report</td> <td>H, S, BHR, P</td> <td>Ind Health 2009; 47:681</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Diisocyanates</td> <td>Case report</td> <td>H, S, BHR</td> <td>Scand J Work Environ Health 1981; 7:310</td> </tr> <tr> <td>Case report</td> <td>H, S, BHR, P</td> <td>Allergy 1996; 51:262</td> </tr> <tr> <td>Experimental</td> <td>S</td> <td>Toxicol App Pharmacol 1987; 89:332</td> </tr> <tr> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1989; 96:297</td> </tr> <tr class=\"divider_top\"> <td>Calcium oxide</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1989; 96:297</td> </tr> <tr class=\"divider_top\"> <td>Ethylene oxide</td> <td>Case report</td> <td>H, S, BHR, P</td> <td>Br J Ind Med 1992; 49:523</td> </tr> <tr class=\"divider_top\"> <td>Heated paints</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1989; 96:297</td> </tr> <tr class=\"divider_top\"> <td>Pulverized paints</td> <td>Case report</td> <td>H, S, BHR, P</td> <td> <p>Chest 1989; 96:297</p> Chest 1985; 88:376</td> </tr> <tr class=\"divider_top\"> <td>Perchloroethylene</td> <td>Case report</td> <td>H, S, BHR</td> <td>Chest 1988; 94:476</td> </tr> <tr class=\"divider_top\"> <td>Vapors (chlorine, mustard, phosgene, etc)</td> <td>Case report</td> <td>H, P</td> <td>Br Med J 1915; 165</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">H: history; S: spirometry; BHR: bronchial hyperresponsiveness; P: pathology.</div><div id=\"graphicVersion\">Graphic 55545 Version 5.0</div></div></div>"},"55546":{"type":"graphic_figure","displayName":"Survival after transplant COPD","title":"Survival by procedure type after lung transplantation for COPD/emphysema","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Survival by procedure type after lung transplantation for COPD/emphysema</div><div class=\"cntnt\"><img style=\"width:680px; height:387px;\" src=\"images/PULM/55546_Survival_aftr_trnsplnt_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival after single or bilateral transplantation for COPD/emphysema was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients.<br />Survival rates were compared using the log-rank test statistic.</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heart-Lung Transplant Report-2014; Focus Theme: Retransplantation. J Heart Lung Transplant 2014; 33:1009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55546 Version 3.0</div></div></div>"},"55548":{"type":"graphic_algorithm","displayName":"Adult BLS algorithm for healthcare providers","title":"Adult BLS algorithm for healthcare providers","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Adult BLS algorithm for healthcare providers</div><div class=\"cntnt\"><img style=\"width:604px; height:582px;\" src=\"images/EM/55548_Adult_BLS_healthcare_provs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AED: automated external defibrillator; ALS: advanced life support; BLS: basic life support.<br />* The boxes bordered with dashed lines are performed by healthcare providers and not by lay rescuers.</div><div class=\"graphic_reference\">Reprinted with permission. Adult Basic Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 55548 Version 16.0</div></div></div>"},"55551":{"type":"graphic_table","displayName":"Clin classif DM foot infx","title":"Clinical classification of a diabetic foot infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of a diabetic foot infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Infection severity</td>\n\t\t\t\t\t<td class=\"subtitle1\">Clinical manifestations of infection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Uninfected</td>\n\t\t\t\t\t<td>Wound lacking purulence or any manifestations of inflammation.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t\n\t\t\t\t\t<td>Mild</td>\n\t\t\t\t\t<td>Presence of &#8805;2 manifestations of inflammation (purulence, or erythema, pain, tenderness, warmth, or induration), but any cellulitis/erythema extends &#8804;2 cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Moderate</td>\n\t\t\t\t\t<td>Infection (as above) in a patient who is systemically well and metabolically stable but which has &#8805;1 of the following characteristics: cellulitis extending &#62;2 cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle, tendon, joint or bone.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Severe</td>\n\t\t\t\t\t<td>Infection in a patient with systemic toxicity or metabolic instability (eg, fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, or azotemia).</td>\t\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Foot ischemia may increase the severity of any infection, and the presence of critical ischemia often makes the infection severe.</div><div class=\"graphic_reference\">Reproduced with permission from: Lipsky, BA, Berendt, AR, Deery, HG, et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 2004; 39:885. Copyright &#169;2004 The University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 55551 Version 1.0</div></div></div>"},"55554":{"type":"graphic_figure","displayName":"Hyponatremia in HF","title":"Hyponatremia associated with reduced survival in patients with severe chronic heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyponatremia associated with reduced survival in patients with severe chronic heart failure</div><div class=\"cntnt\"><img style=\"width:450px; height:243px;\" src=\"images/NEPH/55554_Hyponatremia_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival over time in patients with severe chronic heart failure and a left ventricular ejection fraction less than 30 percent who, at study entry, had either a normal plasma sodium concentration (greater than 137 meq/L, solid line) or hyponatremia (plasma sodium less than or equal to 137 meq/L, dashed line). Survival was significantly reduced in the patients with hyponatremia. The survival rate was very low (approximately 15 percent at 12 months) in those with a baseline plasma sodium concentration less than or equal to 130 meq/L.</div><div class=\"graphic_reference\">Data from: Lee WH, Packer M. Circulation 1986; 73:257.</div><div id=\"graphicVersion\">Graphic 55554 Version 2.0</div></div></div>"},"55556":{"type":"graphic_figure","displayName":"Stomatocytes and echinocytes","title":"Generation of stomatocytes and echinocytes","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Generation of stomatocytes and echinocytes</div><div class=\"cntnt\"><img style=\"width:549px; height:136px;\" src=\"images/HEME/55556_Stomatocytes_and_echinocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the generation of stomatocytes and echinocytes. In vitro, normal discocytes can undergo conversion into stomatocytes under the influence of amphipathic cations that intercalate with the inner half of the phospholipid bilayer. This step is reversible until endocytic vacuoles form, reducing the red cell surface area and forming spherostomatocytes. Discocytes can also be converted to echinocytes by ATP depletion or amphipathic anions which intercalate into the outer half of the phospholipid bilayer. This step is reversible until the tips of the echinocyte projections break off, causing a loss of surface area and spheroechinocytes. The addition of a stomatocytogenic agent to echinocytes can produce a reversal to discocytes if membrane surface area has not been lost.</div><div class=\"graphic_reference\">Data from Scientific American Medicine, Scientific American, New York.</div><div id=\"graphicVersion\">Graphic 55556 Version 1.0</div></div></div>"},"55557":{"type":"graphic_figure","displayName":"ANP BNP LV dysfunction","title":"Serum ANP and BNP correlate with LV dysfunction","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Serum ANP and BNP correlate with LV dysfunction</div><div class=\"cntnt\"><img style=\"width:544px; height:237px;\" src=\"images/CARD/55557_ANP_BNP_LV_dysfunction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 1252 subjects from the general population, median serum concentrations of N-terminal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide were significantly higher in those with left ventricular systolic dysfunction (LVD) as assessed with echocardiography. Among the patients with LVD, 77 percent were asymptomatic. Boxes are median concentrations and vertical lines are the ranges.</div><div class=\"graphic_reference\">Data from McDonagh TA, Robb SD, Murdoch DR, et al. Lancet 1998; 351:9.</div><div id=\"graphicVersion\">Graphic 55557 Version 2.0</div></div></div>"},"55558":{"type":"graphic_table","displayName":"Pediatric blood culture volume","title":"Pediatric bacterial blood cultures: Recommended blood volume","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric bacterial blood cultures: Recommended blood volume</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Patient weight<br /> (lb)</td> <td class=\"subtitle1\">Recommended blood volume per culture<br /> (mL)</td> <td class=\"subtitle1\">Volume of blood equal to 1 percent of patient's total blood volume<br /> (mL)*</td> </tr> <tr> <td>&#60;19</td> <td>1</td> <td>2</td> </tr> <tr> <td>18 to 30</td> <td>3</td> <td>6 to 10</td> </tr> <tr> <td>30 to 60</td> <td>5</td> <td>10 to 20</td> </tr> <tr> <td>60 to 90</td> <td>10</td> <td>20 to 30</td> </tr> <tr> <td>90 to 120</td> <td>15</td> <td>30 to 40</td> </tr> <tr> <td>&#62;120</td> <td>20</td> <td>&#62;40</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Blood volume calculated by assuming 85 mL/kg in newborns and 73 mL/kg in other patients. Two 20 mL blood specimens collected from an 80 kg adult (40 mL total) represent approximately 0.7 percent of the patient's total blood volume.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Kaditis AG, O'Marcaigh AS, Rhodes KH, et al. Yield of positive blood cultures in pediatric oncology patients by a new method of blood culture collection. Pediatr Infect Dis 1996; 15:615. </LI>&#xD;&#xA;<LI>Specimen collection, transport, and processing: Bacteriology. In: Manual of Clinical Microbiology, 10th ed, Versalovic J, Carroll KC, Funke G, et al (Eds), ASM Press, Washington, DC 2007. </LI></OL></div><div id=\"graphicVersion\">Graphic 55558 Version 5.0</div></div></div>"},"55559":{"type":"graphic_diagnosticimage","displayName":"Three types of holoprosencephaly","title":"Three types of holoprosencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three types of holoprosencephaly</div><div class=\"cntnt\"><img style=\"width:203px; height:600px;\" src=\"images/OBGYN/55559_Three_types_holo2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Alobar holoprosencephaly consisting of a single ventricle, fused thalami, and absence of the midline structures (falx cerebri, corpus callosum, cavum septum pellucidum).<br> (B) Semilobar holoprosencephaly consisting of a single ventricle, incomplete fusion of the thalami, and partially separated lateral ventricles. The arrow points to a small falx cerebri.<br> (C) Lobar holoprosencephaly consisting of fusion of the anterior horns of the lateral ventricle and absent cavum septum pellucidum.</div><div class=\"graphic_footnotes\">T: thalami.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 55559 Version 5.0</div></div></div>"},"55560":{"type":"graphic_picture","displayName":"Central line IJ finder","title":"Finder needle for central line placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Finder needle for central line placement</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/SURG/55560_Central_line_IJ_finder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph depicts the use of a finder needle to locate the internal jugular vein.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 55560 Version 2.0</div></div></div>"},"55561":{"type":"graphic_figure","displayName":"Zygomaticomaxillary complex fractures","title":"Zygomaticomaxillary complex fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zygomaticomaxillary complex fractures</div><div class=\"cntnt\"><img style=\"width:418px; height:322px;\" src=\"images/EM/55561_Zygomamaxllyfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Zygomaticomaxillary complex (ZMC, tripod, or malar) fractures are sustained with direct blunt trauma to the zygomatic buttress of the face. The zygoma has four major stability points, with connections as follows: (a) the frontal bone at the frontozygomatic suture; (b) the maxilla at the medial inferior orbital rim; (c) at the zygomaticomaxillary buttress; and (d) the temporal bone at the zygomatic arch. A complete fracture of the complex usually involves all four of these points. Anteriorly, the fracture usually occurs through the infraorbital foramen because of the bone's relative weakness. Physical findings associated with ZMC fractures are numbness or paresthesias (CN V), depression of the zygomatic eminence, ocular dystopia (uneven pupillary levels), lateral canthal ptosis, enophthalmos, and palpable fractures at the inferior and lateral orbital rims.</div><div class=\"graphic_reference\">Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55561 Version 12.0</div></div></div>"},"55568":{"type":"graphic_table","displayName":"Categories retinal vasculitis","title":"Classification of retinal vasculitis by involved vessel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of retinal vasculitis by involved vessel</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Primary vessel involved</td> </tr> <tr> <td>Polyarteritis nodosa</td> <td>Muscular arteries</td> </tr> <tr> <td>Giant cell arteritis</td> <td>Medium to small arteries</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>Small arteries</td> </tr> <tr> <td>Whipple's disease</td> <td>Capillaries</td> </tr> <tr> <td>Beh&#231;et's syndrome; sarcoidosis; multiple sclerosis</td> <td>Veins</td> </tr> <tr> <td>Crohn disease; relapsing polychondritis</td> <td>Arteries and veins</td> </tr> <tr> <td>HLA-B27-associated conditions, such as ankylosing spondylitis</td> <td>Variable or no involvement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div id=\"graphicVersion\">Graphic 55568 Version 4.0</div></div></div>"},"55570":{"type":"graphic_table","displayName":"Criteria CIP","title":"Diagnostic criteria for critical illness polyneuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for critical illness polyneuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Major features</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Setting of critical illness, particularly if complicated by sepsis, multiorgan failure, and the systemic inflammatory response syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Difficulty weaning from ventilator that is not related to cardiopulmonary causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Possible limb weakness</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Electrophysiologic evidence of axonal motor and sensory polyneuropathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Features favoring the diagnosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sensory and motor nerve amplitudes &lt;80 percent of the lower limit of normal in two or more nerves on nerve conduction studies</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Absence of conduction block or prolongation of F-waves</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Needle EMG with reduced recruitment of normal motor unit potentials (MUPs) (early) followed by fibrillation potentials and reduced recruitment of long-duration, high-amplitude MUPs (after weeks)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Absence of a decremental response on repetitive nerve stimulation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Supportive features</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Normal cerebrospinal fluid protein</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Normal serum creatine kinase</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Bolton, CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140.</div><div id=\"graphicVersion\">Graphic 55570 Version 1.0</div></div></div>"},"55571":{"type":"graphic_diagnosticimage","displayName":"Axial CT one year","title":"Axial CT one year","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial CT one year</div><div class=\"cntnt\"><img style=\"width:360px; height:327px;\" src=\"images/ONC/55571_Axial_CT_one_year.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 77-year-old female patient with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk. Axial CT image one-year following RFA shows that the treated area (arrow) continues to decrease in size and now appears as a focal area of volume loss within the left lower lobe.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography; RFA: radiofrequency ablation.</div><div class=\"graphic_reference\">Courtesy of Schirmang, T, MD and Dupuy, D, MD.</div><div id=\"graphicVersion\">Graphic 55571 Version 3.0</div></div></div>"},"55572":{"type":"graphic_figure","displayName":"SEER fast stats results","title":"Age-specific (crude) SEER incidence rates by 'expanded' race for prostate cancer, males SEER 17 registries for 2000-2003","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-specific (crude) SEER incidence rates by 'expanded' race for prostate cancer, males SEER 17 registries for 2000-2003</div><div class=\"cntnt\"><img style=\"width:423px; height:382px;\" src=\"images/ONC/55572_SEER_fast_stats_results.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Statistics for American Indians/Alaska Natives do not include cases for the 2003 diagnosis year.</div><div class=\"graphic_reference\">Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Public-Use, Nov 2005 Sub (2000-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.</div><div id=\"graphicVersion\">Graphic 55572 Version 1.0</div></div></div>"},"55573":{"type":"graphic_waveform","displayName":"Intermediate case 15 answer","title":"Atrioventricular junctional rhythm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Atrioventricular junctional rhythm</div><div class=\"cntnt\"><img style=\"width:540px; height:98px;\" src=\"images/CARD/55573_Intermediate_case_15_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing a regular AV junctional rhythm at a rate of about 65 beats/min. The negative (retrograde) P waves following each QRS in lead II are characteristic of a junctional rhythm.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 55573 Version 3.0</div></div></div>"},"55575":{"type":"graphic_form","displayName":"Preconception care questionnaire","title":"Preconception care questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preconception care questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td colspan=\"4\">1. Are you considering getting pregnant within the next year?</td> </tr> <tr> <td colspan=\"4\">2. Are you currently attempting to conceive?</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">3. Do you use birth control on a regular basis?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">Type of birth control:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">a. Condoms and or diaphragm</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">b. Intrauterine device (IUD)</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">c. Birth control pill</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">d. Depo-vera or norplant</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\">e. Other</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Medical history</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">4. List all chronic medical and psychiatric conditions for which you have been treated.</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">5. Do you take any medications (prescription and over-the-counter) on a regular basis?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">List them:</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">6. List all drug allergies.</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Gynecologic history</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">7. Is there a history of any of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Irregular menstrual cycles</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Abnormal pap smear</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Uterine fibroids</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">d. Ectopic pregnancy</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">e. Gynecologic surgery</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">8. Have you ever had any of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Chlamydia</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Genital wart</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Syphilis</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">d. Gonorrhea (GC)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">e. Herpes</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Prior pregnancy and obstetrical history</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">9. Is there a history of any of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Recurrent miscarriages?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Stillbirth?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Low birth weight?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">d. Diabetes or gestational diabetes?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">e. Phenylketonuria?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">f. Neonate with neural tube defects?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">g. Neonate with other congenital defects?</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">10. Please list all pregnancies below:</td> </tr> <tr> <td class=\"subtitle5\">Pregnancy (date)</td> <td class=\"subtitle5\">Number of weeks pregnant</td> <td class=\"subtitle5\">Outcome</td> <td class=\"subtitle5\">Weight (for live births)</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">11. Have you received the following immunizations (or a history of the illness):</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Rubella (German measles)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Hepatitis B</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Varicella (chicken pox)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Family history</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">12. Is there a family history of any of the following?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Tay Sachs disease</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Beta or alpha thalessemia</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Cystic fibrosis</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">d. Sickle cell disease</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">e. Epilepsy</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">f. Mental retardation</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Habits and exposures</td> </tr> <tr> <td colspan=\"4\">13. Do you drink alcohol? If so, how many drinks per day (week or month)?</td> </tr> <tr> <td colspan=\"4\">14. Do you smoke? If so, how many cigarettes per day?</td> </tr> <tr> <td colspan=\"4\">15. What is your daily caffeine intake?</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">16. Have you ever used any of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. Cocaine</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Heroin</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Other illicit drugs</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">17. Have you ever received blood products? If so, please state dates and type of product.</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">18. Are you on any special diet? Please describe.</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">19. Do you use any herbal, dietary or vitamin supplements?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">List them:</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">20. Do you exercise on a regular basis? Describe type of exercise and frequency.</td> </tr> <tr> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td colspan=\"4\">21. Do you have any cats?</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Employment and occupational history</td> </tr> <tr> <td colspan=\"4\">22. Occupation.</td> </tr> <tr> <td colspan=\"4\">23. Are you currently employed?</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">24. Please list your last three places of work and your positions.</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">1.</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">2.</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">3.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">25. In your daily work are you exposed to any of the following on a regular basis?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">a. X-rays or radiation?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">b. Radioactive substances?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">c. Solvents?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">d. Tuberculosis (TB)? Date and status of last purified protein derivative (PPD) placement?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">e. Needle stick injury? Hepatitis B status?</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">f. Other (please list)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Joyce A Sackey, MD.</div><div id=\"graphicVersion\">Graphic 55575 Version 7.0</div></div></div>"},"55576":{"type":"graphic_diagnosticimage","displayName":"Mirizzi syndrome MRCP","title":"Mirizzi syndrome seen on magentic resonance cholangiopancreatography (MRCP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mirizzi syndrome seen on magentic resonance cholangiopancreatography (MRCP)</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/55576_Mirizzi_syndrome_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRCP study in an 81-year-old woman with jaundice and right upper quadrant pain shows dilation of the common hepatic duct (CHD) and gallbladder (GB) with a filling defect in the common bile duct (arrow) caused by an impacted stone. The patient required surgical resection and stone removal.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 55576 Version 3.0</div></div></div>"},"55578":{"type":"graphic_picture","displayName":"Acute phosphate nephropathy","title":"Light microscopy demonstrating acute phosphate nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy demonstrating acute phosphate nephropathy</div><div class=\"cntnt\"><img style=\"width:339px; height:521px;\" src=\"images/NEPH/55578_Acute_phosphate_nephropathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A low-power view shows abundant tubular and focal interstitial calcium phosphate deposits. The calcifications are confined to distal tubules, with sparing of proximal tubules (hematoxylin and eosin).<br />(B) The tubular calcifications exhibit a positive histochemical reaction with the von Kossa stain, diagnostic of calcium phosphate.</div><div class=\"graphic_reference\">Courtesy of Glen S Markowitz, MD.</div><div id=\"graphicVersion\">Graphic 55578 Version 3.0</div></div></div>"},"55585":{"type":"graphic_table","displayName":"Characteristics of Solenopsis invicta venom antigens","title":"Characteristics of <EM>Solenopsis invicta </EM>venom antigens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of <EM>Solenopsis invicta </EM>venom antigens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">Relative amount</td> <td class=\"subtitle1\">Relative importance</td> <td class=\"subtitle1\">Molecular weight</td> <td class=\"subtitle1\">Corresponding protein in <em>Solenopsis richteri</em></td> </tr> <tr> <td>Sol i 1</td> <td>2 to 4%</td> <td>Minor allergen</td> <td>37 kd</td> <td>Sol r 1</td> </tr> <tr> <td>Sol i 2</td> <td>50 to 65%</td> <td>Major allergen</td> <td>13 kd</td> <td>Sol r 2</td> </tr> <tr> <td>Sol i 3</td> <td>15 to 25%</td> <td>Minor allergen</td> <td>24 kd</td> <td>Sol r 3</td> </tr> <tr> <td>Sol i 4 </td> <td>8 to 10%</td> <td>Minor allergen </td> <td>13 kd </td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman DR. Allergens in Hymenoptera venom. XXIV. The amino acid sequences of imported fire and venom allergens Sol i II, Sol i III and Sol i IV. J Allergy Clin Immunol 1993; 91:71. Copyright © 1993 Elsevier.</div><div id=\"graphicVersion\">Graphic 55585 Version 2.0</div></div></div>"},"55587":{"type":"graphic_figure","displayName":"Open cystectomy cde","title":"Open ovarian cystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open ovarian cystectomy</div><div class=\"cntnt\"><img style=\"width:286px; height:501px;\" src=\"images/OBGYN/55587_Open_cystectomy_cde.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(C) Sharp excision to separate the base of the cyst from the ovary. (D) The deep tissues of the ovary are reapproximated using fine absorbable sutures avoiding the surface of the ovary. (E) The ovarian cortex is approximated with no visible sutures.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 55587 Version 3.0</div></div></div>"},"55588":{"type":"graphic_figure","displayName":"Physiological model vulvar pain","title":"Schematic diagram of physiological model of vulvar pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of physiological model of vulvar pain</div><div class=\"cntnt\"><img style=\"width:348px; height:372px;\" src=\"images/OBGYN/55588_Physiological_model_vulvar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A illustrates the immediate response to cutaneous trauma. Action potentials in C-nociceptors propagate through the dorsal root ganglion (DRG) to the spinal cord where they activate and sensitize wide-dynamic-range (WDR) neurons whose axons ascend to higher centers. In B, the WDR neurons remain sensitized and now respond to activity in large diameter A-mechanoreceptors which are activated by light touch. This state produces allodynia. In C, the same sensitized WDR neurons respond again to A-mechanoreceptors activity, but this activity is initiated by sympathetic efferent actions on the sensory receptor, in the absence of cutaneous stimulation. This phase represents sympathetically maintained pain. Although spinal interneurons are shown to be interposed in the 'pain' pathway, this is just one of the many possible arrangements.</div><div class=\"graphic_reference\">Reproduced with permission from: Roberts, WJ. A hypothesis on the physiological basis for causalgia and related pains. PAIN 1986; 24:297. Copyright &#169; 1986 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 55588 Version 3.0</div></div></div>"},"55590":{"type":"graphic_picture","displayName":"Cocaine purpura on extremity","title":"Purpura and bullae due to levamisole-contaminated cocaine","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Purpura and bullae&nbsp;due to levamisole-contaminated cocaine</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55590_Cocaine_purpura_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura with bullae are present on the leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55590 Version 5.0</div></div></div>"},"55591":{"type":"graphic_figure","displayName":"Ileocolic anastomosis - Stapled anastomosis reinforced","title":"Ileocolic anastomosis - Stapled anastomosis with reinforcing sutures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic anastomosis - Stapled anastomosis with reinforcing sutures</div><div class=\"cntnt\"><img style=\"width:377px; height:370px;\" src=\"images/SURG/55591_Ileocolic-anastomosis-stapled-anast-reinforced.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55591 Version 1.0</div></div></div>"},"55592":{"type":"graphic_algorithm","displayName":"Suspected UTI without pyuria algorithm","title":"Evaluation of the child with suspected urinary tract infection and initial urine with bacteriuria* but no pyuria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of the child with suspected urinary tract infection and initial urine with bacteriuria* but no pyuria</div><div class=\"cntnt\"><img style=\"width:321px; height:217px;\" src=\"images/PEDS/55592_Susp_UTI_wo_pyuria_alg_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* With a pathogen other than <EM>Enterococcus</EM>, <EM>Klebsiella</EM>, or <EM>Pseudomonas aeruginosa.</EM></div><div id=\"graphicVersion\">Graphic 55592 Version 3.0</div></div></div>"},"55593":{"type":"graphic_picture","displayName":"Herpes simplex virus keratitis","title":"Herpes simplex virus <STRONG>​</STRONG>keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus <STRONG>​</STRONG>keratitis</div><div class=\"cntnt\"><img style=\"width:396px; height:275px;\" src=\"images/EM/55593_HSVkeratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein staining pattern of herpes simplex virus corneal infection. Eye is illuminated with blue light to demonstrate yellow/green branching flourescein staining pattern of herpetic dendrite.</div><div class=\"graphic_reference\">Reproduced with permission from: Levin AV. Ophthalmic emergencies. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55593 Version 15.0</div></div></div>"},"55594":{"type":"graphic_table","displayName":"Etiology of obesity","title":"Etiologic classification of obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Iatrogenic causes</td> </tr> <tr> <td>Drugs that cause weight gain</td> </tr> <tr> <td>Hypothalamic surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Dietary obesity</td> </tr> <tr> <td>Infant feeding practices</td> </tr> <tr> <td>Progressive hyperplastic obesity</td> </tr> <tr> <td>Frequency of eating</td> </tr> <tr> <td>High-fat diets</td> </tr> <tr> <td>Overeating</td> </tr> <tr> <td class=\"subtitle1_single\">Neuroendocrine obesities</td> </tr> <tr> <td>Hypothalamic obesity</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Seasonal affective disorder</td> </tr> <tr> <td>Cushing's syndrome</td> </tr> <tr> <td>Polycystic ovary syndrome</td> </tr> <tr> <td>Hypogonadism</td> </tr> <tr> <td>Growth hormone deficiency</td> </tr> <tr> <td>Pseudohypoparathyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">Social and behavioral factors</td> </tr> <tr> <td>Socioeconomic status</td> </tr> <tr> <td>Ethnicity</td> </tr> <tr> <td>Psychological factors</td> </tr> <tr> <td>Restrained eaters</td> </tr> <tr> <td>Night eating syndrome</td> </tr> <tr> <td>Binge eating</td> </tr> <tr> <td class=\"subtitle1_single\">Sedentary lifestyle</td> </tr> <tr> <td>Enforced inactivity (postoperative)</td> </tr> <tr> <td>Aging</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic (dysmorphic) obesities</td> </tr> <tr> <td>Autosomal recessive traits</td> </tr> <tr> <td>Autosomal dominant traits</td> </tr> <tr> <td>X-linked traits</td> </tr> <tr> <td>Chromosomal abnormalities</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Low birth weight</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55594 Version 5.0</div></div></div>"},"55596":{"type":"graphic_figure","displayName":"Anterior view superficial veins of the upper extremity","title":"Anterior view superficial veins of the upper extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior view superficial veins of the upper extremity</div><div class=\"cntnt\"><img style=\"width:386px; height:436px;\" src=\"images/SURG/55596_Upper_extremity_veins_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The cephalic vein originates at the radial aspect of the wrist traversing the radial border of the forearm. It receives tributaries from both the ventral and dorsal surfaces. At the antecubital fossa, it provides a tributary to the median cubital vein. In the upper arm, it travels in the groove between the pectoralis major and deltoid muscles. It pierces the coracoclavicular fascia and, crossing the axillary artery, ends in the axillary vein just below the clavicle. Sometimes it communicates with the external jugular vein by a branch that ascends anterior to the clavicle. </LI>&#xD;&#xA;<LI>The basilic vein originates in the ulnar aspect of the wrist traversing the ulnar side of the forearm to the antecubital fossa where it is joined by the median cubital vein. It ascends in the groove between the biceps brachii and pronator teres, crosses the brachial artery at the elbow, and continues cephalad along the medial border of the biceps brachii. It perforates the deep fascia of the upper arm and joins the brachial vein. </LI></UL></div><div id=\"graphicVersion\">Graphic 55596 Version 8.0</div></div></div>"},"55597":{"type":"graphic_table","displayName":"Laboratory findings in ILD","title":"Laboratory findings in the interstitial lung diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in the interstitial lung diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Associated condition</td> </tr> <tr> <td>Leukopenia</td> <td>Sarcoidosis; connective tissue disease; lymphoma; drug-induced</td> </tr> <tr> <td>Leukocytosis</td> <td>Hypersensitivity pneumonitis; lymphoma; systemic vasculitis</td> </tr> <tr> <td>Eosinophilia</td> <td>Eosinophilic pneumonia; sarcoidosis; systemic vasculitis; drug-induced (sulfa, methotrexate)</td> </tr> <tr> <td>Thrombocytopenia</td> <td>Sarcoidosis; connective tissue disease; drug-induced; Gaucher's disease</td> </tr> <tr> <td>Hemolytic anemia</td> <td>Connective tissue disease; sarcoidosis; lymphoma; drug-induced</td> </tr> <tr> <td>Normocytic anemia</td> <td>Diffuse alveolar hemorrhage syndromes; connective tissue disease; lymphangitic carcinomatosis</td> </tr> <tr> <td>Hypercalcemia</td> <td>Sarcoidosis; lymphangitic carcinomatosis</td> </tr> <tr> <td>Urinary sediment abnormalities</td> <td>Connective tissue disease; systemic vasculitis; drug-induced; systemic lupus erythematosis</td> </tr> <tr> <td>Hypogammaglobulinemia</td> <td>Lymphocytic interstitial pneumonitis</td> </tr> <tr> <td>Hypergammaglobulinemia</td> <td>Connective tissue disease; sarcoidosis; systemic vasculitis; lymphocytic interstitial pneumonia; lymphoma; silicosis</td> </tr> <tr> <td>Anti-glomerular basement membrane antibody (anti-GBM)</td> <td>Anti-GBM disease (Goodpasture disease)</td> </tr> <tr> <td>Anti-neutrophil cytoplasmic antibody (ANCA)</td> <td>Granulomatosis with polyangiitis (Wegener's); Eosinophilic granulomatosis with polyangiitis (Churg-Strauss); microscopic polyangiitis</td> </tr> <tr> <td>Serum precipitating antibodies</td> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Lymphocyte transformation test</td> <td>Chronic beryllium disease; aluminum potroom workers disease; gold-induced pneumonitis</td> </tr> <tr> <td>Elevation of LDH</td> <td>Alveolar proteinosis; idiopathic pulmonary fibrosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Schwarz MI, King TE Jr, Cherniack RM. General principles and diagnostic approach to the interstitial lung diseases. In: Murray JF, Nadel JA (Eds), Textbook of Respiratory Medicine, 2nd ed, Philadelphia, WB Saunders Co, 1994, pp.1803-1826.</div><div id=\"graphicVersion\">Graphic 55597 Version 6.0</div></div></div>"},"55598":{"type":"graphic_picture","displayName":"Lifting exercise PI","title":"Lifting exercise","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Lifting exercise</div><div class=\"cntnt\"><img style=\"width:530px; height:332px;\" src=\"images/PI/55598_Lifting_exercise_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bend your elbows to 90 degrees. Place the rubber band near the elbows and lift your arms four or five inches away from the body, holding for five seconds.</div><div id=\"graphicVersion\">Graphic 55598 Version 4.0</div></div></div>"},"55600":{"type":"graphic_diagnosticimage","displayName":"Breast MRI for evaluating extent of disease - case 1","title":"Breast MRI for evaluating extent of disease - case 1","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Breast MRI for evaluating extent of disease - case 1</div><div class=\"cntnt\"><img style=\"width:509px; height:243px;\" src=\"images/SURG/55600_Breast_MRI_invas_lob_cx_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be used to determine the extent of disease in newly diagnosed cancer patient. The figure depicts the breast MRI of a patient with a palpable mass. Core biopsy revealed invasive lobular carcinoma. Preoperative MRI revealed extensive disease spanning over 7 cm with multiple irregular areas of enhancement (A) with intermediate signal on T2-weighted sequences (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 55600 Version 7.0</div></div></div>"},"55601":{"type":"graphic_figure","displayName":"Genetic model CRC tumorigenesis","title":"A genetic model for colorectal tumorigenesis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">A genetic model for colorectal tumorigenesis</div><div class=\"cntnt\"><img style=\"width:526px; height:184px;\" src=\"images/ONC/55601_Genetic_model_CRC_tumorigen.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LOH: loss of heterozygosity; DCC: deleted in colon cancer gene; APC: adenomatous polyposis coli gene; ACF: aberrant crypt foci; MMR: DMA mismatch repair enzyme. </div><div class=\"graphic_reference\">Modified from: Lynch, JP, Hoops, TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am 2002; 16:775.</div><div id=\"graphicVersion\">Graphic 55601 Version 1.0</div></div></div>"},"55602":{"type":"graphic_picture","displayName":"Chronic tinea pedis PI","title":"Athlete's foot (tinea pedis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Athlete's foot (tinea pedis)</div><div class=\"cntnt\"><img style=\"width:342px; height:296px;\" src=\"images/PI/55602_Chronic_tinea_pedis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ringworm infections of the foot, also called athlete's foot, can cause the skin on the bottom of the foot to turn red and form scales.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 55602 Version 2.0</div></div></div>"},"55603":{"type":"graphic_figure","displayName":"Bounce home test","title":"The bounce home test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The bounce home test</div><div class=\"cntnt\"><img style=\"width:324px; height:393px;\" src=\"images/PEDS/55603_Bounce_home_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bounce home test is a test of knee extension. It is performed with the patient supine. The knee is passively flexed to approximately 15 degrees and then permitted to fall into extension with gravity. The test is positive if the knee does not fully extend.</div><div id=\"graphicVersion\">Graphic 55603 Version 2.0</div></div></div>"},"55604":{"type":"graphic_figure","displayName":"Hypospadias 2 stage repair 2","title":"Stage two of two-stage hypospadias repair","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Stage two of two-stage hypospadias repair</div><div class=\"cntnt\"><img style=\"width:515px; height:647px;\" src=\"images/PEDS/55604_Hypospadias2stagerepai1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Second-stage urethroplasty is done&nbsp;six months after the first-stage surgery. <br />(H) Preoperative view. <br />(I) Initial incision on the ventrum outlining the new urethra. <br />(J) Urethroplasty. <br />(K) Completed urethroplasty with second layer of supporting tissue to prevent fistula. <br />(L) Completed repair.</div><div class=\"graphic_reference\">Figure modified from TTMed (Timely Topics in Medicine)-Urology USA. Copyright © 2009 Prous Science S.A.U. or its licensors. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55604 Version 3.0</div></div></div>"},"55605":{"type":"graphic_form","displayName":"Parent questionnaire D","title":"Questionnaire for parents (continued)","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Questionnaire for parents (continued)</div><div class=\"cntnt\"><img style=\"width:507px; height:657px;\" src=\"images/PEDS/55605_Parent_questionnaire_D.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 55605 Version 2.0</div></div></div>"},"55606":{"type":"graphic_picture","displayName":"Bacterial conjunctivitis","title":"Bacterial conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial conjunctivitis</div><div class=\"cntnt\"><img style=\"width:360px; height:298px;\" src=\"images/PC/55606_Bacterial_conjunctivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The discharge of bacterial conjunctivitis is thick and globular; it may be yellow, white, or green.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe, JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &#169; Jonathan D Trobe, MD.</div><div id=\"graphicVersion\">Graphic 55606 Version 1.0</div></div></div>"},"55607":{"type":"graphic_table","displayName":"Classification of jaundice","title":"Classification of jaundice according to type of bile pigment and mechanism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of jaundice according to type of bile pigment and mechanism</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Unconjugated hyperbilirubinemia</td> </tr> <tr> <td class=\"indent1\"><strong>Increased bilirubin production</strong>*</td> </tr> <tr> <td class=\"indent2\">Extravascular hemolysis</td> </tr> <tr> <td class=\"indent2\">Extravasation of blood into tissues</td> </tr> <tr> <td class=\"indent2\">Intravascular hemolysis</td> </tr> <tr> <td class=\"indent2\">Dyserythropoiesis</td> </tr> <tr> <td class=\"indent2\">Wilson disease</td> </tr> <tr> <td class=\"indent1\"><strong>Impaired hepatic bilirubin uptake</strong></td> </tr> <tr> <td class=\"indent2\">Heart failure</td> </tr> <tr> <td class=\"indent2\">Portosystemic shunts</td> </tr> <tr> <td class=\"indent2\">Some patients with Gilbert syndrome</td> </tr> <tr> <td class=\"indent2\">Certain drugs<sup>&#182;</sup> - rifampin, probenecid, flavaspadic acid, bunamiodyl</td> </tr> <tr> <td class=\"indent1\"><strong>Impaired bilirubin conjugation</strong></td> </tr> <tr> <td class=\"indent2\">Crigler-Najjar syndrome types I and II</td> </tr> <tr> <td class=\"indent2\">Gilbert syndrome</td> </tr> <tr> <td class=\"indent2\">Neonates</td> </tr> <tr> <td class=\"indent2\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent2\">Ethinyl estradiol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Liver diseases - chronic hepatitis, advanced cirrhosis</td> </tr> <tr> <td class=\"subtitle1_single\">Conjugated hyperbilirubinemia</td> </tr> <tr> <td class=\"indent1\"><strong>Defect of canalicular organic anion transport</strong></td> </tr> <tr> <td class=\"indent2\">Dubin-Johnson syndrome</td> </tr> <tr> <td class=\"indent1\"><strong>Defect of sinusoidal reuptake of conjugated bilirubin</strong></td> </tr> <tr> <td class=\"indent2\">Rotor&nbsp;syndrome</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Conjugated hyperbilirubinemia (continued)</td> </tr> <tr> <td class=\"indent1\"><strong>Extrahepatic cholestasis (biliary obstruction)</strong></td> </tr> <tr> <td class=\"indent2\">Choledocholithiasis</td> </tr> <tr> <td class=\"indent2\">Intrinsic and extrinsic tumors (eg, cholangiocarcinoma)</td> </tr> <tr> <td class=\"indent2\">Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"indent2\">AIDS cholangiopathy</td> </tr> <tr> <td class=\"indent2\">Acute and chronic pancreatitis</td> </tr> <tr> <td class=\"indent2\">Strictures after invasive procedures</td> </tr> <tr> <td class=\"indent2\">Certain parasitic infections&nbsp;(eg, <em>Ascaris lumbricoides</em>, liver flukes)</td> </tr> <tr> <td class=\"indent1\"><strong>Intrahepatic cholestasis</strong></td> </tr> <tr> <td class=\"indent2\">Viral hepatitis</td> </tr> <tr> <td class=\"indent2\">Alcoholic hepatitis</td> </tr> <tr> <td class=\"indent2\">Nonalcoholic steatohepatitis</td> </tr> <tr> <td class=\"indent2\">Chronic hepatitis</td> </tr> <tr> <td class=\"indent2\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent2\">Drugs and toxins&nbsp;(eg, alkylated steroids, chlorpromazine, herbal medications [eg, Jamaican bush tea], arsenic)</td> </tr> <tr> <td class=\"indent2\">Sepsis and hypoperfusion states</td> </tr> <tr> <td class=\"indent2\">Infiltrative diseases&nbsp;(eg, amyloidosis, lymphoma, sarcoidosis, tuberculosis)</td> </tr> <tr> <td class=\"indent2\">Total parenteral nutrition</td> </tr> <tr> <td class=\"indent2\">Postoperative cholestasis</td> </tr> <tr> <td class=\"indent2\">Following organ transplantation</td> </tr> <tr> <td class=\"indent2\">Hepatic crisis in sickle cell disease</td> </tr> <tr> <td class=\"indent2\">Pregnancy</td> </tr> <tr> <td class=\"indent2\">End-stage liver disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIDS: acquired immunodeficiency syndrome.<br />* Serum bilirubin concentration usually less than 4 mg/dL (68 mmol/L) in the absence of underlying liver disease.<br />&para; The hyperbilirubinemia induced by drugs usually resolves within 48 hours after the drug is discontinued.</div><div id=\"graphicVersion\">Graphic 55607 Version 9.0</div></div></div>"},"55610":{"type":"graphic_diagnosticimage","displayName":"PET CT panc head mass","title":"PET-CT of adenocarcinoma of the pancreatic head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PET-CT of adenocarcinoma of the pancreatic head</div><div class=\"cntnt\"><img style=\"width:312px; height:536px;\" src=\"images/ONC/55610_PET_CT_panc_head_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal (A) and axial (B) images of an integrated PET/CT in a patient with a large adenocarcinoma of the head of the pancreas (A arrow). The axial image demonstrates a lesion in the liver that is highly suspicious for metastatic involvement (B arrow). Both the primary tumor and the metastatic lesion demonstrate increased uptake of the tracer fluorodeoxyglucose (FDG).</div><div class=\"graphic_footnotes\">PET: positron emission tomography; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 55610 Version 3.0</div></div></div>"},"55612":{"type":"graphic_table","displayName":"Dx criteria generalized anxiety","title":"Diagnostic criteria for generalized anxiety disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for generalized anxiety disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>1. Excessive anxiety and worry about a number of events\nor activities, occurring more days than not for at least six months,\nthat are out of proportion to the likelihood or impact of feared events.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. The worry is pervasive and difficult to control.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">3. The anxiety and worry are associated with three (or\nmore) of the following six symptoms (with at least some symptoms\npresent for more days than not for the past six months):</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Restlessness or feeling\nkeyed up or on edge</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">\nBeing easily fatigued</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> \nDifficulty concentrating or mind going blank </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Irritability</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Muscle tension </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Sleep disturbance\n(difficulty falling or staying asleep, or restless unsatisfying sleep)</td>\n    </tr>\n    <tr>\n\n      <td>4. The anxiety, worry, or physical symptoms cause\nclinically significant distress or impairment in social, occupational,\nor other important areas of functioning.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.</div><div id=\"graphicVersion\">Graphic 55612 Version 1.0</div></div></div>"},"55613":{"type":"graphic_figure","displayName":"Construction of an end colostomy segment through abdominal wall","title":"Construction of an end colostomy - segment through abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of an end colostomy - segment through abdominal wall</div><div class=\"cntnt\"><img style=\"width:450px; height:692px;\" src=\"images/SURG/55613_End-colostomy--segment-through-wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the proximal end of the stapled colon being brought through the ostomy opening in the abdominal wall. The same approach is used when creating an end ileostomy.</div><div id=\"graphicVersion\">Graphic 55613 Version 1.0</div></div></div>"},"55614":{"type":"graphic_figure","displayName":"Prevalence of BPH with age","title":"Prevalence of benign prostatic hyperplasia pathology with age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevalence of benign prostatic hyperplasia pathology with age</div><div class=\"cntnt\"><img style=\"width:444px; height:349px;\" src=\"images/ENDO/55614_Prevalence_of_BPH_with_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-associated increase in pathologic evidence of benign prostatic hyperplasia in 1075 men at autopsy. The percentage with benign prostatic hyperplasia was determined during 10-year intervals from five different studies; the mean values are shown.</div><div class=\"graphic_reference\">Data from Berry, SJ, Coffey, DS, Walsh, PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474.</div><div id=\"graphicVersion\">Graphic 55614 Version 1.0</div></div></div>"},"55616":{"type":"graphic_figure","displayName":"Upper GI anatomy PI","title":"Upper digestive tract","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Upper digestive tract</div><div class=\"cntnt\"><img style=\"width:542px; height:537px;\" src=\"images/PI/55616_Upper_GI_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper digestive tract includes the esophagus&nbsp;(the tube than connects the mouth to the stomach), the stomach, and the duodenum (the first part of the small intestine).</div><div id=\"graphicVersion\">Graphic 55616 Version 5.0</div></div></div>"},"55618":{"type":"graphic_figure","displayName":"Heteroduplex analysis","title":"Heteroduplex analysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heteroduplex analysis</div><div class=\"cntnt\"><img style=\"width:414px; height:545px;\" src=\"images/PC/55618_Heteroduplex_analysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This representation of heteroduplex analysis shows how this technique can be used to distinguish between an individual with normal DNA and heterozygous for a gene mutation. An individual's DNA is amplified by polymerase chain reaction&nbsp;(PCR), and the PCR products from both alleles are mixed and denatured (top section). The PCR products are then reannealed, allowing all combinations of DNA pairing. Homoduplexes are generated by the pairing of normal with normal and mutant with mutant DNA; heteroduplexes are generated from the pairing of of normal with mutant DNA. (middle section). The mutation is denoted by an \"X\".<BR>Lane 2: DNA from an individual homozygous for the normal gene forms only homoduplexes, which run faster through the gel.<BR>Lane 3: DNA from an individual heterozygous for the gene mutation forms heteroduplexes, which contain bubbles. This makes the DNA run more slowly through the gel.</div><div id=\"graphicVersion\">Graphic 55618 Version 3.0</div></div></div>"},"55619":{"type":"graphic_picture","displayName":"Epithelial thymoma Low","title":"Predominantly epithelial, polygonal cell-type thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Predominantly epithelial, polygonal cell-type thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/55619_Epithelial_thymoma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The epithelial cells tend to assume a plump, oval, configuration with eosinophilic cytoplasm and uniform, small nuclei. Perivascular spaces are filled by pale eosinophilic fluid and scattered foamy macrophages and lymphocytes. (Hematoxylin and eosin, magnification x 50).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 55619 Version 1.0</div></div></div>"},"55620":{"type":"graphic_table","displayName":"Radiation dose estimates for spine imaging","title":"Radiation dose estimates for spine imaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation dose estimates for spine imaging</div><div class=\"cntnt\"><table cellspacing=\"0\">&nbsp; <div class=\"graphic\"> <div class=\"figure\">&nbsp;</div> </div> <div>&nbsp;</div> <tbody> </tbody></table><table style=\"height: 236px; width: 80.78%;\" cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Approximate&nbsp;effective dose (mSv)</td> <td class=\"subtitle1\">Comparable duration&nbsp;of natural background radiation (years)</td> </tr> <tr> <td>Spine radiograph (X-ray)</td> <td>1.5</td> <td>0.5</td> </tr> <tr> <td>CT spine</td> <td>6</td> <td>2</td> </tr> <tr> <td>Fluoroscopic&nbsp;interventional angiogram of the head and neck</td> <td>5</td> <td>1.7</td> </tr> <tr> <td>CT angiogram of the head and neck</td> <td>14</td> <td>4.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>RadiologyInfo.org. <A href=\"https://www.radiologyinfo.org/en/info.cfm?pg=safety-xray\">https://www.radiologyinfo.org/en/info.cfm?pg=safety-xray</A> (Accessed on December 6, 2017).</LI>&#xD;&#xA;<LI>Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078.</LI></OL></div><div id=\"graphicVersion\">Graphic 55620 Version 6.0</div></div></div>"},"55621":{"type":"graphic_figure","displayName":"Revasc hibernating myocardium","title":"Improvement after revascularization in hibernating myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Improvement after revascularization in hibernating myocardium</div><div class=\"cntnt\"><img style=\"width:361px; height:288px;\" src=\"images/CARD/55621_Revasc_hibernating_myocardi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular (LV) ejection fraction before (pre-op) and eight weeks after coronary artery bypass surgery in patients with more than seven (group A) or seven or fewer viable segments (group B). A significant increase in LV ejection fraction was observed in patients in group A who had substantial viability before surgery. The analysis was based on a total of 15 segments.</div><div class=\"graphic_reference\">Data from: Ragosta M, Beller G, Watson D, et al. Circulation 1993; 87:1630.</div><div id=\"graphicVersion\">Graphic 55621 Version 2.0</div></div></div>"},"55622":{"type":"graphic_picture","displayName":"Premature puberty in Cushings syndrome","title":"Premature puberty in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Premature puberty in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:260px; height:540px;\" src=\"images/ENDO/55622_Premature_puberty_Cushings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 2.5 year-old boy with an adrenocortical carcinoma that secreted excess cortisol and androgens. He presented with signs of Cushing's syndrome (moon face, obesity) and premature puberty (Tanner III pubic hair and penis enlargement, with prepubertal testicular volume).</div><div class=\"graphic_reference\">Reproduced with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 55622 Version 7.0</div></div></div>"},"55623":{"type":"graphic_table","displayName":"Imaging guidelines for newly diagnosed osteosarcoma","title":"Guidelines for imaging of osteosarcoma from the Children's Oncology Group (all imaging studies are required unless otherwise noted)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for imaging of osteosarcoma from the Children's Oncology Group (all imaging studies are required unless otherwise noted)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">At presentation and repeated prior to surgery/local control</td> </tr> <tr> <td class=\"subtitle2_left\">Site</td> <td class=\"subtitle2_left\">Testing</td> </tr> <tr> <td class=\"indent1\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs</td> </tr> <tr> <td class=\"indent1\">Primary tumor</td> <td class=\"indent1\">MRI of the entire bone with gadolinium and at least a T1 coronal sequence&nbsp;(presurgery exam should be performed within four weeks of surgery)</td> </tr> <tr> <td class=\"indent1\">Bone metastases</td> <td class=\"indent1\">MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)</td> </tr> <tr> <td class=\"indent1\">Chest</td> <td class=\"indent1\">CT; AP and lateral radiographs (recommended at presentation only)</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy (with SPECT recommended) and/or FDG-PET</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Baseline after surgery/local control</td> </tr> <tr> <td class=\"subtitle2_left\">Site</td> <td class=\"subtitle2_left\">Testing and timing</td> </tr> <tr> <td class=\"indent1\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs within two weeks of surgery</td> </tr> <tr> <td class=\"indent1\">Primary tumor</td> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast (in patients without significant metallic artifact at primary tumor site) three or four months after local control</td> </tr> <tr> <td class=\"indent1\">Bone metastases</td> <td class=\"indent1\">MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Surveillance on chemotherapy</td> </tr> <tr> <td class=\"subtitle2_left\">Site</td> <td class=\"subtitle2_left\">Testing and timing</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs after three cycles (approximately halfway through postoperative chemotherapy)</td> </tr> <tr> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)</td> </tr> <tr> <td class=\"indent1\">Chest</td> <td class=\"indent1\">CT after four cycles (approximately halfway through postoperative chemotherapy)</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy (add SPECT of lungs if pulmonary metastases suspected) or FDG-PET (if disease positive on prior FDG-PET) at the end of cytotoxic chemotherapy, sooner if symptoms or abnormal imaging (and surgical or other intervention contemplated)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Surveillance postchemotherapy</td> </tr> <tr> <td class=\"subtitle2_left\">Site</td> <td class=\"subtitle2_left\">Testing and timing</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5</td> </tr> <tr> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Chest</td> <td class=\"indent1\">CT every three months x 8, then every six months x 2, then every 12 months x 2</td> </tr> <tr> <td class=\"indent1\">AP and lateral radiographs every 12 months x 5 (starting after last scheduled chest CT)</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy or FDG-PET (if disease positive on prior FDG-PET) if symptoms or abnormal imaging (and surgical or other intervention contemplated)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AP: anterior-posterior; MRI: magnetic resonance imaging; CT: computed tomography scan; SPECT: single-photon emission computed tomography; FDG-PET: fluorodeoxyglucose positron emission tomography; IV: intravenous.</div><div class=\"graphic_reference\">Data from: Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:63.</div><div id=\"graphicVersion\">Graphic 55623 Version 4.0</div></div></div>"},"55626":{"type":"graphic_table","displayName":"FTT diet feeding history","title":"Important aspects of the feeding history in the evaluation of the child (<2 years of age) with failure to thrive","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the feeding history in the evaluation of the child (&lt;2 years of age) with failure to thrive</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General aspects</td> </tr> <tr> <td class=\"indent1\">When does the child eat? (Are there regular and appropriately spaced feeding intervals?)</td> </tr> <tr> <td class=\"indent1\">How much juice (or other sweetened beverages such as soda) does the child drink per day?</td> </tr> <tr> <td class=\"indent1\">Does the family follow a special diet (eg, vegetarian, \"heart healthy\")? What advice has been followed thus far?</td> </tr> <tr> <td class=\"indent1\">When did the child begin solid foods? How were they introduced? How were they tolerated?</td> </tr> <tr> <td class=\"indent1\">Does the child spit up or vomit in relation to feeding?</td> </tr> <tr> <td class=\"indent1\">Are there any stooling patterns associated with feeding?</td> </tr> <tr> <td class=\"indent1\">Does the infant tire with feeding? (May indicate cardiac or pulmonary disorder.)</td> </tr> <tr> <td class=\"subtitle1_single\">Breastfed infants</td> </tr> <tr> <td class=\"indent1\">How often does the infant nurse? (Should be at least eight times per day between zero to four months; five times per day between four and eight months; and on demand thereafter.)</td> </tr> <tr> <td class=\"indent1\">How long does the infant nurse?</td> </tr> <tr> <td class=\"indent1\">Is feeding providing adequate stimulation of milk production?</td> </tr> <tr> <td class=\"indent1\">Can the mother hear the infant swallow?</td> </tr> <tr> <td class=\"indent1\">Does the baby have a strong suck/strong latch? (A weak suck may indicate neurologic disorder.)</td> </tr> <tr> <td class=\"indent1\">Does the mother feel the sensation of let-down (a warm, tingly feeling as the milk begins to flow from the breast when the infant cries)?</td> </tr> <tr> <td class=\"indent1\">Is the mother stressed or fatigued? (These may result in low milk production.)</td> </tr> <tr> <td class=\"indent1\">Does the infant tolerate vitamin D supplement? &nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Formula-fed infants</td> </tr> <tr> <td class=\"indent1\">How much formula does the child ingest? How often? (Daily intake should be approximately 16 to 32 oz at 0 to 4 months, 24 to 40 oz at 4 to 6 months, 24 to 32 oz at 6 to 8 months, 16 to 32 oz at 8 to 10 months, and 16 to 24 oz at 10 to 12 months.)</td> </tr> <tr> <td class=\"indent1\">How is the formula mixed?</td> </tr> <tr> <td class=\"indent1\">Does the caregiver add anything (eg, infant cereal, baby foods) to the bottle?</td> </tr> <tr> <td class=\"indent1\">Does the caregiver hold the bottle during feedings or prop the bottle in the infant's mouth?</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding environment</td> </tr> <tr> <td class=\"indent1\">Who feeds the child? If the child is fed by multiple caregivers, do they have consistent feeding styles?</td> </tr> <tr> <td class=\"indent1\">Where does the child eat (eg, in a high chair, on a caregiver's lap)?</td> </tr> <tr> <td class=\"indent1\">Does the child usually eat alone or with others?</td> </tr> <tr> <td class=\"indent1\">Are there mealtime distractions (eg, television)?</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding behavior/interactions</td> </tr> <tr> <td class=\"indent1\">How does the caregiver know when the child is hungry?</td> </tr> <tr> <td class=\"indent1\">How does the caregiver know when the child is not hungry?</td> </tr> <tr> <td class=\"indent1\">Does the caregiver say or do anything when the child eats well?</td> </tr> <tr> <td class=\"indent1\">Does the caregiver say or do anything when the child eats poorly?</td> </tr> <tr> <td class=\"indent1\">Does the child refuse food?</td> </tr> <tr> <td class=\"indent1\">Do the caregiver and the child have struggles over feeding?</td> </tr> <tr> <td class=\"indent1\">Does the child have strong likes and dislikes (ie, is the child \"picky\")? If so, can/does the caregiver feed the child accordingly?</td> </tr> <tr> <td class=\"indent1\">Does the child feed differently with different people?</td> </tr> <tr> <td class=\"indent1\">Does the child make a mess when he or she eats? If so, is this difficult for the caregiver?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Zenel JA Jr. Failure to thrive: A general pediatrician's perspective. Pediatr Rev 1997; 18:371.</li>&#xD;&#xA;    <li>Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453.</li>&#xD;&#xA;    <li>Gahagan S, Holmes R. A stepwise approach to evaluation of undernutrition and failure to thrive. Pediatr Clin North Am 1998; 45:169.</li>&#xD;&#xA;    <li>Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114.</li>&#xD;&#xA;    <li>Frank DA, Zeisel SH. Failure to thrive. Pediatr Clin North Am 1988; 35:1187.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55626 Version 6.0</div></div></div>"},"55627":{"type":"graphic_picture","displayName":"Miliaria crystallina","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/PEDS/55627_Miliariacrystallina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Miliaria crystallina consists of 1 to 2 mm vesicles without surrounding erythema. It most commonly occurs on the head, neck, and trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 55627 Version 2.0</div></div></div>"},"55631":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 14a","title":"Frontal chest radiography","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiography</div><div class=\"cntnt\"><img style=\"width:540px; height:469px;\" src=\"images/OBGYN/55631_Tumor_bleeding_14a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal chest radiograph on a 45-year-old woman with recurrent left hemothorax secondary to metastatic leiomyosarcoma of the uterus. There is a large collection of blood (verified by pleural tap) in the left hemithorax with displacement of mediastinal structures to the right. After embolization, she improved clinically with less accumulation of blood in the left hemithorax.</div><div id=\"graphicVersion\">Graphic 55631 Version 2.0</div></div></div>"},"55632":{"type":"graphic_figure","displayName":"Iron stores thalassemia major","title":"Correlation between hepatic iron concentration and total body iron stores in thalassemia major patients without cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correlation between hepatic iron concentration and total body iron stores in thalassemia major patients without cirrhosis</div><div class=\"cntnt\"><img style=\"width:424px; height:296px;\" src=\"images/HEME/55632_Iron_stores_thalassemia_maj.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The correlation is shown for 25 patients with liver biopsy samples that had a dry weight of 1.0 mg or more. The regression line (middle blue line) and 95 percent confidence limits (upper red and lower green lines) are shown.</div><div class=\"graphic_reference\">Adapted from: Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327.</div><div id=\"graphicVersion\">Graphic 55632 Version 2.0</div></div></div>"},"55633":{"type":"graphic_table","displayName":"Clinical features of OSA","title":"Clinical features of obstructive sleep apnea (OSA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of obstructive sleep apnea (OSA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Examination findings</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Narrow or \"crowded\" airway </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obesity </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Large neck circumference </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Retrognathia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Daytime sleepiness </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nonrestorative sleep </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Loud snoring </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Witnessed apneas by bed partner </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Awakening with choking </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nocturnal restlessness </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Insomnia with frequent awakenings </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lack of concentration </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cognitive deficits </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Changes in mood </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Morning headaches </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vivid, strange, or threatening dreams </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Nocturia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Associated conditions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Systemic hypertension </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obesity hypoventilation syndrome&nbsp;</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiovascular disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cerebrovascular disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiac dysrhythmias </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pulmonary hypertension </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cor pulmonale </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Gastroesophageal reflux </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Polycythemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Floppy eyelid syndrome </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For further information refer to UpToDate&nbsp;content on clinical evaluation of obstructive sleep apnea.</div><div id=\"graphicVersion\">Graphic 55633 Version 10.0</div></div></div>"},"55634":{"type":"graphic_figure","displayName":"Diagnosis of HIV by sex and age","title":"Diagnoses of HIV infection among persons aged 13 years and older, by sex and age group, 2013 — United States and 6 dependent areas","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Diagnoses of HIV infection among persons aged 13 years and older, by sex and age group, 2013 &mdash; United States and 6 dependent areas</div><div class=\"cntnt\"><img style=\"width:545px; height:291px;\" src=\"images/PEDS/55634_Dgns_HIV_sex_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reproduced from: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV surveillance&mdash;Adolescents and young adults. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/hiv/pdf/statistics_surveillance_Adolescents.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/hiv/pdf/statistics_surveillance_Adolescents.pdf</a> (Accessed on July 30, 2015).</div><div id=\"graphicVersion\">Graphic 55634 Version 5.0</div></div></div>"},"55635":{"type":"graphic_diagnosticimage","displayName":"Intracranial dissection with intimal flap","title":"Intracranial dissection with intimal flap","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Intracranial dissection with intimal flap</div><div class=\"cntnt\"><img style=\"width:580px; height:586px;\" src=\"images/NEURO/55635_Intracr_diss_intimal_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Diffusion-weighted sequence of MRI of the brain shows acute infarction in the right MCA territory.<br />(C, D) Catheter angiography showed irregularities of the right supraclinoid internal carotid artery, extending into the M1 segment of the right MCA. An intimal flap (arrow) indicates dissection.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MCA: middle cerebral artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Suter B, El-Hakam LM. Child neurology: stroke due to nontraumatic intracranial dissection in a child. Neurology 2009; 72:e100. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55635 Version 6.0</div></div></div>"},"55637":{"type":"graphic_table","displayName":"Calculated risk of natalizumab-related PML","title":"Calculated risk of natalizumab-related PML according to currently known risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculated risk of natalizumab-related PML according to currently known risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Prior immunosuppressant use?</td> <td class=\"subtitle1\">Risk up to 24 months of natalizumab exposure</td> <td class=\"subtitle1\">Risk after 24 months of natalizumab exposure</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td rowspan=\"2\"><strong>JC virus antibody negative</strong></td> <td>No</td> <td>&sim;0.02/1000</td> <td>&sim;0.2/1000</td> <td>&nbsp;</td> </tr> <tr> <td>Yes</td> <td>&sim;0.06/1000</td> <td>&sim;0.9/1000</td> <td>&nbsp;</td> </tr> <tr class=\"subtitle1\"> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Risk up to 24 months of natalizumab exposure</td> <td class=\"subtitle1\">Risk during 25 to 48 months of natalizumab exposure</td> <td class=\"subtitle1\">Risk during 49 to 72 months of natalizumab exposure</td> </tr> <tr> <td rowspan=\"4\"><strong>JC virus antibody positive</strong></td> <td>No, anti-JCV antibody index not available</td> <td>&sim;1/1000</td> <td>&sim;3/1000</td> <td>&sim;6/1000</td> </tr> <tr> <td>No; anti-JCV antibody index &#8804;1.5</td> <td>&sim;0.2/1000</td> <td>&sim;1.1/1000</td> <td>&sim;1.4/1000</td> </tr> <tr> <td>No; anti-JCV antibody index &#62;1.5</td> <td>&sim;1.2/1000</td> <td>&sim;8.8/1000</td> <td>&sim;10.1/1000</td> </tr> <tr> <td>Yes</td> <td>&sim;6/1000</td> <td>&sim;12/1000</td> <td>&sim;13/1000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PML: progressive multifocal leukoencephalopathy.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol 2016.</li>&#xD;&#xA;    <li>Kuesters G, Plavina T, Lee S, et al. Anti-JC virus (JCV) antibody index differentiates risk of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients with no prior immunosuppressant (IS) use: An updated analysis. Poster presentation, 67th American Academy of Neurology Annual Meeting, April 22, 2015 Washington DC, USA. <a href=\"www.abstracts2view.com/aan/view.php?nu=AAN15L1_P4.031\" spellcheck=\"true\" target=\"_blank\">www.abstracts2view.com/aan/view.php?nu=AAN15L1_P4.031</a> (Accessed on February 04, 2016).</li>&#xD;&#xA;    <li>Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76:802.</li>&#xD;&#xA;    <li>Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55637 Version 7.0</div></div></div>"},"55638":{"type":"graphic_picture","displayName":"Mucus layer IBS diarrhea","title":"Mucus production in irritable bowel syndrome with diarrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucus production in irritable bowel syndrome with diarrhea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/55638_Mucus_layer_IBS_diarrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased mucus production as a sign of irritation in patients with irritable bowel syndrome (Panel A) and diarrhea (Panels B, C, and D). In panels A and B, mucus can be seen directly with alcian stain. (Panel D) Disruption of the normally homogenous biostructure of the fecal cylinder and development of multiple striae of slime within the germinal zone demonstrate the increased mucus production (Panels A, B, and C: x100; Panel D: x400).</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 55638 Version 2.0</div></div></div>"},"55640":{"type":"graphic_diagnosticimage","displayName":"Diastasis symphysis pubis","title":"Diastasis of the symphysis pubis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diastasis of the symphysis pubis</div><div class=\"cntnt\"><img style=\"width:360px; height:548px;\" src=\"images/PEDS/55640_Diastasis_symphysis_pubis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative radiograph of the pelvis in a child with classic bladder exstrophy. Note the diastasis of the symphysis pubis and the inability to view the obturator foramina (Top). Postoperative radiograph, after pelvic osteotomy, shows nice approximation of the symphysis pubis and a clear view of the obturator foramina (Bottom).</div><div class=\"graphic_reference\">Courtesy of John Gearhart, MD.</div><div id=\"graphicVersion\">Graphic 55640 Version 3.0</div></div></div>"},"55642":{"type":"graphic_table","displayName":"Acne medications 2","title":"Acne medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acne medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><strong></strong>Medications</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Partial list of preparations</td> <td class=\"subtitle1\">Select adverse effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Topical retinoids</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Tretinoin</td> <td rowspan=\"2\">Once daily, at bedtime</td> <td> <p>Standard&nbsp;vehicles -</p> <p><strong>Creams:</strong> 0.025%, 0.0375%, 0.05%, 0.1%</p> <p><strong>Gels:</strong> 0.01%, 0.025%</p> </td> <td rowspan=\"2\"> <p>Local skin irritation, dryness, and flaking; sun sensitivity</p> NOTE: Micronized gel tretinoin 0.05% (Atralin) contains soluble fish proteins, use&nbsp;with caution in patients with known sensitivity or allergy to fish</td> </tr> <tr> <td> <p>Optimized vehicles - </p> <p><strong>Microsphere gels:</strong> 0.04%, 0.08%, 0.1%</p> <p><strong>Polyolprepolymer-2 cream:</strong> 0.025%</p> <p><strong>Polyolprepolymer-2 gel:</strong> 0.025%</p> <p><strong>Gel (micronized):</strong> 0.05%</p> </td> </tr> <tr> <td class=\"indent1\">Adapalene</td> <td>Once daily, at bedtime</td> <td> <p><strong>Cream:</strong> 0.1%</p> <p><strong>Gels:</strong> 0.1%, 0.3%</p> <strong>Lotion:</strong> 0.1%</td> <td>Local skin irritation, dryness, and flaking; sun sensitivity</td> </tr> <tr> <td class=\"indent1\">Tazarotene</td> <td>Once daily, at bedtime</td> <td> <p><strong>Creams:</strong> 0.05%, 0.1%</p> <p><strong>Gels:</strong> 0.05%, 0.1%</p> <p><strong>Foam:</strong> 0.1%</p> </td> <td>Contraindicated in pregnancy; local skin irritation, dryness, and flaking; sun sensitivity</td> </tr> <tr> <td class=\"indent1\">Isotretinoin (not available in United States)</td> <td>Once daily, at bedtime or twice per day</td> <td><strong>Gel: </strong>0.05%</td> <td>Contraindicated in pregnancy and lactation; local skin irritation, dryness and flaking; sun sensitivity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Topical antimicrobials*</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide (BPO)</td> <td>Twice daily</td> <td>Multiple (prescription and non-prescription)&nbsp;2.5 to 10% gels, lotions, creams, pads, masks, cleansers</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td> <p>Twice daily</p> Once daily (foam)</td> <td>1% gel, lotion, pledget, solution, foam</td> <td>Rare risk of pseudomembranous colitis; usually prescribed with BPO to decrease resistance</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> <td>Twice daily</td> <td>2% gel, solution, pledget</td> <td>Usually prescribed with BPO to decrease resistance</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> <td> <p>Twice daily (5% gel)</p> <p>Once daily (7.5% gel)</p> </td> <td>5% gel, 7.5% gel</td> <td>Yellow-orange skin discoloration when applied at the same time as BPO</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Topical combination products</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 5%/Clindamycin 1%</td> <td>Twice daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 5%/Clindamycin 1.2%</td> <td>Once daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 2.5%/Clindamycin 1.2%</td> <td>Once daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 3.75%/Clindamycin 1.2%</td> <td>Once daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 5%/Erythromycin 3%</td> <td>Twice daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Clindamycin 1.2%/Tretinoin 0.025%</td> <td>Once daily, at bedtime</td> <td>Gel</td> <td>Local skin irritation</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 2.5%/Adapalene 0.1%</td> <td>Once daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td class=\"indent1\">Benzoyl peroxide 2.5%/Adapalene 0.3%</td> <td>Once daily</td> <td>Gel</td> <td>Local skin irritation; may bleach hair or clothing</td> </tr> <tr> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td><strong>Azelaic acid</strong></td> <td>Twice daily</td> <td>20% cream, 15% gel</td> <td>Local skin irritation</td> </tr> <tr> <td><strong>Salicylic acid </strong></td> <td>Once to three times daily</td> <td>Multiple (non-prescription) 0.5 to 2% creams, gels, pads, cleansers,&nbsp;solutions, soaps, pledget, foam </td> <td>Local skin irritation; potential for salicylate absorption</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Oral antibiotics<sup>&#182;&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> <td>500 mg twice daily</td> <td>&nbsp;</td> <td>Photosensitivity, gastrointestinal distress; contraindicated in pregnancy and young children</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td> <p>50 to 100 mg twice daily or 100 mg once daily</p> <p><strong>or</strong></p> <p>Delayed release formulation: 100 mg every 12 hours for one day, then 100 mg per day</p> <p>&nbsp;</p> <p>Subantimicrobial dosing: 20 mg twice daily <strong>or</strong></p> <p>Delayed release formulation given as 40 mg once daily</p> </td> <td>&nbsp;</td> <td>Photosensitivity, gastrointestinal distress; contraindicated in pregnancy and young children</td> </tr> <tr> <td class=\"indent1\">Minocycline</td> <td> <p>50 mg&nbsp;one to three times&nbsp;daily <strong>or</strong></p> <p>Extended release formulation: 1 mg/kg/day (round to nearest available strength)</p> </td> <td>&nbsp;</td> <td>Dizziness, drug-induced lupus, skin discoloration; contraindicated in pregnancy and young children</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> <td>500 mg twice daily (base)</td> <td>&nbsp;</td> <td>Gastrointestinal distress</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> <td>160 mg/800 mg once to twice daily</td> <td>&nbsp;</td> <td>Stevens-Johnson syndrome, toxic epidermal necrolysis</td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> <td>Intermittent dosing due to long drug half-life; optimum regimen unknown</td> <td>&nbsp;</td> <td>Gastrointestinal distress</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Hormonal agents<sup>&#182;&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Combination oral contraceptives (estrogen/progestin)</td> <td>Once daily</td> <td>&nbsp;</td> <td> <p>Nausea, breast tenderness, weight gain, thromboembolic events</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"indent1\">Spironolactone</td> <td>25 to 200 mg/day in one or two equally divided doses; doses of 50 to 100 mg/day may be as effective as higher doses and reduce side effects</td> <td>&nbsp;</td> <td>Contraindicated in pregnancy; menstrual irregularity, breast tenderness, minor gastrointestinal symptoms, orthostatic hypotension, hyperkalemia, dizziness, headaches, fatigue</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Oral retinoid<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Oral isotretinoin</td> <td>0.5 mg/kg/day, increasing to 1 mg/kg/day in one or two equally divided doses; total dose 120 to 150 mg/kg over 20 weeks</td> <td>&nbsp;</td> <td> <p>Teratogenicity (absolutely contraindicated in pregnancy), mucocutaneous effects, hypertriglyceridemia, others</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent; BPO: Benzoyl peroxide (topical).<br />* Topical sulfacetamide (eg, gels, creams,&nbsp;lotions, other)&nbsp;with and without sulfur are also available but not typically used and have limited data; refer to topic.<br />¶&nbsp;Usual oral dose for adult or adolescent.<br />Δ BPO may be prescribed with oral antibiotics to reduce resistance.<br />◊ For additional information refer to topic review of hormonal therapy for acne vulgaris.<br />§ For additional information refer to topic review of oral isotretinoin therapy for acne vulgaris.<br /></div><div id=\"graphicVersion\">Graphic 55642 Version 13.0</div></div></div>"},"55643":{"type":"graphic_diagnosticimage","displayName":"Radiograph osteitis pubis flamingo views","title":"Radiograph of flamingo views showing pelvic instability","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Radiograph of flamingo views showing pelvic instability</div><div class=\"cntnt\"><img style=\"width:583px; height:268px;\" src=\"images/PC/55643_Pubic_macro_instability.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flamingo stress views, obtained with the patient alternately weight-bearing on each leg, shows significant displacement at the symphysis pubis (&gt;2 mm). Note the underlying degenerative changes which include a prominent subchondral cyst superiorly on the right.</div><div class=\"graphic_reference\">Reproduced with permission from: Read JW. Groin disruption injury. Sports Medicine Imaging. For more information, visit <A href=\"http://www.sportsmedicineimaging.com/\" target=_blank>http://www.sportsmedicineimaging.com/</A>. Copyright © 2009 SportsMedicineImaging.com. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55643 Version 7.0</div></div></div>"},"55644":{"type":"graphic_table","displayName":"Canadian Neurological Scale","title":"Canadian Neurological Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Neurological Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\">Patient Name:</td> </tr> <tr> <td colspan=\"3\">Rater Name:</td> </tr> <tr> <td colspan=\"3\">Date:</td> </tr> <tr> <td colspan=\"3\">Time:</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Mentation</td> <td class=\"subtitle1_single\">Score</td> </tr> <tr> <td rowspan=\"2\">Level consciousness</td> <td>Alert</td> <td>3.0</td> </tr> <tr> <td>Drowsy</td> <td>1.5</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Orientation</td> <td>Oriented</td> <td>1.0</td> </tr> <tr> <td>Disoriented/NA</td> <td>0.0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Speech</td> <td>Normal</td> <td>1.0</td> </tr> <tr> <td>Expressive deficit</td> <td>0.5</td> </tr> <tr> <td>Receptive deficit</td> <td>0.0</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">&nbsp;</td> <td>TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Motor functions (no comprehension deficit)</td> <td class=\"subtitle1_single\">Weakness</td> <td class=\"subtitle1_single\">Score</td> </tr> <tr> <td rowspan=\"2\">Face</td> <td>None</td> <td>0.5</td> </tr> <tr> <td>Present</td> <td>0.0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Arm: proximal</td> <td>None</td> <td>1.5</td> </tr> <tr> <td>Mild</td> <td>1.0</td> </tr> <tr> <td>Significant</td> <td>0.5</td> </tr> <tr> <td>Total</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Arm: distal</td> <td>None</td> <td>1.5</td> </tr> <tr> <td>Mild</td> <td>1.0</td> </tr> <tr> <td>Significant</td> <td>0.5</td> </tr> <tr> <td>Total</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Leg</td> <td>None</td> <td>1.5</td> </tr> <tr> <td>Mild</td> <td>1.0</td> </tr> <tr> <td>Significant</td> <td>0.5</td> </tr> <tr> <td>Total</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">&nbsp;</td> <td>TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Motor response (comprehension deficit)</td> <td class=\"subtitle1_single\">Score</td> </tr> <tr> <td rowspan=\"2\">Face</td> <td>Symmetrical</td> <td>.5</td> </tr> <tr> <td>Asymmetrical</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Arms</td> <td>Equal</td> <td>1.5</td> </tr> <tr> <td>Unequal</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Legs</td> <td>Equal</td> <td>1.5</td> </tr> <tr> <td>Unequal</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">&nbsp;</td> <td>TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=88499&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Côté R, Hachinski VC, Shurvell BL, et al. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke 1986; 17:731. Copyright © 1986 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55644 Version 9.0</div></div></div>"},"55645":{"type":"graphic_picture","displayName":"Intrauterine herpes simplex virus","title":"Intrauterine herpes simplex virus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Intrauterine herpes simplex virus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PEDS/55645_Intrauterine_HSV_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented, scaling, and crusted erosions of the trunk and extremities in a neonate with intrauterine herpes simplex virus infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. Pediatr Infect Dis J 2011; 30:153. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55645 Version 6.0</div></div></div>"},"55646":{"type":"graphic_table","displayName":"Risk of complications depending upon cause and degree of CKD","title":"Relationship of GFR, albuminuria, and cause of kidney disease with future outcomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship of GFR, albuminuria, and cause of kidney disease with future outcomes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Outcomes</td> <td class=\"subtitle1\" colspan=\"3\">Kidney measures</td> <td class=\"subtitle1\" rowspan=\"2\">Other measures</td> </tr> <tr> <td class=\"subtitle3\">GFR</td> <td class=\"subtitle3\">Albuminuria</td> <td class=\"subtitle3\">Cause</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Kidney outcomes</td> </tr> <tr> <td class=\"indent1\">Albuminuria rise</td> <td>+</td> <td>+++</td> <td>+++</td> <td>HBP</td> </tr> <tr> <td class=\"indent1\">CKD progression (chronic GFR decline)</td> <td>+</td> <td>+++</td> <td>+++</td> <td>HBP, male sex, black race, younger age</td> </tr> <tr> <td class=\"indent1\">Acute kidney injury (acute GFR decline)</td> <td>+++</td> <td>++</td> <td>&nbsp;</td> <td>Age, drug exposure, radiographic contrast</td> </tr> <tr> <td class=\"indent1\">Kidney failure</td> <td>+++</td> <td>+</td> <td>+++</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Complications</td> </tr> <tr> <td class=\"indent1\">Drug toxicity</td> <td>+++</td> <td>+</td> <td>&nbsp;</td> <td>Drug exposure, liver disease</td> </tr> <tr> <td class=\"indent1\">Metabolic/endocrine</td> <td>+++</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">CVD and mortality</td> <td>+++</td> <td>+++</td> <td>++</td> <td>Age, history of CVD, CVD risk factors</td> </tr> <tr> <td class=\"indent1\">Other (infection, cognitive impairment, frailty)</td> <td>++</td> <td>++</td> <td>++</td> <td>Age, comorbid conditions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+ indicates strength of association of kidney measures to current and future outcomes.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; CKD: chronic kidney disease; HBP: high blood pressure; CVD: cardiovascular disease.</div><div class=\"graphic_reference\">Courtesy of Andrew S Levey, MD.</div><div id=\"graphicVersion\">Graphic 55646 Version 1.0</div></div></div>"},"55647":{"type":"graphic_table","displayName":"Causes abnormal liver tests","title":"Common causes of abnormal liver blood tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of abnormal liver blood tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Tests and findings</td> </tr> <tr> <td rowspan=\"2\">Alcoholic liver disease</td> <td>History of alcohol abuse</td> </tr> <tr> <td>AST/ALT &#62;2 with both being less than 500 international unit/mL if alcoholic hepatitis is present</td> </tr> <tr> <td rowspan=\"2\">Chronic hepatitis C</td> <td>ELISA assay for anti-HCV</td> </tr> <tr> <td>PCR for HCV RNA if confirmatory test is necessary</td> </tr> <tr> <td rowspan=\"2\">Primary biliary cholangitis</td> <td>Antimitochondrial antibodies as an isolated finding</td> </tr> <tr> <td>IgM elevation</td> </tr> <tr> <td rowspan=\"3\">Primary sclerosing cholangitis</td> <td>Strong association with inflammatory bowel disease</td> </tr> <tr> <td>Cholangiography to establish the diagnosis</td> </tr> <tr> <td>Antinuclear and antismooth muscle antibodies and ANCA; these are not diagnostic</td> </tr> <tr> <td rowspan=\"2\">Autoimmune hepatitis</td> <td>Hypergammaglobulinemia</td> </tr> <tr> <td>Antinuclear and smooth muscle antibodies and ANCA in type 1; anti-LKM-1 in type 2</td> </tr> <tr> <td>Chronic hepatitis B</td> <td>HBsAg and HBeAg and, in some cases, HBV DNA by hybridization or bDNA assay</td> </tr> <tr> <td rowspan=\"3\">Hereditary hemochromatosis</td> <td>Family history of cirrhosis</td> </tr> <tr> <td>Transferrin saturation and plasma ferritin should be performed but may be elevated by liver disease itself</td> </tr> <tr> <td>Diagnosis established by genetic testing or&nbsp;liver biopsy and calculation of hepatic iron index</td> </tr> <tr> <td rowspan=\"3\">Wilson disease</td> <td>Family or personal history of cirrhosis at a young age</td> </tr> <tr> <td>Serum ceruloplasmin reduced in 95 percent of patients</td> </tr> <tr> <td>Liver biopsy shows increased copper content, which may also be seen in cholestatic liver diseases</td> </tr> <tr> <td rowspan=\"2\">Alpha-1 antitrypsin deficiency</td> <td>Family or personal history of cirrhosis at a young age</td> </tr> <tr> <td>Serum AAT; phenotyping if low or borderline values</td> </tr> <tr> <td rowspan=\"2\">Nonalcoholic fatty liver disease</td> <td>History of diabetes mellitus or metabolic syndrome</td> </tr> <tr> <td>Diagnosis may be suspected by abnormal liver biochemical tests and hepatic imaging showing fatty infiltration and is confirmed by liver biopsy</td> </tr> <tr> <td rowspan=\"2\">Congestive hepatopathy&nbsp;&nbsp;</td> <td>History of right-sided heart failure, constrictive pericarditis, mitral stenosis, tricuspid regurgitation, cor pulmonale, cardiomyopathy</td> </tr> <tr> <td>Right upper quadrant ultrasonography with Doppler studies of the portal and hepatic veins and hepatic artery, electrocardiogram, and cardiac ultrasound</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AAT: alpha-1 antitrypsin; ANCA: antineutrophil cytoplasmic antibody; anti-LKM-1: anti-liver-kidney microsomal 1 antibodies; ALT: alanine aminotransferase; AST: aspartate aminotransferase; DNA: deoxyribonucleic acid; ELISA: enzyme-linked immunosorbent assay; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCV: hepatitis C virus; Ig: immunoglobulin; PCR: polymerase chain reaction; RNA: ribonucleic acid.</div><div id=\"graphicVersion\">Graphic 55647 Version 7.0</div></div></div>"},"55649":{"type":"graphic_picture","displayName":"Normal bladder","title":"Histology of normal bladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of normal bladder</div><div class=\"cntnt\"><img style=\"width:366px; height:396px;\" src=\"images/ONC/55649_Normal_bladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal urinary bladder histology: urothelium (a); lamina propria (b) with muscularis mucosae and submucosa; and muscularis propria (detrusor muscle) (c).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55649 Version 1.0</div></div></div>"},"55650":{"type":"graphic_table","displayName":"Agents most commonly ingested by children","title":"Agents most commonly ingested by children younger than six years of age, United States, 2012 to 2016","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents most commonly ingested by children younger than six years of age, United States, 2012 to 2016</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cosmetics and personal care products</td> </tr> <tr> <td>Cleaning products (household)</td> </tr> <tr> <td>Analgesics</td> </tr> <tr> <td>Foreign bodies/toys/miscellaneous</td> </tr> <tr> <td>Topical preparations</td> </tr> <tr> <td>Vitamins</td> </tr> <tr> <td>Antihistamines&nbsp;</td> </tr> <tr> <td>Pesticides</td> </tr> <tr> <td>Plants</td> </tr> <tr> <td>Dietary supplements/herbals/homeopathic</td> </tr> <tr> <td>Gastrointestinal preparations</td> </tr> <tr> <td>Antimicrobials</td> </tr> <tr> <td>Cough and cold preparations</td> </tr> <tr> <td>Cardiovascular drugs</td> </tr> <tr> <td>Arts/crafts/office supplies</td> </tr> <tr> <td>Hormones and hormone antagonists</td> </tr> <tr> <td>Electrolytes and minerals</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Annual Reports of the American Association of Poison Control Centers' National Poison Data System (NPDS). Available at: <A spellcheck=true href=\"http://www.aapcc.org/annual-reports/\" target=_blank>www.aapcc.org/annual-reports/</A>. Accessed on January 9, 2018. </div><div id=\"graphicVersion\">Graphic 55650 Version 10.0</div></div></div>"},"55652":{"type":"graphic_table","displayName":"Mgmt pre-exist conditions in ECT","title":"Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Management</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Aortic stenosis</td> <td>Echocardiography should be performed to assess severity if not done within the past year or if there is a change in symptoms. If stenosis is severe, then consult cardiologist before proceeding with ECT.</td> <td>Limited data suggest that ECT is safe with the use of short-acting intravenous beta-blockers to minimize procedure-related hypertension and tachycardia.<sup>[1]</sup></td> </tr> <tr> <td>Asthma or chronic obstructive pulmonary disease</td> <td>Discontinue theophylline by tapering the dose, if possible. Continue outpatient regimen of bronchodilators and inhaled glucocorticoids. Provide standard treatment during an asthma exacerbation (inhaled beta-agonists and, if necessary, glucocorticoids, before proceeding with ECT).</td> <td>Theophylline increases the risk of status epilepticus after ECT.<sup>[2]</sup></td> </tr> <tr> <td>Atrial fibrillation</td> <td>Continue outpatient medications for control of heart rate. Control heart rate with calcium-channel blockers if needed. Manage anticoagulation as described below.</td> <td>ECT appears to be safe in patients with atrial fibrillation. Patients may have conversion to and from sinus rhythm during ECT. The effect of spontaneous rate conversion on embolization rates is unknown.</td> </tr> <tr> <td>Coronary artery disease (stable)</td> <td>Continue medications such as aspirin, statins, antihypertensive agents, and antianginal medications, including nitrates for chronic cardiac conditions. Continue aspirin and clopidogrel in patients with coronary stents.</td> <td>Discontinuation of long-term cardiac medications on the morning of the procedure increases the risk of cardiac ischemia.</td> </tr> <tr> <td>Diabetes</td> <td>Measure blood glucose levels before and after ECT treatment. If breakfast is likely only delayed, patients may delay taking their usual morning insulin until after ECT and before eating. If ECT happens later in the morning, where breakfast and lunch are likely to be missed, then give one-half the usual total morning dose as intermediate-acting insulin. Withhold oral agents and short-acting insulin until patient can eat. Perform ECT early in the morning if possible.</td> <td>The effect of ECT on blood glucose is unpredictable because of changes in diet, appetite, and energy level that may result from ECT. Individual ECT treatments raise blood glucose levels in patients with diabetes to the same degree as in patients without diabetes.</td> </tr> <tr> <td>Hypertension (poorly controlled)</td> <td>Start or intensify antihypertensive medications; delay ECT until blood pressure is &#60;140/90 mmHg. Avoid beta-blockers.</td> <td rowspan=\"2\">Blood pressure increases during the postictal phase of ECT. Beta-blockers may shorten the seizure duration and reduce the efficacy of ECT.<sup>[3]</sup></td> </tr> <tr> <td>Hypertension (well-controlled)</td> <td>Continue usual antihypertensive medication(s).</td> </tr> <tr> <td>Implantable cardioverter-defibrillator (ICD)</td> <td>Turn off detection mode of ICD during ECT. Perform continuous electrocardiographic monitoring throughout treatment. Place resuscitative equipment by the patient's bedside in the event that external defibrillation is necessary. Make sure that ICD has been interrogated routinely.</td> <td>ECT appears to be safe in patients with an ICD.<sup>[4]</sup></td> </tr> <tr> <td>Implanted pacemaker</td> <td>A magnet should be available at the patient's bedside in the event that electrical interference leads to pacemaker inhibition and bradycardia.</td> <td>In rare cases, postprocedural supraventricular tachycardia can occur.<sup>[4]</sup></td> </tr> <tr> <td>Need for long-term anticoagulation</td> <td>Continue anticoagulation to maintain an international normalized ratio of up to 3.5, unless there is an increased risk of intracranial hemorrhage (eg, intracranial mass or aneurysm).</td> <td>ECT appears to be safe in patients who require long-term anticoagulation.<sup>[5]</sup></td> </tr> <tr> <td>Pregnancy</td> <td>The informed-consent and risk-stratification process should include an obstetrician and an anesthesiologist. In addition to standard monitoring of the patient, noninvasive fetal monitoring should be used after 14 to 16 weeks. After 24 weeks, a nonstress test with a tocometer should be performed before and after treatments.</td> <td>Pregnancy would require modification of the anesthetic technique, positioning of the patient, and monitoring requirements.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Sources:<br /><ol>&#xD;&#xA;    <li>Mueller PS, Barnes RD, Varghese R, et al. The safety of electroconvulsive therapy in patients with severe aortic stenosis. Mayo Clin Proc 2007; 82:1360.</li>&#xD;&#xA;    <li>Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in patient receiving theophylline. J Clin Psychopharmacol 1988; 8:153.</li>&#xD;&#xA;    <li>Rumi DO, Solimene MC, Takada JY, et al. Electrocardiographic and blood pressure alterations during electroconvulsive therapy in young adults. Arg Bras Cardiol 2002; 79:149.</li>&#xD;&#xA;    <li>Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG. Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2004; 27:1257.</li>&#xD;&#xA;    <li>Mehta V, Meuller PS, Gonzalez-Arriaza HL, et al. Safety of electroconvulsive therapy in patients receiving long-term warfarin therapy. Mayo Clin Proc 2004; 79:1396.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55652 Version 10.0</div></div></div>"},"55655":{"type":"graphic_table","displayName":"Calculate compatible blood","title":"Calculating availability of blood in a patient with multiple alloantibodies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculating availability of blood in a patient with multiple alloantibodies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"2\">Transfusion candidates with known antibodies require blood negative for that antigen. The ease of finding such blood is inversely proportional to that antigen's frequency in the donor population (ie, the less common the antigen, the easier it will be to find compatible [ie, entigen negative] blood).</td> </tr> <tr> <td colspan=\"2\">In addition, the blood needs to be matched for the patient's ABO and Rh(D) type, since A, B, and Rh(D) are potent antigens.</td> </tr> <tr> <td class=\"subtitle2_left\">Blood group</td> <td class=\"subtitle2_left\">Frequency of antigen POSITIVITY (white population)</td> </tr> <tr> <td class=\"indent1\">O</td> <td>45 percent</td> </tr> <tr> <td class=\"indent1\">A</td> <td>40 percent</td> </tr> <tr> <td class=\"indent1\">B</td> <td>11 percent</td> </tr> <tr> <td class=\"indent1\">AB</td> <td>4 percent</td> </tr> <tr> <td class=\"subtitle2_left\">Blood group</td> <td class=\"subtitle2_left\">Frequency of antigen NEGATIVITY (white population)</td> </tr> <tr> <td class=\"indent1\">Rh (D)</td> <td>15 percent</td> </tr> <tr> <td class=\"indent1\">K</td> <td>91 percent</td> </tr> <tr> <td class=\"indent1\">Jk(b)</td> <td>28 percent</td> </tr> <tr> <td class=\"indent1\">Fy(a)</td> <td>37 percent</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">To estimate the availability of blood, one multiplies the percentage of antigen-appropriate blood in the population for each of the antigens involved. In the example given in the text for a patient with Type O Rh negative blood, with anti-K, anti-Jk(b), and anti Fy(a), the percent of blood available is calculated as shown below:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">O positive (0.45) x Rh negative (0.15) x K negative (0.91) x Jk(b) negative (0.28) x Fy(a) negative (0.37) = 0.006. Thus, six out of one thousand randomly collected units should be compatible.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55655 Version 3.0</div></div></div>"},"55656":{"type":"graphic_diagnosticimage","displayName":"Mitral inflow annular ratio","title":"Mitral inflow to annular ratio","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral inflow to annular ratio</div><div class=\"cntnt\"><img style=\"width:339px; height:365px;\" src=\"images/CARD/55656_Mitral_inflow_annular_ratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows the four chamber view of the two dimensional echocardiogram and panel B is the pulsed Doppler image. The mitral inflow to annular ratio (E/Ea) is obtained using routine pulsed-Doppler of the mitral inflow and pulsed-tissue Doppler of the lateral mitral annulus.</div><div class=\"graphic_footnotes\">E: peak early diastolic mitral inflow velocity; Ea: peak early diastolic mitral annular velocity.</div><div id=\"graphicVersion\">Graphic 55656 Version 2.0</div></div></div>"},"55660":{"type":"graphic_picture","displayName":"Linear morphea - limb abnormalities","title":"Limb length discrepancy in linear morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Limb length discrepancy in linear morphea</div><div class=\"cntnt\"><img style=\"width:182px; height:360px;\" src=\"images/DERM/55660_Linear_morphea_limb_abnorm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesions began on the right leg at age five in this patient. Note muscle atrophy, limb length discrepancy and pes planus foot deformity.</div><div id=\"graphicVersion\">Graphic 55660 Version 1.0</div></div></div>"},"55661":{"type":"graphic_table","displayName":"Management of atrophic rhinosinusitis","title":"Management of atrophic rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of atrophic rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Daily nasal irrigations with normal or hypertonic saline</strong>*<sup>&#182;</sup><strong>:</strong> 200 mL lavage to each nare<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Glucocorticoid lavage<sup>&#182;</sup></strong><strong>:</strong></td> </tr> <tr> <td class=\"indent1\">Budesonide: 2 mL of budesonide nebulizer solution (0.25 mg/2 mL) in 1000 mL saline irrigation solution. Use 50 mL to each nare after saline lavage, twice daily.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Empiric irrigation with a topical nasal antibiotic for purulence (100 mL lavage to each nare after saline irrigation). Some concentrations</strong><sup>&#9674;</sup> <strong>recommended include<sup>&#182;</sup></strong><strong>:</strong></td> </tr> <tr> <td class=\"indent1\">Mupirocin: 5 grams of 2% ointment (NOT nasal ointment or cream) in 1000 mL of saline irrigation solution. May be stored at room temperature.</td> </tr> <tr> <td class=\"indent1\">Tobramycin: 80 mg in 1000 mL of saline irrigation solution. Refrigerate.</td> </tr> <tr> <td class=\"indent1\">Clindamycin: 600 mg in 1000 mL of saline irrigation solution. Refrigerate.</td> </tr> <tr> <td class=\"indent1\">Ceftazidime: 1 gram in 1000 mL of saline irrigation solution. Refrigerate. Use entire solution in 10 days or less.</td> </tr> <tr> <td class=\"indent1\">Levofloxacin: 500 mg in 1000 mL of saline irrigation solution. Refrigerate. Use entire solution in 14 days or less.</td> </tr> <tr> <td><strong>Systemic antibiotics for acute infections</strong></td> </tr> <tr> <td><strong>Nasal moisturizer:</strong> Intranasal application of petrolatum jelly or a personal lubricant product with a cotton pledget. Care must be taken to avoid inhaling to decrease risk for lipid pneumonia.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Saline nasal irrigations may be performed once or twice&nbsp;per day, depending on the return. As long as lavage contains thick mucus or purulent material, we recommend lavage twice&nbsp;per day. When purulence is present, a second lavage with an antibiotic may be performed after completion of the first. We recommend all patient-made saline solutions be made in distilled water rather than tap water. Greater than 3% saline may cause nasal irritation.<br />¶&nbsp;To decrease risk of infection, the preparation, use, storage, and expiration dates of all nasal irrigation solutions should be in accordance with local standards for pharmacy-compounded irrigation products. Note that antibiotic solutions may not contain adequate preservative or bactericide and may become contaminated.<br />Δ Lavages may be performed with NetiPots, squeeze bottles, (such as the NeilMed device), irrigation systems, or using a commercial lavage machine with or without a specialized nasal tip (HydroMed).<br /><FONT class=lozenge>◊</FONT> Elliott KA, Stringer SP. Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis. Am J Rhinol 2006; 20:1.</div><div id=\"graphicVersion\">Graphic 55661 Version 8.0</div></div></div>"},"55662":{"type":"graphic_table","displayName":"Fungal skin infections OLT","title":"Fungal skin infections after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fungal skin infections after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fungi</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Opportunistic</td> </tr> <tr> <td class=\"indent1\">Candida albicans</td> <td rowspan=\"5\">Frequent in recipients of liver grafts (20 percent). The cutaneous lesions can result from direct inoculation or from seeding from hematogenous dissemination (Aspergillus fumigatus). Protean clinical manifestations. Appear as isolated or multiple subcutaneous nodules that are violaceous, and can be necrotic, forming abscesses. Voriconazole might be an efficient alternative to amphotericin B.</td> </tr> <tr> <td class=\"indent1\">Aspergillus flavus</td> </tr> <tr> <td class=\"indent1\">Aspergillus fumigatus</td> </tr> <tr> <td class=\"indent1\">Candida parapsilosis</td> </tr> <tr> <td class=\"indent1\">Candida tropicalis</td> </tr> <tr> <td class=\"indent1\">Chromoblastomycosis</td> <td rowspan=\"9\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Chromomycosis (Alternaria, Exophiala jeanselmei)</td> </tr> <tr> <td class=\"indent1\">Cryptococcus neoformans</td> </tr> <tr> <td class=\"indent1\">Fusarium spp</td> </tr> <tr> <td class=\"indent1\">Histoplasma capsulatum</td> </tr> <tr> <td class=\"indent1\">Mycoleptodiscus indicus</td> </tr> <tr> <td class=\"indent1\">Paecilomyces lilacinus</td> </tr> <tr> <td class=\"indent1\">Scopulariopsis brevicaulis</td> </tr> <tr> <td class=\"indent1\">Zygomycosis</td> </tr> <tr> <td class=\"indent1\">Trichophyton rubrum or mentagrophytes</td> <td rowspan=\"3\">Dermatophytosis is more frequent in patients living in tropical regions. Intertrigo and more unusual manifestations such as folliculitis, inflammatory plaques, invasive lesions, pseudotumoral lesions, and abscess may be seen.</td> </tr> <tr> <td class=\"indent1\">Microsporum canis</td> </tr> <tr> <td class=\"indent1\">Epidermophyton floccosum</td> </tr> <tr> <td class=\"indent1\">Malassezia furfur</td> <td>Tinea versicolor can be found in 10 to 20 percent of recipients of a liver graft. Localization is commonly on the face and buttock. Lesions can be extensive and are sometimes hyperkeratotic.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55662 Version 7.0</div></div></div>"},"55663":{"type":"graphic_picture","displayName":"Ear lesion of chronic HSV","title":"Chronic herpes simplex of the ear and neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic herpes simplex of the ear and neck</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/ID/55663_Ear_lesion_of_chronic_HSV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive lesion with ulceration involving the posterior ear and neck due to herpes simplex in a patient with HIV.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt Jr, MD.&#160;The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 55663 Version 3.0</div></div></div>"},"55666":{"type":"graphic_picture","displayName":"Osteochondroma cross-section","title":"Osteochondroma cross-section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondroma cross-section</div><div class=\"cntnt\"><img style=\"width:432px; height:414px;\" src=\"images/PEDS/55666_Osteochondroma_cross-sect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cross-section of an osteochondroma shows the cap of calcified cartilage overlying poorly organized cancellous bone.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55666 Version 3.0</div></div></div>"},"55667":{"type":"graphic_picture","displayName":"AC joint tenderness","title":"AC joint local tenderness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AC joint local tenderness</div><div class=\"cntnt\"><img style=\"width:391px; height:330px;\" src=\"images/EM/55667_AC_joint_tenderness.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior, lateral, and posterior edges of the acromion are marked with a pen. In this photograph, the examiner's finger is located at the articulation between the acromion and the distal clavicle (AC joint). The subacromial space is palpated just under the lateral edge of the acromion.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55667 Version 2.0</div></div></div>"},"55671":{"type":"graphic_figure","displayName":"Mortality beta blocker amio","title":"Benefit of beta blocker plus amiodarone after myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit of beta blocker plus amiodarone after myocardial infarction</div><div class=\"cntnt\"><img style=\"width:432px; height:231px;\" src=\"images/CARD/55671_Mortality_beta_blocker_amio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pooled analysis of patients in the EMIAT and CAMIAT trials shows that all-cause mortality, arrhythmic death, rescucitated cardiac arrest, and non arrhythmic cardiac death were reduced in patients taking beta blocker; the decrease was most prominent in those treated with the combination of beta blocker and amiodarone.</div><div class=\"graphic_footnotes\">Pl: placebo; Am: Amiodarone.</div><div class=\"graphic_reference\">Data from Boutite F, Boissel JP, Connolly SJ, et al, and the EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.</div><div id=\"graphicVersion\">Graphic 55671 Version 2.0</div></div></div>"},"55672":{"type":"graphic_algorithm","displayName":"Algorithm for overlap disorders","title":"An algorithm for diagnosis and management of systemic rheumatic diseases and overlap syndromes","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">An algorithm for diagnosis and management of systemic rheumatic diseases and overlap syndromes</div><div class=\"cntnt\"><img style=\"width:476px; height:543px;\" src=\"images/RHEUM/55672_Algooverlapdisorders.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MCTD: mixed connective tissue disease; rhupus: overlap of rheumatoid arthritis and systemic lupus erythematosus (SLE); ANA: antinuclear antibody.</div><div id=\"graphicVersion\">Graphic 55672 Version 3.0</div></div></div>"},"55673":{"type":"graphic_figure","displayName":"Transhepatic biliary drain placement","title":"Transhepatic biliary drain placement","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Transhepatic biliary drain placement</div><div class=\"cntnt\"><img style=\"width:505px; height:717px;\" src=\"images/SURG/55673_Transhepatic-biliary-drain-placement.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55673 Version 2.0</div></div></div>"},"55674":{"type":"graphic_figure","displayName":"Capillary hemodynamics","title":"Capillary hemodynamic forces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Capillary hemodynamic forces</div><div class=\"cntnt\"><img style=\"width:370px; height:157px;\" src=\"images/NEPH/55674_Capillary_hemodynamics.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the capillary and interstitial fluid hydraulic (P) and oncotic (&#927;) pressures controlling fluid movement across the capillary wall between the plasma and the interstitial fluid. The arrows point in the direction of fluid movement induced by each of the forces.</div><div id=\"graphicVersion\">Graphic 55674 Version 1.0</div></div></div>"},"55675":{"type":"graphic_diagnosticimage","displayName":"C2 Hangman fracture lateral x-ray","title":"Radiograph of a hangman's (C2) fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of a hangman's (C2)&nbsp;fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:504px;\" src=\"images/EM/55675_Hangmanfxlateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the cervical spine shows a fracture (arrow)&nbsp;through the C2 pedicle (so-called \"hangman's fracture\"). This&nbsp;unstable&nbsp;injury results when the cervicocranium (the skull, atlas, and axis functioning as a unit) is thrown into extreme hyperextension.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 55675 Version 4.0</div></div></div>"},"55677":{"type":"graphic_figure","displayName":"Facial nerve anatomy","title":"Cranial nerve VII (facial nerve) anatomy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Cranial nerve VII (facial nerve) anatomy</div><div class=\"cntnt\"><img style=\"width:540px; height:846px;\" src=\"images/NEURO/55677_Facial_nerve_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial nerve provides motor innervation to all the muscles of facial expression and the three muscle derivatives of the second pharyngeal arch (posterior digastric, stapedius, and stylohyoid). It parasympathetically fires three of the four glands in the head: the submandibular and sublingual salivary glands, and the lacrimal gland (A). Other parasympathetic fibers stimulate mucous secretion in the nose and palate. Taste fibers from the anterior two-thirds of the tongue follow the path of the lingual branch of cranial nerve (CN) V until just before entering the cranium as a distinct chorda tympani nerve (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore, KL, Agur, AMR. Essential Clinical Anatomy, 2nd Edition. Baltimore, Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55677 Version 4.0</div></div></div>"},"55679":{"type":"graphic_table","displayName":"Empiric treatment febrile infant","title":"Empiric antimicrobial regimens for febrile young infants 7 to 90 days of age without focal infections*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antimicrobial regimens for febrile young infants 7 to 90 days of age without focal infections*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Empiric treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Neonate (&#8804;28 days)</td> <td> <p>Common: Group B <em>Streptococcus</em>,<em> E. coli</em></p> Less common: <em>Listeria monocytogenes</em>, <em>Enterococcus</em>, <em>S. aureus</em>, other Gram negative organisms, HSV</td> <td> <ul> <li>Ampicillin<br /> <strong>and</strong><br /> Cefotaxime <strong>or</strong> gentamicin<sup>&#182;</sup> </li> <li>Add acyclovir when indicated<sup>&#916;</sup> </li> <li>Add vancomycin when indicated<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Infant (29 to 60 days)</td> <td> <p>Common: Group B <em>Streptococcus</em>, <em>E. coli</em>, <em>S. pneumoniae</em>, <em>H. influenzae</em>, <em>N. meningitidis</em>, <em>S. aureus</em></p> Less common: <em>Enterococcus</em>, <em>Listeria monocytogenes</em>, Pseudomonas sp., other Gram negative organisms</td> <td> <ul> <li>Cefotaxime <strong>or</strong> ceftriaxone </li> <li>Add ampicillin, when coverage for <em>Enterococcus</em> or <em>Listeria monocytogenes</em> infection is indicated </li> <li>Add vancomycin, when indicated<sup>&#9674;</sup> </li> <li>Add gentamicin, when broader coverage for Gram negative pathogens is indicated </li> <li>Add acyclovir when indicated<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>Infant (61 to 90 days)</td> <td> <p>Common: <em>S. pneumoniae</em>, <em>H. influenzae</em>, <em>N. meningitidis</em></p> Less common: Group B <em>Streptococcus</em>, <em>E. coli</em>, <em>S. aureus</em>, <em>Enterococcus</em>, <em>Listeria monocytogenes</em>, Pseudomonas sp., other Gram negative organisms</td> <td> <ul> <li>Ceftriaxone <strong>or</strong> cefotaxime </li> <li>Add vancomycin when indicated<sup>&#9674;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus.<br />* Broad spectrum coverage is prudent until an organism is identified. For specific drug dosing, refer to Lexicomp drug monographs available by searching UpToDate, or while in an UpToDate, topic clicking on the drug name. Refer to UpToDate topics on management of febrile infants younger than 90 days of age. <br />¶ The choice of regimen should be based on local susceptibility patterns of <EM>E. coli</EM> and likelihood of <EM>L. monocytogenes</EM> infection or <EM>Enterococcus</EM> infection.<br />Δ Acyclovir is indicated in infants ≤28 days with ill-appearance, mucocutaneous vesicles, seizures, or cerebrospinal fluid (CSF) pleocytosis and in older infants with clinical findings of HSV infection.<br /><FONT class=lozenge>◊</FONT> Vancomycin is warranted for coverage of methicillin-resistant <EM>S. aureus</EM> infection in regions with high prevalence (&gt;10 percent of isolates) and for coverage of resistant <EM>S. pneumoniae</EM> in infants older than 28 days of age who are ill-appearing or have findings of bacterial meningitis.</div><div id=\"graphicVersion\">Graphic 55679 Version 6.0</div></div></div>"},"55680":{"type":"graphic_picture","displayName":"Optic disc drusen","title":"Optic disc drusen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc drusen</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/PEDS/55680_Optic_disc_drusen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow, globular granules (arrow) are visible embedded in the disc.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 55680 Version 1.0</div></div></div>"},"55681":{"type":"graphic_picture","displayName":"Acne conglobata face","title":"Cystic acne conglobata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic acne conglobata</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/DERM/55681_Acne_conglobata_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 22-year-old man with a two-year history of severe nodulocystic acne was treated with oral 13-cis retinoic acid.</div><div class=\"graphic_reference\">Copyright © Yahia Albaili, DO, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 55681 Version 7.0</div></div></div>"},"55682":{"type":"graphic_table","displayName":"SSRI-SNRI dosage PTSD","title":"SSRI and SNRI oral dosage (adult) for treatment of post-traumatic stress disorder (PTSD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">SSRI and SNRI oral dosage (adult) for treatment of post-traumatic stress disorder (PTSD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Usual starting dose, mg</td> <td class=\"subtitle1\">Low starting dose, mg</td> <td class=\"subtitle1\">Therapeutic dose (daily), mg</td> </tr> <tr> <td><strong>Paroxetine</strong></td> <td>20</td> <td>5 to 10</td> <td>20 to 60</td> </tr> <tr> <td><strong>Sertraline</strong></td> <td>50</td> <td>12.5 to 25</td> <td>50 to 200</td> </tr> <tr> <td><strong>Fluvoxamine</strong></td> <td>50</td> <td>25</td> <td>100 to 300*</td> </tr> <tr> <td><strong>Fluoxetine</strong></td> <td>20</td> <td>5</td> <td>20 to 60</td> </tr> <tr> <td><strong>Citalopram</strong></td> <td>20</td> <td>10</td> <td>20 to 40<sup>&#182;</sup></td> </tr> <tr> <td><strong>Escitalopram</strong></td> <td>10</td> <td>10</td> <td>20 to 30</td> </tr> <tr> <td><strong>Venlafaxine (extended-release)</strong></td> <td>37.5</td> <td>37.5</td> <td>37.5 to 300</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin norepinephrine reuptake inhibitor.<br />* If an immediate release preparation of fluvoxamine is used, dose shown in table should be given in two divided doses.<br />¶ Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. See UpToDate topic: \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration and side effects\", sections \"Citalopram\" and \"Cardiac\". Specific interactions of citalopram with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.</div><div id=\"graphicVersion\">Graphic 55682 Version 10.0</div></div></div>"},"55683":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid histopathology","title":"Ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:476px; height:356px;\" src=\"images/DERM/55683_Ocular_cicatricial_histopa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin, 164x. Note the complex pathosis with infiltration of multiple inflammatory cell types into the substantia propria of the conjunctiva, and a &quot;microangiopathy&quot;, with clustering of lymphocytes and plasma cells around the vasculature.</div><div id=\"graphicVersion\">Graphic 55683 Version 1.0</div></div></div>"},"55684":{"type":"graphic_diagnosticimage","displayName":"Large left vertebral artery","title":"Large left vertebral artery","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Large left vertebral artery</div><div class=\"cntnt\"><img style=\"width:504px; height:499px;\" src=\"images/SURG/55684_Lg_l_vertebral_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large left vertebral artery in patient with connective tissue disorder with concommitent left carotid and right subclavian aneurysms.</div><div id=\"graphicVersion\">Graphic 55684 Version 1.0</div></div></div>"},"55685":{"type":"graphic_figure","displayName":"Transmitral flow outcome HF","title":"Transmitral flow velocity predicts outcome in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transmitral flow velocity predicts outcome in heart failure</div><div class=\"cntnt\"><img style=\"width:384px; height:260px;\" src=\"images/CARD/55685_Transmitral_flow_outcome_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with heart failure (HF) who had prolongation of the transmitral deceleration time (DT) on Doppler echocardiography to &gt;125 msec on therapy had a lower incidence of all cardiac events including death, transplantation, and hospitalization for worsening HF (36 versus 86 percent, p &lt;0.0001) compared with those in whom the DT was persistently short (≤125 msec).</div><div class=\"graphic_reference\">Data from: Temporelli PL, Corra U, Imparto A, et al. J Am Coll Cardiol 1998; 31:1591.</div><div id=\"graphicVersion\">Graphic 55685 Version 2.0</div></div></div>"},"55686":{"type":"graphic_figure","displayName":"Type III AC joint injury PI","title":"Type III acromioclavicular joint injury","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Type III acromioclavicular joint injury</div><div class=\"cntnt\"><img style=\"width:474px; height:440px;\" src=\"images/PI/55686_Grade_III_AC_joint_spr_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55686 Version 6.0</div></div></div>"},"55687":{"type":"graphic_figure","displayName":"LeFort fractures of the midface","title":"LeFort fractures of the midface","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">LeFort fractures of the midface</div><div class=\"cntnt\"><img style=\"width:477px; height:398px;\" src=\"images/EM/55687_LeFortfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LeFort fractures are those of the midface that involve the maxillary dentoalveolar segment. The mechanism and location of impact usually determine the type of fracture sustained. Fractures tend to occur in certain patterns of the midface and are traditionally classified by the highest level of fracture. Most LeFort fractures are not &quot;pure&quot; and can have comminution, additional levels or lines of fracture, and other associated facial fractures.</div><div class=\"graphic_reference\">Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55687 Version 12.0</div></div></div>"},"55690":{"type":"graphic_figure","displayName":"Child CNS tumor site sympt","title":"Central nervous system tumor presentation and site in children","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Central nervous system tumor presentation and site in children</div><div class=\"cntnt\"><img style=\"width:605px; height:587px;\" src=\"images/PEDS/55690_Child_CNS_tumor_site_sympt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.<br>* Symptom or sign caused by raised intracranial pressure (ICP).</div><div class=\"graphic_reference\">Reproduced with permission from: Wilne, S, Collier, J, Kennedy, C. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol 2007; 8:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 55690 Version 2.0</div></div></div>"},"55691":{"type":"graphic_figure","displayName":"EEG PI","title":"Person having an EEG","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Person having an EEG</div><div class=\"cntnt\"><img style=\"width:528px; height:503px;\" src=\"images/PI/55691_EEG_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person having an EEG (also called an electroencephalogram). An EEG is a test that measures electrical activity in the brain and records brain wave patterns.<br /><br />The electrodes are stuck onto the scalp using paste. In some cases, the person wears a special cap with electrodes on it instead.</div><div id=\"graphicVersion\">Graphic 55691 Version 5.0</div></div></div>"},"55692":{"type":"graphic_table","displayName":"Instructional variables in learning disability","title":"Instructional variables that affect learning: School accommodations and modifications for children with learning disabilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instructional variables that affect learning: School accommodations and modifications for children with learning disabilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Instructional variable </td> <td class=\"subtitle1\">Modifications to accommodate to the requirements of a typical classroom </td> </tr> <tr> <td rowspan=\"3\">Level of task difficulty </td> <td>Provide alternative books with similar concepts but written at an easier reading or language level</td> </tr> <tr> <td>Use peer readers</td> </tr> <tr> <td>Provide audiotapes of textbooks</td> </tr> <tr> <td rowspan=\"6\">Duration of allotted time </td> <td>Shorten assignments to focus on mastery of key concepts</td> </tr> <tr> <td>Shorten spelling tests to focus on mastery of the most functional words</td> </tr> <tr> <td>Provide additional time to complete a task</td> </tr> <tr> <td>Allow extra time to turn in homework without a penalty</td> </tr> <tr> <td>Permit as much time as necessary to complete tests</td> </tr> <tr> <td>Break long-term assignments into small, sequential steps, with daily monitoring and frequent grading</td> </tr> <tr> <td rowspan=\"14\">Level of receptive and expressive language development </td> <td>Use language to match receptive language level of student</td> </tr> <tr> <td>Use simple statements</td> </tr> <tr> <td>Use gestures, diagrams, or models to emphasize meaning</td> </tr> <tr> <td>Reduce speaking tempo</td> </tr> <tr> <td>Maintain visual contact</td> </tr> <tr> <td>Provide summaries of chapters</td> </tr> <tr> <td>Use marker to highlight important textbook sections</td> </tr> <tr> <td>Provide the student with a list of discussion questions prior to reading the text</td> </tr> <tr> <td>Use both oral and printed directions</td> </tr> <tr> <td>Give directions in a series of short sentences</td> </tr> <tr> <td>Provide visual cues</td> </tr> <tr> <td>Grade spelling separately from content</td> </tr> <tr> <td>Provide possible answers for fill-in-the-blank tests</td> </tr> <tr> <td>Read and explain mathematical story problems</td> </tr> <tr> <td rowspan=\"5\">Level of visual-motor integration skills </td> <td>Use worksheets that require minimal writing</td> </tr> <tr> <td>Use multiple-choice or fill-in-the-blank questions rather than an essay</td> </tr> <tr> <td>Provide a print outline of lectures, videotapes, or assignments</td> </tr> <tr> <td>Omit assignments that require copying</td> </tr> <tr> <td>Substitute alternatives for written assignments</td> </tr> <tr> <td rowspan=\"6\">Quality of teacher-pupil relationship </td> <td>Modify school rules that may discriminate against the student</td> </tr> <tr> <td>Minimize the use of punishment; provide positive, as well as negative, consequences</td> </tr> <tr> <td>Provide a partial grade based on individual progress or effort</td> </tr> <tr> <td>Mark the correct responses rather than the incorrect responses</td> </tr> <tr> <td>Evaluate the classroom structure against the student's needs</td> </tr> <tr> <td>Focus instruction, when possible, on student's special interests</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55692 Version 3.0</div></div></div>"},"55693":{"type":"graphic_diagnosticimage","displayName":"Long axis HCM ASH SAM","title":"Asymmetric hypertrophy in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asymmetric hypertrophy in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:209px; height:236px;\" src=\"images/CARD/55693_Long_axis_HCM_ASH_SAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view from a two dimensional echocardiogram in a patient with hypertrophic cardiomyopathy shows asymmetric septal hypertrophy (ASH), with typical thickened septum relative to the posterior wall, and systolic anterior motion (SAM) of the mitral valve. As a result of SAM, the left ventricular outflow tract is almost completely obliterated.</div><div class=\"graphic_footnotes\">LA: left atrium; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 55693 Version 2.0</div></div></div>"},"55694":{"type":"graphic_figure","displayName":"Endotracheal tube positioning","title":"Endotracheal tube positioning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube positioning</div><div class=\"cntnt\"><img style=\"width:339px; height:306px;\" src=\"images/PULM/55694_Endotracheal_tube_positioni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of key distances related to endotracheal tube positioning. Malpositioning of the endotracheal tube can be suspected from the depth of insertion. In the average adult, the 18-24 cm mark will show at the incisors when the tip of the tube is midway between the vocal cords and the carina.</div><div class=\"graphic_reference\">Redrawn from Stone, DJ, Bogdonoff, DL, Anesth Analg 1992; 74:276.</div><div id=\"graphicVersion\">Graphic 55694 Version 1.0</div></div></div>"},"55696":{"type":"graphic_table","displayName":"Proportion CV events SCD","title":"Proportion of coronary fatalities that are sudden deaths: Framingham study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proportion of coronary fatalities that are sudden deaths: Framingham study</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Percent as sudden deaths</td> </tr> <tr> <td class=\"subtitle2\">Age 35 to 64</td> <td class=\"subtitle2\">Age 65 to 94</td> <td class=\"subtitle2\">Age 35 to 94</td> </tr> <tr> <td><strong>Men</strong></td> <td class=\"centered\">54</td> <td class=\"centered\">41</td> <td class=\"centered\">47</td> </tr> <tr> <td><strong>Women</strong></td> <td class=\"centered\">39</td> <td class=\"centered\">29</td> <td class=\"centered\">31</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\">51</td> <td class=\"centered\">36</td> <td class=\"centered\">42</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55696 Version 2.0</div></div></div>"},"55697":{"type":"graphic_picture","displayName":"Factitial dermatitis 2","title":"Factitial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Factitial dermatitis</div><div class=\"cntnt\"><img style=\"width:420px; height:315px;\" src=\"images/DERM/55697_Factitial_derm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Self-induced purpuric lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55697 Version 1.0</div></div></div>"},"55699":{"type":"graphic_figure","displayName":"Creating an omental flap","title":"Construction of an omental flap during pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Construction of an omental flap during pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:514px; height:426px;\" src=\"images/OBGYN/55699_Creating_an_omental_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Omentum is freed starting at the hepatic flexure, with a 4- to 6-cm band left attached at the splenic flexure, and the freed omentum is then placed along the left parocolic gutter into the pelvis, where it is stitched into place as a &quot;lid&quot; to keep small bowel out of the pelvic defect.</div><div id=\"graphicVersion\">Graphic 55699 Version 2.0</div></div></div>"},"55700":{"type":"graphic_table","displayName":"IVC-related infx defs","title":"Commonly used clinical definitions of intravascular catheter-related infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used clinical definitions of intravascular catheter-related infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infection </td> <td class=\"subtitle1\">Definition </td> </tr> <tr> <td>Catheter colonization</td> <td>Significant growth of &#8805;1 microorganism in a quantitative or semiquantitative culture of the catheter tip, subcutaneous catheter segment, or catheter hub</td> </tr> <tr> <td>Phlebitis</td> <td>Induration or erythema, warmth, and pain or tenderness along the tract of a catheterized or recently catheterized vein</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Exit site infection </td> </tr> <tr> <td class=\"sublist1\">Microbiological </td> <td class=\"sublist_other\">Exudate at catheter exit site yields a microorganism with or without concomitant bloodstream infection </td> </tr> <tr> <td class=\"sublist1\">Clinical </td> <td class=\"sublist_other\">Erythema, induration, and/or tenderness within 2 cm of the catheter exit site; may be associated with other signs and symptoms of infection, such as fever or purulent drainage emerging from the exit site, with or without concomitant bloodstream infection* </td> </tr> <tr> <td>Tunnel infection</td> <td>Tenderness, erythema, and/or induration &#62;2 cm from the catheter exit site, along the subcutaneous tract of a tunneled catheter (eg, Hickman or Broviac catheter), with or without concomitant bloodstream infection*</td> </tr> <tr> <td>Pocket infection</td> <td>Infected fluid in the subcutaneous pocket of a totally implanted intravascular device; often associated with tenderness, erythema, and/or induration over the pocket; spontaneous rupture and drainage, or necrosis of the overlying skin, with or without concomitant bloodstream infection*</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Bloodstream infection </td> </tr> <tr> <td class=\"sublist1\">Infusate related </td> <td class=\"sublist_other\">Concordant growth of a microorganism from infusate and cultures of percutaneously obtained blood cultures with no other identifiable source of infection </td> </tr> <tr> <td class=\"sublist1\">Catheter related </td> <td class=\"sublist_other\">Bacteremia or fungemia in a patient who has an intravascular device and &#62;1 positive blood culture result obtained from the peripheral vein, clinical manifestations of infection (eg, fever, chills, and/or hypotension), and no apparent source for bloodstream infection (with the exception of the catheter). One of the following should be present: a positive result of semiquantitative (&#62;15 CFU per catheter segment) or quantitative (&#62;10<sup>2</sup>&nbsp;CFU per catheter segment) catheter culture, whereby the same organism (species) is isolated from a catheter segment and a peripheral blood culture; simultaneous quantitative cultures of blood with a ratio of &#62;3:1 CFU/mL of blood (catheter versus peripheral blood); differential time to positivity (growth in a culture of blood obtained through a catheter hub is detected by an automated blood culture system at least 2 hours earlier than a culture of simultaneously drawn peripheral blood of equal volume). Note that this definition differs from the definition of central line-associated bloodstream infection used for infection control surveillance activities. </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Adapted in part from Pearson<sup>[1]</sup>.</div><div class=\"graphic_footnotes\">CFU: colony forming units.<br />* For surveillance purposes, patients with positive results of blood culture would be classified as having central line-associated bloodstream infection.</div><div class=\"graphic_reference\">1. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:438-73.<br> Reproduced with permission from: Mermel, LA, Allon, M, Bouza, E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</div><div id=\"graphicVersion\">Graphic 55700 Version 4.0</div></div></div>"},"55702":{"type":"graphic_table","displayName":"Antibx not used in pregnancy","title":"Antibiotics to be avoided in the treatment of pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics to be avoided in the treatment of pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Tetracyclines (including doxycycline and minocycline)</td> </tr> <tr> <td>Tigecycline</td> </tr> <tr> <td>Clarithromycin</td> </tr> <tr> <td>Fluoroquinolones*</td> </tr> <tr> <td>Erythromycin estolate<sup>&#182;</sup></td> </tr> <tr> <td>Chloramphenicol</td> </tr> <tr> <td>Kanamycin, streptomycin<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Despite very concerning animal data, increasing human data suggests fluoroquinolones might warrant a role in specific pregnant patients in the future.<br />&para; Only the erythromycin estolate should be avoided in pregnancy. Other forms of erythromycin, such as erythromycin base, ethyl succinate, or stearate are acceptable.<br />&Delta; Kanamycin and streptomycin have been associated with fetal ototoxicity. There are theoretical concerns of ototoxicity and nephrotoxicity with all aminoglycosides. However, experience with other aminoglycosides, particularly gentamicin, in treatment of serious infections in pregnancy is reassuring.</div><div id=\"graphicVersion\">Graphic 55702 Version 4.0</div></div></div>"},"55703":{"type":"graphic_diagnosticimage","displayName":"Low lying placenta","title":"Low lying placenta","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Low lying placenta</div><div class=\"cntnt\"><img style=\"width:504px; height:338px;\" src=\"images/OBGYN/55703_Marginal_previa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal study shows a posterior placenta with the tip of the placenta on the internal os (arrow). The placenta is adjacent to the internal os, but does not cover it.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 55703 Version 4.0</div></div></div>"},"55704":{"type":"graphic_table","displayName":"Treatment recommend ovar GCT","title":"Summary of recommendations for treatment of ovarian germ cell tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for treatment of ovarian germ cell tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumor type</td> <td class=\"subtitle1\">Recommended treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dysgerminoma</td> </tr> <tr> <td class=\"indent1\">Stage IA and IB</td> <td>Surgery</td> </tr> <tr> <td class=\"indent1\">Stage IC, II, or III</td> <td>Surgery plus three cycles of BEP or CE</td> </tr> <tr> <td class=\"indent1\">Stage IV</td> <td>Surgery plus four cycles of BEP</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Immature teratoma</td> </tr> <tr> <td class=\"indent1\">Stage I unruptured, grade 1</td> <td>Surgery</td> </tr> <tr> <td class=\"indent1\">Stage I ruptured or grade 2 or 3, or II or III</td> <td>Surgery plus three cycles of BEP</td> </tr> <tr> <td class=\"indent1\">Stage IV</td> <td>Surgery (if patient is a candidate) plus four to six cycles of BEP</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">All other histologies</td> </tr> <tr> <td class=\"indent1\">Stage I</td> <td>Surgery plus three cycles of BEP*</td> </tr> <tr> <td class=\"indent1\">Stage II to III, completely resected</td> <td>Surgery plus three to four cycles of BEP</td> </tr> <tr> <td class=\"indent1\">Gross residual or stage IV</td> <td>Surgery (if patient is a candidate) plus four to six cycles of BEP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BEP: bleomycin, etoposide, cisplatin; CE: carboplatin etoposide.<br> * Whether carboplatin can be substituted for cisplatin unclear; most prefer cisplatin.</div><div id=\"graphicVersion\">Graphic 55704 Version 2.0</div></div></div>"},"55705":{"type":"graphic_figure","displayName":"Internal jugular cannulation techniques","title":"Internal jugular vein cannulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal jugular vein cannulation</div><div class=\"cntnt\"><img style=\"width:301px; height:530px;\" src=\"images/PEDS/55705_Int_jugular_cannul_techniqu.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">A: anterior route; B: central route; C: posterior route.</div><div id=\"graphicVersion\">Graphic 55705 Version 2.0</div></div></div>"},"55706":{"type":"graphic_picture","displayName":"Short leg splint","title":"Short leg splint","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Short leg splint</div><div class=\"cntnt\"><img style=\"width:514px; height:214px;\" src=\"images/EM/55706_Short_leg_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of photographs demonstrates the basic steps in the application of a short leg splint. Positioning the patient prone allows for easier positioning and application.</div><div class=\"graphic_reference\">Courtesy of Richard Derby, MD.</div><div id=\"graphicVersion\">Graphic 55706 Version 1.0</div></div></div>"},"55708":{"type":"graphic_table","displayName":"Sigmoid and transverse loops","title":"Frequency and types of loops observed during intubation utilizing magnetic imaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency and types of loops observed during intubation utilizing magnetic imaging</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Loop\n   </td>\n   <td  class=\"subtitle1\">\n   Total (n=100)\n   </td>\n   <td  class=\"subtitle1\">\n   Males (n=48)\n   </td>\n   <td  class=\"subtitle1\">\n   Females (n=52)\n   </td>\n   </tr>\n   <tr>\n   <td>None</td>\n   <td>9</td>\n   <td>6</td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">\n   Sigmoid loops\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   N-sigmoid spiral\n   </td>\n   <td  class=\"sublist_other\">\n   79\n   </td>\n   <td  class=\"sublist_other\">\n   38\n   </td>\n   <td  class=\"sublist_other\">\n   41\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Alpha\n   </td>\n   <td  class=\"sublist_other\">\n   12\n   </td>\n   <td  class=\"sublist_other\">\n   5\n   </td>\n   <td  class=\"sublist_other\">\n   7\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Reverse alpha\n   </td>\n   <td  class=\"sublist_other\">\n   11\n   </td>\n   <td  class=\"sublist_other\">\n   2\n   </td>\n   <td  class=\"sublist_other\">\n   9\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Reverse sigmoid spiral\n   </td>\n   <td  class=\"sublist_other\">\n   1\n   </td>\n   <td  class=\"sublist_other\">\n   0\n   </td>\n   <td  class=\"sublist_other\">\n   1\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">\n   Transverse loops\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Deep transverse\n   </td>\n   <td  class=\"sublist_other\">\n   34\n   </td>\n   <td  class=\"sublist_other\">\n   15\n   </td>\n   <td  class=\"sublist_other\">\n   19\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Reverse splenic\n   </td>\n   <td  class=\"sublist_other\">\n   3\n   </td>\n   <td  class=\"sublist_other\">\n   1\n   </td>\n   <td  class=\"sublist_other\">\n   2\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Gamma\n   </td>\n   <td  class=\"sublist_other\">\n   1\n   </td>\n   <td  class=\"sublist_other\">\n   0\n   </td>\n   <td  class=\"sublist_other\">\n   1\n   </td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 55708 Version 1.0</div></div></div>"},"55709":{"type":"graphic_waveform","displayName":"Hemodynamic tracing acute cardiac tamponade","title":"Intracardiac hemodynamic tracings showing acute cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Intracardiac hemodynamic tracings showing acute cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:486px; height:291px;\" src=\"images/CARD/55709_Acute_cardiac_tamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radial arterial tracing shows tachycardia and extreme pulsus paradoxus. The right atrial and pericardial pressures are equally elevated, but the amount of effusion was very small. Note deeper y descent in the pericardial pressure compared with the right atrial pressure. ECG shows low voltage. Heavy time markings = 1 second.</div><div class=\"graphic_reference\">Reproduced with permission from: The Pericardium, 2nd ed, Shabetai R (Ed), Kluwer Academic Publishers, Norwell MS 2003. Copyright © 2003 Kluwer Academic Publishers.</div><div id=\"graphicVersion\">Graphic 55709 Version 4.0</div></div></div>"},"55710":{"type":"graphic_table","displayName":"Pathophysiology and therapy of AIHA","title":"Laboratory characteristics, pathophysiology, and therapy for primary autoimmune hemolytic anemia observed in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory characteristics, pathophysiology, and therapy for primary autoimmune hemolytic anemia observed in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Warm-reactive AIHA</td> <td class=\"subtitle1\">Paroxysmal cold hemoglobinuria</td> <td class=\"subtitle1\">Cold agglutinin disease</td> </tr> <tr> <td>Autoantibody isotype</td> <td>IgG</td> <td>IgG</td> <td>IgM</td> </tr> <tr> <td>Thermal reactivity</td> <td>Warm</td> <td>Cold</td> <td>Cold</td> </tr> <tr> <td>Ability to fix complement</td> <td>Variable</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td> <p>DAT (Coombs test) result</p> </td> <td> <p>4&#176;C: Not typically performed</p> <p>37&#176;C: Positive for IgG, &#177; C3</p> </td> <td> <p>4&#176;C: Positive for IgG&nbsp;and C3</p> <p>37&#176;C: Negative for IgG; positive for C3</p> </td> <td> <p>4&#176;C: Negative for IgG; positive for C3</p> <p>37&#176;C: Negative for IgG; positive for C3</p> </td> </tr> <tr> <td>Antigenic reactivity</td> <td>Rh, others</td> <td>P</td> <td>I or i</td> </tr> <tr> <td>Site&nbsp;of hemolysis</td> <td>Spleen</td> <td>Intravascular</td> <td>Liver, intravascular</td> </tr> <tr> <td>First-line therapy</td> <td>Glucocorticoids</td> <td>Avoidance of cold</td> <td>Avoidance of cold</td> </tr> <tr> <td>Secondary therapy</td> <td>Splenectomy, Rituximab*</td> <td>Glucocorticoids</td> <td>Rituximab*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIHA: autoimmune hemolytic anemia; IgG: immunoglobulin G; IgM: immunoglobulin M; DAT: direct antiglobulin test (Coombs test); C: Celsius; C3: complement component 3; Rh: Rhesus.<br />*&nbsp;This is an off-label use of rituximab.</div><div class=\"graphic_reference\">Adapted from: Chou ST, Schreiber AD. Autoimmune hemolytic anemia. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Look T, et al. (Eds), WB Saunders, Philadelphia 2015. p. 411.</div><div id=\"graphicVersion\">Graphic 55710 Version 7.0</div></div></div>"},"55712":{"type":"graphic_picture","displayName":"Severe otitis externa","title":"Severe otitis externa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe otitis externa</div><div class=\"cntnt\"><img style=\"width:220px; height:324px;\" src=\"images/PC/55712_Severe_otitis_externa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete ear canal closure and auricular erythema extending to periauricular tissue, including the face.</div><div class=\"graphic_reference\">Courtesy of Laura A Goguen, MD.</div><div id=\"graphicVersion\">Graphic 55712 Version 1.0</div></div></div>"},"55713":{"type":"graphic_diagnosticimage","displayName":"Knee osteochondrom x ray","title":"Synovial osteochondromatosis of the knee","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Synovial osteochondromatosis of the knee</div><div class=\"cntnt\"><img style=\"width:520px; height:406px;\" src=\"images/RHEUM/55713_Knee_osteochondrom_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These anteroposterior and lateral views of the knee demonstrate multiple calcified intraarticular loose bodies (arrows) consistent with synovial osteochondromatosis. Also noted&nbsp;are severe medial and lateral joint space narrowing and osteophyte formation consistent with concomitant osteoarthritis of the knee joint.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Celia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 55713 Version 3.0</div></div></div>"},"55714":{"type":"graphic_picture","displayName":"Focal dermal hypoplasia","title":"Focal dermal hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal dermal hypoplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/55714_Focal_dermal_hypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous areas representing dermal hypoplasia are present. Note the digital abnormalities involving the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55714 Version 3.0</div></div></div>"},"55715":{"type":"graphic_figure","displayName":"Coil embolization of internal iliac artery aneurysm","title":"Coil embolization of internal iliac artery aneurysm ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coil embolization of internal iliac artery aneurysm </div><div class=\"cntnt\"><img style=\"width:378px; height:292px;\" src=\"images/SURG/55715_Coil-embolization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolated internal iliac artery aneurysm can be managed with coil embolization of the inflow and outflow vessels.</div><div id=\"graphicVersion\">Graphic 55715 Version 3.0</div></div></div>"},"55716":{"type":"graphic_diagnosticimage","displayName":"Ulnar bowing 2","title":"Ulnar bowing fracture with radius greenstick fracture","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Ulnar bowing fracture with radius greenstick fracture</div><div class=\"cntnt\"><img style=\"width:515px; height:300px;\" src=\"images/EM/55716_Bowing_greenstick_reduced.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radius fracture reduced. Notice that ulna is straighter.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD</div><div id=\"graphicVersion\">Graphic 55716 Version 2.0</div></div></div>"},"55718":{"type":"graphic_table","displayName":"Maternal and fetal benefits of methadone treatment ","title":"Maternal and fetal benefits of methadone treatment for opioid addiction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal and fetal benefits of methadone treatment for opioid addiction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Reduces illegal opiate use as well as the use of other drugs, thus diminishing the risk of hepatitis, HIV/AIDS, and other sexually transmitted diseases</td> </tr> <tr> <td>Helps to remove the opiate-dependent woman from the drug-seeking environment</td> </tr> <tr> <td>Eliminates illegal behaviors, such as prostitution</td> </tr> <tr> <td>Prevents fluctuation of the maternal drug level over the course of the day</td> </tr> <tr> <td>Reduces maternal mortality and severe morbidity</td> </tr> <tr> <td>Avoids fetal stress from <span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">repeated withdrawal due to inconsistent availability of illicit drugs</span></td> </tr> <tr> <td>Leads to improvement in the mother's nutrition and infant birth weight</td> </tr> <tr> <td>Improves the woman's ability to participate in prenatal care and substance abuse treatment</td> </tr> <tr> <td>Enhances the woman's ability to prepare for the birth of her infant and begin homemaking. Stabilized mothers on methadone are more likely to retain custody of their children.</td> </tr> <tr> <td>Children are more closely monitored when the mother is part of a rehabilitation program</td> </tr> <tr> <td>Reduces the frequency of obstetric complications</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immune deficiency syndrome.</div><div class=\"graphic_reference\">Reproduced from: Alcohol and other drug treatment guidelines for pregnant, substance-using women. In: Treatment Improvement Protocol Series 2: Pregnant, Substance-abusing Women, Mitchell JL (Ed), Center for Substance Abuse Treatment, Rockville, MD 1995.</div><div id=\"graphicVersion\">Graphic 55718 Version 8.0</div></div></div>"},"55719":{"type":"graphic_table","displayName":"Unintended loss rate after MPR by finishing number","title":"Unintended loss rate after MPR by finishing number","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unintended loss rate after MPR by finishing number</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finishing number (n)</td> <td class=\"subtitle1\">Loss rate (percent)</td> </tr> <tr> <td class=\"centered\">1 (118)</td> <td class=\"centered\">3.4</td> </tr> <tr> <td class=\"centered\">2 (864)</td> <td class=\"centered\">5.5</td> </tr> <tr> <td class=\"centered\">3 (18)</td> <td class=\"centered\">16.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 55719 Version 3.0</div></div></div>"},"55720":{"type":"graphic_figure","displayName":"Event suppression with Rx","title":"Effects of silent ischemia suppression on cardiac event rate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effects of silent ischemia suppression on cardiac event rate</div><div class=\"cntnt\"><img style=\"width:412px; height:258px;\" src=\"images/CARD/55720_EventsuppressionwithRx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After a one-year follow-up, the 97 patients who responded to bisoprolol (100 percent responders) had a significantly better event-free survival (death, nonfatal myocardial infarction, hospitalization for angina, need for revascularization) than the 186 patients who continued to have episodes of silent ischemia (non-100 percent responders) (p = 0.015).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from: Von Arnim T. For the TIBBS Investigators. J Am Coll Cardiol 1996; 28:20.</div><div id=\"graphicVersion\">Graphic 55720 Version 3.0</div></div></div>"},"55721":{"type":"graphic_picture","displayName":"Clubbing","title":"Clubbing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clubbing</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/PEDS/55721_Clubbing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clubbing of the fingers in a three-year old child with an endocardial cushion defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright © 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 55721 Version 2.0</div></div></div>"},"55722":{"type":"graphic_picture","displayName":"Dyshidrotic eczema hand","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/PC/55722_Dyshidrotic_eczema_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small vesicles are visible on the lateral fingers.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's photoguide to common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55722 Version 1.0</div></div></div>"},"55723":{"type":"graphic_picture","displayName":"Traction-countertraction for shoulder reduction","title":"Traction-countertraction for reduction of anterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction-countertraction for reduction of anterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/EM/55723_Shoulder_reduct_tract_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note how the clinician on the left has the sheet wrapped around him, allowing him to use his body weight to create traction. Some clinicians employ gentle external rotation to the affected arm while providing traction.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 55723 Version 6.0</div></div></div>"},"55724":{"type":"graphic_figure","displayName":"Somatostatin and octreotide","title":"Amino acid sequences of somatostatin 14 and 28 and octreotide","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Amino acid sequences of somatostatin 14 and 28 and octreotide</div><div class=\"cntnt\"><img style=\"width:465px; height:467px;\" src=\"images/GAST/55724_Somatostatin_and_octreotide.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55724 Version 1.0</div></div></div>"},"55726":{"type":"graphic_figure","displayName":"Comparison of the actions of ACE inhibitors and ARBs","title":"Comparison of the actions of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Comparison of the actions of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers</div><div class=\"cntnt\"><img style=\"width:474px; height:227px;\" src=\"images/CARD/55726_ACE_inhibitors_v_ARBs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker.</div><div id=\"graphicVersion\">Graphic 55726 Version 3.0</div></div></div>"},"55727":{"type":"graphic_diagnosticimage","displayName":"Osteonecrosis of the jaw","title":"Osteonecrosis of the jaw: radiographic appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteonecrosis of the jaw: radiographic appearance</div><div class=\"cntnt\"><img style=\"width:396px; height:291px;\" src=\"images/HEME/55727_Osteonecrosis_of_the_jaw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a section from a CT scan of a 72-year-old woman with multiple myeloma treated with monthly bisphosphonate injections. She complained of left-sided jaw pain and swelling following dental extraction. This coronal view of the mandible shows several areas of disruption of cortical bone (arrows), a pathologic fracture line (arrowhead), and a large area of central bone loss (dashed arrow) suggestive of tumor and/or abscess formation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Reed Drews.</div><div id=\"graphicVersion\">Graphic 55727 Version 5.0</div></div></div>"},"55728":{"type":"graphic_table","displayName":"Clinical manifestations of hypothermia","title":"Clinical manifestations of accidental hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of accidental hypothermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td>Neurologic</td> <td>Confusion, slurred speech, impaired judgment, amnesia</td> <td>Lethargy, hallucinations, loss of pupillary reflexes, EEG abnormalities</td> <td>Loss of cerebrovascular regulation, decline in EEG activity, coma, loss of ocular reflexes</td> </tr> <tr> <td>Cardiovascular</td> <td>Tachycardia, increased cardiac output and systemic vascular resistance</td> <td>Progressive bradycardia (unresponsive to atropine); decreased cardiac output and&nbsp;BP; atrial and ventricular arrhythmias, J (Osborn) wave on ECG</td> <td>Decline in BP and cardiac output, ventricular fibrillation (&#60;28&#176;C; 82.4&#176;F) and asystole (&#60;20&#176;C; 68&#176;F)</td> </tr> <tr> <td>Respiratory</td> <td>Tachypnea, bronchorrhea</td> <td>Hypoventilation, decreased oxygen consumption and CO2 production, loss of cough reflex</td> <td>Pulmonary edema, apnea</td> </tr> <tr> <td>Renal</td> <td>Bladder atony, cold diuresis</td> <td>Cold diuresis</td> <td>Decreased renal perfusion, oliguria</td> </tr> <tr> <td>Musculoskeletal</td> <td>Increased shivering</td> <td>Decreased shivering (&#60;32&#176;C; 89.6&#176;F) muscle rigidity</td> <td>Patient may appear dead (\"pseudo-rigor mortis\")</td> </tr> <tr> <td>Metabolic</td> <td>Increased metabolic rate, hyperglycemia</td> <td>&nbsp;</td> <td>Decreased metabolic rate, hyper- or hypoglycemia</td> </tr> <tr> <td>Hematologic</td> <td>Increase in hematocrit, decreased platelet count and white blood cell count, bleeding diathesis, DIC</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Gastrointestinal</td> <td>Ileus, pancreatitis, gastric stress ulcers, hepatic dysfunction</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; CO2: carbon dioxide; DIC: disseminated intravascular coagulation;&nbsp;ECG: electrocardiogram; EEG: electroencephalogram.</div><div class=\"graphic_reference\">Reproduced with permission from Hanania, NA, Zimmerman, JL. Accidental hypothermia. Critical Care Clinincs 1999; 15:235. Copyright © 1999 WB Saunders Company.</div><div id=\"graphicVersion\">Graphic 55728 Version 4.0</div></div></div>"},"55729":{"type":"graphic_table","displayName":"Postcardiac surgery pl effusion","title":"Causes of pleural effusion after cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pleural effusion after cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Nonspecific pleural effusions in early (&#60;30 day) postoperative course</td> </tr> <tr> <td>Nonspecific pleural effusions in late (&#62;30 day) postoperative course</td> </tr> <tr> <td>Postpericardiotomy syndrome</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Pleural infections</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> <tr> <td>Hemothorax</td> </tr> <tr> <td>Central&nbsp;venous catheter&nbsp;erosion through venous structures</td> </tr> <tr> <td>Mediastinitis</td> </tr> <tr> <td>Chylothorax</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55729 Version 3.0</div></div></div>"},"55730":{"type":"graphic_picture","displayName":"Intracellular CPP crystal","title":"Intracellular calcium pyrophosphate dihydrate crystal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracellular calcium pyrophosphate dihydrate crystal</div><div class=\"cntnt\"><img style=\"width:285px; height:189px;\" src=\"images/RHEUM/55730_Intracellular_CPPD_crystal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A faintly yellow, positively birefringent, rhomboidal, intracellular crystal characteristic of calcium pyrophosphate dihydrate (CPP) is seen in the synovial fluid of a patient with acute CPP crystal arthritis (pseudogout) when viewed with compensated, polarized microscopy.</div><div class=\"graphic_reference\">Image courtesy of Ralph Schumacher, MD.</div><div id=\"graphicVersion\">Graphic 55730 Version 5.0</div></div></div>"},"55731":{"type":"graphic_figure","displayName":"Organization of the human T cell receptor-beta chain locus","title":"Organization of the human T cell receptor-beta chain locus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Organization of the human T cell receptor-beta chain locus</div><div class=\"cntnt\"><img style=\"width:598px; height:114px;\" src=\"images/ALLRG/55731_Human_TCR_beta_chain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are approximately 75 V beta genes,&nbsp;2 D beta genes,&nbsp;6 J beta 1 and&nbsp;7 J beta 2 genes, and&nbsp;2 C beta genes.</div><div class=\"graphic_reference\">Adapted from: Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.</div><div id=\"graphicVersion\">Graphic 55731 Version 3.0</div></div></div>"},"55732":{"type":"graphic_picture","displayName":"1-hand method PI","title":"One-handed chest compressions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">One-handed chest compressions</div><div class=\"cntnt\"><img style=\"width:303px; height:429px;\" src=\"images/PI/55732_One-hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressing on the chest for CPR is called doing &quot;compressions.&quot; To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim and place the heel of 1 hand on the center of the victim's chest. Holding your arm straight, press on the chest. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches (5 centimeters) under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.</div><div id=\"graphicVersion\">Graphic 55732 Version 2.0</div></div></div>"},"55738":{"type":"graphic_picture","displayName":"Body wall anomaly in neonate","title":"Body wall anomaly in neonate","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Body wall anomaly in neonate</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/OBGYN/55738_Body_stalk_anomaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heart, stomach, liver, and bowel are outside the abdomen. Notice the&nbsp;surgical clamps on the umbilical cord leading into the abdomen, which never closed.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO and A Hilton, MD.</div><div id=\"graphicVersion\">Graphic 55738 Version 3.0</div></div></div>"},"55740":{"type":"graphic_picture","displayName":"ETOH and HCV Light","title":"Biopsy showing cirrhosis due to hepatitis C and alcohol","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biopsy showing cirrhosis due to hepatitis C and alcohol</div><div class=\"cntnt\"><img style=\"width:396px; height:262px;\" src=\"images/GAST/55740_ETOH_and_HCV_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Needle biopsy of the liver (100x) of a 57-year-old female with cirrhosis from both hepatitis C virus infection and chronic alcohol consumption. Hematoxylin and eosin stain demonstrates prominent steatosis as well as portal and peri-portal inflammation and fibrosis.</div><div class=\"graphic_reference\">Courtesy of Jeremy Ditelberg, MD.</div><div id=\"graphicVersion\">Graphic 55740 Version 2.0</div></div></div>"},"55742":{"type":"graphic_figure","displayName":"Afterload and cardiac output","title":"Effect of increasing afterload on cardiac function","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of increasing afterload on cardiac function</div><div class=\"cntnt\"><img style=\"width:342px; height:240px;\" src=\"images/CARD/55742_Afterload_and_cardiac_outpu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curves relating stroke volume or cardiac to afterload or systemic vascular resistance (SVR) in normal subjects and those with heart failure and increasing degrees of ventricular dysfunction. Increasing afterload has little acute effect in normal subjects but becomes progressively more limiting on cardiac output in HF. Even though the effect is small with mild HF, lowering afterload is still important over the long-term because it slows the rate of loss of myocardial function.</div><div id=\"graphicVersion\">Graphic 55742 Version 1.0</div></div></div>"},"55743":{"type":"graphic_figure","displayName":"Cavity eval device","title":"Cavity evaluation device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavity evaluation device</div><div class=\"cntnt\"><img style=\"width:390px; height:435px;\" src=\"images/SURG/55743_Cavity_eval_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hologic.</div><div id=\"graphicVersion\">Graphic 55743 Version 1.0</div></div></div>"},"55744":{"type":"graphic_picture","displayName":"Erythema nodosum - close view","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/55744_Erythema_nodosum_CV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous nodule is present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55744 Version 3.0</div></div></div>"},"55745":{"type":"graphic_table","displayName":"Risk of death or MI in UA","title":"ACC/AHA guidelines: Short-term risk of death or nonfatal myocardial infarction in patients with symptoms suggesting unstable angina","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guidelines: Short-term risk of death or nonfatal myocardial infarction in patients with symptoms suggesting unstable angina</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">High risk </td>\n\n      <td class=\"subtitle1\">Intermediate risk </td>\n\n      <td class=\"subtitle1\">Low risk</td>\n\n    </tr>\n\n    <tr>\n\n      <td>At least one of the following\nfeatures must be present</td>\n\n      <td>No high-risk feature but must\nhave any of the following</td>\n\n      <td>No high- or intermediate-risk\nfeature but may have any of the following</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">History</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Accelerating tempo of ischemic symptoms in preceding 48\nhours</td>\n\n      <td>Prior MI, peripheral or cerebrovascular disease, CABG,\nor prior aspirin use</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Character\nof pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">Prolonged (&#62;20 min) and ongoing rest pain</td>\n\n      <td>Prolonged rest angina (&#62;20 min), now resolved,\nwith moderate or high likelihood of CAD</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Angina provoked at a low threshold, increased angina frequency, severity or duration. New onset angina with onset two weeks to two months prior to presentation.</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Rest angina (&#62;20 min) or relieved with rest or\nsublingual NTG</td>\n\n      \n\n    </tr>\n\n<tr><td>Nocturnal angina</td>\n\t<td>New or progressive class III or IV angina in past two weeks without prolonged (>20 min) rest pain but with intermediate or high likelihood of CAD.</td></tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Clinical\nfindings</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pulmonary edema, most likely due to ischemia </td>\n\n      <td colspan=\"1\" rowspan=\"5\">Age &#62;70 years</td>\n\n      <td colspan=\"1\" rowspan=\"5\">&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">New or worsening mitral regurgitation murmur</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">S3 or new or worsening rales</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hypotension, bradycardia, tachycardia</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Age &#62;75 years</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">ECG</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Angina at rest with transient ST segment changes\n&#62;0.5 mV</td>\n\n      <td>T-wave changes</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Normal or unchanged ECG </td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">New or presumed new bundle branch block</td>\n\n      <td>Pathologic Q waves or resting ST depression less than 1 mm in multiple lead groups</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sustained ventricular tachycardia</td>\n\n      <td>&nbsp;</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Cardiac\nmarkers</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Markedly elevated (eg, cTnT or cTnI &#62;0.1 ng/mL)</td>\n\n      <td>Slightly elevated (eg, cTnT &#62;0.01 but\n&#60;0.1 ng/mL)</td>\n\n      <td>Normal</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1.</div><div id=\"graphicVersion\">Graphic 55745 Version 2.0</div></div></div>"},"55747":{"type":"graphic_figure","displayName":"Patterns of glycemic control","title":"Patterns of blood glucose control","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Patterns of blood glucose control</div><div class=\"cntnt\"><img style=\"width:500px; height:195px;\" src=\"images/ENDO/55747_Patterns_of_glycemic_contro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood glucose excursions in three hypothetical patients who have the same mean blood glucose concentration of about 200 mg/dL (11.1 mmol/L, equivalent to a hemoglobin A1c value of about 8.2 percent), but who have different overall blood glucose control. Patient B (blue curve) has relatively small variations during the day and on different days; this patient should have little difficulty in lowering daily mean blood glucose concentrations without inducing hypoglycemia. In comparison, patient A (purple curve) has marked blood glucose variations on the same day and patient C (green curve) has marked blood glucose variations on different days. These aspects of blood glucose control must be improved before the mean blood glucose concentration can be safely lowered. Increasing the intensity of insulin therapy can precipitate hypoglycemia in patients A and C, since many of their blood glucose values are already in the low-normal range.</div><div id=\"graphicVersion\">Graphic 55747 Version 1.0</div></div></div>"},"55750":{"type":"graphic_picture","displayName":"Urothelial CIS F","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/ONC/55750_Urothelial_CIS_F.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55750 Version 1.0</div></div></div>"},"55752":{"type":"graphic_figure","displayName":"Shape analysis-AP LAT dimension","title":"Airway shape analysis in obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Airway shape analysis in obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:602px; height:740px;\" src=\"images/PEDS/55752_Shape_analysis-AP_LAT_dimen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shape analysis: Average anterior-posterior (A-P) and lateral (LAT) dimension at several oropharyngeal levels. Lines link segmental volume levels. Subjects with obstructive sleep apnea (OSA) are shown in red; control subjects in blue. Open triangles: inspiratory A-P and lateral dimension in OSA; closed triangles: expiratory A-P and lateral dimension in OSA; open squares: inspiratory A-P and lateral dimension in control subjects; closed squares: expiratory A-P and lateral dimension in control subjects. Ellipses illustrate relative differences in A-P and lateral dimensions in OSA and control subjects. Ellipses are shown for minimum during inspiration (filled ellipses) and maximum during expiration (open ellipses).</div><div class=\"graphic_reference\">Reproduced with permission from: Arens R, Sin S, McDonough J, et al. Changes in upper airway size during tidal breathing in children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2005; 171:1298. Official Journal of the American Thoracic Society. Copyright © 2005 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 55752 Version 3.0</div></div></div>"},"55753":{"type":"graphic_picture","displayName":"EGFR inhibitor acneiform erupt","title":"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitor therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitor therapy</div><div class=\"cntnt\"><img style=\"width:360px; height:491px;\" src=\"images/PC/55753_EGFR_inhbtr_acneiform_erupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythematous follicular papules on the back of this patient treated with gefitinib.</div><div class=\"graphic_reference\">Courtesy of Aimee S Payne, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55753 Version 4.0</div></div></div>"},"55754":{"type":"graphic_picture","displayName":"Anatomy of the parietal pleura","title":"Anatomy of the parietal pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the parietal pleura</div><div class=\"cntnt\"><img style=\"width:241px; height:346px;\" src=\"images/PULM/55754_Anatomy_of_the_parietal_ple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parietal pleura of the sheep, an animal with similar pleural anatomy to humans. The parietal pleura consists of a superficial single layer of mesothelial cells (M) and a subpleural layer. Within the subpleural layer lies loose and dense connective tissue of the endothoracic fascia (EF) through which run the blood microvessels (B) from the intercostal arteries and lymphatic lacunae (L), which open into the pleural space (PS) via stomata. The intercostal microvessels are about 10 to 12 from the pleural space.</div><div class=\"graphic_reference\">Staub, NC, Wiener-Kronish, JP, Albertine, KH, in: The Pleural in Health and Disease, Chretien, J, Bignon, J, Hirsch, A (Eds), Marcel Dekker, New York, 1985, by courtesy of Marcel Dekker, Inc.</div><div id=\"graphicVersion\">Graphic 55754 Version 2.0</div></div></div>"},"55757":{"type":"graphic_picture","displayName":"CSF cytology in a patient with adenocarcinoma of the lung","title":"CSF cytology in a patient with adenocarcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">CSF cytology in a patient with adenocarcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:540px; height:348px;\" src=\"images/ONC/55757_CSF_cyto_patient_w_Adenocar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two cells seen in this figure are carcinoma cells that establish the diagnosis of leptomeningeal metastases.</div><div class=\"graphic_reference\">Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.</div><div id=\"graphicVersion\">Graphic 55757 Version 3.0</div></div></div>"},"55758":{"type":"graphic_table","displayName":"Neurologic complications CA Rx","title":"Neurologic complications of chemotherapy, hormone therapy, and biological response modifiers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic complications of chemotherapy, hormone therapy, and biological response modifiers</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute encephalopathy </td> </tr> <tr> <td>Asparaginase</td> </tr> <tr> <td>5-Azacytidine</td> </tr> <tr> <td>BCNU (IA or HD)</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Cytarabine (HD)</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Fluorouracil (FU)</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td>Hexamethylmelamine</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Interferons</td> </tr> <tr> <td>Interleukin-1 and -2</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Mitomycin C</td> </tr> <tr> <td>Nelarabine</td> </tr> <tr> <td>Nitrogen mustard</td> </tr> <tr> <td>Pentostatin</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td>Sunitinib</td> </tr> <tr> <td>Tamoxifen</td> </tr> <tr> <td>Thiotepa (HD)</td> </tr> <tr> <td>Tumor necrosis factor</td> </tr> <tr> <td>Vinca alkaloids</td> </tr> <tr> <td class=\"subtitle1_single\">Headaches </td> </tr> <tr> <td>Asparaginase</td> </tr> <tr> <td>Cytarabine (IT)</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Hexamethylmelamine</td> </tr> <tr> <td>Interferons</td> </tr> <tr> <td>Interleukins 1, 2, and 4</td> </tr> <tr> <td>Mechlorethamine</td> </tr> <tr> <td>Methotrexate (IT)</td> </tr> <tr> <td>Nelarabine</td> </tr> <tr> <td>Retinoic acid</td> </tr> <tr> <td>Tamoxifen</td> </tr> <tr> <td>Temozolomide</td> </tr> <tr> <td>Thiotepa (IT)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Vasculopathies and \"Strokes\" </td> </tr> <tr> <td>&nbsp;Aflibercept</td> </tr> <tr> <td>Antiangiogenic tyrosine kinase inhibitors (axitinib, cabozantinib, lenvatinib, pazopanib, ponatinib, regorafenib, sorafenib, sunitinib, vandetanib)</td> </tr> <tr> <td>Asparaginase</td> </tr> <tr> <td>BCNU (IA)</td> </tr> <tr> <td>Bevacizumab</td> </tr> <tr> <td>Cisplatin (IA)</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Estramustine</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Ramucirumab&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Seizures </td> </tr> <tr> <td>Asparaginase</td> </tr> <tr> <td>BCNU</td> </tr> <tr> <td>Busulfan (HD)</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cytarabine (HD)</td> </tr> <tr> <td>Dacarbazine</td> </tr> <tr> <td>Enzalutamide</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>FU</td> </tr> <tr> <td>Gemcitabine</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Interferon</td> </tr> <tr> <td>Interleukin-2</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Nelarabine</td> </tr> <tr> <td>Nitrogen mustard</td> </tr> <tr> <td>Pentostatin</td> </tr> <tr> <td>Vinca alkaloids</td> </tr> <tr> <td>Teniposide</td> </tr> <tr> <td class=\"subtitle1_single\">Retinal toxicity</td> </tr> <tr> <td>BRAF inbibitors (dabrafenib, vemurafenib)</td> </tr> <tr> <td>MEK inhibitors (trametinib)</td> </tr> <tr> <td>Ipilimumab</td> </tr> <tr> <td>Alkylating agents (procarbazine, carboplatin, cisplatin, oxaliplatin)</td> </tr> <tr> <td>Antimetabolites (methotrexate, fludarabine, capecitabine, cytarabine)&nbsp;</td> </tr> <tr> <td>Docetaxel, paclitaxel&nbsp;</td> </tr> <tr> <td>Tamoxifen, toremifene</td> </tr> <tr> <td>Vincristine</td> </tr> <tr> <td class=\"subtitle1_single\">Uveitis</td> </tr> <tr> <td>Ipilimumab</td> </tr> <tr> <td>Nivolumab</td> </tr> <tr> <td>Rituximab</td> </tr> <tr> <td>Vemurafenib </td> </tr> <tr> <td class=\"subtitle1_single\">&nbsp;Aseptic meningitis </td> </tr> <tr> <td>Cytarabine (IT)</td> </tr> <tr> <td>Methotrexate (IT)</td> </tr> <tr> <td class=\"subtitle1_single\">Dementia </td> </tr> <tr> <td>BCNU (IA and HD)</td> </tr> <tr> <td>Cytarabine</td> </tr> <tr> <td>Interferon-alpha</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Methotrexate</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Myelopathy </td> </tr> <tr> <td>Cytarabine (IT)</td> </tr> <tr> <td>Methotrexate (IT)</td> </tr> <tr> <td>Thiotepa (IT)</td> </tr> <tr> <td class=\"subtitle1_single\">Cranial neuropathy </td> </tr> <tr> <td>BCNU (IA) (ototoxicity)</td> </tr> <tr> <td>Cisplatin (ototoxicity, optic neuropathy)</td> </tr> <tr> <td>Crizotinib (optic neuropathy)</td> </tr> <tr> <td>Docetaxel, paclitaxel (optic neuropathy)</td> </tr> <tr> <td>Imatinib (optic neuropathy)</td> </tr> <tr> <td>Vincristine (extraocular palsies, optic neuropathy)</td> </tr> <tr> <td class=\"subtitle1_single\">Neuropathy </td> </tr> <tr> <td>5-Azacytidine</td> </tr> <tr> <td>Bortezomib</td> </tr> <tr> <td>Carboplatin</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cytarabine</td> </tr> <tr> <td>Eribulin</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>5-FU</td> </tr> <tr> <td>Gemcitabine</td> </tr> <tr> <td>Hexamethylmelamine</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Interferon-alpha</td> </tr> <tr> <td>Ipilimumab</td> </tr> <tr> <td>Ixabepilone</td> </tr> <tr> <td>Lenalidomide</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td>Purine analogs (fludarabine, cladribine, nelarabine, pentostatin)</td> </tr> <tr> <td>Suramin</td> </tr> <tr> <td>Teniposide (VM-26)</td> </tr> <tr> <td>Thalidomide</td> </tr> <tr> <td>Tumor necrosis factor</td> </tr> <tr> <td>Vinca alkaloids</td> </tr> <tr> <td class=\"subtitle1_single\">Acute cerebellar syndrome </td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Cytarabine (HD)</td> </tr> <tr> <td>FU</td> </tr> <tr> <td>Hexamethylmelamine</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td>Vinca alkaloids</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HD: high dose; IT: intrathecal; IA: intraarterial.</div><div id=\"graphicVersion\">Graphic 55758 Version 4.0</div></div></div>"},"55761":{"type":"graphic_diagnosticimage","displayName":"EUS microcystic lesion","title":"EUS image of pancreatic serous cystadenoma (microcystic variety)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS image of pancreatic serous cystadenoma (microcystic variety)</div><div class=\"cntnt\"><img style=\"width:400px; height:323px;\" src=\"images/GAST/55761_EUS_microcystic_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image revealing a microcystic lesion with a honeycomb appearance.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.</div><div id=\"graphicVersion\">Graphic 55761 Version 3.0</div></div></div>"},"55762":{"type":"graphic_waveform","displayName":"Advanced case 15","title":"Advanced case 15","html":"<div class=\"graphic normal\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Advanced case 15</div><div class=\"cntnt\"><img style=\"width:531px; height:99px;\" src=\"images/CARD/55762_Advanced_case_15.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55762 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"55764":{"type":"graphic_table","displayName":"Clinical risk factors for overuse tendinopathy","title":"Clinical risk factors for overuse tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical risk factors for overuse tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intrinsic</td> </tr> <tr> <td>Increased age</td> </tr> <tr> <td>Increased body mass index (BMI)&nbsp;</td> </tr> <tr> <td>Gender</td> </tr> <tr> <td>Biomechanical abnormalities</td> </tr> <tr> <td>Prior tendon lesions</td> </tr> <tr> <td>Fluoroquinolone use</td> </tr> <tr> <td class=\"subtitle1_single\">Extrinsic</td> </tr> <tr> <td>Training errors</td> </tr> <tr> <td>Environmental conditions</td> </tr> <tr> <td>Poor equipment</td> </tr> <tr> <td>Poor ergonomics</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55764 Version 2.0</div></div></div>"},"55765":{"type":"graphic_table","displayName":"Diseases associated with methotrexate pneumonitis","title":"Methotrexate pneumonitis: Underlying diseases and dose of methotrexate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methotrexate pneumonitis: Underlying diseases and dose of methotrexate</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Histological study<br /> (n = 49)</td> <td class=\"subtitle1\">Dose of MTX<br /> (mg/week)</td> </tr> <tr> <td><strong>RA</strong></td> <td>62</td> <td>24</td> <td>2.5 to 15</td> </tr> <tr> <td><strong>Leukaemia (in remission)</strong></td> <td>23</td> <td>8</td> <td>20 to 80</td> </tr> <tr> <td><strong>Cancer (breast, lung, other)</strong></td> <td>10</td> <td>9</td> <td>15 to 1400*</td> </tr> <tr> <td><strong>Psoriasis</strong></td> <td>8</td> <td>2</td> <td>2.5 to 37.5</td> </tr> <tr> <td><strong>Primary biliary cirrhosis<sup>&#182;</sup></strong></td> <td>6</td> <td>1</td> <td>15</td> </tr> <tr> <td><strong>Lymphoma</strong></td> <td>3</td> <td>2</td> <td>6.25 to 80</td> </tr> <tr> <td><strong>Polymyositis</strong></td> <td>2</td> <td>1</td> <td>20 to 50</td> </tr> <tr> <td><strong>Ectopic pregnancy</strong></td> <td>2</td> <td>0</td> <td>12.5 to 88<sup>&#916;</sup></td> </tr> <tr> <td><strong>Asthma</strong></td> <td>1</td> <td>1</td> <td>5 to 15</td> </tr> <tr> <td><strong>Mycosis fungoides</strong></td> <td>1</td> <td>1</td> <td>50</td> </tr> <tr> <td><strong>Pemphigus vulgaris</strong></td> <td>1</td> <td>0</td> <td>50 to 75</td> </tr> <tr> <td><strong>Medulloblastoma</strong></td> <td>1</td> <td>0</td> <td>7.5</td> </tr> <tr> <td><strong>Polyarticular juvenile RA</strong></td> <td>1</td> <td>0</td> <td>0.5<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Psoriatic arthritis</strong></td> <td>1</td> <td>0</td> <td>15</td> </tr> <tr> <td><strong>COPD</strong></td> <td>1</td> <td>0</td> <td>7.5 to 15</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RA: rheumatoid arthritis; COPD: chronic obstructive pulmonary disease.<br />* One patient received ten intrathecal doses of methotrexate at two day intervals.<br />¶ Primary biliary cirrhosis has been renamed primary biliary cholangitis. <br />Δ&nbsp;Single intramuscular administration.<br />◊&nbsp;mg/kg per week.</div><div class=\"graphic_reference\">Reproduced with permission of the European Respiratory Society. Eur Respir J February 1, 2000 15:373-381. Copyright &copy; 2000.</div><div id=\"graphicVersion\">Graphic 55765 Version 5.0</div></div></div>"},"55766":{"type":"graphic_picture","displayName":"Kissing bug bites","title":"Cutaneous reactions to kissing bug bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous reactions to kissing bug bites</div><div class=\"cntnt\"><img style=\"width:318px; height:432px;\" src=\"images/ALLRG/55766_Kissing_bug_bites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous reactions consisting of erythema and edema may develop at the site of kissing bug bites.</div><div class=\"graphic_reference\">Courtesy of Peter Lynch, MD.</div><div id=\"graphicVersion\">Graphic 55766 Version 3.0</div></div></div>"},"55769":{"type":"graphic_picture","displayName":"Epidermal inclusion cyst","title":"Infected epidermal inclusion cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected epidermal inclusion cyst</div><div class=\"cntnt\"><img style=\"width:378px; height:268px;\" src=\"images/PC/55769_Epidermal_inclusion_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A discrete nodule is present with surrounding erythema.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 55769 Version 2.0</div></div></div>"},"55770":{"type":"graphic_picture","displayName":"Scrotal incision during vasectomy","title":"Scrotal incision during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scrotal incision during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:339px;\" src=\"images/PC/55770_Scrotal_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Local anesthesia is instilled and a small incision is made overlying the vas.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &#169;1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 55770 Version 2.0</div></div></div>"},"55773":{"type":"graphic_picture","displayName":"Livedoid vasculopathy","title":"Livedoid vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedoid vasculopathy</div><div class=\"cntnt\"><img style=\"width:360px; height:284px;\" src=\"images/RHEUM/55773_Livedoid_vasculopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental hyalinizing vasculopathy. Hyalinized changes within the subintimal layer of blood vessel walls and vascular thrombosis in the superficial and deep dermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Hairston BR, Davis MD, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003; 139:987. Copyright © 2003 American Medical Association.</div><div id=\"graphicVersion\">Graphic 55773 Version 3.0</div></div></div>"},"55774":{"type":"graphic_figure","displayName":"Dissection isthmus","title":"Dissection isthmus","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Dissection isthmus</div><div class=\"cntnt\"><img style=\"width:522px; height:393px;\" src=\"images/SURG/55774_Dissection_isthmus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Creating plane behind the isthmus, anterior to trachea. A cross-section diagram with the Kelly clamp in this plane.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55774 Version 9.0</div></div></div>"},"55777":{"type":"graphic_figure","displayName":"Citrate and aluminum absorption","title":"Increase in urinary aluminum excretion with administration of aluminum hydroxide, sodium bicarbonate, and citrate","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Increase in urinary aluminum excretion with administration of aluminum hydroxide, sodium bicarbonate, and citrate</div><div class=\"cntnt\"><img style=\"width:490px; height:251px;\" src=\"images/NEPH/55777_Citrate_and_aluminum_absorp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increase in urinary aluminum excretion in subjects on a control diet and those given aluminum hydroxide (AlOH) alone or with sodium bicarbonate or sodium citrate. Aluminum excretion rose markedly in the last group due to increased intestinal absorption.</div><div class=\"graphic_reference\">Data from: Walker JA, Sherman RA, Cody RF. The effect of oral bases on enteral aluminum absorption. Arch Intern Med 1990; 150:2037.</div><div id=\"graphicVersion\">Graphic 55777 Version 4.0</div></div></div>"},"55778":{"type":"graphic_picture","displayName":"Photomicrograph of urine sediment with a red cell cast","title":"Photomicrograph of urine sediment with a red cell cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of urine sediment with a red cell cast</div><div class=\"cntnt\"><img style=\"width:375px; height:251px;\" src=\"images/NEPH/55778_Red_cell_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing free red cells and a red cell cast that is tightly packed with red cells. It is more common for red cell casts to have fewer red cells trapped within a hyaline or granular cast. Red cell casts are virtually diagnostic of glomerulonephritis or vasculitis.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 55778 Version 3.0</div></div></div>"},"55779":{"type":"graphic_table","displayName":"Causes of fetomaternal hemorrhage","title":"Events thought to be associated with fetomaternal hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Events thought to be associated with fetomaternal hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Delivery</td> </tr> <tr> <td>Induced abortion</td> </tr> <tr> <td>Spontaneous abortion</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Partial molar pregnancy</td> </tr> <tr> <td>Chorionic villus sampling</td> </tr> <tr> <td>Cordocentesis</td> </tr> <tr> <td>Percutaneous fetal procedures (eg, fetoscopy)</td> </tr> <tr> <td>Amniocentesis</td> </tr> <tr> <td>External cephalic version</td> </tr> <tr> <td>Abruptio placenta</td> </tr> <tr> <td>Antenatal hemorrhage</td> </tr> <tr> <td>Maternal abdominal trauma (eg, motor vehicle accident, fall, assault)</td> </tr> <tr> <td>Manual removal of the placenta</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Fetal-maternal&nbsp;hemorrhage&nbsp;can also be&nbsp;idiopathic.&nbsp;</div><div id=\"graphicVersion\">Graphic 55779 Version 4.0</div></div></div>"},"55781":{"type":"graphic_movie","displayName":"Membranous VSD short axis color","title":"Membranous VSD short axis color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD short axis color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/55781_MembranousVSDshortmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:546px; height:369px;\" src=\"images/CARD/55781_MembranousVSDshortposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moving short axis clip demonstrating left-to-right flow at a large membranous ventricular septal defect (VSD). The color flow jet of systolic left-to-right flow can be seen coursing from the left ventricular outflow tract into the right ventricle.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; RV: right ventricle; LVOT: left ventricular outflow tract; PA: pulmonary artery; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 55781 Version 2.0</div></div></div>"},"55782":{"type":"graphic_picture","displayName":"Lentigines after laser therapy","title":"Lentigines on the dorsal hands after laser treatment","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lentigines on the dorsal hands after laser treatment</div><div class=\"cntnt\"><img style=\"width:576px; height:283px;\" src=\"images/DERM/55782_Lentigines_after_laser.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lentigines on the dorsal hands resolved after a single treatment with a Q-switched alexandrite laser.</div><div id=\"graphicVersion\">Graphic 55782 Version 2.0</div></div></div>"},"55783":{"type":"graphic_diagnosticimage","displayName":"T4 pancreatic cancer EUS","title":"Pancreatic cancer staging with endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic cancer staging with endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:342px; height:297px;\" src=\"images/GAST/55783_T4_pancreatic_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound view of pancreatic cancer (MASS) that can be seen invading into the portal vein (PV) with loss of the vascular interface (arrow). This tumor is stage T4.</div><div class=\"graphic_reference\">Courtesy of Frank G Gress, MD.</div><div id=\"graphicVersion\">Graphic 55783 Version 3.0</div></div></div>"},"55785":{"type":"graphic_diagnosticimage","displayName":"Sonogram abn ut bleeding1","title":"Transvaginal pelvic sonogram of a perimenopausal patient with abnormal uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal pelvic sonogram of a perimenopausal patient with abnormal uterine bleeding</div><div class=\"cntnt\"><img style=\"width:384px; height:266px;\" src=\"images/OBGYN/55785_Sonogram_abn_ut_bleeding1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central uterine echo measures 14 mm (calipers).</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 55785 Version 3.0</div></div></div>"},"55786":{"type":"graphic_table","displayName":"Causes of stool withholding children","title":"Causes of voluntary stool withholding in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of voluntary stool withholding in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Painful defecation</td> </tr> <tr> <td class=\"sublist1\">Anal fissure</td> </tr> <tr> <td class=\"sublist1\">Perianal irritation</td> </tr> <tr> <td class=\"sublist1\">Sexual abuse</td> </tr> <tr> <td class=\"sublist1\">Hemorrhoids</td> </tr> <tr> <td class=\"sublist1_start\">Change of enviroment</td> </tr> <tr> <td class=\"sublist1\">New school, traveling, or other change in routine</td> </tr> <tr> <td class=\"sublist1\">Family stress</td> </tr> <tr> <td>Improper toilet training</td> </tr> <tr> <td>Emotional disturbance</td> </tr> <tr> <td>Severe mental retardation</td> </tr> <tr> <td>Depression</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.</div><div id=\"graphicVersion\">Graphic 55786 Version 4.0</div></div></div>"},"55787":{"type":"graphic_diagnosticimage","displayName":"Imaging medulloblastoma","title":"MRI and CT scans of a medulloblastoma in a child","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI and CT scans of a medulloblastoma in a child</div><div class=\"cntnt\"><img style=\"width:504px; height:288px;\" src=\"images/PEDS/55787_Imaging_medulloblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) MRI sagittal image of a posterior fossa mass causing compression and dilatation of the 3<SUP>rd</SUP> and lateral ventricles.<br />(B) CT with contrast: Axial image that demonstrates a large posterior fossa mass causing compression of the 4<SUP>th</SUP> ventricle (arrow) and dilation of the temporal horns.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance image; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 55787 Version 6.0</div></div></div>"},"55788":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR II","title":"Infected subcarinal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected subcarinal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:328px;\" src=\"images/PULM/55788_Med_bronchogen_cyst_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a bronchogenic cyst prior to infection.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55788 Version 2.0</div></div></div>"},"55791":{"type":"graphic_picture","displayName":"Peripheral IV catheters","title":"Peripheral IV catheters","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral IV catheters</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/EM/55791_Peripheral_IV_catheters.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows two Becton-Dickinson™ Autoguard™ catheter-over-needle intravenous catheters with retractable safety needles. The pink catheter is 20 guage and the green is 18 guage.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 55791 Version 2.0</div></div></div>"},"55795":{"type":"graphic_picture","displayName":"Hyst microinsert PI","title":"Hysteroscopic microinsert","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic microinsert</div><div class=\"cntnt\"><img style=\"width:432px; height:487px;\" src=\"images/PI/55795_Hyst_microinsert_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: www.essure.com. Copyright &#169; Conceptus Incorporated.</div><div id=\"graphicVersion\">Graphic 55795 Version 2.0</div></div></div>"},"55798":{"type":"graphic_figure","displayName":"Missense mutation","title":"Missense mutation","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Missense mutation</div><div class=\"cntnt\"><img style=\"width:478px; height:281px;\" src=\"images/ALLRG/55798_Missense_mutation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: United States National Library of Medicine. Available online at: http://ghr.nlm.nih.gov/handbook/illustrations/missense (Accessed on 1/12/2009).</div><div id=\"graphicVersion\">Graphic 55798 Version 1.0</div></div></div>"},"55800":{"type":"graphic_picture","displayName":"Ectopic pregnancy 1","title":"Six-week ectopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Six-week ectopic pregnancy</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/OBGYN/55800_Ectopicpregnancy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright © Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 55800 Version 2.0</div></div></div>"},"55801":{"type":"graphic_picture","displayName":"Seborrheic dermatitis peds","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:315px; height:498px;\" src=\"images/PEDS/55801_Seborrheic_dermatitis_peds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Infantile seborrheic dermatitis is commonly called \"cradle cap\" when it occurs on the scalp.<br />(B) Seborrheic dermatitis can affect the scalp, face, ears, neck, and diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 55801 Version 3.0</div></div></div>"},"55802":{"type":"graphic_diagnosticimage","displayName":"DIP osteoarthritis xray","title":"Osteoarthritis of the distal interphalangeal (DIP) joints","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis of the distal interphalangeal (DIP) joints</div><div class=\"cntnt\"><img style=\"width:315px; height:322px;\" src=\"images/PC/55802_DIP_osteoarthritis_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain film demonstrates complete loss of the articular cartilage at all four DIP joints, large osteophytes, and ankylosis of the DIP joint of the middle finger.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 55802 Version 2.0</div></div></div>"},"55803":{"type":"graphic_picture","displayName":"Combined exophytic-endophytic retinoblastoma","title":"Combined exophytic-endophytic retinoblastoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combined exophytic-endophytic retinoblastoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/55803_Combined_exo-endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exophytic retinoblastoma that has eroded through the overlying retina and into the vitreous cavity, giving the clinical appearance of a combined exophytic-endophytic lesion.</div><div class=\"graphic_reference\">Courtesy of Ronald GW Teed, MD.</div><div id=\"graphicVersion\">Graphic 55803 Version 1.0</div></div></div>"},"55804":{"type":"graphic_diagnosticimage","displayName":"Meningocele","title":"Meningocele","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Meningocele</div><div class=\"cntnt\"><img style=\"width:559px; height:172px;\" src=\"images/OBGYN/55804_Meningocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound scan of a 27 week fetus showing a cystic structure in the midline consistent with a meningocele.<br> (A) The calipers are demarcating the area of the skull defect measuring 0.7 cm.<br> (B) A zoomed view of the area of the connection between the cyst and the brain.<br> (C) Power Doppler demonstrates a vessel arising from the brain which connects to the meningocele. The diagnosis was confirmed at postnatal surgery.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 55804 Version 1.0</div></div></div>"},"55805":{"type":"graphic_figure","displayName":"Classification of complex acetabular fractures","title":"Letournel and Judet classification of complex acetabulum fractures","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Letournel and Judet classification of complex acetabulum fractures</div><div class=\"cntnt\"><img style=\"width:526px; height:505px;\" src=\"images/EM/55805_Acetab_complex_fx_scheme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Posterior wall and posterior column. B) Transverse and posterior wall. C) T-shaped. D) Anterior column and posterior hemi-transverse. E) Anterior and posterior columns.</div><div class=\"graphic_reference\">Reproduced with permission from: Matta, JM. Surgical Treatment of Acetabular Fractures. In: Skeletal Trauma: Basic Science, Management, and Reconstruction, Browner, BD, Jupiter, JB, Levine, AM, Trafton, PG (Eds), Saunders, Philadelphia 2003. p. 1110. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &#169;2003 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 55805 Version 2.0</div></div></div>"},"55806":{"type":"graphic_diagnosticimage","displayName":"Cervical wedge fracture close up","title":"Radiograph of a cervical spine wedge fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of a cervical&nbsp;spine wedge fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:507px;\" src=\"images/EM/55806_Cervicalwedgefxlat1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the cervical spine of a patient following extreme flexion injury shows&nbsp;loss of height of the anterior C5 vertebral body (arrow).</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 55806 Version 3.0</div></div></div>"},"55808":{"type":"graphic_figure","displayName":"Patient position for suprapubic aspiration","title":"Positioning of the patient for suprapubic bladder aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positioning of the patient for suprapubic bladder aspiration</div><div class=\"cntnt\"><img style=\"width:374px; height:295px;\" src=\"images/PEDS/55808_Patient_position_SPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child is restrained in the supine and frog leg position. This permits adequate stabilization of the pelvis. The site for needle insertion is in the midline, approximately one to two centimeters above the pubic symphysis.</div><div class=\"graphic_reference\">Adapted from: King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.</div><div id=\"graphicVersion\">Graphic 55808 Version 2.0</div></div></div>"},"55810":{"type":"graphic_table","displayName":"Levels of dyspnea in ILD","title":"Levels of dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Levels of dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Level of dyspnea</td> <td class=\"subtitle1\">Number of points</td> </tr> <tr> <td>None (or same as peers) even after 30 min of vigorous activity, such as running; ability to lift and carry 27 kg (60 lbs) for a prolonged period of time</td> <td class=\"centered\">0</td> </tr> <tr> <td>After 5 flights of stairs or 10 min of vigorous activity/prolonged use of heavy tools</td> <td class=\"centered\">2</td> </tr> <tr> <td>After walking more than a mile (1609 m) on level ground or up three flights of stairs; less than 10 min of vigorous activity, such as running or tennis</td> <td class=\"centered\">4</td> </tr> <tr> <td>Upon walking 0.25 to 1 mile (402 to 1604 m) on level ground or up 2 flights of stairs; dyspnea with paper hanging</td> <td class=\"centered\">6</td> </tr> <tr> <td>Upon walking 300 to 1,320 feet (91.4 to 402.3 m) on level ground; bed-making* </td> <td class=\"centered\">8</td> </tr> <tr> <td>Upon walking 150 to 300 feet (45.7 to 91.4 m) on level ground or up 1 flight of stairs; scrubbing; truck driving; assembly-line work<sup>&#182;</sup></td> <td class=\"centered\">10</td> </tr> <tr> <td>Upon walking 50 to 150 feet (15.2 to 45.7 m) on level ground at approximately 3 mph; light janitorial work<sup>&#182;</sup></td> <td class=\"centered\">12</td> </tr> <tr> <td>Upon walking 20 to 50 feet (6.1 to 15.2 m) on level ground; light steady work at one's own pace; seated operation of heavy equipment<sup>&#182;</sup></td> <td class=\"centered\">14</td> </tr> <tr> <td>With minor exertion, such as dressing, walking less than 20 feet (6.1 meters), or prolonged talking<sup>&#182;</sup></td> <td class=\"centered\">16</td> </tr> <tr> <td>With minimal activity, such as eating, defecating, writing, sitting up<sup>&#182;</sup></td> <td class=\"centered\">18</td> </tr> <tr> <td>At rest<sup>&#182;</sup></td> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Defined as moderately severe breathlessness.<br />¶ Defined as severe breathlessness.</div><div class=\"graphic_reference\">Redrawn from: Watters, LC, King, TE, Schwarz, MI, et al, Am Rev Respir Dis 1986; 133:97.</div><div id=\"graphicVersion\">Graphic 55810 Version 2.0</div></div></div>"},"55811":{"type":"graphic_diagnosticimage","displayName":"RUL SPN PET","title":"Malignant solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Malignant solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:561px; height:241px;\" src=\"images/PULM/55811_RUL_SPN_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal (left) and axial (right) PET scans demonstrate a glucose avid nodule in the right upper lobe without evidence for mediastinal lymph node involvement.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55811 Version 3.0</div></div></div>"},"55812":{"type":"graphic_table","displayName":"Silicosis occupations","title":"Occupations associated with silicosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occupations associated with silicosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Underground coal mining</td> </tr> <tr> <td>Surface coal mining</td> </tr> <tr> <td>Hard rock mining</td> </tr> <tr> <td>Tunneling</td> </tr> <tr> <td>Hydraulic fracturing of gas and oil wells</td> </tr> <tr> <td>Quarrying and stone cutting</td> </tr> <tr> <td>Foundry work</td> </tr> <tr> <td>Masonry</td> </tr> <tr> <td>Blast furnaces</td> </tr> <tr> <td>Steelworks</td> </tr> <tr> <td>Rolling and finishing mills</td> </tr> <tr> <td>Sandblasting, including denim sandblasting and sandblasting by dental technicians</td> </tr> <tr> <td>Construction, including fabrication and installation of engineered stone countertops</td> </tr> <tr> <td>Production or use of silica flour</td> </tr> <tr> <td>Glass manufacturing</td> </tr> <tr> <td>Cement and concrete production</td> </tr> <tr> <td>Ceramics production</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55812 Version 2.0</div></div></div>"},"55813":{"type":"graphic_picture","displayName":"Lymphomatous uveitis","title":"Lymphomatous uveitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphomatous uveitis</div><div class=\"cntnt\"><img style=\"width:402px; height:322px;\" src=\"images/RHEUM/55813_Lymphomatous_uveitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chorioretinal infiltrates from a patient with a primary lymphoma of the central nervous system.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum.</div><div id=\"graphicVersion\">Graphic 55813 Version 2.0</div></div></div>"},"55814":{"type":"graphic_figure","displayName":"Operative approach to the left cervical esophagus - positioning","title":"Operative approach to the left cervical esophagus - position and skin incision","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Operative approach to the left cervical esophagus - position and skin incision</div><div class=\"cntnt\"><img style=\"width:508px; height:322px;\" src=\"images/SURG/55814_OR-position-cerv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the skin incision in the left neck, as the preferred approach to the perforated cervical esophagus. The patient is positioned supine, with a support under the head and the back. The head is extended to enhance exposure of the esophagus. The incision is made medial to the left sternocleidomastoid muscle. If the perforation occurs in the right cervical esophagus, the approach is through the right side of the neck.</div><div id=\"graphicVersion\">Graphic 55814 Version 4.0</div></div></div>"},"55815":{"type":"graphic_table","displayName":"Romiplostim in chronic ITP","title":"Romiplostim increases the platelet count response in adult patients with chronic immune thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Romiplostim increases the platelet count response in adult patients with chronic immune thrombocytopenia (ITP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Treatment</td> <td class=\"subtitle1\" colspan=\"3\">Overall platelet response</td> </tr> <tr> <td class=\"subtitle2\">Splenectomized (63)</td> <td class=\"subtitle2\">Non-splenectomized (62)</td> <td class=\"subtitle2\">Total (125)</td> </tr> <tr> <td>Placebo</td> <td>0.0 percent (21)</td> <td>14.3 percent (21)</td> <td>7.1 percent (42)</td> </tr> <tr> <td>Romiplostim</td> <td>78.6 percent (42)*</td> <td>87.8 percent (41)*</td> <td>83.1 percent (83)*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Splenectomized and non-splenectomized adult patients with chronic ITP were treated for 24 weeks in a blinded, controlled study with romiplostim (AMG-531) or placebo. The overall platelet response (weekly platelet count &gt;50 x 10<sup>9</sup>/L for four or more of the 24 weeks of the study) is shown in this table. Numbers of patients in each group are shown in parentheses.</div><div class=\"graphic_footnotes\">* All comparisons were statistically significant, with p&lt;0.0001.</div><div class=\"graphic_reference\">Data from: Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.</div><div id=\"graphicVersion\">Graphic 55815 Version 6.0</div></div></div>"},"55816":{"type":"graphic_figure","displayName":"In-line percutaneous transtracheal ventilation control valve","title":"In-line commercially available percutaneous transtracheal ventilation control valve","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">In-line commercially available percutaneous transtracheal ventilation control valve</div><div class=\"cntnt\"><img style=\"width:573px; height:445px;\" src=\"images/EM/55816_InlinePTVcontrolvalve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Positive pressure ventilation is administered by pressing and releasing the valve (or opening and occluding the Y-connector, three-way stopcock, etc.). If necessary, a standard self-inflating resuscitation bag can be used as a temporizing measure. B) Permanent in-line valve PTV system.</div><div class=\"graphic_reference\">Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55816 Version 12.0</div></div></div>"},"55817":{"type":"graphic_table","displayName":"Ovarian tumor markers","title":"Markers secreted by germ cell and sex cord-stromal tumors of the ovary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Markers secreted by germ cell and sex cord-stromal tumors of the ovary</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">AFP</td> <td class=\"subtitle1\">hCG</td> <td class=\"subtitle1\">LDH</td> <td class=\"subtitle1\">E2</td> <td class=\"subtitle1\">Inhibin</td> <td class=\"subtitle1\">Testost</td> <td class=\"subtitle1\">Andro</td> <td class=\"subtitle1\">DHEA</td> <td class=\"subtitle1\">AMH&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Germ cell tumors</td> </tr> <tr> <td class=\"indent1\">Dysgerminoma</td> <td class=\"centered\">&ndash;*</td> <td class=\"centered\">&#177;<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Embryonal</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Immature teratoma</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Choriocarcinoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Yolk sac tumor (endodermal sinus tumor)</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Gonadoblastoma<sup>&#916;</sup></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Polyembryona</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mixed germ cell</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Sex cord-stromal tumors</td> </tr> <tr> <td class=\"indent1\">Thecoma-fibroma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Granulosa cell</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sertoli-Leydig</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; hCG: human chorionic gonadotrophin; LDH: lactate dehydrogenase; E2: estradiol; testost: testosterone; andro: androstenedione; DHEA: dihydroepiandrostenedione; AMH: anti-Müllerian hormone.<br />* Borderline elevations in case reports (&lt;16 ng/mL).<br />¶ Low level seen in dysgerminomas with either nondysgerminomatous elements of syncytiotrophobalstic cells.<br />Δ Type of germ cell-sex cord stromal tumor consisting of neoplastic germ cells and sex cord-stromal derivatives.</div><div id=\"graphicVersion\">Graphic 55817 Version 8.0</div></div></div>"},"55819":{"type":"graphic_table","displayName":"Etiology dysuria in children and adolescents","title":"Etiology of dysuria in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of dysuria in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Infants and children</td> <td class=\"subtitle1\">Adolescents</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic illnesses</strong></td> <td> <p>Stevens-Johnson syndrome</p> <p>Beh&#231;et syndrome</p> <p>Reactive arthritis (formerly Reiter syndrome)</p> Varicella</td> <td> <p>Stevens-Johnson syndrome</p> <p>Beh&#231;et syndrome</p> Reactive arthritis (formerly Reiter syndrome)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Genitourinary infections</strong></td> <td> <p>Pyelonephritis</p> <p>Cystitis (viral or bacterial)</p> <p>Vaginitis</p> <p>Urethritis</p> <p>Balanitis/balanoposthitis</p> <p>Genital herpes</p> </td> <td> <p>Pyelonephritis</p> <p>Pelvic inflammatory disease</p> <p>Cystitis (viral or bacterial)</p> <p>Cervicitis</p> <p>Vaginitis</p> <p>Urethritis</p> <p>Balanitis/balanoposthitis</p> <p>Genital herpes</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other genital conditions</strong></td> <td> <p>Nonspecific (chemical) urethritis</p> <p>Urethral stricture</p> <p>Virginal vaginal ulcers</p> <p>Labial adhesions</p> <p>Lichen sclerosis</p> <p>Local trauma (eg, sexual abuse, masturbation)</p> <p>Diaper dermatitis (infants)</p> </td> <td> <p>Nonspecific (chemical) urethritis</p> <p>Urethral stricture</p> <p>Virginal vaginal ulcers</p> <p>Local trauma (eg, sexual activity, masturbation)</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Miscellaneous</strong></td> <td> <p>Urinary stones</p> <p>Psychogenic urethritis</p> <p>Idiopathic hypercalciuria</p> <p>Sexual abuse</p> <p>Chemical irritation</p> <p>Dysfunction elimination</p> </td> <td> <p>Urinary stones</p> <p>Psychogenic urethritis</p> <p>Idiopathic hypercalciuria</p> </td> </tr> <tr> <td><strong>Related entities</strong></td> <td>Pinworms</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><span class=red></span></div><div id=\"graphicVersion\">Graphic 55819 Version 7.0</div></div></div>"},"55823":{"type":"graphic_table","displayName":"Aeroallergen SCIT - One-day modified schedule - A","title":"Aeroallergen subcutaneous immunotherapy (SCIT): One-day modified schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT): One-day modified&nbsp;schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Color vial</td> </tr> <tr> <td>0</td> <td>0.025</td> <td>1:10,000</td> <td>Silver</td> </tr> <tr> <td>15</td> <td>0.25</td> <td>1:10,000</td> <td>Silver</td> </tr> <tr> <td>30</td> <td>0.025</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>45</td> <td>0.25</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>60</td> <td>0.025</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>75</td> <td>0.25</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>90</td> <td>0.025</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>105</td> <td>0.1</td> <td>1:10</td> <td>Yellow</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Smits WL, Giese JK, Letz KL, Inglefield JT, Schlie AR. Safety of rush immunotherapy using a modified schedule:&nbsp;A cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc 2007; 28:305.</div><div id=\"graphicVersion\">Graphic 55823 Version 6.0</div></div></div>"},"55824":{"type":"graphic_figure","displayName":"Audiogram with consonant and vowel sounds","title":"Audiogram with consonant and vowel sounds","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Audiogram with consonant and vowel sounds</div><div class=\"cntnt\"><img style=\"width:528px; height:482px;\" src=\"images/PC/55824_Normal_audiogram_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal audiogram, showing hearing thresholds for the right (blue circles) and left (red x's) ears. Normal thresholds are at or below 25 dB (shaded rectangle). The frequency and loudness of normal conversational sounds is shown in grey letters. Vowels tend to be lower in frequency and louder, while the consonants, which carry the majority of meaning of words, tend to be of higher frequency and softer.</div><div id=\"graphicVersion\">Graphic 55824 Version 4.0</div></div></div>"},"55825":{"type":"graphic_table","displayName":"Clinical manifestations of CBD","title":"Clinical manifestations of corticobasal degeneration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of corticobasal degeneration</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Movement disorders</td> </tr> <tr> <td>Akinesia</td> </tr> <tr> <td>Rigidity</td> </tr> <tr> <td>Postural instability</td> </tr> <tr> <td>Falls</td> </tr> <tr> <td>Freezing of gait</td> </tr> <tr> <td>Postural-action tremor</td> </tr> <tr> <td>Limb dystonia</td> </tr> <tr> <td>Focal reflex myoclonus</td> </tr> <tr> <td>Orolingual dyskinesia</td> </tr> <tr> <td>Athetosis</td> </tr> <tr> <td>Chorea</td> </tr> <tr> <td>Rest tremor</td> </tr> <tr> <td>Axial dystonia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cerebral cortical signs</td> </tr> <tr> <td>Cortical sensory loss</td> </tr> <tr> <td>Apraxia</td> </tr> <tr> <td>Alien limb phenomenon</td> </tr> <tr> <td>Frontal release reflexes</td> </tr> <tr> <td>Cognitive impairment</td> </tr> <tr> <td>Aphasia</td> </tr> <tr> <td>Behavioral change</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Other manifestations</td> </tr> <tr> <td>Hyperreflexia</td> </tr> <tr> <td>Babinski signs</td> </tr> <tr> <td>Impaired ocular motility</td> </tr> <tr> <td>Impaired eyelid motion</td> </tr> <tr> <td>Dysarthria</td> </tr> <tr> <td>Dysphagia</td> </tr> <tr> <td>Dysphonia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203.</div><div id=\"graphicVersion\">Graphic 55825 Version 3.0</div></div></div>"},"55827":{"type":"graphic_figure","displayName":"Diuresis in minimal change","title":"Time course of natriuresis during recovery from minimal change disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of natriuresis during recovery from minimal change disease</div><div class=\"cntnt\"><img style=\"width:329px; height:248px;\" src=\"images/NEPH/55827_Diuresis_in_minimal_change.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractional excretion of sodium (FENa, percent), plasma creatinine concentration (PCr, mg/dL), plasma renin activity, and plasma albumin concentration (PAlb, g/dL) in patients with minimal change disease both before therapy and at the time of peak diuresis during corticosteroid-induced remission. The FENa rose, in association with reductions in the plasma creatinine concentration and plasma renin activity, and a minimal elevation in the plasma albumin concentration.</div><div class=\"graphic_reference\">Data from Koomans, HA, Boer, WH, Dorhout Mees, EJ, Nephron 1987; 47:173.</div><div id=\"graphicVersion\">Graphic 55827 Version 1.0</div></div></div>"},"55828":{"type":"graphic_figure","displayName":"Pain Pathogenesis LPHS","title":"Proposed pathogenesis of pain in patients with primary LPHS","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Proposed pathogenesis of pain in patients with primary LPHS</div><div class=\"cntnt\"><img style=\"width:562px; height:687px;\" src=\"images/NEPH/55828_Pain_Pathogenesis_LPHS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the proposed mechanism is initiated by glomerular hematuria.</div><div class=\"graphic_reference\">Reproduced with permission: Spetie DN, Nadasdy T, Nadasdy G, Agarwal G, Mauer M, Agarwal AK, Khabiri H, Nagaraja, HN, Nahman Jr NS, Hartman JA, Hebert LA: Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 47(3):419-427, 2006. Copyright &#169; 2006 National Kidney Foundation.</div><div id=\"graphicVersion\">Graphic 55828 Version 1.0</div></div></div>"},"55829":{"type":"graphic_table","displayName":"Modified FOLFOX7 regimen","title":"Modified FOLFOX7 chemotherapy for gastrointestinal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified FOLFOX7 chemotherapy for gastrointestinal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>85 mg/m<sup>2</sup> IV*</td> <td>Dilute with 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#916;</sup></td> <td>200 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL D5W<sup>&#182;</sup> and administer over two hours concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not justified (estimated risk of febrile neutropenia &#60;5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[2]</sup> A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle one week for total white blood cell count &#60;3000/microL, absolute neutrophil count &#60;1500/microL, or platelets &#60;75,000/microL on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce infusional FU by 20% and reduce oxaliplatin dose from 85 to 65 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25%. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.<sup>[1]</sup> The United States Prescribing Information recommends a dose reduction in oxaliplatin (to 75 mg/m<sup>2</sup> in patients treated in the adjuvant setting, and to 65 mg/m<sup>2</sup> in patients with advanced disease) for persistent grade 2 neurosensory events that do not resolve, and discontinuation for persistent grade 3 neurosensory events.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment for grade 2 or worse diarrhea and restart at a lower dose after complete resolution.<sup>[3]</sup> The United States Prescribing Information recommends dose reduction of oxaliplatin (to 75 mg/m<sup>2</sup> in patients treated in the adjuvant setting and to 65 mg/m<sup>2</sup> for patients treated for advanced disease), as well as a reduction of infusional FU after recovery from grade 3 or 4 diarrhea during the prior cycle.<sup>[2]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count.<br />* Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ Leucovorin dose is given for d,l-racemic mixture.<SUP>[4]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hochster HS, et al. Ann Oncol 2014; 25:1172.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 55829 Version 29.0</div></div></div>"},"55830":{"type":"graphic_figure","displayName":"Exercise-induced LBBB and outcomes","title":"Exercise-induced left bundle branch block (LBBB) predicts worse outcomes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exercise-induced left bundle branch block (LBBB) predicts worse outcomes</div><div class=\"cntnt\"><img style=\"width:329px; height:346px;\" src=\"images/CARD/55830_Exercise_LBBB_and_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 17,277 patients who underwent exercise stress testing, patients who developed left bundle branch block (LBBB) during exercise testing had a significant reduction in cardiac event-free survival during follow-up.</div><div class=\"graphic_reference\">Data from: Grady TA, Chiu AC, Snader CE, et al. JAMA 1998; 279:153.</div><div id=\"graphicVersion\">Graphic 55830 Version 3.0</div></div></div>"},"55832":{"type":"graphic_figure","displayName":"Clamping uterine vessels","title":"Clamping and suture ligation of the uterine vasculature during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clamping and suture ligation of the uterine vasculature during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:385px; height:390px;\" src=\"images/OBGYN/55832_Clamping_uterine_vessels.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55832 Version 2.0</div></div></div>"},"55833":{"type":"graphic_table","displayName":"Glucocorticoid nasal sprays","title":"Glucocorticoid nasal sprays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glucocorticoid nasal sprays</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">United States trade name</td> <td class=\"subtitle1\">Generic available in United States</td> <td class=\"subtitle1\">Available without a prescription in United States</td> <td class=\"subtitle1\">Usual adult dose<br /> (per nostril)</td> <td class=\"subtitle1\">Usual pediatric dose<br /> (per nostril)</td> <td class=\"subtitle1\">Type of preparation<br /> (alcohol content*)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Second-generation (systemic bioavailability &#60;1% or undetectable)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ciclesonide</td> <td>Omnaris</td> <td>No</td> <td>No</td> <td>Two sprays once daily</td> <td>Two sprays once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td>Zetonna</td> <td>No</td> <td>No</td> <td>One spray once daily</td> <td>One spray once daily for children &#8805;12 years</td> <td>Pressurized aerosol spray (3.4% alcohol)</td> </tr> <tr> <td class=\"indent1\">Fluticasone furoate</td> <td>Flonase Sensimist (OTC)</td> <td>No</td> <td>Yes</td> <td>Two sprays once daily</td> <td>One spray once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"indent1\">Fluticasone propionate</td> <td>Flonase Allergy Relief (OTC), GoodSense Nasoflow (OTC),&nbsp;Ticaspray</td> <td>Yes</td> <td>Yes</td> <td>Two sprays once daily or one spray twice daily</td> <td>One spray once daily</td> <td>Aqueous suspension pump spray (0.25% alcohol)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mometasone</td> <td>Nasonex</td> <td>Yes</td> <td>No</td> <td>Two sprays once daily</td> <td>One spray once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">First-generation (systemic bioavailability 10 to 50%)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Beclomethasone</td> <td>Beconase AQ</td> <td>No</td> <td>No</td> <td>One or two sprays twice daily</td> <td>One spray twice daily</td> <td>Aqueous suspension pump spray (0.25% alcohol)</td> </tr> <tr> <td>Qnasl</td> <td>No</td> <td>No</td> <td>Two sprays once daily</td> <td>Two sprays once daily for children &#8805;12 years</td> <td>Pressurized aerosol spray (8% alcohol)</td> </tr> <tr> <td class=\"indent1\">Budesonide</td> <td>Rhinocort Allergy (OTC)</td> <td>Yes</td> <td>Yes</td> <td>One spray once daily</td> <td>One spray once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"indent1\">Flunisolide</td> <td>Generic (former United States brand: Nasarel)</td> <td>Yes</td> <td>No</td> <td>Two sprays twice daily</td> <td>One spray three times per day or two sprays twice daily</td> <td>Aqueous suspension pump spray (contains propylene glycol, a possible irritant)</td> </tr> <tr> <td class=\"indent1\">Triamcinolone</td> <td>GoodSense Nasal Allergy (OTC), Nasacort Allergy 24 Hr (OTC), Nasal Allergy 24 Hour (OTC), generic (former United States brand: Nasacort AQ)</td> <td>Yes</td> <td>Yes</td> <td>Two sprays once daily</td> <td> <p>One spray once daily (age 2 to 5 years)</p> One to two sprays once daily (age 6 to 11 years)</td> <td>Aqueous suspension pump spray</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Nasal sprays work best when they are administered properly and the medication remains in the nose rather than draining down the back of the throat. Note that the recommended techniques for the aqueous and aerosol sprays are different. If the nose is crusted or contains mucus, it should first be cleaned with a saline nasal spray prior to use of intranasal sprays. Some people find that holding the other nostril closed with a finger improves their ability to draw the spray into the upper nose.<br />Once symptoms are controlled, the daily dose can be reduced to the lowest dose that maintains control.<br />​</div><div class=\"graphic_footnotes\">OTC: over-the-counter (available without a prescription in United States).<br />* Alcohol may contribute to dryness or irritation.<br /></div><div id=\"graphicVersion\">Graphic 55833 Version 28.0</div></div></div>"},"55834":{"type":"graphic_picture","displayName":"Verrucous carcinoma - oral florid papillomatosis","title":"Verrucous carcinoma of the oral cavity","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Verrucous carcinoma of the oral cavity</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55834_Verr_carcin_oral_florid_pap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous carcinoma of the oral cavity (oral florid papillomatosis).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55834 Version 3.0</div></div></div>"},"55836":{"type":"graphic_table","displayName":"Bullous drug eruptions","title":"Bullous drug eruptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bullous drug eruptions</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Drug eruption</td>\r\n            <td class=\"subtitle1\">Clinical features</td>\r\n            <td class=\"subtitle1\">Common medications</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Linear IgA bullous dermatosis</strong></td>\r\n            <td>Annular erythema and blisters (\"crown of jewels\").</td>\r\n            <td>Vancomycin, penicillin, cephalosporins, ACE inhibitors, NSAIDs</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Pseudoporphyria</strong></td>\r\n            <td>Photodistributed blisters on dorsal hands, forearms, face. Similar clinical presentation as porphyria cutanea tarda (with negative porphyrin studies).</td>\r\n            <td>NSAIDs, tetracyclines, furosemide</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Fixed drug eruption</strong></td>\r\n            <td>Dusky violaceous patch. Hemorrhagic vesicle or bulla. History of recurrences at same location with medication usage.</td>\r\n            <td>Sulfonamides, NSAIDs, tetracyclines</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td><strong>Stevens-Johnson syndrome, toxic epidermal necrolysis</strong></td>\r\n            <td>Widespread dusky erythema with epidermal detachment and flaccid blisters. Prominent mucosal involvement.</td>\r\n            <td>Antibiotics, anticonvulsants, allopurinol, dapsone, NSAIDs</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">NSAIDs: Nonsteroidal antiinflammatory drugs</div><div id=\"graphicVersion\">Graphic 55836 Version 1.0</div></div></div>"},"55837":{"type":"graphic_figure","displayName":"Ankle fracture ring","title":"Ring scheme for ankle fractures","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Ring scheme for ankle fractures</div><div class=\"cntnt\"><img style=\"width:549px; height:417px;\" src=\"images/EM/55837_Ankle_fracture_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ankle can be conceived of as a ring of supporting structures surrounding the talus (picture A). If the ring is broken at one site (picture B), the injury is stable and can generally be managed nonoperatively. If the ring is broken at two or more sites (picture C), the injury is unstable and is managed operatively. Fractures or ligament ruptures constitute breaks in the ring.</div><div id=\"graphicVersion\">Graphic 55837 Version 3.0</div></div></div>"},"55838":{"type":"graphic_picture","displayName":"Esophageal erythema Endosc","title":"Esophageal erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal erythema</div><div class=\"cntnt\"><img style=\"width:215px; height:288px;\" src=\"images/GAST/55838_Esophageal_erythema_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy showing a short linear erosion with erythema (upper arrow) and a small island (less than 5 mm) of salmon-colored mucosa (lower arrow) in the distal esophagus.</div><div class=\"graphic_reference\">Courtesy of Harry Anastopoulos, MD and Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 55838 Version 1.0</div></div></div>"},"55839":{"type":"graphic_picture","displayName":"Smith Lemli Opitz genitalia","title":"Smith-Lemli-Opitz Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Smith-Lemli-Opitz Syndrome</div><div class=\"cntnt\"><img style=\"width:321px; height:319px;\" src=\"images/PEDS/55839_Smith_Lemli_Opitz_genitalia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature, ambiguous genitalia.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright &#169; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 55839 Version 2.0</div></div></div>"},"55841":{"type":"graphic_figure","displayName":"M mode mitral valve HCM","title":"Mitral valve in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:416px; height:287px;\" src=\"images/CARD/55841_M_mode_mitral_valve_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram recorded from an area of the left ventricular outflow tract in a patient with hypertrophic cardiomyopathy. There is significant anterior movement (SAM) of the anterior leaflet of the mitral valve, and prolonged appositon of the mitral valve leaflet with the septum.</div><div id=\"graphicVersion\">Graphic 55841 Version 1.0</div></div></div>"},"55842":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor on CT","title":"Pancoast tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancoast tumor</div><div class=\"cntnt\"><img style=\"width:432px; height:284px;\" src=\"images/PULM/55842_Pancoast_tumor_on_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image of a 60-year-old woman presenting with a four month history of right shoulder pain and numbness and tingling in the right arm. The cavitary mass involved the rib and was squamous histology on biopsy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 55842 Version 3.0</div></div></div>"},"55844":{"type":"graphic_figure","displayName":"Femoral hernia repair","title":"Femoral hernia repair","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Femoral hernia repair</div><div class=\"cntnt\"><img style=\"width:507px; height:423px;\" src=\"images/SURG/55844_Femoral_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;placement of mesh during&nbsp;femoral hernia repair is illustrated.&nbsp;The circular component of the mesh is placed&nbsp;in the preperitoneal space, and the oblong portion is placed between the external oblique and internal oblique muscles extending downward to the inguinal ligament.</div><div id=\"graphicVersion\">Graphic 55844 Version 2.0</div></div></div>"},"55845":{"type":"graphic_table","displayName":"Counsel prevention HBV recs","title":"Recommendations for counseling and prevention of transmission of hepatitis B from individuals with chronic hepatitis B virus (HBV) infection:","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for counseling and prevention of transmission of hepatitis B from individuals with chronic hepatitis B virus (HBV) infection:</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>HBsAg-positive persons&nbsp;should be counseled regarding prevention of transmission of HBV</td> </tr> <tr> <td>Sexual and household contacts of HBsAg-positive persons who are negative for HBV seromarkers should receive hepatitis B vaccination</td> </tr> <tr> <td>Newborns of&nbsp;HBsAg-positive mothers should receive HBIG and hepatitis B vaccine at delivery and complete the recommended vaccination series. In addition, antiviral therapy should be offered to mothers with a high HBV DNA level.*</td> </tr> <tr> <td class=\"sublist1_start\">Persons who remain at risk for HBV infection such as infants of HBsAg-positive mothers, healthcare workers, dialysis patients, and sexual partners of&nbsp;HBsAg-positive persons&nbsp;should be tested for response to vaccination </td> </tr> <tr> <td class=\"sublist1\">&#8226; Postvaccination testing should be performed at&nbsp;1 to&nbsp;2 months after the last dose, except for infants born to HBsAg-positive mothers in whom testing should be performed at age 9 to 12 months or 1 to 2 months after the last dose of hepatitis B vaccine if immunization is delayed</td> </tr> <tr> <td class=\"sublist1\">&#8226; Follow-up testing of vaccine responders is recommended annually for chronic hemodialysis patients </td> </tr> <tr> <td>Abstinence or only limited use of alcohol is recommended in HBsAg-positive persons</td> </tr> <tr> <td>Persons who are positive only for anti-HBc (HBsAg-negative) and who are from a low endemic area with no risk factors for HBV should be given the full series of hepatitis B vaccine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Anti-HBc: hepatitis B core antibody; HBIG: hepatitis B immune globulin; HBsAg: hepatitis&nbsp;B surface antigen;&nbsp;HBV: hepatitis B virus.<br />* Refer to the topic that discusses hepatitis B and pregnancy.</div><div class=\"graphic_reference\">References:&nbsp;<br /><OL>&#xD;&#xA;<LI>Lok, ASF, McMahon, BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at http://publish.aasld.org/Pages/Default.aspx. Accessed September 8, 2009. ​</LI>&#xD;&#xA;<LI>Schillie S, Murphy TV, Fenlon N, et al. Update:Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers. MMWR Morb Mortal Wkly Rep 2015; 64:1118.</LI>&#xD;&#xA;<LI>Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261-83. </LI></OL></div><div id=\"graphicVersion\">Graphic 55845 Version 2.0</div></div></div>"},"55848":{"type":"graphic_algorithm","displayName":"Approach to fertility preservation","title":"Approach to fertility preservation","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Approach to fertility preservation</div><div class=\"cntnt\"><img style=\"width:547px; height:500px;\" src=\"images/OBGYN/55848_Strats_preserve_fert_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heterotopic transplantation is preferred when the risk of ovarian metastasis is moderate/high, when the patient tests positive for BRCA I/II, and when the pelvis is unavailable for transplantation due to extensive scarring.</div><div class=\"graphic_footnotes\">* These technologies are still experimental in humans.</div><div class=\"graphic_reference\">Modified with permission from: Sonmezer, M, Oktay, K. Fertility preservation in female patients. Hum Reprod Update 2004; 10:251. Copyright ©2004 Oxford University Press/Human Reproduction.</div><div id=\"graphicVersion\">Graphic 55848 Version 5.0</div></div></div>"},"55849":{"type":"graphic_picture","displayName":"Delayed TRAM reconstruction","title":"Delayed TRAM reconstruction","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Delayed TRAM reconstruction</div><div class=\"cntnt\"><img style=\"width:551px; height:286px;\" src=\"images/ONC/55849_Delayed_TRAM_reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following mastectomy, transverse rectus abdominis muscle (TRAM) reconstruction was delayed until after chemotherapy and radiation therapy and performed with a single-pedicle right TRAM flap. Left panel: preoperative appearance; right panel: postoperative appearance.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 55849 Version 3.0</div></div></div>"},"55850":{"type":"graphic_figure","displayName":"CDC weight for stature boys 2 to 5 years","title":"Weight-for-stature percentiles for boys 2 to 5 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Weight-for-stature percentiles for boys 2 to 5 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:559px; height:680px;\" src=\"images/PEDS/55850_Weight_stature_boys_mor_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 55850 Version 4.0</div></div></div>"},"55852":{"type":"graphic_picture","displayName":"Cap polyposis Endosc I","title":"Cap polyposis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cap polyposis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/GAST/55852_Cap_polyposis_Endosc_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy showing multiple erythematous polyps with an overlying white exudate typical of cap polyposis.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 55852 Version 1.0</div></div></div>"},"55853":{"type":"graphic_picture","displayName":"Resectoscope instruments","title":"Hysteroscopy: Resectoscopic instruments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: Resectoscopic instruments</div><div class=\"cntnt\"><img style=\"width:289px; height:432px;\" src=\"images/OBGYN/55853_Resectoscope_instruments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Roller ball.<br />(B) Loop electrode.<br />(C) Punctate electrode.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 55853 Version 3.0</div></div></div>"},"55855":{"type":"graphic_figure","displayName":"LV wall motion analysis","title":"Analysis of wall motion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Analysis of wall motion</div><div class=\"cntnt\"><img style=\"width:261px; height:453px;\" src=\"images/CARD/55855_LV_wall_motion_analysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 16-segment model for the analysis of left ventricular wall motion, recommended by the American Society of Echocardiography, is shown.</div><div class=\"graphic_footnotes\">A: anterior; AL: anterolateral; IL: inferolateral; I: inferior; IS: inferior septum; AS: anterior septum; PL: posterior lateral.</div><div class=\"graphic_reference\">Reprinted with permission of the American Society of Echocardiography.</div><div id=\"graphicVersion\">Graphic 55855 Version 2.0</div></div></div>"},"55857":{"type":"graphic_figure","displayName":"Anticholinergic agents","title":"Anticholinergic agents","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Anticholinergic agents</div><div class=\"cntnt\"><img style=\"width:531px; height:424px;\" src=\"images/PULM/55857_Anticholinergic_agents.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chemical structure of two naturally occurring tertiary ammonium compounds (atropine and scopolamine) and their synthetic quaternary derivatives (ipratropium and tiotropium). The ammonium group responsible for the difference in the properties of these compounds is at the top left corner of each structure.</div><div id=\"graphicVersion\">Graphic 55857 Version 1.0</div></div></div>"},"55859":{"type":"graphic_figure","displayName":"Displaced femoral neck fracture","title":"Displaced femoral neck fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced femoral neck fracture</div><div class=\"cntnt\"><img style=\"width:418px; height:391px;\" src=\"images/EM/55859_Femoral_neck_fx_pict2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral neck fractures are intracapsular. The tenuous blood supply to the femoral neck increases the risk of complications, such as avascular necrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 55859 Version 3.0</div></div></div>"},"55860":{"type":"graphic_diagnosticimage","displayName":"Middle phalanx fracture with impaction - Lateral view","title":"Middle phalanx fracture with impaction: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle phalanx fracture with impaction: Lateral view</div><div class=\"cntnt\"><img style=\"width:432px; height:247px;\" src=\"images/EM/55860_Mid_phalanx_fx_pip_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows significant volar impaction and dorsal subluxation of the middle phalanx.</div><div class=\"graphic_reference\">Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 55860 Version 4.0</div></div></div>"},"55861":{"type":"graphic_table","displayName":"Infection exclusion organ donor","title":"Infectious considerations in the evaluation of potential organ donors and recipients (possible exclusion criteria*)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious considerations in the evaluation of potential organ donors and recipients (possible exclusion criteria*)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Central nervous system (CNS) infection</td> </tr> <tr> <td class=\"indent1\">Encephalitis and/or meningitis of unknown etiology</td> </tr> <tr> <td class=\"indent1\">Untreated or incompletely treated encephalitis and/or meningitis</td> </tr> <tr> <td class=\"indent1\">Herpes simplex encephalitis</td> </tr> <tr> <td class=\"indent1\">History of JC virus infection</td> </tr> <tr> <td class=\"indent1\">West Nile virus infection or other active arbovirus infection</td> </tr> <tr> <td class=\"indent1\">Cryptococcal infection of any site (or other disseminated fungal infection)</td> </tr> <tr> <td class=\"indent1\">Rabies</td> </tr> <tr> <td class=\"indent1\">Creutzfeld-Jacob disease</td> </tr> <tr> <td class=\"subtitle1_single\">Viral infection (see also CNS infections above)</td> </tr> <tr> <td class=\"indent1\">Acute viremia (eg, herpes simplex virus, adenovirus, lymphocytic choriomeningitis virus, hepatitis A, West Nile virus)</td> </tr> <tr> <td class=\"indent1\">Active shingles (varicella-zoster infection) or herpes virus pneumonitis</td> </tr> <tr> <td class=\"indent1\">Acute Epstein-Barr virus (mononucleosis)</td> </tr> <tr> <td class=\"indent1\">HIV infection (serologic or molecular evidence)</td> </tr> <tr> <td class=\"indent1\">Active hepatitis B or hepatitis C<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Human T cell lymphotropic virus-I/-II (no longer an absolute contraindication in non-endemic regions)</td> </tr> <tr> <td class=\"indent1\">Severe acute respiratory syndrome (SARS)</td> </tr> <tr> <td class=\"subtitle1_single\">Bacterial infection</td> </tr> <tr> <td class=\"indent1\">Active tuberculosis</td> </tr> <tr> <td class=\"indent1\">Untreated pneumonia</td> </tr> <tr> <td class=\"indent1\">Untreated bacterial or fungal sepsis (eg, candidemia)</td> </tr> <tr> <td class=\"indent1\">Untreated syphilis</td> </tr> <tr> <td class=\"indent1\">Multisystem organ failure due to overwhelming sepsis or gangrenous bowel</td> </tr> <tr> <td class=\"subtitle1_single\">Parasitic infection</td> </tr> <tr> <td class=\"indent1\">Active <em>Trypanosoma cruzi</em> infection</td> </tr> <tr> <td class=\"indent1\">Active toxoplasmosis (prophylaxis effective)</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Strongyloidiasis (prophylaxis effective)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The use of organs for specific recipients must be considered in the clinical context of the intended recipient. This list is not all inclusive.<br />&para; Donor organs that are infected with hepatitis B or C are used occasionally if the recipient is infected with the same virus or when the transplant would be life saving (eg, heart transplant).</div><div id=\"graphicVersion\">Graphic 55861 Version 8.0</div></div></div>"},"55862":{"type":"graphic_table","displayName":"Common viral infections in SOT recipients","title":"Common viral infections in solid organ transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common viral infections in solid organ transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Herpes group</td> </tr> <tr> <td class=\"indent1\">Herpes simplex</td> </tr> <tr> <td class=\"indent1\">Varicella zoster</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">HHV6</td> </tr> <tr> <td class=\"indent1\">HHV7</td> </tr> <tr> <td class=\"indent1\">HHV8/KSHV</td> </tr> <tr> <td class=\"subtitle2_left\">Donor-derived</td> </tr> <tr> <td class=\"indent1\">West Nile virus</td> </tr> <tr> <td class=\"indent1\">Rabies</td> </tr> <tr> <td class=\"indent1\">LCMV</td> </tr> <tr> <td class=\"subtitle2_left\">Hepatitis B</td> </tr> <tr> <td class=\"subtitle2_left\">Hepatitis C</td> </tr> <tr> <td class=\"subtitle2_left\">Papillomavirus</td> </tr> <tr> <td class=\"subtitle2_left\">Polyomavirus BK/JC</td> </tr> <tr> <td class=\"subtitle2_left\">Respiratory viruses</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"indent1\">RSV</td> </tr> <tr> <td class=\"indent1\">Influenza</td> </tr> <tr> <td class=\"indent1\">Parainfluenza</td> </tr> <tr> <td class=\"indent1\">Metapneumovirus</td> </tr> <tr> <td class=\"indent1\">SARS coronavirus</td> </tr> <tr> <td class=\"subtitle2_left\">Parvovirus B19</td> </tr> <tr> <td class=\"subtitle2_left\">HIV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HHV: human herpesvirus; KSHV: Kaposi's sarcoma-associated herpesvirus; LCMV: lymphocytic choriomeningitis virus; RSV: respiratory syncytial virus; SARS: severe acute respiratory syndrome.</div><div id=\"graphicVersion\">Graphic 55862 Version 4.0</div></div></div>"},"55866":{"type":"graphic_table","displayName":"Framingham criteria Dx HF","title":"Modified Framingham clinical criteria for the diagnosis of heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Framingham clinical criteria for the diagnosis of heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major </td> </tr> <tr> <td>Paroxysmal nocturnal dyspnea</td> </tr> <tr> <td>Orthopnea</td> </tr> <tr> <td>Elevated jugular venous pressure</td> </tr> <tr> <td>Pulmonary rales</td> </tr> <tr> <td>Third heart sound</td> </tr> <tr> <td>Cardiomegaly on chest x-ray</td> </tr> <tr> <td>Pulmonary edema on chest x-ray</td> </tr> <tr> <td>Weight loss &#8805;4.5 kg in five days in response to treatment of presumed heart failure* </td> </tr> <tr> <td class=\"subtitle1_single\">Minor </td> </tr> <tr> <td>Bilateral leg edema</td> </tr> <tr> <td>Nocturnal cough</td> </tr> <tr> <td>Dyspnea on ordinary exertion</td> </tr> <tr> <td>Hepatomegaly</td> </tr> <tr> <td>Pleural effusion</td> </tr> <tr> <td>Tachycardia (heart rate &#8805;120 beats/min)</td> </tr> <tr> <td>Weight loss &#8805;4.5 kg in five days</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnosis </td> </tr> <tr> <td>The diagnosis of heart failure requires that <strong>2 major or 1 major and 2 minor criteria</strong> cannot be attributed to another medical condition.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*This criterion was noted in the text of the source paper.</div><div class=\"graphic_reference\">From Senni M, Tribouilloy CM, Rodeheffer RJ, et al, Circulation 1998; 98:2282; adapted from McKee, PA, Castelli, WP, McNamara, PM, Kannel, WB. N Engl J Med 1971; 85:1441.</div><div id=\"graphicVersion\">Graphic 55866 Version 3.0</div></div></div>"},"55868":{"type":"graphic_figure","displayName":"MII pH monitoring","title":"Acid and non-acid reflux identified by combined MII-pH monitoring","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Acid and non-acid reflux identified by combined MII-pH monitoring</div><div class=\"cntnt\"><img style=\"width:547px; height:450px;\" src=\"images/GAST/55868_MII_pH_monitoring.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reflux is identified by changes in impedance progressing distally to proximally as liquid advances from the stomach into the esophagus. Information from the pH electrode is used to classify reflux as acid (ie, pH drops from above to below 4) or non-acid (ie, pH remains above 4).</div><div class=\"graphic_reference\">Courtesy of Radu Tutuian, MD and Donald O Castell, MD.</div><div id=\"graphicVersion\">Graphic 55868 Version 1.0</div></div></div>"},"55870":{"type":"graphic_table","displayName":"Hysterectomy outcome","title":"Frequency of common, severe symptoms before and after hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of common, severe symptoms before and after hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom</td>\n\n\n      <td class=\"subtitle1\">Frequency before, percent</td>\n\n      <td class=\"subtitle1\">Frequency after, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vaginal bleeding</td>\n\n\n      <td>59</td>\n\n      <td> &#60;1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pelvic pain</td>\n\n\n      <td>63</td>\n\n      <td>8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Back pain</td>\n\n\n      <td>43</td>\n\n      <td> 17</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Activity limitation</td>\n\n\n      <td>58</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sleep disturbance</td>\n\n\n      <td>41</td>\n\n      <td> 21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fatigue</td>\n\n\n      <td>70</td>\n\n      <td> 25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal bloating</td>\n\n\n      <td>48</td>\n\n      <td> 12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary incontinence</td>\n\n\n      <td>20</td>\n\n      <td> 8</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from data in Kjerulff, KH, Langenberg, PW, Rhodes, JS, et al. Obstet Gynecol 2000; 95:319.</div><div id=\"graphicVersion\">Graphic 55870 Version 1.0</div></div></div>"},"55871":{"type":"graphic_figure","displayName":"Ligament of Berry","title":"Ligament of Berry","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Ligament of Berry</div><div class=\"cntnt\"><img style=\"width:463px; height:501px;\" src=\"images/SURG/55871_LigamentofBerry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ligament of Berry dissection with cautery after isthmus divided, before it is tied with Dandy clamp still on, providing retraction.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55871 Version 10.0</div></div></div>"},"55873":{"type":"graphic_picture","displayName":"Multiple cutaneous fusarial skin lesions","title":"Multiple cutaneous fusarial skin lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple cutaneous fusarial skin lesions</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/55873_Mult_cut_fusarial_skin_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple cutaneous fusarial skin lesions on the abdomen of an 8-year-old girl who experienced relapse of leukemia. The infection started as paranasal sinusitis, which was followed by pneumonia and skin lesions. Patient died 30 days later with persistent fusariosis and leukemia. </div><div class=\"graphic_reference\">Courtesy of Dr. Flavio Queiroz-Telles, University Hospital, Universidade Federal do Parana, Curitiba, Brazil. Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright © 2002.</div><div id=\"graphicVersion\">Graphic 55873 Version 2.0</div></div></div>"},"55874":{"type":"graphic_picture","displayName":"Nevus peripheral globules starburst","title":"Dermoscopic images of nevi with peripheral globules and/or starburst pattern","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Dermoscopic images of nevi with peripheral globules and/or starburst pattern</div><div class=\"cntnt\"><img style=\"width:512px; height:471px;\" src=\"images/DERM/55874_Nevus_peri_glob_starburst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Single row of peripheral globules indicative of growing nevus.<BR>(B) More than one row of globules (tiered globules) creating a starburst pattern.<BR>(C) Pseudopods around the entire perimeter creating a starburst pattern suggestive of pigmented spindle cell tumor.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 55874 Version 4.0</div></div></div>"},"55875":{"type":"graphic_picture","displayName":"Acute cutaneous lupus erythematosus - malar eruption","title":"Acute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/DERM/55875_ACLE_malar_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, edematous eruption is present on the malar area. Note the sparing of the nasolabial folds.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55875 Version 3.0</div></div></div>"},"55877":{"type":"graphic_figure","displayName":"Congenital syphilis US","title":"Congenital syphilis: Reported cases among infants by year of birth and rates of primary and secondary syphilis among women, United States, 2006-2015","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Reported cases among infants by year of birth and rates of primary and secondary syphilis among women, United States, 2006-2015</div><div class=\"cntnt\"><img style=\"width:756px; height:324px;\" src=\"images/PEDS/55877_Congenital_syphilis_US_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CS: congenital syphilis; P&amp;S: primary and secondary syphilis.</div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Disease Surveillance 2015. Centers for Disease Control and Prevention. Available at: <A href=\"http://www.cdc.gov/std/stats/\" target=_blank>www.cdc.gov/std/stats/</A> (Accessed on October 25, 2016).</div><div id=\"graphicVersion\">Graphic 55877 Version 5.0</div></div></div>"},"55878":{"type":"graphic_diagnosticimage","displayName":"Adult cystic fibrosis PA","title":"Chest radiograph of an adult patient with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an adult patient with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:348px; height:348px;\" src=\"images/PULM/55878_Adult_cystic_fibrosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows a typical bronchial pattern with marked hyperexpansion, upper lobe bronchiectases with mucoid impactions, retraction of both hilar regions cephalad due to scarring, and pulmonary arterial hypertension with dilatation of both central pulmonary arteries.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55878 Version 4.0</div></div></div>"},"55879":{"type":"graphic_table","displayName":"Factors to consider pre OFC","title":"Factors to consider before undertaking an oral food challenge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors to consider before undertaking an oral food challenge</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Risk of continued allergy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Potential severity of a reaction (safety)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nutritional importance of the avoided food</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Quality of life associated with inclusion/exclusion of the avoided food</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ability to cooperate with challenge procedures (eg, age, temperament)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Personal motivation to add the food to the diet</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Psychological factors</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chance of intentional ingestion of a food because the patient/family thinks the allergy has resolved (eg, reduce risk taking if the allergy persists)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 55879 Version 2.0</div></div></div>"},"55880":{"type":"graphic_figure","displayName":"Flow volume loops in lung disease","title":"Flow-volume curves in obstructive and restrictive lung disease","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Flow-volume curves in obstructive and restrictive lung disease</div><div class=\"cntnt\"><img style=\"width:552px; height:361px;\" src=\"images/PULM/55880_Flow_volume_loops_2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sample flow-volume curves during a maximal forced expiration in normals and in obstructive and restrictive lung disease. The normal expiratory portion of the flow volume curve is characterized by a rapid rise to the peak flow rate, followed by a nearly linear fall in flow as the patient exhales toward residual volume. With obstructive disease, maximal expiration begins and ends at higher lung volumes and lower flow rates than normal. With restrictive disease, the lung volumes and flow rates are reduced but the flow in relation to lung volume is actually higher than normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Levitzky MG. Pulmonary Physiology, Seventh Edition. McGraw-Hill, New York 2007. Copyright © 2007 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 55880 Version 14.0</div></div></div>"},"55881":{"type":"graphic_diagnosticimage","displayName":"Proliferation extrapleural CT","title":"Fatty proliferation of extrapleural fat after tuberculous pleurisy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fatty proliferation of extrapleural fat after tuberculous pleurisy</div><div class=\"cntnt\"><img style=\"width:358px; height:348px;\" src=\"images/PULM/55881_Proliferation_extrapleural.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fatty proliferation of the extrapleural fat between the parietal pleura and the endothoracic fascia as a sequel of previous tuberculous pleurisy. CT shows right posterior pleural thickening with a subjacent fatty layer. This likely results from the restriction of the lung and pulling of the chest wall fat inward.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55881 Version 4.0</div></div></div>"},"55882":{"type":"graphic_figure","displayName":"Antigenic peptide processing","title":"Degradation and transport of antigens","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Degradation and transport of antigens</div><div class=\"cntnt\"><img style=\"width:509px; height:384px;\" src=\"images/RHEUM/55882_Antigenicpeptideprocessin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The process of degradation of proteins into peptides, transport to the endoplasmic reticulum, binding of antigenic peptides to MHC class I molecules, presentation of antigen to a CD8+ T cell, followed by intracellular signaling (steps a-l): (a) In an APC, newly synthesized MHC class I molecules bind to calnexin, which retains them in a partially folded state in the ER. (b) Binding of MHC class I molecules to beta-2m displaces calnexin and allows binding of chaperonin proteins (calreticulin and tapasin; not shown). (c) The MHC-class-I-beta-2m complex binds to the TAP complex (TAP1-TAP2), which awaits the delivery of peptides. (d) Peptides (eg, from antigens) are formed from the degradation of cytosolic proteins (self-, pathogen-, and tumor-derived proteins in the cytoplasm). (e) These are degraded by proleasomes into (f) short peptides. (g) Peptides are transported into the ER by the TAPs, where they meet the MHC-class-I-beta-2m complex (h). This peptide binding in the antigenic groove of the MHC stabilizes the structure of the MHC class I molecule and (i) releases the TAP complex. (j) The fully folded MHC class I molecule with its peptide is transported to the cell surface via the Golgi apparatus. (k) Recognition of the MHC class I-peptide complex by the TCR of an antigen-specific (CD8*, CD3*) CTL takes place and (l) a signal transduction event activates effector functions in the MHC-class-I-restricted T cell; this requires co-simulation to occur (not shown).</div><div class=\"graphic_footnotes\">APC: antigen-producing cell; MHC: major histocompatibility complex; TCR: T-cell receptor; CTL: cytotoxic T lymphocyte; TAP: transporter associated with antigen processing; β2-m: beta-2-microglobulum; ER: endoplasmic reticulum.</div><div class=\"graphic_reference\">Reproduced with permission from: Man, S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Exp Rev Mol Med, Cambridge University Press 1998. Reprinted with permission of Cambridge University Press</div><div id=\"graphicVersion\">Graphic 55882 Version 3.0</div></div></div>"},"55883":{"type":"graphic_picture","displayName":"Endoprosthesis cholangioscopy","title":"Percutaneous cholangioscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous cholangioscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/GAST/55883_Endoprosthesis_cholangiosco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">End of a broken endoprosthesis seen through a cholangioscope.</div><div class=\"graphic_reference\">Courtesy of Jurgen F Riemann, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55883 Version 1.0</div></div></div>"},"55885":{"type":"graphic_picture","displayName":"Erysipeloid","title":"Erysipeloid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erysipeloid</div><div class=\"cntnt\"><img style=\"width:374px; height:252px;\" src=\"images/ID/55885_Erysipeloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erysipeloid is the localized cutaneous form of the infection caused by <EM>Erysipelothrix rhusiopathiae</EM>. In this patient, violaceous maculopapular lesions of the fingers developed after cleaning fish.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 55885 Version 4.0</div></div></div>"},"55888":{"type":"graphic_table","displayName":"Analgesics for labor delivery","title":"Systemic analgesics used for labor and vaginal delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic analgesics used for labor and vaginal delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"14%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Onset</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Fentanyl</td> <td class=\"divider_bottom\" rowspan=\"2\">Opioid</td> <td>25 to 50 mcg IV</td> <td>1 to 3 minutes IV</td> <td>30 to 60 minutes IV</td> <td class=\"divider_bottom\" rowspan=\"2\">Short-acting, potent respiratory depressant; best used by PCA.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>PCA:<br /> Loading dose 50 to 100 mcg IV</p> <p>Patient bolus 10 to 25 mcg IV</p> Lockout 5 to 12 minutes</td> <td>1 to 3 minutes</td> <td>30 to 60 minutes</td> </tr> <tr class=\"divider_bottom\"> <td>Remifentanil</td> <td>Opioid</td> <td> <p>PCA:<br /> Bolus 15 to 50 mcg IV</p> Lockout 1 to 5 minutes</td> <td>30 to 60 seconds</td> <td>5 to 10 minutes</td> <td>PCA only, start with low dose and titrate to effect; ultrashort acting, potent respiratory depressant. Oxygenation and respiratory rate should be continuously monitored and 1:1 nursing should be strongly considered.</td> </tr> <tr class=\"divider_bottom\"> <td>Meperidine</td> <td>Opioid</td> <td>25 to 50 mg IV</td> <td>5 minutes IV</td> <td>2 to 3 hours</td> <td>Active metabolite is normeperidine, a potent respiratory depressant; neonatal effect most likely if delivery occurs between 1 and 4 hours after administration.</td> </tr> <tr class=\"divider_bottom\"> <td>Morphine</td> <td>Opioid</td> <td>2 to 5 mg IV</td> <td>3 to 5 minutes IV</td> <td>&nbsp;</td> <td>Infrequently used during labor; greater neonatal respiratory depression than meperidine.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Nalbuphine</td> <td class=\"divider_bottom\" rowspan=\"2\">Mixed opioid agonist/antagonist</td> <td>10 mg IV</td> <td>2 to 3 minutes IV</td> <td class=\"divider_bottom\" rowspan=\"2\">3 to 6 hours</td> <td class=\"divider_bottom\" rowspan=\"2\">Less nausea and vomiting than with meperidine; ceiling of respiratory depression.</td> </tr> <tr class=\"divider_bottom\"> <td>10 mg IM</td> <td>10 to 15 minutes IM</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Butorphanol</td> <td class=\"divider_bottom\" rowspan=\"2\">Mixed opioid agonist/antagonist</td> <td class=\"divider_bottom\" rowspan=\"2\">1 to 2 mg IV or IM</td> <td>5 to 10 minutes IV</td> <td class=\"divider_bottom\" rowspan=\"2\">3 to 4 hours</td> <td class=\"divider_bottom\" rowspan=\"2\">Maternal sedation similar to meperidine and phenothiazine; ceiling of respiratory depression; dysphoria.</td> </tr> <tr class=\"divider_bottom\"> <td>10 to 15 minutes IM</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Pentazocine (Talwin)</td> <td class=\"divider_bottom\" rowspan=\"2\">Mixed opioid agonist/antagonist</td> <td class=\"divider_bottom\" rowspan=\"2\">20 to 40 mg IV/IM</td> <td>2 to 3 minutes IV</td> <td class=\"divider_bottom\" rowspan=\"2\">2 to 3 hours</td> <td class=\"divider_bottom\" rowspan=\"2\">Ceiling of respiratory depression; dysphoria.</td> </tr> <tr class=\"divider_bottom\"> <td>5 to 20 minutes IM</td> </tr> <tr class=\"divider_bottom\"> <td>Promethazine (Phenergan)</td> <td>Phenothiazine</td> <td>25 to 75 mg IV/IM</td> <td>10 to 20 minutes</td> <td>3 to 4 hours</td> <td>Commonly used with opioids to mitigate nausea and vomiting; may produce hypotension.</td> </tr> <tr class=\"divider_bottom\"> <td>Hydroxyzine (Vistaril)</td> <td>Antihistamine</td> <td>25 to 50 mg IM</td> <td>30 minutes</td> <td>4 hours</td> <td>Commonly used with opioids to mitigate nausea and vomiting; not used IV (painful on injection).</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine (Ketalar&#174;)</td> <td>Phencyclidine derivative</td> <td>10 to 20 mg IV</td> <td>&#60;1 minute</td> <td>5 minutes</td> <td>IV dose should not exceed 1 mg/kg per 30 minutes; psychiatric effects may be prevented with concomitant benzodiazepine; sedation for vaginal delivery; potent amnestic and analgesic.</td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam (Versed)</td> <td>Benzodiazepine</td> <td>1 to 5 mg IV</td> <td>3 to 5 minutes</td> <td>1 to 2 hours</td> <td>Sedation and anxiolysis for vaginal delivery; non-irritating when given IV; potent amnestic; rapid onset/offset; used for eclamptic seizures.</td> </tr> <tr class=\"divider_bottom\"> <td>Diazepam (Valium)</td> <td>Benzodiazepine</td> <td>2 to 5 mg IV</td> <td>5 minutes</td> <td>1 to 2 hours IV</td> <td>Sedation and anxiolysis for vaginal delivery; potent amnestic; rapid onset/offset; prolonged half-life; used for eclamptic seizures.</td> </tr> <tr> <td>Nitrous oxide</td> <td>Anesthetic gas</td> <td>50% inhaled</td> <td>Up to 50 seconds</td> <td>Varies, very rapid offset</td> <td>In United States, must administer with blender and scavenging; lag time for effect; inhalation should begin approximately 30 seconds before contraction, and end as contraction recedes.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; PCA: patient-controlled analgesia; IM: intramuscular.</div><div id=\"graphicVersion\">Graphic 55888 Version 3.0</div></div></div>"},"55889":{"type":"graphic_figure","displayName":"Tricyclics for diabetic neuropathy","title":"Tricyclic drugs improve pain in diabetic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricyclic drugs improve pain in diabetic neuropathy</div><div class=\"cntnt\"><img style=\"width:438px; height:244px;\" src=\"images/NEURO/55889_Rx_of_diabetic_neuropathy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean changes in pain score (a negative value indicates improvement) in patients with painful diabetic neuropathy who were treated with placebo (n=15), fluoxetine (n=12), desipramine (n=18), or amitriptyline (n=12). Drug therapy was begun at week one after one week of observation. Desipramine and amitriptyline were equally beneficial and more effective than fluoxetine or placebo.</div><div class=\"graphic_reference\">Data from Max MB, Lynch SA, Muir J, et al, N Engl J Med 1992; 326:1250.</div><div id=\"graphicVersion\">Graphic 55889 Version 2.0</div></div></div>"},"55890":{"type":"graphic_figure","displayName":"CCK and gastrin homology","title":"Molecular forms of cholecystokinin (CCK) and gastrin","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Molecular forms of cholecystokinin (CCK) and gastrin</div><div class=\"cntnt\"><img style=\"width:453px; height:422px;\" src=\"images/GAST/55890_CCK_and_gastrin_homology.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amino acid sequences of CCK-58, -33, and -8, and gastrin-34 and -17, all of which are biologically active. All forms of CCK and gastrin share an identical carboxyl terminal pentapeptide sequence (highlighted in the boxes).</div><div id=\"graphicVersion\">Graphic 55890 Version 4.0</div></div></div>"},"55892":{"type":"graphic_diagnosticimage","displayName":"Aortic atherosclerosis on MRI","title":"Aortic atherosclerosis on MRI","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Aortic atherosclerosis on MRI</div><div class=\"cntnt\"><img style=\"width:504px; height:398px;\" src=\"images/SURG/55892_Aortic_atherosclerosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortic atherosclerosis (arrow) visualized by MRI (T2 weighted images with fat suppression).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dr. Pierre Maldjian.</div><div id=\"graphicVersion\">Graphic 55892 Version 2.0</div></div></div>"},"55893":{"type":"graphic_figure","displayName":"Alpha thalassemia by gap PCR","title":"Alpha thalassemia detection by gap PCR","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Alpha thalassemia detection by gap PCR</div><div class=\"cntnt\"><img style=\"width:587px; height:621px;\" src=\"images/HEME/55893_Alpha_thal_gap_PCR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Detection of common alpha thalassemia mutations by gap PCR.<br> (A) Diagram depicting the -alpha 3.7 deletion. A1, A2, and A3 show the location of the primers used in the detection of common -alpha 3.7 deletion. The deletion removes the 3' portion of the alpha 2 gene and the 5' portion of the alpha 1 gene (the area between the two diagonal lines in the top portion of the figure), resulting in a hybrid alpha2/alpha1 gene, as shown in the lower portion. This results in the amplification of a 2065 base pair fragment with primers A1 and A3 when deletion is present.<br> (B) Table showing the nucleotide (nt) sequence of the primers A1, A2, and A3 and their positions (location) in the alpha globin gene cluster on the reference sequence HUMHBB.<br> (C) Detection of the common -alpha 3.7 deletion by gap PCR. Lanes 1 and 8: DNA size markers (1 kb ladder). Lanes 2, 4, and 6 use primers (A1 and A2) for the normal alpha2 gene, while lanes 3, 5, and 7 use primers (A1 and A3) to detect the hybrid gene. Lanes 2 and 3: heterozygous -alpha 3.7 deletion; 1789 bp fragment is generated by the normal control, located on the alpha 2 gene in trans chromosome; 2065 bp fragment is generated by the deletion. Lanes 4 and 5: individual with homozygous deletion; note that there is no amplification of the 1789 bp fragment (lane 4) indicating the absence of the normal gene. Lanes 6 and 7: individual with normal alpha chains; note that there is no amplification of the 2065 bp fragment (lane 7) indicating that there is no -alpha 3.7 deletion (hence the presence of only the 1789 bp fragment in lane 6).</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction.</div><div id=\"graphicVersion\">Graphic 55893 Version 7.0</div></div></div>"},"55895":{"type":"graphic_picture","displayName":"Frova introducer","title":"Frova introducer (bougie)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frova introducer (bougie)</div><div class=\"cntnt\"><img style=\"width:396px; height:347px;\" src=\"images/EM/55895_Frova_introducer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Frova tracheal tube introducer includes a fenestrated tip to allow oxygentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Cook Incorporated. Copyright ©2008 Cook Incorporated.</div><div id=\"graphicVersion\">Graphic 55895 Version 4.0</div></div></div>"},"55896":{"type":"graphic_figure","displayName":"SC central line supra","title":"Supraclavicular approach to the subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Supraclavicular approach to the subclavian vein</div><div class=\"cntnt\"><img style=\"width:555px; height:409px;\" src=\"images/EM/55896_SC_central_line_supra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The supraclavicular approach allows ready access to the subclavian vein. The point of needle entry lies 1 cm posterior to the sternocleidomastoid and 1 cm superior to the clavicle. Be sure the angle of the needle is depressed 10 to 15 degrees below the coronal plane (ie, needle tip aimed upwards). Advance the needle behind the medial clavicle along a trajectory directed just below the contralateral nipple.</div><div id=\"graphicVersion\">Graphic 55896 Version 3.0</div></div></div>"},"55897":{"type":"graphic_algorithm","displayName":"Diagnosis of adrenal insufficiency","title":"Diagnostic approach to suspected adrenal insufficiency","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to suspected adrenal insufficiency</div><div class=\"cntnt\"><img style=\"width:515px; height:367px;\" src=\"images/ENDO/55897_Diagnosis_adrenal_insuf_ed3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACTH: corticotropin; ITT: insulin tolerance test;&nbsp;CRH: corticotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 55897 Version 6.0</div></div></div>"},"55900":{"type":"graphic_form","displayName":"Asthma action plan","title":"Asthma action plan","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Asthma action plan</div><div class=\"cntnt\"><img style=\"width:608px; height:789px;\" src=\"images/PULM/55900_Asthma_action_plan.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 55900 Version 3.0</div></div></div>"},"55901":{"type":"graphic_table","displayName":"Important features of the history in musculoskeletal chest pain","title":"Important features of the history in musculoskeletal chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important features of the history in musculoskeletal chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Features suggestive of visceral cause</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Middle-aged or older adult patient </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Risk factors for coronary disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Exertional pain </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cough </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fever </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Dyspnea </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Atypical location </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Features suggestive of musculoskeletal cause<sup>[1]</sup></strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Not squeezing or oppressive </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Localized on the left or median-left part of the chest wall </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Not exercise-induced </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Influenced by movement or posture </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Reproducible by palpation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Features suggestive of associated condition</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Neck, thoracic, or shoulder pain (eg, pain referred to chest) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chronic low back pain, young patient (eg, ankylosing spondylitis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ocular inflammation (eg, ankylosing spondylitis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Diffuse musculoskeletal pain/sleep disturbance (eg, fibromyalgia) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Peripheral joint pain and swelling (eg, rheumatoid arthritis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Skin lesions (eg, psoriasis) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Verdon F, Burnand B, Herzig L, et al. Chest wall syndrome among primary care patients: a cohort study. BMC Fam Pract 2007; 8:51.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55901 Version 5.0</div></div></div>"},"55902":{"type":"graphic_table","displayName":"Uveitis with systemic disease","title":"Systemic immune-mediated causes of uveitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic immune-mediated causes of uveitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ankylosing spondylitis</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Blau syndrome</td> </tr> <tr> <td>Crohn's disease</td> </tr> <tr> <td>Drug or hypersensitivity reaction</td> </tr> <tr> <td>Interstitial nephritis</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Kawasaki's disease</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Neonatal onset multisystem inflammatory disease</td> </tr> <tr> <td>Psoriatic arthritis</td> </tr> <tr> <td>Reactive arthritis</td> </tr> <tr> <td>Relapsing polychondritis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> </tr> <tr> <td>Sweet syndrome</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Ulcerative colitis</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Vitiligo</td> </tr> <tr> <td>Vogt-Koyanagi-Harada syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55902 Version 7.0</div></div></div>"},"55903":{"type":"graphic_picture","displayName":"Subacute cutaneous lupus - Annular plaques","title":"Subacute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/55903_Sub_cut_lupus_annul_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, annular plaques with scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55903 Version 6.0</div></div></div>"},"55908":{"type":"graphic_figure","displayName":"4 generation pedigree","title":"An example of a 4-generation medical pedigree","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">An example of a 4-generation medical pedigree</div><div class=\"cntnt\"><img style=\"width:523px; height:375px;\" src=\"images/PC/55908_4_generation_pedigree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient denoted with arrow. From top, left to right: I. 1 = Paternal grandfather, died age 82 of unknown cause; I-2 paternal grandmother, alive age 77; I-3 maternal grandfather, died age 66, history of MI and hyperlipidemia; I-4 maternal grandmother, alive age 70. II-1 Father age 57; II-2 Mother, alive age 54 with coronary disease onset at age 52; II-3 Maternal uncle, alive age 52, with coronary disease onset at age 49; II-4 Maternal aunt, age 48; II-5 husband of II-4, age 50. III-1 sister, age 35; III-2 a sibling (gender unknown) who died at birth; III-3 patient, age 32; III-4 patient's husband, age 36; III-5 brother, age 31 with hyperlipidemia; III-6 brother, age 28 with hyperlipidemia; III-7 female cousin, age 20. IV-1 daughter, age 3.</div><div id=\"graphicVersion\">Graphic 55908 Version 2.0</div></div></div>"},"55911":{"type":"graphic_table","displayName":"Frequency and survival for appendix neoplasms SEER","title":"Frequency and disease-specific survival for primary malignant neoplasms of the appendix from SEER data, 1973-2007","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency and disease-specific survival for primary malignant neoplasms of the appendix from SEER data, 1973-2007</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neoplasm</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Percent of total</td> <td class=\"subtitle1\">Five-year disease-specific survival (percent)</td> </tr> <tr> <td>Mucinous adenocarcinoma</td> <td class=\"centered\">2101</td> <td class=\"centered\">37</td> <td class=\"centered\">58</td> </tr> <tr> <td>Colonic-type adenocarcinoma</td> <td class=\"centered\">1544</td> <td class=\"centered\">27</td> <td class=\"centered\">55</td> </tr> <tr> <td>Adenocarcinoid</td> <td class=\"centered\">1072</td> <td class=\"centered\">19</td> <td class=\"centered\">81</td> </tr> <tr> <td>Malignant carcinoid</td> <td class=\"centered\">625</td> <td class=\"centered\">11</td> <td class=\"centered\">93</td> </tr> <tr class=\"divider_bottom\"> <td>Signet ring cell carcinoma</td> <td class=\"centered\">313</td> <td class=\"centered\">6</td> <td class=\"centered\">27</td> </tr> <tr> <td><strong>Total:</strong></td> <td class=\"centered\"><strong>5655</strong></td> <td class=\"centered\"><strong>100</strong></td> <td class=\"centered\"></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology and End Results.</div><div class=\"graphic_reference\">Data from: Turaga KK, et al. Ann Surg Oncol 2012; 19:1379.</div><div id=\"graphicVersion\">Graphic 55911 Version 3.0</div></div></div>"},"55913":{"type":"graphic_table","displayName":"CRS case definition","title":"Case definition and classification criteria for congenital rubella syndrome (CRS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Case definition and classification criteria for congenital rubella syndrome (CRS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Clinical case definition </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">An illness, usually manifesting in infancy, resulting from rubella infection in utero and characterized by clinical findings from the following categories: </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Category A: Cataracts/congenital glaucoma, congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis), hearing impairment, pigmentary retinopathy </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Category B: Purpura, hepatosplenomegaly, jaundice, microcephaly, developmental delay, meningoencephalitis, radiolucent bone disease </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Laboratory criteria (any one of the following) </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Isolation of rubella </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Demonstration of rubella-specific immunoglobulin M (IgM) </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Infant rubella antibody level (immunoglobulin G, IgG) that persists at a higher level and for a longer time than expected from passive transfer of maternal antibody (ie, rubella titer that does not drop at the expected rate of a twofold dilution per month)* </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Polymerase chain reaction (PCR) positive for rubella virus </td> </tr> <tr> <td class=\"subtitle1_single\">Classification </td> <td class=\"subtitle1_single\">Criteria </td> </tr> <tr> <td class=\"indent1\">Suspected</td> <td class=\"indent1\">An infant&nbsp;that does not meet the criteria for a probable or confirmed case but has one of more of the above clinical findings</td> </tr> <tr> <td class=\"indent1\">Probable<sup>&#182;</sup></td> <td class=\"indent1\">An infant&nbsp;without an alternative etiology that does not have laboratory confirmation of rubella infection but has&nbsp;either: <ul class=\"decimal_heading\"> <li>At least&nbsp;two clinical findings from category A above, <strong>or</strong> </li> <li>One&nbsp;finding from category A and one or more from category B above </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Confirmed</td> <td class=\"indent1\">An infant with at least one of the above clinical findings that is clinically consistent with congenital rubella syndrome; and laboratory evidence of congenital rubella infection as demonstrated by any of the above laboratory criteria</td> </tr> <tr> <td class=\"indent1\">Infection only<sup>&#916;</sup></td> <td class=\"indent1\">An infant without any clinical symptoms or signs but with laboratory evidence of infection as demonstrated by any of the above laboratory criteria</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Infants with symptoms consistent with CRS who test negative soon after birth should be retested at age one month. Approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month.<br />&para; In probable cases, either or both of the eye-related findings (cataracts and congenital glaucoma) count as a single complication.<br />&Delta; If any compatible signs or symptoms (eg, hearing impairment) are identified later, the case is reclassified as confirmed.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Rubella, congenital syndrome 2010 case definition. Available at: <A href=\"http://wwwn.cdc.gov/nndss/conditions/rubella-congenital-syndrome/case-definition/2010/\">http://wwwn.cdc.gov/nndss/conditions/rubella-congenital-syndrome/case-definition/2010/</A>. Accessed on July 30, 2015.</div><div id=\"graphicVersion\">Graphic 55913 Version 4.0</div></div></div>"},"55914":{"type":"graphic_picture","displayName":"HCM myocyte disarray","title":"Myocyte disarray in hypertrophic cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myocyte disarray in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:393px; height:252px;\" src=\"images/CARD/55914_HCM_myocyte_disarray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic appearance of the myocardium in hypertrophic cardiomyopathy, stained with hematoxylin and eosin, shows myocyte disarray with an irregular arrangement of abnormal shaped myocytes that contain bizarre nuclei and surrounding areas of increased connective tissue.</div><div class=\"graphic_reference\">Courtesy of Professor Michael Davies, St. George's Hospital, London.</div><div id=\"graphicVersion\">Graphic 55914 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial biopsy</div><div class=\"cntnt\"><img style=\"width:358px; height:235px;\" src=\"images/CARD/61625_Normal_myocardium_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal endomyocardial biopsy in longitudinal section.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 61625 Version 1.0</div></div></div>"},"55915":{"type":"graphic_table","displayName":"Stress fracture site in adolescents by sport","title":"Common sites of lower extremity stress fractures in adolescents by sport","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common sites of lower extremity stress fractures in adolescents by sport</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Sport</td>\n<td class=\"subtitle1\">Stress fracture site(s)</td>\n</tr>\n<tr>\n<td>Baseball</td>\n<td>Tibia</td>\n</tr>\n<tr>\n<td>Basketball</td>\n<td>Anterior cortex of tibia, tarsal navicular</td>\n</tr>\n<tr>\n<td>Gymnastics</td>\n<td>Tibia, fibula</td>\n</tr>\n<tr>\n<td>Ice skating</td>\n<td>Distal fibula</td>\n</tr>\n<tr>\n<td>Running</td>\n<td>Proximal tibial metaphysis, distal tibial metaphysis, fibula, tarsal navicular, midshaft of femur, distal femur, femoral neck</td>\n</tr>\n<tr>\n<td>Soccer</td>\n<td>Patella</td>\n</tr>\n<tr>\n<td>Swimming</td>\n<td>Proximal tibia</td>\n</tr>\n<tr>\n<td>Volleyball</td>\n<td>Tibia</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Yngve DA. Stress fractures. In: Care of the young athlete, Sullivan JA, Anderson SJ (Eds), American Academy of Orthopedic Surgeons and American Academy of Pediatrics, 2000.</div><div id=\"graphicVersion\">Graphic 55915 Version 5.0</div></div></div>"},"55916":{"type":"graphic_figure","displayName":"Monoclonal pattern immunofixation","title":"Monoclonal gammopathy on immunofixation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monoclonal gammopathy on immunofixation</div><div class=\"cntnt\"><img style=\"width:307px; height:387px;\" src=\"images/HEME/55916_Monocl_pattern_immuno_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the serum protein electrophoretic pattern (SPEP) and immunofixation pattern of a single serum sample with antisera to heavy chain determinants of IgG, IgA, and IgM, and to kappa and lambda light chains. It shows a discrete band on SPEP (red asterisk) and a band with similar mobility reacting only with the antisera to IgG (blue asterisk) and the kappa light chain (black asterisk), indicative of an IgG kappa monoclonal protein.</div><div class=\"graphic_reference\">Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 55916 Version 4.0</div></div></div>"},"55918":{"type":"graphic_picture","displayName":"Guttate morphea","title":"Guttate morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Guttate morphea</div><div class=\"cntnt\"><img style=\"width:396px; height:256px;\" src=\"images/RHEUM/55918_Guttate_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Guttate morphea is characterized by multiple, small (2 to 10 mm in diameter), hypopigmented and pigmented papules.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 55918 Version 1.0</div></div></div>"},"55919":{"type":"graphic_diagnosticimage","displayName":"Stroke in newborn with seizures","title":"Stroke in a three-day-old term newborn with left-sided clonic seizures","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Stroke in a three-day-old term newborn with left-sided clonic seizures</div><div class=\"cntnt\"><img style=\"width:595px; height:233px;\" src=\"images/PEDS/55919_Neonatal_stroke.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Head CT on day of life 3 shows focal hypodensity (arrows) consistent with right MCA territory arterial ischemic stroke. Brain MRI confirms acute infarction (arrows) on axial diffusion-weighted sequences (B) and T2-weighted sequences (C). On diffusion-weighted sequences (B), subtle diffusion restriction (asterisk and dashed lines) in ipsilateral internal capsule, corpus callosum and thalamus depict foci of probable Wallerian or trans-synaptic degeneration.</div><div class=\"graphic_footnotes\">MCA: middle cerebral artery; MRI: magnetic resonance imaging; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Rebecca Ichord, MD.</div><div id=\"graphicVersion\">Graphic 55919 Version 3.0</div></div></div>"},"55921":{"type":"graphic_figure","displayName":"Normal female anatomy detail","title":"Normal female reproductive anatomy","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Normal female reproductive anatomy</div><div class=\"cntnt\"><img style=\"width:559px; height:471px;\" src=\"images/OBGYN/55921_Normal_female_anat_detail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55921 Version 5.0</div></div></div>"},"55922":{"type":"graphic_figure","displayName":"Amiodarone and SCD mortality","title":"Amiodarone reduces total and sudden death mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amiodarone reduces total and sudden death mortality</div><div class=\"cntnt\"><img style=\"width:431px; height:276px;\" src=\"images/CARD/55922_Amiodarone_and_SCD_mortalit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis of randomized trials involving 6553 patients with heart failure or a recent myocardial infarction found that, compared to placebo or usual care, amiodarone significantly reduced total mortality by 13 percent and sudden death mortality by 29 percent. There was no difference in treatment effect between heart failure and postinfarction trials.</div><div class=\"graphic_reference\">Data from Amiodarone Trials Meta-Analysis Investigators, Lancet 1997; 350:1417.</div><div id=\"graphicVersion\">Graphic 55922 Version 1.0</div></div></div>"},"55923":{"type":"graphic_algorithm","displayName":"Etiology of red urine","title":"Approach to the patient with red or brown urine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with red or brown urine</div><div class=\"cntnt\"><img style=\"width:368px; height:368px;\" src=\"images/NEPH/55923_Etlg_rd_urn.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55923 Version 5.0</div></div></div>"},"55925":{"type":"graphic_figure","displayName":"Mother on her side","title":"Mother on her side","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Mother on her side</div><div class=\"cntnt\"><img style=\"width:454px; height:277px;\" src=\"images/OBGYN/55925_Mother_on_her_side.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of positions for pushing and delivery.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 55925 Version 1.0</div></div></div>"},"55928":{"type":"graphic_picture","displayName":"Superficial burn","title":"Superficial burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial burn</div><div class=\"cntnt\"><img style=\"width:272px; height:319px;\" src=\"images/EM/55928_Superficialburn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red burns that blanch are typical of superficial burns.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan, MD,&nbsp;and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 55928 Version 4.0</div></div></div>"},"55930":{"type":"graphic_figure","displayName":"Wedge resection for uterine decompression during hysterectomy","title":"Wedge resection for uterine decompression during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Wedge resection for uterine decompression during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:486px; height:371px;\" src=\"images/OBGYN/55930_Morcellation_by_wedge_resec.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55930 Version 3.0</div></div></div>"},"55931":{"type":"graphic_figure","displayName":"Effects of dynamic intrathoracic airway obstruction","title":"Effects of dynamic intrathoracic airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effects of dynamic intrathoracic airway obstruction</div><div class=\"cntnt\"><img style=\"width:327px; height:266px;\" src=\"images/PULM/55931_Intrathoracic_airway_obstr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel, during forced expiration, the intrathoracic intratracheal pressure (P<sub>tr</sub>) is less than the pleural pressure (P<sub>pl</sub>), worsening the obstruction. Right panel, during forced inspiration, P<sub>tr </sub>exceeds P<sub>pl</sub>, lessening the degree of obstruction.</div><div class=\"graphic_reference\">Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.</div><div id=\"graphicVersion\">Graphic 55931 Version 3.0</div></div></div>"},"55932":{"type":"graphic_diagnosticimage","displayName":"Lung CT rheumatoid nodules","title":"CT image of rheumatoid nodules in the lung","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">CT image of rheumatoid nodules in the lung</div><div class=\"cntnt\"><img style=\"width:764px; height:385px;\" src=\"images/PULM/55932_Rheumatoid_nodule_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial high resolution computed tomography (HRCT) images of rheumatoid nodules in a 49-year-old woman with long-standing rheumatoid arthritis treated with methotrexate and low-dose prednisolone. The diagnosis was based on the clinical presentation and long-term follow-up. These images show bilateral cavitary and solid nodules. The inner walls of the cavities are irregular, as though studded with nodules. Pulmonary rheumatoid nodules range in size from a few millimeters to several centimeters and may be single or multiple, solid or cavitary. Additionally, the nodules are typically subpleural or adjacent to interlobular septa, as seen in these images.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 55932 Version 4.0</div></div></div>"},"55933":{"type":"graphic_table","displayName":"Dose dense AC-T breast cancer","title":"Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) chemotherapy for adjuvant treatment of breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) chemotherapy for adjuvant treatment of breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days.<br /> <strong>Total cycles:</strong> 4.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5% dextrose in water (D5W). The presence of local erythematous streaking along the vein as well as facial flushing may be signs that administration is too rapid. If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Rapid infusions may produce nasal burning or congestion that is relieved by slowing the rate.</td> <td>Day 1</td> </tr> <tr> <td colspan=\"4\"><strong>After complete of AC, administer:</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>175 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W (final concentration of 0.3 to 1.2 mg/mL) and administer over three hours.*</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. Paclitaxel can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Hematopoietic growth factors (filgrastim [G-CSF] 5 mcg/kg subcutaneously rounded to 300 mcg or 480 mcg on days 3 through 10, or pegfilgrastim 6 milligrams subcutaneously on day 2 or 3) with each cycle is <strong>required</strong>. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment is not necessary for doxorubicin or paclitaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin.<sup>[2]</sup> A baseline assessment of left ventricular ejection fraction (LVEF) is recommended, with periodic reassessment of during therapy. Further information on anthracycline-associated cardiotoxicity, including discussion about prevention and treatment, is available. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment cycle of paclitaxel. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>During treatment with doxorubicin or paclitaxel, assess line site periodically during infusion of chemotherapy for signs and symptoms of extravasation. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Subsequent cycles should be delayed until the absolute neutrophil count is &#62;1000/microL and platelet count &#62;100,000/microL. If there is more than a three week delay in treatment, a dose reduction of 25% is recommended.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe neuropathy (grade 3 or 4) that persists for a week or longer, the dose of paclitaxel should be reduced by 20% for subsequent courses of paclitaxel; hold if severe toxicity persists after dose reduction.<sup>[4]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin, cyclophosphamide, and paclitaxel in patients who have changes in kidney or liver function during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count.<br />* Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Citron ML, et al. J Clin Oncol 2003; 21:1431.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 55933 Version 23.0</div></div></div>"},"55934":{"type":"graphic_figure","displayName":"Barker method of vacuum assisted temporary abdominal closure","title":"Barker method of vacuum assisted temporary abdominal closure","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Barker method of vacuum assisted temporary abdominal closure</div><div class=\"cntnt\"><img style=\"width:603px; height:369px;\" src=\"images/SURG/55934_Barker_meth_vac_temp_abd.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 55934 Version 1.0</div></div></div>"},"55935":{"type":"graphic_figure","displayName":"Insertion of Nexplanon","title":"Insertion of Nexplanon","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Insertion of Nexplanon</div><div class=\"cntnt\"><img style=\"width:549px; height:681px;\" src=\"images/OBGYN/55935_Insertion_of_Nexplanon.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of MSD Oss B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. NEXPLANON is a registered trademark of MSD Oss B.V. All requests to reproduce this copyrighted material should be directed to MSD Oss B.V.</div><div id=\"graphicVersion\">Graphic 55935 Version 3.0</div></div></div>"},"55936":{"type":"graphic_table","displayName":"Material safety data sheet","title":"Minimal information requirements for the material safety data sheet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimal information requirements for the material safety data sheet</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Chemical identity as it appears on the label</td> </tr> <tr> <td>Manufacturer's name and contact information, preparation date</td> </tr> <tr> <td>Hazardous ingredients, permissible exposure limits, threshold level value </td> </tr> <tr> <td>Physical and chemical characteristics of the substance</td> </tr> <tr> <td>Fire and explosion hazard data</td> </tr> <tr> <td>Reactivity data such as chemical instability, substances the product may react with, hazardous byproducts, hazardous polymerization</td> </tr> <tr> <td>Health hazard data such as route of entry, carcinogenicity, signs and symptoms of exposure, emergency and first aid procedure</td> </tr> <tr> <td>Precaution for safe handling and use, including steps to be taken if spilled or released, waste disposal method, precaution for handling and storage</td> </tr> <tr> <td>Control measures including protection methods and equipment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55936 Version 1.0</div></div></div>"},"55938":{"type":"graphic_table","displayName":"Lactose content of different foods PI","title":"Lactose content of different foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lactose content of different foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Lactose content (grams)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Milk (1 cup)</strong></td> </tr> <tr> <td class=\"indent1\">Whole, 2 percent, 1 percent, skim</td> <td>9 to 14</td> </tr> <tr> <td class=\"indent1\">Buttermilk</td> <td>9 to 12</td> </tr> <tr> <td class=\"indent1\">Evaporated milk</td> <td>24 to 28</td> </tr> <tr> <td class=\"indent1\">Sweetened condensed milk</td> <td>31 to 50</td> </tr> <tr> <td class=\"indent1\">Lactaid milk (lactose-reduced)</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Goat's milk</td> <td>11 to 12</td> </tr> <tr> <td class=\"indent1\">Acidophilus, skim</td> <td>11</td> </tr> <tr> <td><strong>Yogurt, low fat, 1 cup</strong></td> <td>4 to 17</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Cheese, 1 ounce</strong></td> </tr> <tr> <td class=\"indent1\">Cottage cheese (1/2 cup)</td> <td>0.7 to 4</td> </tr> <tr> <td class=\"indent1\">Cheddar (sharp)</td> <td>0.4 to 0.6</td> </tr> <tr> <td class=\"indent1\">Mozzarella (part skim, low moisture)</td> <td>0.08 to 0.9</td> </tr> <tr> <td class=\"indent1\">American (pasteurized, processed)</td> <td>0.5 to 4</td> </tr> <tr> <td class=\"indent1\">Ricotta (1/2 cup)</td> <td>0.3 to 6</td> </tr> <tr> <td class=\"indent1\">Cream cheese</td> <td>0.1 to 0.8</td> </tr> <tr> <td><strong>Butter (1 pat)</strong></td> <td>0.04 to 0.5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Cream (1 tablespoon)</strong></td> </tr> <tr> <td class=\"indent1\">Light, whipping, sour</td> <td>0.4 to 0.6</td> </tr> <tr> <td><strong>Ice cream (1/2 cup)</strong></td> <td>2 to 6</td> </tr> <tr> <td><strong>Ice milk (1/2 cup)</strong></td> <td>5</td> </tr> <tr> <td><strong>Sherbet (1/2 cup)</strong></td> <td>0.6 to 2</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988; 48:1079. Copyright © 1988 American Society for Clinical Nutrition.</div><div id=\"graphicVersion\">Graphic 55938 Version 5.0</div></div></div>"},"55939":{"type":"graphic_table","displayName":"Internal concealment of drugs of abuse (body packing)","title":"Internal concealment of drugs of abuse (body packing)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Internal concealment of drugs of abuse (body packing)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span class=\"red\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span class=\"red\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Inquire about type of drug, method of wrapping, number of packets</td> </tr> <tr> <td class=\"subtitle1_single\">Physical exam</td> </tr> <tr> <td class=\"sublist1_start\">Assess for heroin toxicity</td> </tr> <tr> <td class=\"sublist1\">Depressed mental status, decreased respirations, pinpoint pupils, absent bowel sounds</td> </tr> <tr> <td class=\"sublist1_start\">Assess for cocaine toxicity</td> </tr> <tr> <td class=\"sublist1\">Agitation, hypertension, tachycardia, seizures, cardiac dysrhythmias</td> </tr> <tr> <td>Assess for evidence of packets on physical examination (abdominal and rectal exams)</td> </tr> <tr> <td>Assess for evidence of gastrointestinal obstruction or perforation (distension, tenderness)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td>A plain abdominal radiograph is the best screening study</td> </tr> <tr> <td>If suspicion is high but plain radiograph is negative, CT (or barium enhanced abdominal radiography) should be performed</td> </tr> <tr> <td>Urinalysis lacks sensitivity as a screening test, but may identify packet content(s)</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist1_start\">Asymptomatic</td> </tr> <tr> <td class=\"sublist1\">Whole bowel irrigation (polyethylene glycol electrolyte lavage solution), 2 L/h plus promotility agent (erythromycin 500 mg IV, or metoclopramide 10 mg IV)</td> </tr> <tr> <td class=\"sublist1_start\">Gastrointestinal obstruction or perforation</td> </tr> <tr> <td class=\"sublist1\">Surgical decontamination</td> </tr> <tr> <td class=\"sublist1_start\">Evidence of heroin toxicity</td> </tr> <tr> <td class=\"sublist1\">Naloxone (high doses may be required: eg, 2 to 5 mg IV, may be given every 5 minutes until patient responsive)</td> </tr> <tr> <td class=\"sublist1\">Whole bowel irrigation, 2 L/h plus promotility agent</td> </tr> <tr> <td class=\"sublist1_start\">Evidence of cocaine toxicity</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines (eg, midazolam 1 to 2 mg IV, may be repeated); aggressive supportive care</td> </tr> <tr> <td class=\"sublist1\">Surgical decontamination</td> </tr> <tr> <td class=\"subtitle1_single\">Endpoint of therapy</td> </tr> <tr> <td>Contrast-enhanced abdominal CT (or barium-enhanced radiography) to document clearance of all packets from the GI tract</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55939 Version 5.0</div></div></div>"},"55940":{"type":"graphic_picture","displayName":"Nodular anterior scleritis","title":"Nodular anterior scleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular anterior scleritis</div><div class=\"cntnt\"><img style=\"width:335px; height:215px;\" src=\"images/RHEUM/55940_Nodular_anterior_scleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular anterior scleritis in a patient with rheumatoid arthritis. Nodular elevation of the sclera is surrounded by deep scleral vascular engorgement.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 55940 Version 2.0</div></div></div>"},"55941":{"type":"graphic_figure","displayName":"Hydrocele PI","title":"Hydrocele","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Hydrocele</div><div class=\"cntnt\"><img style=\"width:457px; height:549px;\" src=\"images/PI/55941_Hydrocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hydrocele is a sac of fluid that forms inside the scrotum around 1 of the testicles.</div><div id=\"graphicVersion\">Graphic 55941 Version 1.0</div></div></div>"},"55942":{"type":"graphic_table","displayName":"Microbiology CIED infection","title":"Microbiology of cardiac implantable electronic device (CIED) infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology of cardiac implantable electronic device&nbsp;(CIED)&nbsp;infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\"> <p>Pacemaker endocarditis</p> <p>Number of patients (percent)<sup>[1]</sup>*</p> </td> <td class=\"subtitle1\"> <p>All CIED infections (pocket and bloodstream)</p> <p>Number of pathogens (percent)<sup>[2]</sup></p> </td> </tr> <tr> <td>Coagulase-negative staphylococci</td> <td>99 (61)</td> <td>&nbsp;183 (44)</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td>49 (30)</td> <td>148 (36)</td> </tr> <tr> <td>Enterobacteriaceae</td> <td>8 (5)</td> <td>18 (4)</td> </tr> <tr> <td>Streptococci</td> <td>7 (4)</td> <td>12 (3)</td> </tr> <tr> <td><em>Pseudomonas</em></td> <td>6 (4)</td> <td>12 (3)</td> </tr> <tr> <td>Other gram-negative bacteria</td> <td>-</td> <td>8 (2)</td> </tr> <tr> <td><em>Candida</em></td> <td>3 (2)</td> <td>2 (&#60;1)</td> </tr> <tr> <td>Enterococci</td> <td>3 (2)</td> <td>20 (5)</td> </tr> <tr> <td><em>Corynebacterium</em></td> <td>2 (1)</td> <td>2 (&#60;1)</td> </tr> <tr> <td><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em></td> <td>1 (&#60;1)</td> <td>1 (&#60;1)</td> </tr> <tr> <td><em>Listeria</em></td> <td>1 (&#60;1)</td> <td>-</td> </tr> <tr> <td>Anaerobes</td> <td>-</td> <td>5 (1)</td> </tr> <tr> <td>Micrococci</td> <td>1 (&#60;1)</td> <td>-</td> </tr> <tr> <td><em>Mycobacterium</em> spp</td> <td>-</td> <td>2 (&#60;1)</td> </tr> <tr> <td><em>Apergillus</em></td> <td>-</td> <td>1 (&#60;1)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Polymicrobial infection occurred in 11 percent of cases.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Arber N, Pras E, Copperman Y, et al. Medicine (Baltimore) 1994; 73:299; Duval X, Selton-Suty C, Alla F, et al. Clin Infect Dis 2004; 39:68; Klug D, Lacroix D, Savoye C, et al. Circulation 1997; 95:2098; and Cacoub P, Leprince P, Nataf P, et al. Am J Cardiol 1998; 82:480.</LI>&#xD;&#xA;<LI>Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Heart Rhythm 2010; 7:1043.</LI></OL></div><div id=\"graphicVersion\">Graphic 55942 Version 5.0</div></div></div>"},"55943":{"type":"graphic_figure","displayName":"Pneumonia anatomy PI","title":"Pneumonia","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Pneumonia</div><div class=\"cntnt\"><img style=\"width:554px; height:533px;\" src=\"images/PI/55943_Pneumonia_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Alveoli\" are air sacs in your lungs that are surrounded by tiny blood vessels called capillaries. The air sacs have thin walls that allow the exchange of gases. When blood flows through the capillaries around the air sacs, it picks up oxygen that you have breathed in and dumps off carbon dioxide that you then breathe out. But if you have pneumonia, your alveoli swell and fill with inflammatory cells and fluid, containing white blood cells, red blood cells, macrophages, fibrin, cell debris, and microorganisms. This makes you cough and makes it hard to breathe.</div><div id=\"graphicVersion\">Graphic 55943 Version 7.0</div></div></div>"},"55944":{"type":"graphic_table","displayName":"Causes of Eisenmenger syndrome","title":"Causes of Eisenmenger syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of Eisenmenger syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Atrial shunts*</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Atrial septal defects</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Primum, secundum, sinus venosus</td>\n    </tr>\n    <tr>\n\n      <td>Common atrium</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Total anomalous pulmonary venous connection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Partial anomalous pulmonary venous connection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ventricular shunts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ventricular septal defect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Single ventricle</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transposition of the great vessels with VSD</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Double outlet right ventricle</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Atrioventricular canal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Aortic shunts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patent ductus arteriosus</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aortopulmonary window (defect)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Truncus arteriosus</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonic valve atresia with VSD and large collateral vessels</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">*&#160;There is controversy regarding the role of atrial septal defects (ASDs) in the development of Eisenmenger syndrome. Some experts believe that pulmonary hypertension in patients with secundum ASDs (which occurs in less than 10 percent) is due to the coincidental occurrence of primary pulmonary hypertension in these patients.</div><div id=\"graphicVersion\">Graphic 55944 Version 1.0</div></div></div>"},"55945":{"type":"graphic_table","displayName":"Hypertens CKD T163","title":"90th percentile of blood pressure in boys 2 to 17 years of age according to height percentile","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">90th percentile of blood pressure in boys 2 to 17 years of age according to height percentile</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age</td>\n\n\t\t\t\t<td colspan=\"5\" rowspan=\"1\" class=\"subtitle1\">90th percent systolic BP for height percentile of:</td>\n\n\t\t\t\t<td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">90th percent diastolic BP for height percentile of:</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2\">5th</td>\n\n\t\t\t\t<td class=\"subtitle2\">25th</td>\n\n\t\t\t\t<td class=\"subtitle2\">50th</td>\n\n\t\t\t\t<td class=\"subtitle2\">75th</td>\n\n\t\t\t\t<td class=\"subtitle2\">95th</td>\n\n\t\t\t\t<td class=\"subtitle2\">5th</td>\n\n\t\t\t\t<td class=\"subtitle2\">25th</td>\n\n\t\t\t\t<td class=\"subtitle2\">50th</td>\n\n\t\t\t\t<td class=\"subtitle2\">75th</td>\n\n\t\t\t\t<td class=\"subtitle2\">95th</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>2</td>\n\n\t\t\t\t<td>98</td>\n\n\t\t\t\t<td>100</td>\n\n\t\t\t\t<td>102</td>\n\n\t\t\t\t<td>104</td>\n\n\t\t\t\t<td>105</td>\n\n\t\t\t\t<td>55</td>\n\n\t\t\t\t<td>56</td>\n\n\t\t\t\t<td>57</td>\n\n\t\t\t\t<td>58</td>\n\n\t\t\t\t<td>59</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>4</td>\n\n\t\t\t\t<td>102</td>\n\n\t\t\t\t<td>105</td>\n\n\t\t\t\t<td>107</td>\n\n\t\t\t\t<td>109</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>62</td>\n\n\t\t\t\t<td>63</td>\n\n\t\t\t\t<td>64</td>\n\n\t\t\t\t<td>65</td>\n\n\t\t\t\t<td>66</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>6</td>\n\n\t\t\t\t<td>105</td>\n\n\t\t\t\t<td>108</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>111</td>\n\n\t\t\t\t<td>113</td>\n\n\t\t\t\t<td>67</td>\n\n\t\t\t\t<td>69</td>\n\n\t\t\t\t<td>70</td>\n\n\t\t\t\t<td>70</td>\n\n\t\t\t\t<td>71</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>8</td>\n\n\t\t\t\t<td>107</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>112</td>\n\n\t\t\t\t<td>114</td>\n\n\t\t\t\t<td>115</td>\n\n\t\t\t\t<td>71</td>\n\n\t\t\t\t<td>72</td>\n\n\t\t\t\t<td>73</td>\n\n\t\t\t\t<td>74</td>\n\n\t\t\t\t<td>75</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>10</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>113</td>\n\n\t\t\t\t<td>115</td>\n\n\t\t\t\t<td>117</td>\n\n\t\t\t\t<td>118</td>\n\n\t\t\t\t<td>73</td>\n\n\t\t\t\t<td>74</td>\n\n\t\t\t\t<td>75</td>\n\n\t\t\t\t<td>76</td>\n\n\t\t\t\t<td>77</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>12</td>\n\n\t\t\t\t<td>115</td>\n\n\t\t\t\t<td>117</td>\n\n\t\t\t\t<td>119</td>\n\n\t\t\t\t<td>121</td>\n\n\t\t\t\t<td>123</td>\n\n\t\t\t\t<td>75</td>\n\n\t\t\t\t<td>76</td>\n\n\t\t\t\t<td>77</td>\n\n\t\t\t\t<td>78</td>\n\n\t\t\t\t<td>78</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>14</td>\n\n\t\t\t\t<td>120</td>\n\n\t\t\t\t<td>123</td>\n\n\t\t\t\t<td>125</td>\n\n\t\t\t\t<td>126</td>\n\n\t\t\t\t<td>128</td>\n\n\t\t\t\t<td>76</td>\n\n\t\t\t\t<td>77</td>\n\n\t\t\t\t<td>78</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>80</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>16</td>\n\n\t\t\t\t<td>125</td>\n\n\t\t\t\t<td>128</td>\n\n\t\t\t\t<td>130</td>\n\n\t\t\t\t<td>132</td>\n\n\t\t\t\t<td>133</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>80</td>\n\n\t\t\t\t<td>81</td>\n\n\t\t\t\t<td>82</td>\n\n\t\t\t\t<td>83</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>17</td>\n\n\t\t\t\t<td>128</td>\n\n\t\t\t\t<td>131</td>\n\n\t\t\t\t<td>133</td>\n\n\t\t\t\t<td>134</td>\n\n\t\t\t\t<td>136</td>\n\n\t\t\t\t<td>81</td>\n\n\t\t\t\t<td>82</td>\n\n\t\t\t\t<td>83</td>\n\n\t\t\t\t<td>84</td>\n\n\t\t\t\t<td>85</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=37193&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Hypertens_CKD_T163.htm</title></head></div><div id=\"graphicVersion\">Graphic 55945 Version 1.0</div></div></div>"},"55948":{"type":"graphic_picture","displayName":"Shikani optical stylet","title":"Shikani optical stylet","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Shikani optical stylet</div><div class=\"cntnt\"><img style=\"width:488px; height:319px;\" src=\"images/EM/55948_ShikaniopticalstyletPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 55948 Version 7.0</div></div></div>"},"55949":{"type":"graphic_picture","displayName":"Tinea corporis - multiple lesions","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/55949_Tinea_corporis_mult_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple annular, erythematous plaques with peripheral scale are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 55949 Version 4.0</div></div></div>"},"55951":{"type":"graphic_table","displayName":"Causes of hypopituitarism","title":"Major causes of hypopituitarism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypopituitarism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hypothalamic diseases</td> </tr> <tr> <td>Mass lesions&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Benign (craniopharyngiomas) and malignant tumors (metastatic from lung, breast, etc)</td> </tr> <tr> <td>Radiation&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> For CNS and nasopharyngeal malignancies</td> </tr> <tr> <td>Infiltrative lesions <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Sarcoidosis, Langerhans cell histiocytosis</td> </tr> <tr> <td>Infections <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Tuberculous meningitis</td> </tr> <tr> <td>Other <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Traumatic brain injury, stroke</td> </tr> <tr> <td class=\"subtitle1_single\">Pituitary diseases </td> </tr> <tr> <td>Mass lesions <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Pituitary adenomas, other benign tumors, cysts</td> </tr> <tr> <td>Pituitary surgery</td> </tr> <tr> <td>Pituitary radiation</td> </tr> <tr> <td>Infiltrative lesions <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Hypophysitis, hemochromatosis</td> </tr> <tr> <td>Infection/abscess</td> </tr> <tr> <td>Infarction <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> Sheehan syndrome</td> </tr> <tr> <td>Apoplexy</td> </tr> <tr> <td>Genetic mutations</td> </tr> <tr> <td>Empty sella&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 55951 Version 5.0</div></div></div>"},"55952":{"type":"graphic_table","displayName":"Nausea vomiting terms","title":"Definitions of terminology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of terminology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Vomiting</td> <td>Forceful oral expulsion of gastric contents associated with contraction of the abdominal, diaphragmatic,&nbsp;and chest wall musculature</td> </tr> <tr> <td class=\"subtitle1_left\">Nausea</td> <td>The unpleasant sensation of the imminent need to vomit, usually referred to the throat or epigastrium; a sensation that may or may not ultimately lead to the act of vomiting</td> </tr> <tr> <td class=\"subtitle1_left\">Regurgitation</td> <td>The act by which food is brought back into the mouth without the abdominal and diaphragmatic muscular activity that characterizes vomiting</td> </tr> <tr> <td class=\"subtitle1_left\">Anorexia</td> <td>Loss of desire to eat, that is, a true loss of appetite</td> </tr> <tr> <td class=\"subtitle1_left\">Sitophobia</td> <td>Fear of eating because of subsequent or associated discomfort</td> </tr> <tr> <td class=\"subtitle1_left\">Early satiety</td> <td>The feeling of being full after eating an unusually small quantity of food</td> </tr> <tr> <td class=\"subtitle1_left\">Retching</td> <td>Spasmodic respiratory movements against a closed glottis with contractions of the abdominal musculature without expulsion of any gastric contents, referred to as \"dry heaves\"</td> </tr> <tr> <td class=\"subtitle1_left\">Rumination</td> <td>Chewing and swallowing of regurgitated food that has come back into the mouth through a voluntary increase in abdominal pressure within minutes of eating or during eating</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2001; 120:263.</div><div id=\"graphicVersion\">Graphic 55952 Version 2.0</div></div></div>"},"55953":{"type":"graphic_table","displayName":"Thrombopoietic factors","title":"Thrombopoietic growth factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thrombopoietic growth factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First generation thrombopoietic growth factors</td> </tr> <tr> <td class=\"indent1\">rHuTPO</td> </tr> <tr> <td class=\"indent1\">PEG-rHuMGDF</td> </tr> <tr> <td class=\"subtitle1_single\">Second generation thrombopoietic growth factors</td> </tr> <tr> <td class=\"subtitle2_single\">Peptide TPO receptor agonists</td> </tr> <tr> <td class=\"indent1\">Romiplostim (AMG 531, Nplate)</td> </tr> <tr> <td class=\"subtitle2_single\">Non-peptide TPO receptor&nbsp;agonists</td> </tr> <tr> <td class=\"indent1\">Eltrombopag (SB497115, Promacta/Revolade)</td> </tr> <tr> <td class=\"indent1\">Lusutrombopag (Mulpleta)</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Avatrombopag (</span>E5501, AKR-501, YM-477)</td> </tr> <tr> <td class=\"indent1\">LGA-4665</td> </tr> <tr> <td class=\"indent1\">NIP-004, NIP-022</td> </tr> <tr> <td class=\"indent1\">Butyzamide</td> </tr> <tr> <td class=\"subtitle2_single\">TPO receptor agonist antibodies (anti-Mpl antibody)</td> </tr> <tr> <td class=\"indent1\">Minibodies (VB22 sc(Fv)2)</td> </tr> <tr> <td class=\"indent1\">Domain subclass-converted TPO agonist antibodies (MA01G4G344)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TPO: thrombopoietin.</div><div id=\"graphicVersion\">Graphic 55953 Version 6.0</div></div></div>"},"55957":{"type":"graphic_picture","displayName":"Normal pap smear","title":"Normal pap smear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal pap smear</div><div class=\"cntnt\"><img style=\"width:396px; height:271px;\" src=\"images/PC/55957_Normal_pap_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Douglas K. Hanks, MD.</div><div id=\"graphicVersion\">Graphic 55957 Version 2.0</div></div></div>"},"55961":{"type":"graphic_diagnosticimage","displayName":"Melioidosis prostatic abscess","title":"Computed tomography of prostatic abscess due to melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of prostatic abscess due to melioidosis</div><div class=\"cntnt\"><img style=\"width:414px; height:244px;\" src=\"images/ID/55961_Melioidosis_prostatic_absce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large prostatic abscess in a case of melioidosis seen on CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 55961 Version 5.0</div></div></div>"},"55963":{"type":"graphic_figure","displayName":"Port placement for laparoscopic radical cystectomy","title":"Port placement for laparoscopic radical cystectomy","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Port placement for laparoscopic radical cystectomy</div><div class=\"cntnt\"><img style=\"width:478px; height:581px;\" src=\"images/ONC/55963_Port_placement_LRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For laparoscopic/robotic cystectomy, port placement is as shown in the figure. The camera port (12 mm, pink) is placed in the midline between the umbilicus and the xiphoid. The assistant uses ports, one placed lateral to the rectus muscle in the subcostal region (12 mm, purple) and the other placed superior to the iliac crest in the anterior axillary line (15 mm, brown). Three robotic ports (8 mm, green) are positioned at the same level, approximately 3 cm cephalad to the umbilicus.</div><div id=\"graphicVersion\">Graphic 55963 Version 4.0</div></div></div>"},"55964":{"type":"graphic_picture","displayName":"Hospital phototherapy PI","title":"Baby getting light therapy in the hospital","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Baby getting light therapy in the hospital</div><div class=\"cntnt\"><img style=\"width:638px; height:358px;\" src=\"images/PI/55964_Hospital_phototherapy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eyes are protected with a blindfold, and the temperature is monitored with the small white cord taped to the chest.</div><div class=\"graphic_reference\">Copyright &copy; Design that Matters, Inc. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 55964 Version 4.0</div></div></div>"},"55965":{"type":"graphic_table","displayName":"Normal GFR children","title":"Normal glomerular filtration rate (GFR) in children and young adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal glomerular filtration rate (GFR) in children and young adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (gender)</td> <td class=\"subtitle1\">Mean GFR &#177; SD mL/min/1.73m<sup>2</sup></td> </tr> <tr> <td>1 week (males and females)</td> <td class=\"centered\">40.6 &#177; 14.8</td> </tr> <tr> <td>2 to 8 weeks (males and females)</td> <td class=\"centered\">65.8 &#177; 24.8</td> </tr> <tr> <td>&#62;8 weeks (males and females)</td> <td class=\"centered\">95.7 &#177; 21.7</td> </tr> <tr> <td>2 to 12 years (males and females)</td> <td class=\"centered\">133.0 &#177; 27.0</td> </tr> <tr> <td>13 to 21 years (males)</td> <td class=\"centered\">140.0 &#177; 30.0</td> </tr> <tr> <td>13 to 21 years (females)</td> <td class=\"centered\">126.0 &#177; 22.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Modified with permission from: National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Am J Kidney Dis 2002:39(Suppl 1):S1-S266. Table 24 (page S56). Copyright &copy; 2002 National Kidney Foundation.</div><div id=\"graphicVersion\">Graphic 55965 Version 5.0</div></div></div>"},"55967":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum 2","title":"Bullous pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:432px; height:264px;\" src=\"images/ALLRG/55967_Pyoderma_gangrenosum_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three large hemorrhagic bullae on the dorsum of the hand and fingers. The bulla on the index finger has ruptured, resulting in a large erosion with an irregular, raised, pustular border and a purulent hemorrhagic exudate.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al. Color atlas and synopsis of clinical dermatology, 3rd ed, McGraw-Hill, New York 1997. Copyright &#169; 1997 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 55967 Version 3.0</div></div></div>"},"55968":{"type":"graphic_figure","displayName":"Drug therapy in type 2 diabetes","title":"Metabolic effects of drug therapy in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Metabolic effects of drug therapy in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:471px; height:358px;\" src=\"images/ENDO/55968_Drug_therapy_in_type_2_diab.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean changes in body weight (top) and fasting plasma insulin concentrations (bottom) over six years in patients with type 2 diabetes mellitus in the primary diet failure group who were allocated to therapy with insulin (red), sulfonylurea (blue), or, only in obese subjects, metformin (green). Left panels show data from nonobese patients, right panels show data from obese patients. Metformin did not increase weight or raise plasma insulin. To convert plasma insulin values to µU/mL divide by 6.</div><div class=\"graphic_reference\">Data from: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998; 128:165.</div><div id=\"graphicVersion\">Graphic 55968 Version 2.0</div></div></div>"},"55970":{"type":"graphic_table","displayName":"Number needed to screen to prevent cancer-specific death","title":"Number needed to screen to prevent cancer-specific death","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Number needed to screen to prevent cancer-specific death</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Age 50</td>\n\n\n      <td class=\"subtitle1\">Age 70</td>\n\n\n      <td class=\"subtitle1\">Age 75</td>\n\n\n      <td class=\"subtitle1\">Age 80</td>\n\n\n      <td class=\"subtitle1\">Age 85</td>\n\n\n      <td class=\"subtitle1\">Age 90</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">Mammography</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Upper quartile life expectancy</td>\n\n\n      <td>95</td>\n\n\n      <td>142</td>\n\n\n      <td>176</td>\n\n\n      <td>240</td>\n\n\n      <td>417</td>\n\n\n      <td>1066</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Middle quartile life expectancy</td>\n\n\n      <td>133</td>\n\n\n      <td>242</td>\n\n\n      <td>330</td>\n\n\n      <td>533</td>\n\n\n      <td>2131 </td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Lower quartile life expectancy</td>\n\n\n      <td>226</td>\n\n\n      <td>642</td>\n\n\n      <td>1361</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">Papanicolaou\nsmear</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Upper quartile life expectancy</td>\n\n\n      <td>533</td>\n\n\n      <td>934</td>\n\n\n      <td>1177</td>\n\n\n      <td>1694</td>\n\n\n      <td>2946</td>\n\n\n      <td>7528</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Middle quartile life expectancy</td>\n\n\n      <td>728</td>\n\n\n      <td>1521</td>\n\n\n      <td>2113</td>\n\n\n      <td>3764</td>\n\n\n      <td>15,056</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Lower quartile life expectancy</td>\n\n\n      <td>1140</td>\n\n\n      <td>4070</td>\n\n\n      <td>8342</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">Fecal\noccult blood test (women)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Upper quartile life expectancy</td>\n\n\n      <td>145</td>\n\n\n      <td>178</td>\n\n\n      <td>204</td>\n\n\n      <td>262</td>\n\n\n      <td>455</td>\n\n\n      <td>1163</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Middle quartile life expectancy</td>\n\n\n      <td>263</td>\n\n\n      <td>340</td>\n\n\n      <td>408</td>\n\n\n      <td>581</td>\n\n\n      <td>2326</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Lower quartile life expectancy</td>\n\n\n      <td>577</td>\n\n\n      <td>1046</td>\n\n\n      <td>1805</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">Fecal\noccult blood test (men)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Upper quartile life expectancy</td>\n\n\n      <td>138</td>\n\n\n      <td>177</td>\n\n\n      <td>207</td>\n\n\n      <td>277</td>\n\n\n      <td>554</td>\n\n\n      <td>2008</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Middle quartile life expectancy</td>\n\n\n      <td>255</td>\n\n\n      <td>380</td>\n\n\n      <td>525</td>\n\n\n      <td>945</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\"> Lower quartile life expectancy</td>\n\n\n      <td>630</td>\n\n\n      <td>1877</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n      <td>-</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60012&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>NNS_to_prevent_cancer_death.htm</title></head></div><div class=\"graphic_footnotes\">Number needed to screen refers to the number needed to screen over the remaining lifetime to prevent one cancer-specific death for women and men at selected ages and life expectancy quartiles. The life expectancy quartiles are those shown in the accompanying graphic. Details about how the numbers are derived are provided in the text of the study.</div><div class=\"graphic_reference\">Data from Walter, LC, Covinsky, KE, JAMA 2001; 285:2750. </div><div id=\"graphicVersion\">Graphic 55970 Version 2.0</div></div></div>"},"55973":{"type":"graphic_table","displayName":"Patient counseling for ESA use","title":"Patient counseling regarding the risks and benefits of therapy with an erythropoiesis-stimulating agent for anemia associated with chemotherapy for malignant disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient counseling regarding the risks and benefits of therapy with an erythropoiesis-stimulating agent for anemia associated with chemotherapy for malignant disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>The following issues should be discussed with patients regarding the risks and benefits of therapy with an erythropoiesis stimulating agent (ESA) for symptomatic anemia in patients receiving chemotherapy for malignant disease:</td> </tr> <tr> <td class=\"indent1\">1. The goal of ESA therapy for patients with chemotherapy-induced anemia is to reduce red blood cell (RBC) transfusion requirements.</td> </tr> <tr> <td class=\"indent1\">2. Although there are some suggestions that ESA treatment may improve fatigue or quality of life (QOL) in some patients, the primary goal is to reduce transfusion requirements.</td> </tr> <tr> <td class=\"indent1\">3. There are potential harms and benefits of ESAs versus RBC transfusions.</td> </tr> <tr> <td class=\"indent1\">4. ESAs have been found to shorten overall survival and/or speed tumor growth in some patients with cancer. It is for this reason that the US Food and Drug Administration (FDA) has indicated that ESAs should not be given to patients who are being treated for cancer when the goal is to cure the patient (of cancer).</td> </tr> <tr> <td class=\"indent1\">5. ESAs have risks of adverse events, such as blood clots, and individual risk factors for blood clots have to be considered when weighing the risks versus benefits.</td> </tr> <tr> <td class=\"indent1\">6. ESAs are not recommended for patients with cancer who are not receiving chemotherapy or who are receiving radiotherapy without chemotherapy, because ESAs have been associated with an increased risk of death in such patients.</td> </tr> <tr> <td class=\"indent1\">7. An acknowledgment form needs to be signed by patients to confirm that they have talked to their health care professional about the risks of ESAs.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract 2010; 6:317.</div><div id=\"graphicVersion\">Graphic 55973 Version 4.0</div></div></div>"},"55974":{"type":"graphic_table","displayName":"Toll-like receptors","title":"Toll-like receptors (TLRs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toll-like receptors (TLRs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">PRRs</td> <td class=\"subtitle1\">Localization</td> <td class=\"subtitle1\">Ligand</td> <td class=\"subtitle1\">Microbial origin of ligand</td> </tr> <tr> <td>TLR1</td> <td>Plasma membrane</td> <td>Triacyl lipoprotein</td> <td>Bacteria</td> </tr> <tr> <td>TLR2</td> <td>Plasma membrane</td> <td>Lipoprotein</td> <td>Bacteria, viruses, parasites</td> </tr> <tr> <td>TLR3</td> <td>Endolysosome*</td> <td>dsRNA</td> <td>Viruses</td> </tr> <tr> <td>TLR4</td> <td>Plasma membrane</td> <td>LPS</td> <td>Bacteria, viruses</td> </tr> <tr> <td>TLR5</td> <td>Plasma membrane</td> <td>Flagellin</td> <td>Bacteria</td> </tr> <tr> <td>TLR6</td> <td>Plasma membrane</td> <td>Diacyl lipoprotein</td> <td>Bacteria, viruses</td> </tr> <tr> <td>TLR7/8</td> <td>Endolysosome</td> <td>ssRNA</td> <td>Viruses, bacteria</td> </tr> <tr> <td>TLR9</td> <td>Endolysosome</td> <td>CpG-DNA</td> <td>Viruses, bacteria, protozoa</td> </tr> <tr> <td>TLR10</td> <td>Endolysosome</td> <td>Unknown</td> <td>Influenza virus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PRRs: pattern recognition receptors; TLR: toll-like receptor; dsRNA: double-stranded RNA; LPS: lipopolysaccharide; ssRNA: single-stranded RNA; CpG: cytosine guanine dinucleotides.<br />* An endosome is an intracellular membrane-bound compartment of the endocytic transport pathway from the plasma membrane to the lysosome. In the context of host defense, endolysosomal refers to localization in a vesicle containing internalized microbial debris or virus that has fused with lysosomes that contain degradative enzymes.</div><div id=\"graphicVersion\">Graphic 55974 Version 7.0</div></div></div>"},"55976":{"type":"graphic_figure","displayName":"Bleeding risk gastric varices","title":"Bleeding according to site of gastric varices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bleeding according to site of gastric varices</div><div class=\"cntnt\"><img style=\"width:420px; height:268px;\" src=\"images/GAST/55976_Bleeding_risk_gastric_varic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of a prospective study of 568 consecutive patients with gastric varices. Isolated gastric varices in the fundus (IGV1) bled much more frequently (about 90 percent) than either gastroesophageal varices (GOV1 and GOV2) or isolated gastric varices at other loci in the stomach (IGV2).</div><div class=\"graphic_reference\">Data from: Sarin SK, Lahoti D, Saxena SP, et al. Hepatology 1992; 16:1343.</div><div id=\"graphicVersion\">Graphic 55976 Version 2.0</div></div></div>"},"55977":{"type":"graphic_picture","displayName":"Disseminated candidiasis skin","title":"Skin lesions of disseminated candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesions of disseminated candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ID/55977_Disseminated_candidiasis_sk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tiny pustular lesions due to the hematogenous dissemination of <EM>Candida albicans</EM> can be seen in this hospitalized patient with fever and signs of sepsis.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 55977 Version 2.0</div></div></div>"},"55978":{"type":"graphic_table","displayName":"First-line TB drugs: Dosing","title":"Dosing of first-line antituberculosis drugs in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of first-line antituberculosis drugs in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" rowspan=\"2\">Preparations</td> <td class=\"subtitle1\" colspan=\"4\">Doses</td> </tr> <tr> <td class=\"subtitle2\">Daily</td> <td class=\"subtitle2\">1x/week</td> <td class=\"subtitle2\">2x/week</td> <td class=\"subtitle2\">3x/week</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">First-line drugs</td> </tr> <tr> <td class=\"indent1\">Isoniazid<sup>&#182;</sup></td> <td>Tablets (50 mg, 100 mg, 300 mg);&nbsp;elixir (50 mg/5 mL); aqueous solution (100 mg/mL) for intravenous or intramuscular injection</td> <td>5 mg/kg (usual maximum dose 300 mg)</td> <td>15 mg/kg (usual maximum dose 900 mg)</td> <td>15 mg/kg (usual maximum dose 900 mg)</td> <td>15 mg/kg (usual maximum dose 900 mg)</td> </tr> <tr> <td class=\"indent1\">Rifampin (rifampicin)<sup>&#916;</sup></td> <td>Capsules (150 mg, 300 mg); capsule contents may be suspended for oral administration; aqueous solution for intravenous injection</td> <td>10 mg/kg (usual maximum dose 600 mg)</td> <td>&ndash;</td> <td>10 mg/kg (usual maximum dose 600 mg)</td> <td>10 mg/kg (usual maximum dose 600 mg)</td> </tr> <tr> <td class=\"indent1\">Rifabutin<sup>&#916;</sup></td> <td>Capsule (150 mg)</td> <td>5 mg/kg (usual maximum dose 300 mg)</td> <td>&ndash;</td> <td>Not recommended</td> <td>Not recommended</td> </tr> <tr> <td class=\"indent1\">Rifapentine<sup>&#916;</sup></td> <td>Tablet (150 mg, film coated)</td> <td>&ndash;</td> <td>10 to 20 mg/kg once weekly during continuation phase of treatment<sup>&#9674;</sup></td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">Pyrazinamide</td> <td>Tablet (500 mg, scored)</td> <td>Dosing summarized in separate table</td> <td>&ndash;</td> <td>Dosing summarized in separate table</td> <td>Dosing summarized in separate table</td> </tr> <tr> <td class=\"indent1\">Ethambutol</td> <td>Tablets (100 mg, 400 mg)</td> <td>Dosing summarized in separate table</td> <td>&ndash;</td> <td>Dosing summarized in separate table</td> <td>Dosing summarized in separate table</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Adult dosing listed in this table is used in patients &ge;15 years old or weighing &gt;40 kg.</li>&#xD;&#xA;    <li>Antituberculous agents are used in multidrug combination regimens of varying duration, which are described in detail in a separate table (refer to the UpToDate table on regimens for treatment of drug-susceptible tuberculosis) and in the accompanying text.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Dosing based on actual weight is acceptable in patients who are not obese. For obese patients (&gt;20% above ideal body weight [IBW]), dosing based on IBW may be preferred for initial doses. Some clinicians prefer a modified IBW (IBW + [0.40 × (actual weight – IBW)]) as is done for initial aminoglycoside doses. Because tuberculosis drug dosing for obese patients has not been established, therapeutic drug monitoring may be considered for such patients.<br />¶ Pyridoxine (vitamin B6; 25 to 50 mg/day) is given with isoniazid to individuals at risk for neuropathy (eg, pregnant women, breastfeeding infants, and individuals with HIV infection, diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.<br />Δ&nbsp;Rifabutin dose may need to be adjusted when there is concomitant use of protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Refer to the UpToDate topic on treatment of pulmonary tuberculosis in HIV-infected adults for specific dose adjustments.<br />◊&nbsp;Rarely used in practice; it may be an alternative in the continuation phase of treatment in a once-weekly regimen to facilitate directly observed therapy. For further details, refer to the UpToDate topic on rifamycins.</div><div class=\"graphic_reference\">Data adapted from:<br /><br /><OL>&#xD;&#xA;<LI>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016. Epub ahead of print</LI>&#xD;&#xA;<LI>Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</LI></OL></div><div id=\"graphicVersion\">Graphic 55978 Version 8.0</div></div></div>"},"55985":{"type":"graphic_figure","displayName":"Cardiac output in pregnancy","title":"Systemic hemodynamics during normal pregnancy","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Systemic hemodynamics during normal pregnancy</div><div class=\"cntnt\"><img style=\"width:472px; height:534px;\" src=\"images/OBGYN/55985_Cardiac_output_in_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Bonica JJ, McDonald JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2<SUP>nd</SUP> ed, Williams &amp; Wilkins, Baltimore 1994. p.60.</div><div id=\"graphicVersion\">Graphic 55985 Version 4.0</div></div></div>"},"55986":{"type":"graphic_picture","displayName":"Atypical lymphocytes","title":"Atypical lymphocytes in infectious mononucleosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical lymphocytes in infectious mononucleosis</div><div class=\"cntnt\"><img style=\"width:417px; height:266px;\" src=\"images/HEME/55986_Atypical_lymphocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with infectious mononucleosis shows three atypical lymphocytes with generous cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 55986 Version 2.0</div></div></div>"},"55987":{"type":"graphic_table","displayName":"Follicular lymphoma international prognostic index","title":"Follicular lymphoma international prognostic index (FLIPI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Follicular lymphoma international prognostic index (FLIPI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"4\">&#8226; Age &#62;60 years</td> </tr> <tr> <td colspan=\"4\">&#8226; Serum lactate dehydrogenase concentration above normal</td> </tr> <tr> <td colspan=\"4\">&#8226; Hemoglobin level &#60;12.0 g/dL</td> </tr> <tr> <td colspan=\"4\">&#8226; Ann Arbor stage III or IV</td> </tr> <tr> <td colspan=\"4\">&#8226; Number of involved nodal areas &#62;4</td> </tr> <tr> <td colspan=\"4\">One point is given for each of the above characteristics present in the patient with FL, for a total score ranging from zero to five. When applied to an international study of long-term survival in 4167 patients with FL diagnosed between 1985 and 1992 and treated without rituximab, the following three risk groups and their corresponding five- and 10-year OS were, as follows<sup>[1]</sup>:</td> </tr> <tr> <td class=\"subtitle2\">Score </td> <td class=\"subtitle2\">Risk group</td> <td class=\"subtitle2\">Five-year OS, percent</td> <td class=\"subtitle2\">10-year OS, percent</td> </tr> <tr> <td>0 to 1</td> <td>Low risk</td> <td>91 </td> <td>71</td> </tr> <tr> <td>2</td> <td>Intermediate risk </td> <td>78 </td> <td>51</td> </tr> <tr> <td>3 or more </td> <td>High risk </td> <td>52</td> <td>36</td> </tr> <tr> <td colspan=\"4\">This same score was applied to 2192 patients diagnosed between 2004 and 2007, the majority of&nbsp;whom (68 percent) received rituximab in the initial management, with the following results<sup>[2]</sup>:</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Two-year OS, percent</td> <td class=\"subtitle2\">Two-year PFS, percent</td> <td class=\"subtitle2\">Median PFS, months</td> </tr> <tr> <td>0 to 1</td> <td>98</td> <td>84</td> <td>84</td> </tr> <tr> <td>2</td> <td>94</td> <td>72</td> <td>70</td> </tr> <tr> <td>3 or more</td> <td>87</td> <td>65</td> <td>42</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FL: follicular lymphoma; OS: overall survival; PFS: progression-free survival.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Solal-C&eacute;ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258.</li>&#xD;&#xA;    <li>Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 2013; 24:441.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 55987 Version 4.0</div></div></div>"},"55989":{"type":"graphic_picture","displayName":"NBI tumor vessels","title":"Narrow band imaging of tumor vessels in cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Narrow band imaging of tumor vessels in cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:381px; height:376px;\" src=\"images/GAST/55989_NBI_tumor_vessels_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video cholangioscopy using narrow band imaging showing tumor vessels in a patient with cholangiocarcinoma.</div><div id=\"graphicVersion\">Graphic 55989 Version 5.0</div></div></div>"},"55990":{"type":"graphic_algorithm","displayName":"Management upper airway obstruction with FB in children","title":"Management of upper airway obstruction due to a foreign body in children*","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Management of upper airway obstruction due to a foreign body in children*</div><div class=\"cntnt\"><img style=\"width:732px; height:1069px;\" src=\"images/EM/55990_Complete_obstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FB: foreign body; CPR: cardiopulmonary resuscitation; RSI: rapid sequence intubation; ETT: endotracheal tube; OR: operating room.<br />* The following findings suggest upper airway obstruction: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Inspiratory stridor, wheezing, or stertor</LI>&#xD;&#xA;<LI>Suprasternal or supraclavicular retractions</LI>&#xD;&#xA;<LI>Prolonged inspiratory phase</LI>&#xD;&#xA;<LI>Oral mucosa or tongue swelling</LI>&#xD;&#xA;<LI>Drooling</LI>&#xD;&#xA;<LI>Dysphagia</LI></UL>&nbsp;&nbsp;Positions of comfort to help maintain airway patency in patients with severe obstruction: &#xD;&#xA;<UL>&#xD;&#xA;<LI>\"Sniffing\" position (neck is mildly flexed and head is mildly extended)</LI>&#xD;&#xA;<LI>Tripod position (leaning forward while bracing on the arms with neck hyperextended and chin thrust forward)</LI></UL>¶ Refer to UpToDate algorithms and topics on pediatric basic life support for health care providers and foreign body obstruction.<br />Δ Refer to UpToDate topics on evaluation of upper airway obstruction in children.<br /><FONT class=lozenge>◊</FONT> Surgical cricothyrotomy may be appropriate in selected patients younger than 12 years of age, as determined by cricothyroid membrane size. Refer to UpToDate topics on needle and surgical cricothyroidotomy.</div><div id=\"graphicVersion\">Graphic 55990 Version 3.0</div></div></div>"},"55993":{"type":"graphic_picture","displayName":"AIP plasma cells Light HP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/55993_AIP_plasma_cells_Light_HP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power (200x) view of a pancreas biopsy in a patients with autoimmune pancreatitis showing an infiltrate composed primarily of plasma cells admixed with lymphocytes.</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 55993 Version 1.0</div></div></div>"},"55994":{"type":"graphic_diagnosticimage","displayName":"Hurler brain MRI lateral","title":"Lateral brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome)</div><div class=\"cntnt\"><img style=\"width:331px; height:311px;\" src=\"images/PEDS/55994_Hurler_brain_MRI_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral T1-weighted MR cranial image showing severe hydrocephalus in a child with Hurler syndrome. The temporal horn of the lateral ventricle is dialated.</div><div class=\"graphic_footnotes\">MR: magnetic resonance; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 55994 Version 4.0</div></div></div>"},"55996":{"type":"graphic_table","displayName":"Symptoms of focal seizures","title":"Symptoms of focal seizures without impairment of consciousness (also called simple partial seizures or auras)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of focal seizures without impairment of consciousness (also called simple partial seizures or auras)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Black out</td> </tr> <tr> <td>Body size or weight alteration in perception</td> </tr> <tr> <td>Breathing difficulty</td> </tr> <tr> <td>Chewing movements</td> </tr> <tr> <td>Confusion</td> </tr> <tr> <td>Convulsion</td> </tr> <tr> <td>Deja-vu</td> </tr> <tr> <td>Dizziness</td> </tr> <tr> <td>Drooling</td> </tr> <tr> <td>Electric shock feeling</td> </tr> <tr> <td>Eyelid fluttering</td> </tr> <tr> <td>Eyes rolling up</td> </tr> <tr> <td>Falling down</td> </tr> <tr> <td>Foot stomping</td> </tr> <tr> <td>Hand waving</td> </tr> <tr> <td>Heart racing</td> </tr> <tr> <td>Inability to move</td> </tr> <tr> <td>Incontinence</td> </tr> <tr> <td>Jamais vu</td> </tr> <tr> <td>Lightheadedness</td> </tr> <tr> <td>Lip smacking</td> </tr> <tr> <td>Loss of consciousness</td> </tr> <tr> <td>Making sounds</td> </tr> <tr> <td>Memory loss</td> </tr> <tr> <td>One side of body different than other</td> </tr> <tr> <td>Out-of-body experience</td> </tr> <tr> <td>Oversensitivity to stimulation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Psychic experience</td> </tr> <tr> <td>Racing thoughts</td> </tr> <tr> <td>Rising epigastric sensation&nbsp;</td> </tr> <tr> <td>Running</td> </tr> <tr> <td>Shaking</td> </tr> <tr> <td>Skin color changes</td> </tr> <tr> <td>Sound perception distortion</td> </tr> <tr> <td>Spacial perception distortion</td> </tr> <tr> <td>Spacing out</td> </tr> <tr> <td>Spinning feeling</td> </tr> <tr> <td>Staring</td> </tr> <tr> <td>Stiffening</td> </tr> <tr> <td>Swallowing</td> </tr> <tr> <td>Sweating</td> </tr> <tr> <td>Talking difficulty</td> </tr> <tr> <td>Teeth clenching/grinding</td> </tr> <tr> <td>Tightness</td> </tr> <tr> <td>Time perception distortion</td> </tr> <tr> <td>Tingling feeling</td> </tr> <tr> <td>Tongue biting</td> </tr> <tr> <td>Tremors</td> </tr> <tr> <td>Twitching movements</td> </tr> <tr> <td>Undressing</td> </tr> <tr> <td>Urge to urinate or defecate</td> </tr> <tr> <td>Visual distortion</td> </tr> <tr> <td>Visual loss or blurring</td> </tr> <tr> <td>Walking</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 55996 Version 5.0</div></div></div>"},"55997":{"type":"graphic_figure","displayName":"Noncontact map focal AF","title":"Noncontact endocardial activation map of focal atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Noncontact endocardial activation map of focal atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:455px; height:291px;\" src=\"images/CARD/55997_Noncontact_map_focal_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The noncontact endocardial activation map of the half-open left atrium shows that the initial depolarization from an ectopic focus spreads centrifugally from the ostium of the right upper pulmonary vein (RUP), indicated by the white-blue color.</div><div class=\"graphic_footnotes\">LUP: left upper pulmonary vein.</div><div class=\"graphic_reference\">Reproduced with permission from Schneider MA, Ndrepepa G, Zrenner B, et al. Noncontact mapping-guided catheter ablation of atrial fibrillation associated with left atrial ectopy. J Cardiovascular Electrophysiol 2000; 11:475. Copyright &#169; 2000 Futura Publishing Company, Inc.</div><div id=\"graphicVersion\">Graphic 55997 Version 2.0</div></div></div>"},"55998":{"type":"graphic_picture","displayName":"Oropharynx of a snorer I","title":"Oropharynx of a snorer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oropharynx of a snorer</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/PULM/55998_Oropharynx_of_a_snorer_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Erythema and edema of the uvula are present, probably secondary to the tissue vibration that accompanies the snoring sound.</div><div id=\"graphicVersion\">Graphic 55998 Version 2.0</div></div></div>"},"55999":{"type":"graphic_diagnosticimage","displayName":"Pulmonary hemorrhage in GPA","title":"Pulmonary hemorrhage in granulomatosis with polyangiitis (Wegener's)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hemorrhage in granulomatosis with polyangiitis (Wegener's)</div><div class=\"cntnt\"><img style=\"width:374px; height:296px;\" src=\"images/PULM/55999_Wegeners_granulomatosis_lun.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ill-defined nodule with an air bronchogram due to hemorrhage and necrosis in granulomatosis with polyangiitis (Wegener's).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 55999 Version 3.0</div></div></div>"}};